

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 February 2010 (25.02.2010)

PCT

(10) International Publication Number
WO 2010/022055 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2009/054169

(22) International Filing Date:
18 August 2009 (18.08.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/189,501 20 August 2008 (20.08.2008) US
61/196,012 14 October 2008 (14.10.2008) US

(71) Applicant (for all designated States except US): **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUCHANAN, John L.** [US/US]; 970 Dedham Street, Newton, Massachusetts 02459 (US). **BREGMAN, Howard** [US/US]; 12 Howard Street, Melrose, Massachusetts 02176 (US). **CHAKKA, Nagasree** [CA/US]; 13 Judith Lane, Apt. #1, Waltham, Massachusetts 02452 (US). **DIMAURO, Erin F.** [US/US]; 113 Brookline St., Cambridge, Massachusetts 02139 (US). **DU, Bingfan** [US/US]; 18 Springfield Street, Cambridge, Massachusetts 02139 (US). **NGUYEN, Hanh Nho** [US/US]; 185 Brattle Street, Arlington, Massachusetts 02474 (US). **ZHENG, Xiao Mei** [CA/US]; 23 Lakeview Gardens, Apt. 716, Natick, Massachusetts 01760 (US).

(74) Agent: **BANSAL, Rekha P.**; AMGEN INC., 1120 Veterans Blvd., ASF1-1, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS

(57) Abstract: The present invention provides compounds that are inhibitors of voltage-gated sodium channel (Nav), in particular Nav 1.7 and are therefore useful for the treatment of diseases 5 treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.



WO 2010/022055 A2

INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS

Cross-Reference to Related Applications

5 This application claims the benefit of U.S. Provisional Application Nos. 61/189,501, filed August 20, 2008 and 61/196,012, filed October 14, 2008, the disclosures of which are incorporated herein by reference in their entirety.

Field of the Invention

10 The present invention provides compounds that are inhibitors of voltage-gated sodium channel (Nav), in particular Nav 1.7 and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Background


15 Chronic pain by definition involves abnormal electrical spiking of neurons in the pain pathways: peripheral sensory neurons, spinal cord neurons, neurons in the pain matrix of the brain (e.g., somatosensory cortex, insular cortex, anterior cingular cortex), and / or neurons in
20 brainstem. Although firing of these neurons is modulated and governed by many different receptors, enzymes, and growth factors, in most neurons the fast upstroke of the electrical spike is produced by entry of sodium ions through voltage-gated sodium channels (Hille B, Ion Channels of Excitable Membranes. Sinauer Associates, Inc.: Sunderland MA, 3rd Ed. 2001). There are nine different isoforms of voltage-gated sodium channel (Nav1.1-Nav1.9), and they
25 have distinct expression patterns in tissues including neurons and cardiac and skeletal muscle (Goldin, A. L, "Resurgence of sodium channel research," *Ann Rev Physiol* 63:871-894, 2001; Wood, J. N. and, Boorman, J. "Voltage-gated sodium channel blockers; target validation and therapeutic potential," *Curr. Top Med. Chem.* 5:529-537, 2005). Nonselective sodium channel
30 inhibitors such as lidocaine, mexiletine, and carbamazepine show clinical efficacy in chronic pain, including neuropathic pain, but they are limited in dose and in use, likely due to effects on sodium channels outside the pain pathway.

 Recent evidence from several independent genetic studies has shown that the tetrodotoxin-sensitive voltage-gated sodium ion channel Nav1.7 (SCN9A) is required to sense pain. Rare genetic forms of severe chronic pain, Primary Erythromelalgia and Paroxysmal
35 Extreme Pain Disorder, result from mutations that increase the activity of Nav1.7 (Fertleman

C. R., Baker M. D., Parker K. A., Moffatt S., et al., "SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes," *Neuron* 52:767-774, 2006; Yang Y., Wang Y., Li S., et al., "Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythralgia," *J. Med. Genet.* 41:171-174, 2004; Drenth J. P. H., te Morsche R. H. M., Guillet G., Taieb A., et al., "SCN9A mutations define primary erythralgia as a neuropathic disorder of voltage gated sodium channels," *J Invest Dermatol* 124:1333-1338). Conversely, two separate clinical studies have determined that the root cause of the genetic disorder Congenital Indifference to Pain (CIP) is a loss of function of Nav1.7 via mutations that truncate the protein and destroy function (Cox J. J., Reimann F, Nicholas A. K., et al. "An SCN9A channelopathy causes congenital inability to experience pain," *Nature* 444:894-898, 2006; Goldberg Y. P., MacFarlane J., MacDonald M. L., Thompson J., et al. "Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations," *Clin Genet* 71:311-319, 2007). The disorder is inherited in Mendelian recessive manner with 100% penetrance. The phenotype associated with CIP is extreme: affected individuals are reported to have experienced painless burns, childbirth, appendicitis, and bone fractures, as well as to have insensitivity to clinical measures of pain such as pinprick or tendon pressure. Yet sensory, motor, autonomic, and other measured functions are normal, with the only reported abnormality being anosmia (inability to smell). These studies indicate that among the many possible targets in the pain pathway, Nav1.7 governs one or more control points critical for pain perception. Accordingly, a drug that inhibits Nav1.7 should effectively treat chronic pain in humans. The present invention fulfils this and related needs.

SUMMARY

In one aspect, provided herein are compounds of Formula (I):



where:

X is -NH-, -O-, -S-, or -SO₂-;

Y is O, S, or N-CN

A is aryl or heteroaryl;

R¹ is alkyl, haloalkyl, substituted alkyl, acyloxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl wherein the ring in cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, alkoxy, hydroxyl, or haloalkoxy;

R² is hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, alkoxyalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, amino, monosubstituted or disubstituted amino, sulfonyl, or alkoxyalkyl;


R³ is hydrogen, halo, alkyl, alkoxy, cyano, or haloalkyl;

R⁴ is hydrogen, alkyl, substituted alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxycarbonyl, aryl, heteroaryl, cycloalkyl, cyano, amino, monoalkylamino, or dialkylamino;

R⁵ is hydrogen, alkyl, substituted alkyl, aryl, or heteroaryl; and

R⁶ is aryl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or aralkyl wherein one or two carbon atoms in the alkyl chain in aralkyl are optionally replaced by -N-, -O-, or -CO- provided that -N-, -O-, or -CO- are not on adjacent atoms; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form ring B having the formula:



wherein ring B is a heteroaryl, four membered heterocyclyl, heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring, and


wherein each aforementioned ring in R⁵, R⁶ and ring B is substituted with R^a, R^b or R^c where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, thio, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, or acylamino and R^b and R^c are independently selected from hydrogen, alkyl, substituted alkyl, substituted alkynyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, sulfonylamino, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, aryloxy, heteroaryloxy, cycloalkoxy, aryloxyalkyl, aralkyloxy, aralkylthio,

heteroaralkyloxy, heterocyclalkyloxy, or cycloalkylalkyloxy where the aromatic or alicyclic ring in R^a, R^b and R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxyacetyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, cycloalkyl, cycloalkenyl, phenyl, phenoxyl, heteroaryl, heterocycl, heterocyclalkyl, aralkyl or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxyl, alkoxy, acetyl, amino, alkylsulfonyl, or cyano;

or a pharmaceutically acceptable salt thereof, provided that:

- (i) two of R^a, R^b and R^c are not simultaneously amino; (ii) the compound of Formula (I) is not N-(4-(4-(2-amino-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-phenylcyclopropylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(benzylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)-acetamide, N-(3-(4-(2-(indol-5-ylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, and N-(4-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)-1,3,5-triazin-2-yl)phenylamino)acetamide; (iii) when A is phenyl, Y is O, R¹ is alkyl or phenyl, R² is hydrogen or alkyl, R³ is hydrogen or halo, R⁴ is hydrogen, halo, or haloalkyl, R⁵ is hydrogen; and R⁶ is phenyl, then (a) when two of R^a, R^b and R^c are hydrogen then the third of R^a, R^b and R^c is not halo, aminocarbonyl, or acylamino or (b) R^a, R^b and R^c are not all simultaneously alkoxy; (iv) when A is phenyl, Y is O, R¹ is alkyl, R² is hydrogen, R³ is hydrogen, R⁴ is hydrogen, R⁵ is hydrogen; and R⁶ is pyrazole, then when two of R^a, R^b and R^c are hydrogen then the third of R^a, R^b and R^c is not furanyl; (v) when A is phenyl, Y is O, R¹ is alkyl, R² is hydrogen or alkyl, R³ is hydrogen, R⁴ is hydrogen, and R⁵ is hydrogen or alkyl; and R⁶ is indazolyl, then when two of R^a, R^b and R^c are hydrogen then the third of R^a, R^b and R^c is not alkyl or aralkyl; and (vi) when A is phenyl, Y is O, R¹ is alkyl or phenyl, R² is hydrogen or alkoxy, and R³ is alkyl or halo, and R⁴ is hydrogen or alkoxy, then ring B is not 4-(2-hydroxyethyl)piperazin-1-yl, or 4-(4-methoxyphenyl)piperazin-1-yl or salts thereof.

In a second aspect, provided herein are compounds of Formula (II):



5 where:

X is -NH-, -O-, -S-, or -SO₂-;

Y is O, S, or N-CN

A is aryl or heteroaryl;

10 R¹ is alkyl, haloalkyl, substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl wherein the ring in cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, alkoxy, hydroxyl, or haloalkoxy;

15 R² is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, amino, monosubstituted or disubstituted amino, sulfonyl, or alkoxyalkyl;


R³ is hydrogen;

R⁴ is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, amino, monoalkylamino, or dialkylamino; and

20 ring B is a heteroaryl, heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring, each ring substituted with R^a, R^b or R^c where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, thio, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, or acylamino and R^b and R^c are independently selected from hydrogen, alkyl, 25 halo, haloalkyl, haloalkoxy, alkylthio, cyano, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, sulfonylamino, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, aralkyl, 30 heteroaralkyl, heterocyclylalkyl, aryloxy, heteroaryloxy, cycloalkoxy, aralkyloxy, aralkylthio,

heteroaralkyloxy, heterocyclalkyloxy, or cycloalkylalkyloxy where the aromatic or alicyclic ring in R^a, R^b and R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxy carbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, cycloalkenyl, phenyl, heteroaryl, heterocycl, heterocyclalkyl, aralkyl or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxyl, alkoxy, acetylamino, alkylsulfonyl, or cyano; or a pharmaceutically acceptable salt thereof, provided that (i) two of R^a, R^b and R^c are not simultaneously amino, and (ii) the compound of Formula (I) is not N-(4-(4-(2-amino-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(benzylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(indol-5-ylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, and N-(4-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)-1,3,5-triazin-2-yl)phenylamino)acetamide, or salts thereof.

In one embodiment, the compound of Formula (II) has the structure (II'):



where X is -NH-, -O-, -S-, or -SO₂-; and Y is O or S; and other groups are as in Formula (II) above.

In a third aspect, provided is a pharmaceutical composition comprising a compound of Formula (I), (II) or (II'), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

In a fourth aspect, provided is a method of treating a disease by inhibition of voltage-gated sodium channel in a patient which method comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In one embodiment, the disease is chronic pain. In another aspect, the embodiment is chronic pain associated with, but are not limited to, post-herpetic neuralgia


(shingles), osteoarthritis, painful diabetic neuropathy, complex regional pain syndrome (CRPS), cancer- or chemotherapy-induced pain, chronic back pain, phantom limb pain, trigeminal neuralgia, HIV-induced neuropathy, cluster headache disorders, and migraine, Primary Erythromelalgia, and Paroxysmal Extreme Pain Disorder. Other potential indications for Nav1.7 inhibitors include but are not limited to depression (Morinville et al., *J Comp Neurol.*, 504:680-689 (2007)), bipolar and other CNS disorders (Ettinger and Argoff, *Neurotherapeutics*, 4:75-83 (2007)), epilepsy: *ibid.*, and Gonzalez, Termin, Wilson, *Methods and Principles in Medicinal Chemistry*, 29:168-192 (2006)), multiple sclerosis (Waxman, *Nature Neurosci.* 7 :932-941 (2006)), Parkinson's (Do and Bean, *Neuron* 39 :109-120 (2003); Puopolo et al., *J. Neurosci.* 27 :645-656 (2007)), restless legs syndrome, ataxia, tremor, muscle weakness, dystonia, tetanus (Hamann M., et. al., *Exp. Neurol.* 184(2):830-838, 2003), anxiety, depression: McKinney B. C, et. al., *Genes Brain Behav.* 7(6):629-638, 2008), learning and memory, cognition (Woodruff-Pak D. S., et. al., *Behav. Neurosci.* 120(2):229-240, 2006), cardiac arrhythmia and fibrillation, contractility, congestive heart failure, sick sinus syndrome (Haufe V., et. al., *J Mol. Cell Cardiol.* 42(3):469-477, 2007), schizophrenia, neuroprotection after stroke, drug and alcohol abuse (Johannessen L. C., *CNS Drugs* 22(1)27-47, 2008), Alzheimer's (Kim D. Y., et. al., *Nat. Cell. Biol.* 9(7):755-764, 2007), and cancer (Gillet L., et. al., *J Biol Chem* 2009, Jan 28 (epub)).

In a fifth aspect this invention is directed to use of the compounds of Formula (I), (II) and (II') as a medicament. In one aspect, the medicament is used in the treatment of chronic pain. In another aspect, the embodiment is chronic pain associated with, but are not limited to, post-herpetic neuralgia (shingles), osteoarthritis, painful diabetic neuropathy, complex regional pain syndrome (CRPS), cancer- or chemotherapy-induced pain, chronic back pain, phantom limb pain, trigeminal neuralgia, HIV-induced neuropathy, cluster headache disorders, and migraine, Primary Erythromelalgia, and Paroxysmal Extreme Pain Disorder. Other potential indications include but are not limited to depression, bipolar and other CNS disorders, multiple sclerosis, Parkinson's disease, restless legs syndrome, ataxia, tremor, muscle weakness, dystonia, tetanus, anxiety, depression, learning and memory, cognition, cardiac arrhythmia and fibrillation, contractility, congestive heart failure, sick sinus syndrome, schizophrenia, neuroprotection after stroke, drug and alcohol abuse, Alzheimer's, and cancer.

In a sixth aspect this invention is directed compounds of Formula (I), (II) and (II') for use in the treatment of chronic pain. In another aspect, the embodiment is chronic pain associated with, but are not limited to, post-herpetic neuralgia (shingles), osteoarthritis, painful diabetic neuropathy, complex regional pain syndrome (CRPS), cancer- or chemotherapy-

induced pain, chronic back pain, phantom limb pain, trigeminal neuralgia, HIV-induced neuropathy, cluster headache disorders, and migraine, Primary Erythromelalgia, and Paroxysmal Extreme Pain Disorder. Other potential indications include but are not limited to depression, bipolar and other CNS disorders, multiple sclerosis, Parkinson's disease, restless legs syndrome, ataxia, tremor, muscle weakness, dystonia, tetanus, anxiety, depression, learning and memory, cognition, cardiac arrhythmia and fibrillation, contractility, congestive heart failure, sick sinus syndrome, schizophrenia, neuroprotection after stroke, drug and alcohol abuse, Alzheimer's, and cancer.

In a seventh aspect, provided are intermediates of Formula (III):



where:

X is -NH-, -O-, -S-, or -SO₂-;

A is aryl or heteroaryl;

R² is hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, alkoxyalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, amino, monosubstituted or disubstituted amino, sulfonyl, or alkoxyalkyl;


R³ is hydrogen, halo, alkyl, alkoxy, cyano, or haloalkyl;

R⁴ is hydrogen, alkyl, substituted alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxycarbonyl, aryl, heteroaryl, cycloalkyl, cyano, amino, monoalkylamino, or dialkylamino;

R⁵ is hydrogen, alkyl, substituted alkyl, aryl, or heteroaryl; and

R⁶ is aryl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or aralkyl wherein one or two carbon atoms in the alkyl chain in aralkyl are optionally replaced by -N-, -O-, or -CO- provided that -N-, -O-, or -CO- are not on adjacent atoms; or

R⁵ and R⁶ together with the nitrogen atom to which they are attached form ring B having the formula:



wherein ring B is a heteroaryl, four membered heterocyclyl, heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring, and

wherein each aforementioned ring in R⁵, R⁶ and ring B is substituted with R^a, R^b or R^c where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, thio, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, or acylamino and R^b and R^c are independently selected from hydrogen, alkyl, substituted alkyl, substituted alkynyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, sulfonylamino, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, aryloxy, heteroaryloxy, cycloalkoxy, aryloxyalkyl, aralkyloxy, aralkylthio, heteroaralkyloxy, heterocyclylalkyloxy, or cycloalkylalkyloxy where the aromatic or alicyclic ring in R^a, R^b and R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, cycloalkyl, cycloalkenyl, phenyl, phenoxyl, heteroaryl, heterocyclyl, heterocyclylalkyl, aralkyl or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxyl, alkoxy, acetylamino, alkylsulfonyl, or cyano; or a salt thereof.

Detailed Description

Definitions:

Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:

"Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.

"Alicyclic" means a non-aromatic ring e.g., cycloalkyl or heterocyclyl ring.

"Alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.

5 "Alkylthio" means a -SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.

"Alkylsulfonyl" means a -SO₂R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.

"Amino" means a -NH₂.

10 "Alkylamino" means a -NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, propylamino, or 2-propylamino, and the like.

"Alkoxy" means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, *n*-, *iso*-, or *tert*-butoxy, and the like.

15 "Alkoxycarbonyl" means a -C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.

"Alkoxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, preferably one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.

20 "Alkoxyalkyloxy" or "alkoxyalkoxy" means a -OR radical where R is alkoxyalkyl as defined above, e.g., methoxyethoxy, 2-ethoxyethoxy, and the like.

"Aminoalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one, preferably one or two, -NRR' where R is hydrogen, alkyl, or -COR^a where R^a is
 25 alkyl, each as defined above, and R' is selected from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or haloalkyl, each as defined herein, e.g., aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, 1,3-diaminopropyl, dimethylaminomethyl, diethylaminoethyl, acetylaminopropyl, and the like.

30 "Aminoalkoxy" means a -OR radical where R is aminoalkyl as defined above, e.g., 2-aminoethoxy, 2-dimethylaminopropoxy, and the like.

"Aminocarbonyl" means a -CONRR' radical where R is independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein and R' is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl,

heterocyclalkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein, e.g., -CONH₂, methylaminocarbonyl, 2-dimethylaminocarbonyl, and the like.

"Aminosulfonyl" means a -SO₂NRR' radical where R is independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein and R' is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclalkyl, heterocyclalkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein, e.g., -SO₂NH₂, methylaminosulfonyl, 2-dimethylaminosulfonyl, and the like.

"AcyI" means a -COR radical where R is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclalkyl, or heterocyclalkyl, each as defined herein, e.g., acetyl, propionyl, benzoyl, pyridinylcarbonyl, and the like. When R is alkyl, the radical is also referred to herein as alkylcarbonyl.

"Acyloxyalkyl" means a -alkyleneOCOR radical where R is alkyl as defined above.

"AcyIamino" means a -NHCOR radical where R is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclalkyl, or heterocyclalkyl, each as defined herein, e.g., acetylamino, propionylamino, and the like.

"AryI" means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.

"Aralkyl" means a -(alkylene)-R radical where R is aryl as defined above.


"Aryloxy" means a -OR radical where R is aryl as defined above, e.g., phenoxy, naphthyloxy.

"Aryloxyalkyl" means a -alkylene-OR radical where R is aryl as defined above, e.g., phenoxyethyl, phenoxyethyl, and the like.

"Aralkyloxy" means a -OR radical where R is aralkyl as defined above.

"Aralkylthio" means a -SR radical where R is aralkyl as defined above.

"Bridged heterocyclalkyl" means a saturated or unsaturated monovalent bicyclic group of 5 to 10 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(O)_n, where n is an integer from 0 to 2, the remaining ring atoms being C, where some of the rings are created by one or more bridges. Representative examples include but are not limited to:



"Cycloalkyl" means a cyclic, saturated, monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like. The

cycloalkyl ring can optionally be fused to phenyl or monocyclic heteroaryl ring as defined herein. When the cycloalkyl ring is referred to herein as "fused cycloalkyl", it means that the cycloalkyl ring is fused to phenyl or monocyclic heteroaryl ring. When the cycloalkyl ring is referred to herein as "monocyclic cycloalkyl", it means that the cycloalkyl ring is not fused to phenyl or monocyclic heteroaryl ring.

"Cycloalkylalkyl" means a $-(\text{alkylene})-\text{R}$ radical where R is cycloalkyl as defined above; e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, or cyclohexylmethyl, and the like.

"Cycloalkoxy" means a $-\text{OR}$ radical where R is cycloalkyl as defined above, e.g., cyclopropoxy, cyclobutoxy, and the like.

"Cycloalkylalkyloxy" means a $-\text{OR}$ radical where R is cycloalkylalkyl as defined above.

"Cycloalkenyl" means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms containing one or two double bond(s), e.g., cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl, and the like.

"Carboxy" means $-\text{COOH}$.

"Disubstituted amino" means a $-\text{NRR}'$ radical where R and R' are independently alkyl, cycloalkyl, cycloalkylalkyl, acyl, sulfonyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein, e.g., dimethylamino, phenylmethylamino, and the like. When R and R' are alkyl, the group is referred to herein as dialkylamino

"Four-membered heterocyclyl" means saturated monovalent monocyclic group of 4 ring atoms in which one ring atom is N, the remaining ring atoms being C.

"Halo" means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.

"Haloalkyl" means alkyl radical as defined above, which is substituted with one or more halogen atoms, preferably one to five halogen atoms, preferably fluorine or chlorine, including those substituted with different halogens, e.g., $-\text{CH}_2\text{Cl}$, $-\text{CF}_3$, $-\text{CHF}_2$, $-\text{CH}_2\text{CF}_3$, $-\text{CF}_2\text{CF}_3$, $-\text{CF}(\text{CH}_3)_2$, and the like. When the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkyl.

"Haloalkoxy" means a $-\text{OR}$ radical where R is haloalkyl as defined above e.g., $-\text{OCF}_3$, $-\text{OCHF}_2$, and the like. When R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.

"Hydroxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with

one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.

"Hydroxyalkoxy" or "hydroxyalkyloxy" means a –OR radical where R is hydroxyalkyl as defined above.

"Hydroxyalkoxyalkyl" or "hydroxyalkyloxyalkyl" means a –(alkylene)-OR radical where R is hydroxyalkyl as defined above.

"Heterocyclyl" means a saturated or unsaturated monovalent monocyclic group of 5 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(O)_n, where n is an integer from 0 to 2, the remaining ring atoms being C. The heterocyclyl ring is optionally fused to a (one) aryl or heteroaryl ring as defined herein provided the aryl and heteroaryl rings are monocyclic. The heterocyclyl ring fused to monocyclic aryl or heteroaryl ring is also referred to in this Application as "bicyclic heterocyclyl" ring. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a –CO– group. More specifically the term heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydropyranyl, thiomorpholino, tetrahydroisoquinoliny, and the like. When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic. When the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino and is a subset of the heterocyclyl group. When the heterocyclyl group is a saturated ring and is not fused to aryl or heteroaryl ring as stated above, it is also referred to herein as saturated monocyclic heterocyclyl. It will be apparent to a person skilled in the art, that when ring B in Formula (I) is heterocyclyl, there is at least one nitrogen atom present in the heterocyclyl ring.

"Heterocyclylalkyl" means a –(alkylene)-R radical where R is heterocyclyl ring as defined above e.g., tetrahydrofuranylmethyl, piperazinylmethyl, morpholinylethyl, and the like.

"Heterocyclylalkyloxy" means a –OR radical where R is heterocyclylalkyl as defined above.

"Heteroaryl" means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, 5 isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinoliny, isoquinoliny, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. It will be apparent to a person skilled in the art, that when ring B in Formula (I) is heteroaryl, there is at least one nitrogen atom present in the heteroaryl ring.

"Heteroaralkyl" means a $-(\text{alkylene})-\text{R}$ radical where R is heteroaryl as defined above.

10 "Heteraryloxy" means a $-\text{OR}$ radical where R is heteroaryl as defined above, e.g., pyridinyloxy, thiophenyloxy, and the like.

"Heteroaralkyloxy" means a $-\text{OR}$ radical where R is heteroaralkyl as defined above.

"Monosubstituted amino" means a $-\text{NHR}$ radical where R is alkyl, cycloalkyl, cycloalkylalkyl, acyl, sulfonyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, 15 heterocyclylalkyl, hydroxyalkyl, alkoxyalkyl, or aminoalkyl, each as defined herein, e.g., methylamino, 2-phenylamino, hydroxyethylamino, and the like. When R is alkyl, the group is referred to herein as monoalkylamino.

The present invention also includes the prodrugs of compounds of Formula (I). The term prodrug is intended to represent covalently bonded carriers, which are capable of 20 releasing the active ingredient of Formula (I) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs *in vivo*. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups *in vivo* or by routine manipulation. Prodrugs of compounds of 25 Formula (I) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., *N,N*-dimethylaminocarbonyl) of hydroxy or amino functional groups in compounds of Formula (I), amides (e.g., trifluoroacetyl amino, acetyl amino, and the like), and the like. Prodrugs of compounds of Formula (I) are also within 30 the scope of this invention.

The present invention also includes protected derivatives of compounds of Formula (I). For example, when compounds of Formula (I) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups. A comprehensive list of suitable protective groups can be found in T.W.

Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. (1999), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula (I) can be prepared by methods well known in the art.

A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include:

acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or

salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, *N*-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference.

The compounds of the present invention may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, racemic forms are within the scope of this invention, unless the specific stereochemistry or isomeric form is specifically indicated.

Certain compounds of Formula (I) can exist as tautomers and/or geometric isomers. All possible tautomers and *cis* and *trans* isomers, as individual forms and mixtures thereof are within the scope of this invention. Additionally, as used herein the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth.

Furthermore, when the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all the positional isomers albeit only a few examples are set forth. Furthermore, all polymorphic forms and hydrates of a compound of Formula (I) are within the scope of this invention.

5 "Oxo" or "carbonyl" means $=\text{(O)}$ group.


"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "heterocyclyl group optionally substituted with an alkyl group" means that the alkyl may but need not be present, and the description includes situations where the heterocyclyl group is substituted with an alkyl group and situations where the heterocyclyl group is not substituted with alkyl.

A "pharmaceutically acceptable carrier or excipient" means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable carrier/excipient" as used in the specification and claims includes both one and more than one such excipient.

"Sulfonyl" means a $-\text{SO}_2\text{R}$ radical where R is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, each as defined herein, e.g., methylsulfonyl, phenylsulfonyl, benzylsulfonyl, pyridinylsulfonyl, and the like. When R is alkyl, it is also referred to herein as alkylsulfonyl.

"Sulfonylamino" means a $-\text{NHSO}_2\text{R}$ radical where R is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, each as defined herein.

"Spiroheterocyclyl" means a bicyclic compound ring of 6 to 14, preferably 6 to 12 carbon ring atoms where the rings are connected through one carbon atom and in which one or two ring atoms are heteroatom selected from N, O, or $\text{S}(\text{O})_n$, where n is an integer from 0 to 2, the remaining ring atoms being C. The spiroheterocyclyl ring optionally contains one or two oxo group within the ring and is optionally substituted with phenyl or monocyclic heteroaryl ring. Representative examples include, but are not limited to,

30 , and the like. It will be apparent to a person skilled in the art, that when ring B in Formula (I) is spiroheterocyclyl, there is at least one nitrogen atom present in the spiroheterocyclyl ring.

"Substituted alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms where one or two hydrogen atoms in the alkyl chain are independently replaced by hydroxyl, alkoxy, amino, monosubstituted amino, disubstituted amino, cyano, sulfonyl, aminocarbonyl, aminosulfonyl, -NHCONH₂, carboxy, acyl, acylamino, or alkoxycarbonyl, each group as defined herein.

"Substituted alkynyl" means a linear saturated monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing a triple bond where one or two hydrogen atoms in the alkynyl chain are independently replaced by phenyl, hydroxyl, alkoxy, amino, monosubstituted amino, disubstituted amino, cyano, sulfonyl, aminocarbonyl, aminosulfonyl, -NHCONH₂, carboxy, acyl, acylamino, or alkoxycarbonyl, each group as defined herein.

"Thio" means a -SR radical where R is alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclalkyl, each as defined herein, e.g., methylthio, phenylthio, benzylthio, pyridinylthio, and the like. When R is alkyl, it is also referred to herein as alkylthio.

The phrase in the definition of ring B in the claims and in the specification of this Application "...ring B is a heteroaryl, heterocyclyl, bridged heterocycle, or spiroheterocycl ring, each ring substituted with R^a, R^b or R^c....." and similar phrases used for others groups in the claims and in the specification with respect to the compound of Formula (I) means that the rings can be mono-, di-, or trisubstituted unless indicated otherwise.

"Treating" or "treatment" of a disease includes:

preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;


inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or

relieving the disease, i.e., causing regression of the disease or its clinical symptoms.



A "therapeutically effective amount" means the amount of a compound of Formula (I) that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.


Representative compounds of the Invention are shown in Tables I - IV below:


Table I shows representative compounds of Formula (I) where A is phenyl, R³ and R⁴ are hydrogen, Y is –O– and other groups are as listed below. Note, the carbon atom in the phenyl ring to which –NHCOR¹ group is attached is position 1





5


Cpd #	X	R ¹		
1	5-NH	CH ₃	2-chloro	4-(benzyloxy)piperidin-1-yl
2	3-NH	CH ₃	H	4-phenylpiperazin-1-yl
3	3-NH	CH ₃	H	4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl
4	3-NH	CH ₃	H	4-(3-methylphenyl) piperazin-1-yl
5	5-NH	CH ₃	2-methyl	4-(benzyloxy)piperidin-1-yl
6	3-NH	CH ₃	2-methyl	4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl
7	3-NH	CH ₃	H	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
8	3-NH	CH ₃	H	5-methoxycarbonyl-1,2,3,4-tetrahydro-isoquinolin-2-yl
9	3-NH	CH ₃	H	4-(2,5-dimethylphenyl)piperazin-1-yl
10	3-NH	CH ₃	H	4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl) piperazin-1-yl
11	3-NH	CH ₃	H	4-(2-methylphenyl)piperazin-1-yl
12	3-NH	CH ₃	2-methyl	4-(4-chlorophenoxy)piperidin-1-yl
13	3-NH	CH ₃	H	4-(2-methoxyphenyl) piperazin-1-yl
14	3-NH	CH ₃	H	4-(2,3-dichlorophenyl)piperazin-1-yl
15	3-NH	CH ₃	H	4-(5-chloro-2-methoxyphenyl)piperazin-1-yl
16	3-NH	CH ₃	H	4-(2-chlorophenyl)piperazin-1-yl
17	3-NH	CH ₃	H	4-(3-chlorophenyl)piperazin-1-yl
18	3-NH	CH ₃	H	4-(3-methoxyphenyl)piperazin-1-yl
19	3-NH	CH ₃	H	4-(4-fluorophenyl)piperazin-1-yl
20	5-NH	CH ₃	2-methyl	4-(6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
21	3-NH	CH ₃	H	4-(3,4-dimethylphenyl)piperazin-1-yl
22	5-NH	CH ₃	2-chloro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
23	3-NH	CH ₃	H	4-(2-acetylphenyl)piperazin-1-yl


Cpd #	X	R ¹		
24	3-NH	CH ₃	H	4-phenylpiperidin-1-yl
25	3-NH	CH ₃	H	4-(2-fluorophenyl)piperazin-1-yl
26	3-NH	CH ₃	H	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
27	3-NH	CH ₃	H	4-(3-(trifluoromethyl)phenyl)piperazin-1-yl
28	3-NH	CH ₃	2-methyl	4-(4-cyanophenyl)piperidin-1-yl
29	3-NH	CH ₃	H	4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
30	3-NH	-CH ₂ OCOCH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
31	3-NH	CH ₃	H	4-(benzylsulfanyl)piperidin-1-yl
32	3-NH	CH ₃	H	4-(2,3-dimethylphenyl)piperazin-1-yl
33	3-NH	CH ₃	H	4-(2-biphenyl)l)piperazin-1-yl
34	3-NH	CH ₃	H	4-(4-methoxyphenyl)piperazin-1-yl
35	3-NH	CH ₃	H	4-(3,4-dichlorophenyl)piperazin-1-yl
36	3-NH	CH ₃	H	4-(benzyloxy)piperidin-1-yl
37	3-NH	CH ₃	H	4-(4-cyanophenyl)piperidin-1-yl
38	3-NH	CH ₃	H	4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl
39	3-NH	CH ₃	H	4-(4-chlorophenoxy)piperidin-1-yl
40	3-NH	CH ₃	H	5-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
41	3-NH	CH ₃	H	4-(4-(thiophen-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl
42	3-NH	CH ₃	H	4-((1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl
43	3-NH	CH ₃	H	4-(2-hydroxyphenyl)piperazin-1-yl
44	3-NH	CH ₃	H	4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
45	3-NH	CH ₃	H	4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl
46	3-NH	CH ₃	2-methyl	4-(benzyloxy)piperidin-1-yl
47	3-NH	2(RS)-tetrahydrofuran-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
48	3-NH	CH ₃	H	4-(2-ethoxyphenyl)piperazin-1-yl
49	3-NH	CH ₃	H	4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl
50	3-NH	CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
51	3-NH	CH ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
52	3-NH	-CH ₂ CN	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
53	3-NH	CH ₃	H	5-cyano-3,4-dihydro-(1H)-


Cpd #	X	R ¹		
				isoquinolin-2-yl
54	3-NH	CH ₃	H	4-(4-fluorophenoxy)piperidin-1-yl
55	3-NH	CH ₃	2-methyl	4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl
56	3-NH	CH ₃	H	4-(4-methoxyphenyl)piperidin-1-yl
57	3-NH	-CH ₂ cyclopropyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
58	3-NH	CH ₃	H	3,4-dihydro-(1H)-isoquinolin-2-yl
59	3-NH	CH ₃	H	5-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
60	3-NH	CH ₃	H	7-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
61	3-NH	CH ₃	H	4-((3R)-3-phenyl-1-pyrrolidinyl)-piperidin-1-yl
62	3-NH	CH ₃	H	7-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
63	3-NH	CH ₃	H	4-(5-phenyl-1,3,4-thiadiazol-2-yl)-piperidin-1-yl
64	3-NH	CH ₃	H	4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl
65	3-NH	CH ₃	H	4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl
66	3-NH	CH ₃	H	5-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
67	3-NH	CH ₃	H	4-(4-phenyl-1H-1,2,3-triazol-1-yl)-piperidin-1-yl
68	3-NH	CH ₃	H	4-(2-pyridinyloxy)piperidin-1-yl
69	3-NH	CH ₃	H	7-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
70	3-NH	CH ₃	H	6-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
71	3-NH	-CH ₂ CH ₂ CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
72	3-NH	CH ₃	2-methyl	4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl
73	3-NH	-CH ₂ NHCOCH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
74	3-NH	CH ₃	H	6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
75	3-NH	CH ₃	H	4-(3-chloro-4-fluorophenoxy)piperidin-1-yl
76	3-NH	CH ₃	H	4-((2-methylbenzyl)oxy)piperidin-1-yl
77	3-NH	3(RS)-tetrahydro-furan-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
78	3-NH	CH ₃	H	4-(4-chlorophenyl)piperazin-1-yl
79	3-NH	CH ₃	H	6-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl


Cpd #	X	R ¹		
80	3-NH	CH ₃	H	3-cyano-2-pyridinylpiperazin-1-yl
81	3-NH	CH ₃	H	4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl
82	3-NH	CH ₃	2-methyl	5-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
83	3-NH	CH ₃	H	4-(3,5-dimethylphenoxy)piperidin-1-yl
84	3-NH	CH ₃	H	4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl
85	3-NH	CH ₃	H	4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl
86	3-NH	CH ₃	H	4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl
87	3-NH	-CH ₂ CN	H	4-(benzyloxy)piperidin-1-yl
88	3-NH	CH ₃	H	(1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl
89	3-NH	-CH ₂ OCH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
90	3-NH	CH ₃	H	4-(4-cyanophenyl)piperazin-1-yl
91	3-NH	CH ₃	H	4-(3-methylphenoxy)piperidin-1-yl
92	3-NH	CH ₃	2-methyl	4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl
93	3-NH	CH ₃	H	4-((2-biphenylmethyl)(methyl)amino)piperidin-1-yl
94	3-NH	CH ₃	H	6-(2-phenoxyphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
95	3-NH	CH ₃	H	4-(4-chlorophenyl)piperidin-1-yl
96	3-NH	CH ₃	H	6-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
97	3-NH	2-(S)-CH ₂ CH(OH)CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
98	3-NH	CH ₃	H	(3RS)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
99	3-NH	CH ₃	H	6-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
100	3-NH	CH ₃	H	4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl
101	3-NH	CH ₃	H	4-(4-(2-chlorophenoxy)piperidin-1-yl
102	3-NH	CH ₃	H	4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl
103	3-NH	CH ₃	H	4-(4-bromophenyl)-4-hydroxypiperidin-1-yl
104	3-NH	CH ₃	H	2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl


Cpd #	X	R ¹		
105	3-NH	CH ₃	H	4-(3-phenylpropoxy)piperidin-1-yl
106	3-NH	CH ₃	H	6-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
107	3-NH	CH ₃	H	8-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
108	3-NH	CH ₃	H	4-(2-chloro-4-fluorophenoxy)piperidin-1-yl
109	3-NH	CH ₃	H	4-(3-chloro-4-cyanophenoxy)piperidin-1-yl
110	3-NH	CH ₃	H	4-butoxypiperidin-1-yl
111	3-NH	CH ₃	H	5-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
112	3-NH	CH ₃	H	4-(2-methylphenoxy)piperidin-1-yl
113	3-NH	CH ₃	H	4-(2,4-difluorophenoxy)piperidin-1-yl
114	3-NH	CH ₃	2-methyl	6-cyclopropyl-3,4-dihydro-(1H)-isoquinolin-2-yl
115	3-NH	CH ₃	H	4-(3,4-difluorophenoxy)piperidin-1-yl
116	3-NH	CH ₃	H	(1R)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
117	3-NH	2-(RS)-5-oxopyrrolidin-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
118	3-NH	CH ₃	H	(3S)-3-phenyl-1-pyrrolidinylpiperidin-1-yl
119	3-NH	CH ₃	H	6,8-difluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
120	3-NH	CH ₃	H	4-(4-hydroxyphenyl)piperazin-1-yl
121	3-NH	CH ₃	H	(1RS)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
122	3-NH	CH ₃	H	(1RS)-1-benzyl-3,4-dihydro-(1H)-isoquinolin-2-yl
123	3-NH	CH ₃	2-methyl	5-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl
124	3-NH	CH ₃	H	4-(4-methyl-2-pyridinyl)piperazin-1-yl
125	3-NH	CH ₃	H	7-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
126	3-NH	CH ₃	H	4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
127	3-NH	CH ₃	H	4-(2-chlorobenzyl)piperazin-1-yl
128	3-NH	CH ₃	H	6-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
129	3-NH	CH ₃	H	4-(phenylcarbonyl)piperidin-1-yl
130	3-NH	CH ₃	2-methyl	4-(phenylsulfanyl)piperidin-1-yl
131	3-NH	CH ₃	H	4-(4-fluorophenyl)piperidin-1-yl
132	3-NH	CH ₃	H	4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl
133	3-NH	CH ₃	H	(3S)-3-methyl-3,4-dihydro-(1H)-


Cpd #	X	R ¹		
				isoquinolin-2-yl
134	3-NH	CH ₃	H	4-((3-methylbenzyl)oxy)piperidin-1-yl
135	3-NH	CH ₃	H	Racemic mixture of (1S,8R)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl
136	3-NH	CH ₃	H	4-((3-cyanophenyl)amino)piperidin-1-yl
137	3-NH	CH ₃	H	8-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
138	3-NH	CH ₃	H	4-((4-chlorophenyl)amino)piperidin-1-yl
139	3-NH	CH ₃	H	4-(5-(trifluoromethyl)-2-pyridinyl)-piperazin-1-yl
140	3-NH	CH ₃	H	4-((3-chlorobenzyl)oxy)piperidin-1-yl
141	3-NH	CH ₃	H	4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl
142	3-NH	CH ₃	H	2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl
143	3-NH	CH ₃	H	4-(2,3-difluorophenoxy)piperidin-1-yl
144	3-NH	CH ₃	H	6-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl
145	3-NH	CH ₃	H	4-hydroxy-4-phenylpiperidin-1-yl
146	3-NH	CH ₃	H	6-hydroxy-3,4-dihydro-(1H)-isoquinolin-2-yl
147	3-NH	CH ₃	H	4-(4-cyano-2-(trifluoromethyl)phenoxy)-piperidin-1-yl
148	3-NH	CH ₃	H	4-(2-chloro-5-methylphenoxy)piperidin-1-yl
149	3-NH	CH ₃	H	3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
150	3-NH	CH ₃	H	4-(3-phenyl-5-isoxazolyl)piperidin-1-yl
151	3-NH	CH ₃	H	3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
152	3-NH	CH ₃	H	4-(3-propyl-5-isoxazolyl)piperidin-1-yl
153	3-NH	CH ₃	2-methyl	5-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
154	3-NH	CH ₃	H	4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl
155	3-NH	CH ₃	H	4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
156	3-NH	CH ₃	H	4-(1-naphthalenyloxy)piperidin-1-


Cpd #	X	R ¹		
				yl
157	3-NH	CH ₃	H	4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
158	3-NH	CH ₃	H	4-(4-benzyl-4-hydroxy)piperidin-1-yl
159	3-NH	CH ₃	H	4-benzylpiperidin-1-yl
160	3-NH	CH ₃	H	4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)piperidin-1-yl
161	3-NH	CH ₃	H	4-(2-methoxyphenoxy)piperidin-1-yl
162	3-NH	CH ₃	H	7-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
163	3-NH	-CH ₂ cyclopentyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
164	3-O	CH ₃	H	3,4-dihydro-(1H)-isoquinolin-2-yl
165	3-NH	CH ₃	H	4-(3-(acetylamino)phenoxy)piperidin-1-yl
166	3-NH	CH ₃	H	4-(1,2-benzisoxazol-3-yl)piperazin-1-yl
167	3-NH	CH ₃	H	4-benzyl-1,4'-bipiperidin-1'-yl
168	3-NH	CH ₃	H	4-(2-cyclohexylethoxy)piperidin-1-yl
169	3-NH	CH ₃	H	4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl
170	3-NH	CH ₃	H	4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl
171	3-NH	CH ₃	2-methyl	7-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
172	3-NH	CH ₃	H	4-((3-chloro-4-cyanophenyl)amino)piperidin-1-yl
173	3-NH	CH ₃	H	4-ethoxypiperidin-1-yl
174	4-NH	CH ₃	2-methyl	3,4-dihydro-(1H)-isoquinolin-2-yl
175	3-NH	CH ₃	H	4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
176	3-NH	CH ₃	H	5,8-dihydro-1,7-naphthyridin-7(6H)-yl
177	4-NH	CH ₃	H	4-(4-cyanophenyl)piperidin-1-yl
178	3-NH	CH ₃	H	4-methoxypiperidin-1-yl
179	3-NH	CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
180	3-NH	CH ₃	4-methoxy	4-(3-bromophenoxy)piperidin-1-yl
181	3-NH	CHF ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
182	3-NH	CH ₃	H	4-(2-(1-methylethyl)phenoxy)piperidin-1-yl
183	4-NH	CH ₃	2-methyl	4-(4-cyanophenyl)piperidin-1-yl


Cpd #	X	R ¹		
184	3-NH	CH ₃	H	4-(5-methyl-1H-benzimidazol-2-yl)-piperidin-1-yl
185	3-NH	CH ₃	2-methyl	(3RS)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
186	3-NH	CH ₃	H	4,4-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl
187	3-NH	CH ₃	H	(3RS)-3-(2-cyanophenoxy)piperidin-1-yl
188	3-NH	CH ₃	H	4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl
189	3-NH	CH ₃	H	(3RS)-3-(2-methoxy-4-methylphenoxy)-piperidin-1-yl
190	3-NH	CH ₃	H	1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl
191	3-NH	-CH ₂ morpholin-4-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
192	3-NH	(S)-CHOHCH ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
193	3-NH	CH ₃	H	4-(2-cyanophenoxy)piperidin-1-yl
194	3-NH	CH ₃	H	4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
195	3-NH	CH ₃	H	4-(4-chloro-2-(trifluoromethyl)phenoxy)piperidin-1-yl
196	3-NH	CH ₃	H	4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl
197	3-NH	CH ₃	H	4-((6-methyl-3-pyridinyl)oxy)piperidin-1-yl
198	3-NH	CH ₃	2-methyl	7-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
199	3-NH	CH ₃	H	4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl
200	3-NH	CH ₃	H	4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl
201	3-NH	CH ₃	H	(3R)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
202	3-NH	CH ₃	H	5-hydroxy-3,4-dihydro-(1H)-isoquinolin-2-yl
203	3-NH	CH ₃	H	3,3-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl
204	3-NH	CH ₃	H	4-(2-fluorophenoxy)piperidin-1-yl
205	3-NH	CH ₃	H	7-sulfamoyl-3,4-dihydro-(1H)-isoquinolin-2-yl
206	3-NH	CH ₃	H	4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
207	3-NH	CH ₃	H	6-(4-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
208	3-NH	CH ₃	H	4-(1-pyrrolidinyl)piperidin-1-yl


Cpd #	X	R ¹		
209	3-NH	CH ₃	H	racemic mixture of (4aS,8aR)-octahydro-(1H)-isoquinolin-2-yl and (4aR,8aS)-octahydro-(1H)-isoquinolin-2-yl
210	3-NH	CH ₃	H	4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
211	3-NH	CH ₃	5-methyl	4-(benzyloxy)piperidin-1-yl
212	3-NH	CH ₃	H	4-(3,4-dichlorophenoxy)piperidin-1-yl
213	3-NH	CH ₃	H	4-(cyclopropylmethoxy)piperidin-1-yl
214	3-NH	CH ₃	H	4-ethoxycarbonylpiperidin-1-yl
215	3-NH	CH ₃	H	7-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl
216	3-NH	<i>S</i> -CH(CH ₃)NH ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
217	3-NH	CH ₃	H	5-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
218	3-NH	CH ₃	H	racemic mixture of (1S,8R)-9-azatricyclo[6.2.2.0-2,7-]dodeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.2.0-2,7-]dodeca-2,4,6-trien-9-yl
219	3-NH	CH ₃	H	6-amino-3,4-dihydro-(1H)-isoquinolin-2-yl
220	3-NH	CH ₃	H	4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl
221	3-NH	CH ₃	H	(3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
222	3-NH	CH ₃	H	(1S)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl
223	3-NH	CH ₃	H	6-(3-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
224	3-NH	CH ₃	2-methyl	6-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl
225	3-NH	-CH ₂ SO ₂ CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
226	3-NH	CH ₃	H	4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
227	3-NH	cyclopropyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
228	3-NH	CH ₃	H	4-(4-propyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl
229	3-NH	CH ₃	H	4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyloxy)piperidin-1-yl
230	3-NH	CH ₃	H	4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl
231	3-NH	CH ₃	2-methyl	(1RS)-1-methyl-3,4-dihydro-(1H)-


Cpd #	X	R ¹		
				isoquinolin-2-yl
232	3-NH	CH ₃	H	8-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
233	3-NH	CH ₃	H	4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)piperidin-1-yl
234	3-NH	CH ₃	H	4-(4-bromophenoxy)piperidin-1-yl
235	3-NH	CH ₃	H	4-((4-methylphenyl)sulfanyl)piperidin-1-yl
236	3-NH	CH ₃	H	4-(3,5-dichlorophenyl)piperazin-1-yl
237	3-NH	isoxazol-5-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
238	3-NH	CH ₃	H	4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl
239	3-NH	CH ₃	H	8-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
240	3-NH	CH ₃	H	4-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)piperidin-1-yl
241	3-NH	CH ₃	H	6-(acetylamino)-3,4-dihydro-(1H)-isoquinolin-2-yl
242	3-NH	CH ₃	H	4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl
243	3-NH	CH ₃	H	4-(5,6,7,8-tetrahydro-1-naphthalenylamino)piperidin-1-yl
244	4-NH	CH ₃	H	3,4-dihydro-(1H)-isoquinolin-2-yl
245	3-NH	-CH ₂ piperidin-1-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
246	3-NH	CH ₃	H	(3RS)-3-(4-chlorophenoxy)piperidin-1-yl
247	3-NH	CH ₃	H	6-(3-fluorophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
248	3-NH	CH ₃	H	4-phenyl-4-propanoylpiperidin-1-yl
249	3-NH	CH ₃	H	(2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl
250	3-NH	CH ₃	H	4-(4-tert-butylphenoxy)piperidin-1-yl
251	3-NH	CH ₃	H	4-(tetrahydro-2-furanylmethyl)piperazin-1-yl
252	3-NH	CH ₃	H	4-(2-propylaminocarbonylphenoxy)piperidin-1-yl
253	3-NH	CH ₃	H	4-(3-pyridinyloxy)piperidin-1-yl
254	3-NH	CH ₃	4-chloro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
255	5-NH	CH ₃	3-chloro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl


Cpd #	X	R ¹		
256	3-NH	CH ₃	H	2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl
257	3-NH	-CH ₂ imidazol-4-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
258	3-NH	CH ₃	H	5-carboxy-1,2,3,4-dihydro-(1H)-isoquinolin-2-yl
259	3-NH	CH ₃	H	4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl
260	3-NH	CH ₃	H	4-((4-methoxyphenyl)amino)piperidin-1-yl
261	3-NH	CH ₃	H	(2RS)-2-phenylpyrrolidin-1-yl
262	3-NH	CH ₃	H	4-((2-(trifluoromethyl)phenyl)amino)piperidin-1-yl
263	3-NH	CH ₃	H	4-(phenylsulfonyl)piperidin-1-yl
264	3-NH	CH ₃	H	4-(2-furanylcarbonyl)piperazin-1-yl
265	3-NH	CH ₃	2-methyl	4-(4-(1-methylethyl)piperazin-1-yl
266	3-NH	CH ₃	H	4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl
267	3-NH	CH ₃	H	3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl
268	3-NH	CH ₃	H	4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)piperidin-1-yl
269	3-NH	1-methylimidazol-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
270	3-NH	CH ₃	H	4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
271	3-NH	CH ₃	H	4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl
272	3-NH	-CH ₂ N(CH ₃) ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
273	3-NH	CH ₃	2-methyl	6-tert-butyl-3,4-dihydro-(1H)-isoquinolin-2-yl
274	4-NH	CH ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
275	3-NH	CH ₃	H	4-(2-pyrimidinyl)oxy)piperidin-1-yl
276	3-NH	CH ₃	H	4-(2-biphenyl)oxy)piperidin-1-yl
277	3-NH	CH ₃	H	(3RS)-3-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl
278	3-NH	CH ₃	H	4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
279	3-NH	CH ₃	H	4-(2-chloro-6-fluorobenzyl)piperazin-1-yl
280	3-NH	CH ₃	H	4-(4-pyridinyl)oxy)piperidin-1-yl
281	3-NH	CH ₃	H	4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl


Cpd #	X	R ¹		
282	3-NH	CH ₃	H	4-(methyl(2-(trifluoromethoxy)phenyl)amino)piperidin-1-yl
283	3-NH	CH ₃	H	4-((2-(trifluoromethyl)phenyl)sulfonyl)-piperidin-1-yl
284	3-NH	-CH ₂ NH ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
285	3-NH	CH ₃	4-fluoro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
286	3-NH	CH ₃	H	4-(6-quinolinylamino)piperidin-1-yl
287	2-NH	CH ₃	H	4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
288	3-NH	CH ₂ phenyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
289	3-NH	CH ₃	H	4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl
290	3-NH	CH ₃	H	4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl
291	3-NH	CH ₃	H	1-(methylsulfonyl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl
292	3-NH	CH ₃	2-methyl	4-(benzylsulfonyl)piperidin-1-yl
293	5-NH	CH ₃	3-fluoro	4-(benzyloxy)piperidin-1-yl
294	3-NH	CH ₃	H	4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl
295	3-NH	CH ₃	H	4-(4-(2-pyrimidinyl)piperazin-1-yl)piperidin-1-yl
296	3-NH	CH ₃	H	8-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl
297	3-NH	CH ₃	H	4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl
298	3-NH	CH ₃	H	4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
299	3-NH	S-1-hydroxyethyl	H	4-(4-CN-phenyl)piperidin-1-yl
300	3-NH	CH ₃	H	4-(3-pyridinylmethyl)piperazin-1-yl
301	3-NH	CH ₃	H	4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl
302	3-NH	CH ₃	H	8-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
303	3-NH	CH ₃	H	4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl
304	3-NH	CH ₃	H	(3RS)-3-(4-cyano-2-methoxyphenoxy)-piperidin-1-yl
305	3-NH	S-2-hydroxypropyl	H	4-(4-CN-phenyl)piperidin-1-yl
306	3-NH	furan-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl


Cpd #	X	R ¹		
307	3-NH	CH ₃	H	4-aminocarbonylpiperidin-1-yl
308	3-NH	cycloheptyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
309	3-NH	CH ₃	H	4-((3-fluorophenyl)carbonyl)piperazin-1-yl
310	3-NH	CH ₃	H	5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl
311	3-NH	CH ₃	H	4-(4-(8-quinoliny)-1H-pyrazol-1-yl)-piperidin-1-yl
312	3-NH	CH ₃	H	4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl
313	3-NH	cyclopentyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
314	3-NH	CH ₃	H	4-((2-(trifluoromethyl)phenyl)carbonyl)-piperazin-1-yl
315	3-NH	CH ₃	H	4-(4-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl)
316	3-NH	-CH ₂ thiophen-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
317	3-NH	pyridin-4-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
318	3-NH	CH ₃	H	(4-(3-hydroxypropyl)piperazin-1-yl)
319	3-S	CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
320	3-NH	CH ₃	H	4-carboxypiperidin-1-yl
321	3-NH	1-CH ₃ pyrrol-2-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
322	3-NH	CH ₃	H	4-(3-methoxybenzyl)-3-oxopiperazin-1-yl
323	3-NH	CH ₃	H	4-((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl
324	3-NH	CH ₃	H	4-(4-(((dimethylamino)methyl)phenoxy))-piperidin-1-yl
325	3-NH	thiazol-5-yl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
326	3-NH	CH ₃	H	4-(tetrahydro-2 (RS)-furanylcabonyl)-piperazin-1-yl
327	3-NH	CH ₃	H	4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl
328	3-NH	-CH ₂ NHCONH ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
329	3-NH	CH ₃	6-chloro	4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl
330	3-NH	CH ₃	2-methyl	4-(2-biphenyl)-1,2,3,6-tetrahydro-


Cpd #	X	R ¹		
				piperidin-1-yl
331	3-NH	CH ₃	6-chloro	4-(4-chlorophenoxy)piperidin-1-yl
332	3-NH	CH ₃	2-methyl	4-(3-biphenyl)piperidin-1-yl
333	3-NH	CH ₃	6-chloro	4-(4-CNphenyl)piperidin-1-yl
334	3-NH	CH ₃	2-methyl	4-(2-biphenyl)piperidin-1-yl
335	3-NH	CH ₃	6-methyl	4-(2-methylphenyl)piperazin-1-yl
336	3-NH	CH ₃	2-methyl	4-(2,3-diClphenyl)piperazin-1-yl
337	3-NH	CH ₃	2-methyl	4-(4-CF ₃ -benzyloxy)piperidin-1-yl
338	3-NH	CH ₃	2-methyl	4-(4-CF ₃ O-benzyloxy)piperidin-1-yl
339	3-NH	CH ₃	6-methyl	4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl
340	3-NH	R-1-methoxyethyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
341	3-NH	CH ₃	2-methyl	4-(4-Br-benzyloxy)piperidin-1-yl
342	3-NH	CH ₃	2-methyl	4-(phenyl)piperidin-1-yl
343	3-NH	CH ₃	2-methyl	4-(benzylthio)piperidin-1-yl
344	3-NH	CH ₃	2-methyl	4-(3,4-difluoro-benzyloxy)piperidin-1-yl
345	3-NH	CH ₃	6-chloro	4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl
346	3-NH	CH ₃	2-methyl	4-(3,4-diCH ₃ phenyl)piperazin-1-yl
347	3-NH	CH ₃	2-methyl	4-(3-Clphenyl)piperazin-1-yl
348	3-NH	CH ₃	2-methyl	4-(2,3-diCH ₃ phenyl)piperazin-1-yl
349	3-NH	CH ₃	2-methyl	4-(4-Cl-3-F-phenoxy)piperidin-1-yl
350	3-NH	CH ₃	2-methyl	4-(4-Clphenyl)piperazin-1-yl
351	3-NH	CH ₃	2-methyl	4-(2-CH ₃ phenyl)piperazin-1-yl
352	3-NH	CH ₃	2-methyl	4-(2-Clphenyl)piperazin-1-yl
353	3-NH	CH ₃	2-methyl	4-(4-CF ₃ phenyl)piperazin-1-yl
354	3-NH	CH ₃	6-methyl	4-(3-OCH ₃ phenyl)piperazin-1-yl
355	3-NH	CH ₃	H	4-(2-CNphenyl)piperazin-1-yl
356	3-NH	CH ₃	2-methyl	4-(3-CF ₃ -benzyloxy)piperidin-1-yl
357	3-NH	CH ₃	2-methyl	4-(3,4-diClphenyl)piperazin-1-yl
358	3-NH	CH ₃	2-methyl	4-(4-CN-phenyl)-1,2,3,6-tetrahydro-piperidin-1-yl
359	3-NH	CH ₃	6-methyl	4-(4-Cl-phenoxy)piperidin-1-yl
360	3-NH	CH ₃	2-methyl	4-(3-CH ₃ phenyl)piperazin-1-yl
361	3-NH	CH ₃	2-methyl	4-(4-CN-2-CH ₃ -phenyl)-1,2,3,6-tetrahydro-piperidin-1-yl
362	3-NH	CH ₃	4-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
363	3-NH	CH ₃	2-methyl	4-(4-Cl-3-CH ₃ -phenoxy)piperidin-1-yl
364	3-NH	CH ₃ OCH ₂	H	4-(benzyloxy)piperidin-1-yl


Cpd #	X	R ¹		
365	3-NH	CH ₃	2-methyl	4-(2-F-phenyl)piperazin-1-yl
366	3-NH	CH ₃	H	6-(<i>tert</i> -butyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
367	3-NH	CH ₃	6-methyl	4-(2,3-diCl-phenyl)piperazin-1-yl
368	3-NH	CH ₃	2-methyl	6-OCF ₃ -3,4-dihydro-(1H)-isoquinolin-2-yl
369	3-NH	CH ₃	2-methyl	4-(3-OCH ₃ -phenyl)piperazin-1-yl
370	3-NH	CH ₃	2-methyl	4-(3-biphenyl)-1,2,3,6-tetrahydro-piperidin-1-yl
371	3-NH	CH ₃	6-methyl	4-(4-CN-phenyl)piperidin-1-yl
372	3-NH	S-tetrahydrofuran-2-yl	H	4-(benzyloxy)piperidin-1-yl
373	3-NH	CH ₃	2-methyl	4-(4-F-benzyloxy)piperidin-1-yl
374	3-NH	CH ₃	2-methyl	4-(2-ethoxy-phenyl)piperazin-1-yl
375	3-NH	CH ₃	2-methyl	4-(2,6-diF-benzyloxy)piperidin-1-yl
376	3-NH	CH ₃	2-methyl	4-(benzthiazol-2-yl)piperidin-1-yl
377	3-NH	CH ₃	2-methyl	4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl
378	3-NH	<i>S</i> -1-methoxyethyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
379	3-NH	ethyl	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
380	3-NH	CF ₃	H	4-(benzyloxy)piperidin-1-yl
381	3-NH	CH ₃	2-methyl	4-(4-phenyl-1,2,3-triazol-1-yl)piperidin-1-yl
382	3-NH	cyclopropyl-methyl	H	4-(benzyloxy)piperidin-1-yl
383	3-NH	CH ₃	6-methyl	4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl
384	3-NH	CH ₃	2-methyl	4-(5-Cl-2-OCH ₃ -phenyl)piperazin-1-yl
385	3-NH	CH ₃	2-chloro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
386	3-NH	CH ₃	2-methyl	4-(3-Cl-4-CN-phenyl)piperidin-1-yl
387	3-NH	2-OH-2-CH ₃ -propyl	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
388	3-NH	CH ₃	2-methyl	4-(3,4-diCl-phenoxy)piperidin-1-yl
389	3-NH	CH ₃	2-methyl	4-(4-methoxyphenyl)piperazin-1-yl
390	3-NH	S-tetrahydrofuran-2-yl	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
391	3-NH	CH ₃	2-methyl	4-(4-ethoxyphenyl)piperazin-1-yl
392	3-NH	CH ₃	2-methyl	4-(benzoxazol-2-yl)piperidin-1-yl
393	3-NH	<i>S</i> -2-hydroxypropyl	H	4-(benzyloxy)piperidin-1-yl
394	3-NH	CH ₃	2-methyl	4-(5-phenyl-1,3,4-oxadiazol-2-yl)-piperidin-1-yl
395	3-NH	CH ₃	H	6,8-dimethoxy-3,4-dihydro-(1H)-isoquinolin-2-yl


Cpd #	X	R ¹		
396	3-NH	CH ₃	2-methyl	5-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
397	3-NH	CH ₃	H	5-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
398	3-NH	CH ₃	H	6-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
399	3-NH	CH ₃	H	6-(2-methoxyethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
400	3-NH	CH ₃	H	6-(2,2,2-trifluoroethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
401	3-NH	CH ₃	H	6-(3,3,3-trifluoropropoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
402	3-NH	CH ₃	2-methyl	5-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
403	3-NH	CH ₃	2-methyl	6-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
404	3-NH	CH ₃	2-methyl	6-(2-methoxyethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
405	3-NH	CH ₃	2-methyl	6-(2,2,2-trifluoroethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
406	3-NH	CH ₃	2-methyl	6-(3,3,3-trifluoropropoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
407	3-NH	CH ₃	6-(2-methoxyethoxy)	4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl
408	3-NH	CH ₃	2-methyl	5,6-dimethoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
409	3-NH	-CH ₂ NHCONH ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
410	3-NH	S-CH(OH)CH ₃	H	4-(benzyloxy)piperidin-1-yl
411	3-NH	R-tetrahydrofuran-2-yl	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
412	3-NH	R-CH ₂ CH(OH)CH ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
413	3-NH	-C(OH)(CH ₃) ₂	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
414	3-NH	CF ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
415	3-NH	-CH ₂ NHCONH ₂	H	4-(benzyloxy)piperidin-1-yl
416	3-NH	R-tetrahydrofuran-2-yl	H	4-(benzyloxy)piperidin-1-yl
417	3-NH	R-pyrrolidin-2-yl	H	4-(benzyloxy)piperidin-1-yl
418	3-NH	R-CH ₂ CH(OH)CH ₃	H	4-(benzyloxy)piperidin-1-yl
419	3-NH	-CH ₂ NHCOCH ₃	H	4-(4-cyanophenyl)piperidin-1-yl
420	3-NH	R-tetrahydrofuran-2-yl	H	4-(4-cyanophenyl)piperidin-1-yl
421	3-NH	C(CH ₃) ₃	H	4-(benzyloxy)piperidin-1-yl
422	3-NH	CH(CH ₃) ₂	H	4-(benzyloxy)piperidin-1-yl
423	3-NH	S-CH(OCH ₃)CH ₃	H	4-(benzyloxy)piperidin-1-yl


Cpd #	X	R ¹		
424	3-NH	R-CH(OCH ₃)CH ₃	H	4-(benzyloxy)piperidin-1-yl
425	3-NH	CH ₂ CH ₃	H	4-(benzyloxy)piperidin-1-yl
426	3-NH	cyclopropyl	H	4-(benzyloxy)piperidin-1-yl
427	3-NH	CH(CH ₃)CH ₂ CH ₃	H	4-(benzyloxy)piperidin-1-yl
428	3-NH	CH ₂ CH(CH ₃) ₂	H	4-(benzyloxy)piperidin-1-yl
429	3-NH	CHFCH ₃	H	4-(benzyloxy)piperidin-1-yl
430	3-NH	(CH ₂) ₂ CH ₃	H	4-(benzyloxy)piperidin-1-yl
431	3-NH	CH ₂ CH(CH ₃)CF ₃	H	4-(benzyloxy)piperidin-1-yl
432	3-NH	CF ₂ CH ₃	H	4-(benzyloxy)piperidin-1-yl
433	3-NH	R-CH(OCH ₃)CH ₃	2-methyl	4-(benzyloxy)piperidin-1-yl
434	3-NH	S-CH(OCH ₃)CH ₃	2-methyl	4-(benzyloxy)piperidin-1-yl
435	3-NH	CH(CH ₃) ₂	2-methyl	4-(benzyloxy)piperidin-1-yl
436	3-NH	RS-5-oxopyrrolidin-2-yl	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
437	3-NH	cyclopropylmethyl	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
438	3-NH	-CH ₂ NHCOCH ₃	2-methyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
439	3-NH	RS-5-oxopyrrolidin-2-yl	H	4-(benzyloxy)piperidin-1-yl
440	3-NH	-CH ₂ NHCOCH ₃	H	4-(benzyloxy)piperidin-1-yl
441	3-NH	-C(OH)(CH ₃) ₂	H	4-(benzyloxy)piperidin-1-yl
442	3-NH	RS-5-oxopyrrolidin-2-yl	H	4-(4-cyanophenyl)piperidin-1-yl
443	3-NH	R-CH ₂ CH(OH)CH ₃	H	4-(4-cyanophenyl)piperidin-1-yl
444	3-NH	C(OH)(CH ₃) ₂	H	4-(4-cyanophenyl)piperidin-1-yl
445	3-NH	-CH ₂ OCH(CH ₃) ₂	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
446	3-NH	CH ₃	2-methyl	4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
447	3-NH	CH ₃	2-methyl	4-(4-chloro-3-trifluoromethylphenoxy)piperidin-1-yl
448	3-NH	CH ₃	2-methyl	4-benzyl-1,4-diazepan-1-yl
449	3-NH	CH ₃	2-methyl	4-(4-cyanophenyl)piperazin-1-yl
450	3-NH	CH ₃	2-methyl	4-(4-cyano-3-methylphenyl)piperidin-1-yl
451	3-NH	CH ₃	2-methyl	4-(2-cyanobenzyloxy)piperidin-1-yl
452	3-NH	CH ₃	2-methyl	4-(2-CF ₃ benzyloxy)piperidin-1-yl
453	3-NH	CH ₃	2-methyl	4-(1-RS-1-phenylethoxy)piperidin-1-yl
454	3-NH	CH ₃	2-methyl	4-(4-chloro-3,5-dimethylphenoxy)piperidin-1-yl
455	3-NH	CH ₃	2-methyl	4-(4-chlorobenzoyl)piperidin-1-yl
456	3-NH	CH ₃	2-methyl	4-(4-dimethylaminophenyl)-


Cpd #	X	R ¹		
				piperidin-1-yl
457	3-NH	CH ₃	2-methyl	4-(4-fluorophenoxy)piperidin-1-yl
458	3-NH	CH ₃	2-methyl	4-(2-CF ₃ phenyl)piperidin-1-yl
459	3-NH	CH ₃	2-methyl	3-phenoxy-8-azabicyclo-[3.2.1]oct-8-yl
460	3-NH	CH ₃	2-methyl	3-benzyloxy-8-azabicyclo-[3.2.1]oct-8-yl
461	3-NH	CH ₃	2-methyl	3-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl
462	3-NH	CH ₃	2-methyl	3-(4-chlorobenzyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl
463	3-NH	CH ₃	2-methyl	4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl
464	3-NH	CH ₃	2-methyl	4-(3-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
465	3-NH	CH ₃	2-methyl	4-(2-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
466	3-NH	CH ₃	2-methyl	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
467	3-NH	CH ₃	2-methyl	4-(2-OCF ₃ benzyloxy)piperidin-1-yl
468	3-NH	CH ₃	2-methyl	4-(4-butylbenzyloxy)piperidin-1-yl
469	3-NH	CH ₃	2-methyl	4-(4-isopropylbenzyloxy)-piperidin-1-yl
470	3-NH	CH ₃	2-methyl	4-(4-methylbenzyloxy)piperidin-1-yl
471	3-NH	CH ₃	2-methyl	4-(4-OCHF ₂ benzyloxy)piperidin-1-yl
472	3-NH	CH ₃	2-methyl	4-(2,4,6-trifluorobenzyloxy)-piperidin-1-yl
473	3-NH	CH ₃	2-methyl	4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl
474	3-NH	CH ₃	2-methyl	4-(2,3-difluorobenzyloxy)-piperidin-1-yl
475	3-NH	CH ₃	2-methyl	4-(2,4-difluorobenzyloxy)-piperidin-1-yl
476	3-NH	CH ₃	2-methyl	4-(2,3,4-trifluorobenzyloxy)-piperidin-1-yl
477	3-NH	CH ₃	2-methyl	4-(4-cyanobenzyloxy)-piperidin-1-yl
478	3-NH	CH ₃	2-methyl	2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
479	3-NH	CH ₃	2-methyl	4-(4-cyano-2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
480	3-NH	CH ₃	2-methyl	4-(3-chloro-4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
481	3-NH	CH ₃	2-methyl	4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl
482	3-NH	CH ₃	2-methyl	4-(4-chlorobenzyl)piperidin-1-yl


Cpd #	X	R ¹		
483	3-NH	CH ₃	2-methyl	4-(3-OCF ₃ phenoxy)piperidin-1-yl
484	3-NH	CH ₃	2-methyl	3-(4-fluorophenoxy)azetidin-1-yl
485	3-NH	CH ₃	2-methyl	3-(phenoxy)azetidin-1-yl
486	3-NH	CH ₃	2-methyl	4-(3-fluoro-4-OCF ₃ benzyloxy)-piperidin-1-yl
487	3-NH	CH ₃	2-methyl	3-fluoro-4-(phenyl)piperidin-1-yl
488	3-NH	CH ₃	2-methyl	3-(4-fluoro-2-methylphenoxy)-pyrrolidin-1-yl
489	3-NH	CH ₃	2-methyl	3-(3,4-dichlorophenoxy)azetidin-1-yl
490	3-NH	CH ₃	2-methyl	3-(2-chlorophenoxy)pyrrolidin-1-yl
491	3-NH	CH ₃	2-methyl	4-(2-biphenyloxy)piperidin-1-yl
492	3-NH	CH ₃	2-methyl	4-(3-cyanophenoxy)piperidin-1-yl
493	3-NH	CH ₃	2-methyl	4-(4-cyanophenoxy)piperidin-1-yl
494	3-NH	CH ₃	2-methyl	4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl
495	3-NH	CH ₃	2-methyl	4-methyl-4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl
496	3-NH	CH ₃	2-methyl	3-(4-trifluoromethoxybenzyloxy)azetidin-1-yl
497	3-NH	CH ₃	2-methyl	4-[4-(2-methoxyethoxy)benzyloxy]piperidin-1-yl
498	3-NH	CH ₃	2-methyl	6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl
499	3-NH	CH ₃	2-methyl	2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl
500	3-NH	CH ₃	2-methyl	(3R,4R)-3-fluoro-4-phenylpiperidin-1-yl
501	3-NH	CH ₃	2-methyl	(3S,4S)-3-fluoro-4-phenylpiperidin-1-yl
502	3-NH	CH ₃	2-methyl	3-(2,5-difluorophenoxy)azetidin-1-yl
503	3-NH	CH ₃	2-methyl	2-phenyl-2,8-diazaspiro[4.5]dec-8-yl
504	3-NH	CH ₃	2-methyl	4-(3-chloro-4-fluorophenoxy)-piperidin-1-yl
505	3-NH	CH ₃	2-methyl	8-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
506	3-NH	CH ₃	2-methyl	4-(4-tert-butylbenzyloxy)-piperidin-1-yl
507	3-NH	CH ₃	2-methyl	5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl
508	3-NH	CH ₃	2-methyl	4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl
509	3-NH	CH ₃	2-methyl	3-(3-fluoro-4-trifluoromethoxyphenoxy)-azetidin-1-yl
510	3-NH	CH ₃	2-methyl	3-(2-chloro-4-trifluoromethylphenoxy)-azetidin-1-yl
511	3-NH	CH ₃	2-methyl	3-(4-chloro-3-fluorophenoxy)-


Cpd #	X	R ¹		
				azetidin-1-yl
512	3-NH	CH ₃	2-methyl	3-(4-chlorophenoxy)-azetidin-1-yl
513	3-NH	CH ₃	2-methyl	3-(3-fluoro-4-methylphenoxy)-azetidin-1-yl
514	3-NH	CH ₃	2-methyl	3-(3-trifluoromethoxyphenoxy)-azetidin-1-yl
515	3-NH	CH ₃	2-methyl	3-(3-chlorophenoxy)-azetidin-1-yl
516	3-NH	CH ₃	2-methyl	3-(2-trifluoromethylphenoxy)-azetidin-1-yl
517	3-NH	CH ₃	2-methyl	3-(4-methylphenoxy)-azetidin-1-yl
518	3-NH	CH ₃	2-methyl	3-(4-fluoro-3-methylphenoxy)-azetidin-1-yl
519	3-NH	CH ₃	2-methyl	3-(4-fluoro-3-chlorophenoxy)-azetidin-1-yl
520	3-NH	CH ₃	2-methyl	3-(3-fluorophenoxy)-azetidin-1-yl
521	3-NH	CH ₃	2-methyl	3-(3,4-difluorophenoxy)-azetidin-1-yl
522	3-NH	CH ₃	2-methyl	3-(2,3-difluorophenoxy)-azetidin-1-yl
523	3-NH	CH ₃	2-methyl	3-(2,4-difluorophenoxy)-azetidin-1-yl
524	3-NH	CH ₃	2-methyl	3-(2,6-difluorophenoxy)-azetidin-1-yl
525	3-NH	CH ₃	2-methyl	3-(4-cyanophenoxy)-azetidin-1-yl
526	3-NH	CH ₃	6-fluoro	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
527	3-NH	CH ₃	2-fluoro	4-(4-(trifluoromethyl)-benzyloxy)piperidin-1-yl
528	3-NH	CH ₃	2-methyl	4-benzyl-4-fluoropiperidin-1-yl
529	3-NH	CH ₃	2-methyl	4-(2-methylsulfonylphenoxy)-piperidin-1-yl
530	3-NH	CH ₃	2-methyl	4-(4-fluorophenyl)piperazin-1-yl
531	3-NH	CH ₃	2-methyl	4-(2-methoxyphenyl)piperazin-1-yl
532	3-NH	CH ₃	2-methyl	4-(4-hydroxyphenyl)piperazin-1-yl
533	3-NH	CH ₃	2-methyl	4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl
534	3-NH	CH ₃	6-chloro	4-(3-methoxyphenyl)piperazin-1-yl
535	3-NH	CH ₃	6-chloro	4-(2-methylphenyl)piperazin-1-yl
536	3-NH	CH ₃	6-chloro	4-(3-methylphenyl)piperazin-1-yl
537	3-NH	CH ₃	6-chloro	4-(3-chlorophenyl)piperazin-1-yl
538	3-NH	CH ₃	6-chloro	4-(2,3-dichlorophenyl)piperazin-1-yl
539	3-NH	CH ₃	2-methyl	6-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
540	3-NH	CH ₃	6-chloro	6-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl
541	3-NH	CH ₃	6-chloro	6-trifluoromethoxy-3,4-dihydro-(1H)-isoquinolin-2-yl
542	3-NH	CH ₃	6-methyl	4-(4-OCF ₃ phenyl)piperazin-1-yl


Cpd #	X	R ¹		
543	3-NH	CH ₃	6-chloro	(1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl
544	3-NH	CH ₃	6-chloro	4-(2-fluorophenyl)piperazin-1-yl
545	3-NH	CH ₃	6-chloro	4-(3,4-dimethylphenyl)piperazin-1-yl
546	3-NH	CH ₃	6-chloro	4-(2,3-dimethylphenyl)piperazin-1-yl
547	3-NH	CH ₃	2-fluoro	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
548	3-NH	CH ₃	2-methyl	4-(phenyl)piperazin-1-yl
549	3-NH	CH ₃	2-methyl	4-(2-cyanophenyl)piperazin-1-yl
550	3-NH	CH ₃	2-methyl	4-(2,5-dimethylphenyl)piperazin-1-yl
551	3-NH	CH ₃	2-methyl	4-(4-OCF ₃ phenyl)piperazin-1-yl
552	3-NH	CH ₃	6-chloro	4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl
553	3-NH	CH ₃	2-methyl	4-(4-bromobenzyl)piperazin-1-yl
554	3-NH	CH ₃	2-methyl	4-(3,4-dichlorobenzyl)piperazin-1-yl
555	3-NH	CH ₃	2-methyl	4-(2-phenylethyl)piperazin-1-yl
556	3-NH	CH ₃	2-methyl	4-(3,4-difluorophenyl)piperazin-1-yl
557	3-NH	CH ₃	2-methyl	4-(3-OCF ₃ benzyl)piperazin-1-yl
558	3-NH	CH ₃	2-methyl	4-(4-chlorobenzyl)piperazin-1-yl
559	3-NH	CH ₃	2-methyl	4-(4-tert-butylbenzyl)piperazin-1-yl
560	3-NH	CH ₃	2-methyl	4-(2,4-difluorophenyl)piperazin-1-yl
561	3-NH	CH ₃	2-methyl	4-(3-chloro-4-fluorophenyl)-piperazin-1-yl
562	3-NH	CH ₃	2-methyl	4-(4-chloro-3-fluorophenyl)-piperazin-1-yl
563	3-NH	CH ₃	2-methyl	4-(4-chloro-3-methylphenyl)-piperazin-1-yl
564	3-NH	CH ₃	2-methyl	4-(3-fluoro-4-methylphenyl)-piperazin-1-yl
565	3-NH	CH ₃	2-methyl	4-(4-fluoro-3-methylphenyl)-piperazin-1-yl
566	3-NH	CH ₃	2-methyl	6-ethyl-3,4-dihydro-(1H)-isoquinolin-2-yl
567	3-NH	CH ₃	2-methyl	4-(4-chloro-2-fluorophenyl)-piperazin-1-yl
568	3-NH	CH ₃	2-methyl	4-(3,4-difluorobenzyl)piperazin-1-yl
569	3-NH	CH ₃	2-methyl	4-(3,4-dimethylbenzyl)piperazin-1-yl
570	3-NH	CH ₃	2-methyl	6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
571	3-NH	CH ₃	2-fluoro	4-(3,4-dimethylphenyl)piperazin-1-


Cpd #	X	R ¹		
				yl
572	3-NH	CH ₃	2-methyl	4-(3-fluoro-5-CF ₃ benzyloxy)-piperidin-1-yl
573	3-NH	CH ₃	2-methyl	4-(4-fluoro-3-CF ₃ benzyloxy)-piperidin-1-yl
574	3-NH	CH ₃	2-methyl	4-(2-fluoro-4-CF ₃ benzyloxy)-piperidin-1-yl
575	3-NH	CH ₃	2-methyl	4-(2-fluoro-3-CF ₃ benzyloxy)-piperidin-1-yl
576	3-NH	CH ₃	2-methyl	4-(3-fluoro-4-CF ₃ benzyloxy)-piperidin-1-yl
577	3-NH	CH ₃	2-methyl	4-(2-fluoro-5-CF ₃ benzyloxy)-piperidin-1-yl
578	3-NH	CH ₃	2-methyl	4-(3-CF ₃ benzyl)piperazin-1-yl
579	3-NH	CH ₃	2-methyl	4-(3-CF ₃ phenyl)piperazin-1-yl
580	3-NH	CH ₃	2-methyl	4-(4-fluorobenzyl)piperazin-1-yl
581	3-NH	CH ₃	2-methyl	4-(7-chloroquinolin-4-yl)-piperazin-1-yl
582	3-NH	CH ₃	2-methyl	4-(3-chlorobenzyl)piperazin-1-yl
583	3-NH	CH ₃	2-methyl	4-(2-fluorobenzyl)piperazin-1-yl
584	3-NH	CH ₃	2-methyl	4-(3-fluorobenzyl)piperazin-1-yl
585	3-NH	CH ₃	2-methyl	4-(2-chlorobenzyl)piperazin-1-yl
586	3-NH	CH ₃	2-methyl	6-acetyl-3,4-dihydro-1H-isoquinolin-2-yl
587	3-NH	CH ₃	H	6-(1-fluoroethyl)-3,4-dihydro-1H-isoquinolin-2-yl
588	3-NH	CH ₃	2-methyl	4-(2,4,5-trifluorobenzyloxy)-piperidin-1-yl
589	3-NH	CH ₃	H	6-(ethyl)-3,4-dihydro-1H-isoquinolin-2-yl
590	3-NH	CH ₃	2-methyl	4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl
591	3-NH	CH ₃	2-methyl	4-(2,4-diCF ₃ benzyloxy)piperidin-1-yl
592	3-NH	CH ₃	2-methyl	4-(2-fluorobenzyloxy)piperidin-1-yl
503	3-NH	CH ₃	2-methyl	4-(3-fluorobenzyloxy)piperidin-1-yl
594	3-NH	CH ₃	2-methyl	4-(4-CF ₃ benzyl)piperazin-1-yl
595	3-NH	CH ₃	2-methyl	4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl
596	3-NH	CH ₃	2-methyl	4-(3,5-difluorobenzyloxy)piperidin-1-yl
597	3-NH	CH ₃	2-methyl	4-(2,5-diCF ₃ benzyloxy)piperidin-1-yl
598	3-NH	CH ₃	2-methyl	4-(4-(2-methoxyethoxy)phenyl)-piperazin-1-yl
599	3-NH	CH ₃	H	6-(acetyl)-3,4-dihydro-1H-isoquinolin-2-yl


Cpd #	X	R ¹		
600	3-NH	CH ₃	2-fluoro	4-(4-OCF ₃ phenyl)piperazin-1-yl
601	3-NH	CH ₃	2-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
602	3-NH	CH ₃	2-methyl	4-(2-OCF ₃ benzyl)piperazin-1-yl
603	3-NH	CH ₃	2-methyl	4-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)piperidin-1-yl
604	3-NH	CH ₃	2-methyl	4-(3-chloro-4-cyanophenoxy)-piperidin-1-yl
605	3-NH	CH ₃	2-methyl	4-(2,3-dichlorophenoxy)piperidin-1-yl
606	3-NH	CH ₃	2-methyl	4-(2-chlorophenoxy)piperidin-1-yl
607	3-NH	CH ₃	2-methyl	4-(3-chloro-4-methylphenoxy)-piperidin-1-yl
608	3-NH	CH ₃	2-methyl	4-(4-chloro-3-OCF ₃ phenoxy)-piperidin-1-yl
609	3-NH	CH ₃	2-methyl	4-(3-chlorophenoxy)piperidin-1-yl
610	3-NH	CH ₃	2-methyl	4-(3,4-dimethylphenoxy)-piperidin-1-yl
611	3-NH	CH ₃	2-methyl	4-(2,3-dimethylphenoxy)-piperidin-1-yl
612	3-NH	CH ₃	2-methyl	4-(3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl
613	3-NH	CH ₃	2-methyl	6-(1,3-thiazol-5-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl
614	3-NH	CH ₃	2-methyl	4-(2-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
615	3-NH	CH ₃	2-methyl	6-(2-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
616	3-NH	CH ₃	2-methyl	4-(3-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
617	3-NH	CH ₃	2-methyl	4-(3-thiophenylmethoxy)-piperidin-1-yl
618	3-NH	CH ₃	2-methyl	6-(3-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl
619	3-NH	CH ₃	2-methyl	6-(1,3-thiazol-4-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl
620	3-NH	CH ₃	2-methyl	3-(4-CF ₃ phenoxy)pyrrolidin-1-yl
621	3-NH	CH ₃	2-methyl	1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl
622	3-NH	CH ₃	2-methyl	4-(2-fluoro-5-OCF ₃ phenoxy)-piperidin-1-yl
623	3-NH	CH ₃	2-methyl	4-(3,4-difluorophenoxy)-piperidin-


Cpd #	X	R ¹		
				1-yl
624	3-NH	CH ₃	2-methyl	4-(2,4-difluorophenoxy)-piperidin-1-yl
625	3-NH	CH ₃	2-methyl	4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl
626	3-NH	CH ₃	2-methyl	4-(3-fluoro-4-OCF ₃ phenoxy)-piperidin-1-yl
627	3-NH	CH ₃	2-methyl	4-(4-fluoro-3-OCF ₃ phenoxy)-piperidin-1-yl
628	3-NH	CH ₃	2-methyl	4-(2,6-difluorophenoxy)-piperidin-1-yl
629	3-NH	CH ₃	2-methyl	4-(2,3-difluorophenoxy)-piperidin-1-yl
630	3-NH	CH ₃	2-methyl	4-(3-fluorophenoxy)-piperidin-1-yl
631	3-NH	CH ₃	2-methyl	4-(2-fluorophenoxy)-piperidin-1-yl
632	3-NH	CH ₃	2-methyl	4-(2,4,6-trifluorophenoxy)-piperidin-1-yl
633	3-NH	CH ₃	2-methyl	4-(2,3,6-trifluorophenoxy)-piperidin-1-yl
634	3-NH	CH ₃	2-methyl	1-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl
635	3-NH	CH ₃	2-methyl	4-(4-CF ₃ phenoxy)-piperidin-1-yl
636	3-NH	CH ₃	2-methyl	4-(4-OCF ₃ phenoxy)-piperidin-1-yl
637	3-NH	CH ₃	2-methyl	4-(2,3,4-trifluorophenoxy)-piperidin-1-yl
638	3-NH	CH ₃	2-methyl	4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
639	3-NH	CH ₃	2-methyl	((3R)-3-(benzyloxy)pyrrolidin-1-yl
640	3-NH	CH ₃	2-methyl	4-(3-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
641	3-NH	CH ₃	2-methyl	4-(4-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
642	3-NH	CH ₃	2-methyl	4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
643	3-NH	CH ₃	2-methyl	4-(3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
644	3-NH	CH ₃	2-methyl	4-phenylethynylpiperidin-1-yl
645	3-NH	CH ₃	2-methyl	4-(2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
646	3-NH	CH ₃	2-methyl	4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl
647	3-NH	CH ₃	2-methyl	4-(4-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
648	3-NH	CH ₃	2-methyl	4-(2-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
649	3-NH	CH ₃	2-methyl	4-(4-cyano-2,3-difluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl

Cpd #	X	R ¹		
650	3-NH	CH ₃	2-methyl	4-(3,5-difluorophenoxy)-piperidin-1-yl
651	3-NH	CH ₃	2-methyl	4-(3-chlorophenyl)-piperidin-1-yl
652	3-NH	CH ₃	6-chloro	4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
653	3-NH	CH ₃	6-chloro	4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl
654	3-NH	CH ₃	2-methyl	4-(2-OCF ₃ phenyl)piperazin-1-yl
655	3-NH	CH ₃	2-methyl	4-(3-OCF ₃ phenyl)piperazin-1-yl
656	3-NH	CH ₃	H	4-(2-OCF ₃ phenyl)piperazin-1-yl
657	3-NH	CH ₃	H	4-(phenoxy)-piperidin-1-yl
658	3-NH	CH ₃	2-methyl	4-(phenoxy)-piperidin-1-yl
659	3-NH	CH ₃	6-chloro	4-(phenoxy)-piperidin-1-yl
660	3-NH	CH ₃	2-methyl	4-(2-SCH ₃ phenyl)piperazin-1-yl
601	3-NH	CH ₃	2-methyl	4-(2-CF ₃ phenyl)piperazin-1-yl
662	3-NH	CH ₃	2-methyl	4-(pyridin-2-yl)piperazin-1-yl
663	3-NH	CH ₃	2-methyl	4-(6-methylpyridin-2-yl)piperazin-1-yl
664	3-NH	CH ₃	2-methyl	4-(5-chloropyridin-2-yl)piperazin-1-yl
665	3-NH	CH ₃	2-methyl	(1S,4S)-5-(4-chlorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl
666	3-NH	CH ₃	2-methyl	5-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl
667	3-NH	CH ₃	2-methyl	8-OCF ₃ -3,4-dihydro-(1H)-isoquinolin-2-yl
668	3-NH	CH ₃	2-methyl	(1S,4S)-5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl
669	3-NH	CH ₃	6-methyl	4-(3-methylphenyl)piperazin-1-yl
670	3-NH	CH ₃	6-methyl	4-(3-chlorophenyl)piperazin-1-yl
671	3-NH	CH ₃	6-methyl	6-OCF ₃ -3,4-dihydro-(1H)-isoquinolin-2-yl
672	3-NH	CH ₃	2-methyl	(3R,4R)-3-fluoro-4-(4-trifluoromethoxyphenyl)piperidin-1-yl
673	3-NH	CH ₃	2-methyl	(3S,4S)-3-fluoro-4-(4-trifluoromethoxyphenyl)-piperidin-1-yl
674	3-NH	CH ₃	2-methyl	4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl
675	3-NH	CH ₃	2-methyl	4-(5,6-dimethylpyridin-2-yl)-piperazin-1-yl
676	3-NH	CH ₃	2-methyl	4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl
677	3-NH	CH ₃	2-methyl	4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl
678	3-NH	CH ₃	2-methyl	4-(4-chlorophenoxymethyl)-piperidin-1-yl
679	3-NH	CH ₃	2-methyl	4-(phenoxymethyl)piperidin-1-yl

Cpd #	X	R ¹		
680	3-NH	CH ₃	2-methyl	6-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl
681	3-NH	CH ₃	2-methyl	4-(3-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
682	3-NH	CH ₃	2-methyl	4-(4-CF ₃ phenyl)piperidin-1-yl
683	3-NH	CH ₃	2-methyl	4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
684	3-NH	CH ₃	2-methyl	4-(3,4-dimethylphenyl)piperidin-1-yl
685	3-NH	CH ₃	2-methyl	4-(3,4-dimethylphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
686	3-NH	CH ₃	2-methyl	4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
687	3-NH	CH ₃	2-methyl	4-(4-(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl
688	3-NH	CH ₃	2-methyl	4-(4-chloro-2-OCF ₃ phenoxy)-piperidin-1-yl
689	3-NH	CH ₃	2-methyl	4-(2-methylphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
690	3-NH	CH ₃	2-methyl	4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl
691	3-NH	cyclopropyl	6-fluoro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
692	3-NH	C(CH ₃) ₃	2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
693	3-NH	CH(CH ₃) ₂	2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
694	3-NH	CH ₃	6-chloro	4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
695	3-NH	CH ₃	6-methoxy	4-(benzyloxy)piperidin-1-yl
696	3-NH	CH ₃	6-phenyl	4-(benzyloxy)piperidin-1-yl
697	3-NH	CH ₃	H	4-(2-biphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
698	3-NH	CH ₃	6-chloro	4-(2-biphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
699	3-NH	CH ₃	6-methyl	4-(2-biphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
700	3-NH	CH ₃	6-chloro	4-(2-biphenyl)-piperidin-1-yl
701	3-NH	CH ₃	6-methyl	4-(2-biphenyl)-piperidin-1-yl
702	3-NH	CH ₃	6-methyl	4-(2-trifluoromethoxyphenyl)-3,6-dihydro-(2H)-pyridin-1-yl
703	3-NH	CH ₃	6-methyl	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
704	3-NH	CH ₃	6-methyl	4-(2-OCF ₃ benzyloxy)piperidin-1-yl
705	3-NH	CH ₃	6-methyl	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
706	3-NH	CH ₃	6-methyl	4-(4-CF ₃ benzyloxy)piperidin-1-yl
707	3-NH	CH ₃	6-fluoro	4-(4-CF ₃ benzyloxy)piperidin-1-yl

Cpd #	X	R ¹		
708	3-NH	CH ₃	2-fluoro	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
709	3-NH	CH ₃	2-fluoro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
710	3-NH	CH ₃	2-fluoro	4-(4-(2-methoxyethoxy)-benzyloxy)piperidin-1-yl
711	3-NH	CH ₃	6-fluoro	4-(4-(2-methoxyethoxy)-benzyloxy)piperidin-1-yl
712	3-NH	CH ₃	5-fluoro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
713	3-NH	CH ₃	6-methyl	4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
714	3-NH	CH ₃	2-methyl	3-(4-trifluoromethylphenoxy)-azetidin-1-yl
715	3-NH	CH ₃	2-methyl	2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
716	3-NH	CH ₃	6-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
717	3-NH	CH ₃	6-fluoro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
718	3-NH	CH ₃	6-cyclopropyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
719	3-NH	CH ₃	6-chloro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
720	3-NH	CH ₃	2-chloro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
721	3-NH	CH ₃	6-trifluoromethoxy	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
722	3-NH	CH ₃	6-phenyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
723	3-NH	CH ₃	2-methyl	4-(4-chlorophenyl)piperidin-1-yl
724	3-NH	CH ₃	2-methyl	4-(2-fluorophenyl)piperidin-1-yl
725	3-NH	CH ₃	2-methyl	4-(3-fluorophenyl)piperidin-1-yl
726	3-NH	CH ₃	2-methyl	4-(4-fluorophenyl)piperidin-1-yl
727	3-NH	CH ₃	2-methyl	4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
728	3-NH	CH ₃	2-methyl	4-(4-cyano-3-fluorophenyl)-piperidin-1-yl
729	3-NH	CH ₃	2-methyl	4-(4-cyano-3-CF ₃ phenyl)-piperidin-1-yl
730	3-NH	CH ₃	2-methyl	4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl
731	3-NH	CH ₃	2-methyl	4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl
732	3-NH	CH ₃	2-methyl	4-(2,4,5-trifluorophenoxy)-piperidin-1-yl
733	3-NH	CH ₃	6-methyl	4-(3-CF ₃ benzyloxy)piperidin-1-yl
734	3-NH	CH ₃	6-chloro	4-(3-CF ₃ benzyloxy)piperidin-1-yl
735	3-NH	CH ₃	2-fluoro	4-(3-CF ₃ benzyloxy)piperidin-1-yl

Cpd #	X	R ¹		
736	3-NH	CH ₃	6-fluoro	4-(3-CF ₃ benzyloxy)piperidin-1-yl
737	3-NH	CH ₃	2-methyl	4-(4-cyano-3-CF ₃ phenyl)-piperidin-1-yl
738	3-NH	CH ₃	6-chloro	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
739	3-NH	CH ₃	6-fluoro	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
740	3-NH	CH ₃	2-fluoro	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
741	3-NH	CH ₃	2-chloro	4-(benzyloxy)piperidin-1-yl
742	3-NH	CH ₃	2-fluoro	4-(benzyloxy)piperidin-1-yl
743	3-NH	CH ₃	6-cyclopropyl	4-(benzyloxy)piperidin-1-yl
744	3-NH	CH ₃	6-OCF ₃	4-(benzyloxy)piperidin-1-yl
745	3-NH	CH ₃	6-methyl	4-(3,4-dimethylphenyl)piperazin-1-yl
746	3-NH	CH ₃	2-fluoro	4-(4-OCF ₃ benzyl)piperazin-1-yl
747	3-NH	CH ₃	6-chloro	4-(4-OCF ₃ benzyl)piperazin-1-yl
748	3-NH	CH ₃	6-OCF ₃	4-(4-OCF ₃ benzyl)piperazin-1-yl
749	3-NH	CH ₃	6-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
750	3-NH	CH ₃	6-fluoro	4-(4-OCF ₃ benzyl)piperazin-1-yl
751	3-NH	CH ₃	6-methyl	4-(4-fluorophenyl)piperazin-1-yl
752	3-NH	CH ₃	6-fluoro	4-(4-fluorophenyl)piperazin-1-yl
753	3-NH	CH ₃	6-fluoro	4-(4-cyanophenyl)piperidin-1-yl
754	3-NH	CH ₃	6-fluoro	4-(4-phenyl-1H-pyrazol-1-yl)-piperidin-1-yl
755	3-NH	CH ₃	6-fluoro	4-(4-chloro-3-fluorophenoxy)-piperidin-1-yl
756	3-NH	CH ₃	6-fluoro	4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl
757	3-NH	CH ₃	2-fluoro	4-(4-fluorophenyl)piperazin-1-yl
758	3-NH	CH ₃	2-fluoro	4-(4-cyanophenyl)piperidin-1-yl
759	3-NH	CH ₃	2-fluoro	4-(4-phenyl-1H-pyrazol-1-yl)-piperidin-1-yl
760	3-NH	CH ₃	2-fluoro	4-(4-chloro-3-fluorophenoxy)-piperidin-1-yl
761	3-NH	CH ₃	2-fluoro	4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl
762	3-NH	CH ₃	2-fluoro	4-(4-chloro-3-methylphenoxy)-piperidin-1-yl
763	3-NH	CH ₃	6-fluoro	4-(phenoxy)-piperidin-1-yl
764	3-NH	CH ₃	2-fluoro	4-(phenoxy)-piperidin-1-yl
765	3-NH	CH ₃	6-fluoro	4-(pyridin-2-yloxy)-piperidin-1-yl
766	3-NH	CH ₃	2-fluoro	4-(pyridin-2-yloxy)-piperidin-1-yl
767	3-NH	CH ₃	2-fluoro	4-(phenyl)-piperidin-1-yl
768	3-NH	CH ₃	2-fluoro	4-phenyl-3,6-dihydro-(2H)-pyridin-1-yl
769	3-NH	CH ₃	6-fluoro	4-(phenyl)-piperidin-1-yl
770	3-NH	CH ₃	6-fluoro	4-phenyl-3,6-dihydro-(2H)-pyridin-1-yl

Cpd #	X	R ¹		
771	3-NH	CH ₃	H	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
772	3-NH	CH ₃	6-methyl	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
773	3-NH	CH ₃	6-chloro	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
774	3-NH	CH ₃	2-fluoro	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
775	3-NH	CH ₃	6-methyl	3-(4-fluorophenoxy)-azetidin-1-yl
776	3-NH	CH ₃	6-chloro	3-(4-fluorophenoxy)-azetidin-1-yl
777	3-NH	CH ₃	2-fluoro	3-(4-fluorophenoxy)-azetidin-1-yl
778	3-NH	CH ₃	6-fluoro	3-(4-fluorophenoxy)-azetidin-1-yl
779	3-NH	CH ₃	2-bromo	4-(benzyloxy)-piperidin-1-yl
780	3-NH	cyclopropyl	2-methyl	4-(4-CF ₃ benzyloxy)piperidin-1-yl
781	3-NH	CH ₃	6-fluoro	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
782	3-NH	cyclopropyl	2-methyl	4-(3,4-difluorobenzyloxy)-piperidin-1-yl
783	3-NH	cyclopropyl	2-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
784	3-NH	CH ₃	2-bromo	4-(benzyloxy)-piperidin-1-yl
785	3-NH	cyclopropyl	2-fluoro	4-(4-OCF ₃ benzyloxy)-piperidin-1-yl
786	3-NH	CH ₃	6-tert-butyl	4-(benzyloxy)-piperidin-1-yl
787	3-NH	CH ₃	6-fluoro	4-(6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
788	3-NH	CH ₃	6-fluoro	4-(benzyloxy)-piperidin-1-yl
789	3-NH	cyclopropyl	2-methyl	4-(benzyloxy)-piperidin-1-yl
790	3-NH	CH ₂ CH ₃	6-methyl	4-(benzyloxy)-piperidin-1-yl
791	3-NH	CH ₂ CH ₃	2-methyl	4-(benzyloxy)-piperidin-1-yl
792	3-NH	CH ₂ CH ₃	2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
793	3-NH	cyclopropyl	2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
794	3-NH	CH ₃	2-cyano	4-(benzyloxy)-piperidin-1-yl
795	3-NH	CH ₃	2-methyl	2-(4-(trifluoromethoxy)-phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
796	3-NH	CH ₃	2-methyl	2-(4-chlorophenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
797	3-NH	CH ₃	2-methyl	2-(4-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
798	3-NH	CH ₃	2-methyl	2-(3-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
799	3-NH	CH ₃	2-methyl	2-(4-(2-methoxyethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
800	3-NH	CH ₃	2-methyl	2-(1-piperidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl
801	3-NH	CH ₃	2-methyl	2-(1-pyrrolidinyl)-7,8-dihydro-1,6-





Cpd #	X	R ¹		
				naphthyridin-6(5H)-yl

Table II shows representative compounds of Formula (I) where A is phenyl, R³ is hydrogen, Y is -O- and other groups are as listed below. Note, the carbon atom in the phenyl ring to which -NHCOR¹ group is attached is position 1



10

Cpd #	X	R ¹		
1	3-NH	CH ₃	2,6-dichloro	4-benzyloxypiperidin-1-yl
2	3-NH	CH ₃	4-fluoro-2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
3	3-NH	CH ₃	2,6-dimethyl	3-(4-chlorophenoxy)azetidin-1-yl
4	3-NH	CH ₃	2,6-dimethyl	3-(4-fluorophenoxy)azetidin-1-yl
5	3-NH	CH ₃	2,6-dimethyl	3-(4-chloro-3-fluorophenoxy)-azetidin-1-yl
6	3-NH	CH ₃	2,6-dimethyl	6-(3,3,3-trifluoropropoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
7	3-NH	CH ₃	2,6-dimethyl	4-(4-chlorophenyl)piperidin-1-yl
8	3-NH	CH ₃	2,6-dimethyl	4-(3-OCF ₃ phenyl)piperazin-1-yl
9	3-NH	CH ₃	2,6-dimethyl	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
10	3-NH	CH ₃	2,6-dimethyl	4-(3-chloro-4-fluorophenyl)-piperiazin-1-yl
11	3-NH	CH ₃	2,6-dimethyl	4-(3,4-difluorobenzyloxy)piperidin-1-yl
12	3-NH	CH ₃	2,6-dimethyl	4-(4-CF ₃ benzyloxy)piperidin-1-yl
13	3-NH	CH ₃	2,6-dimethyl	4-(4-OCF ₃ phenyl)-piperiazin-1-yl
14	3-NH	CH ₃	2,6-dimethyl	4-(4-OCF ₃ phenoxy)piperidin-1-yl
15	3-NH	CH ₃	2,6-dimethyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
16	3-NH	CH ₃	2,6-dichloro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
17	3-NH	CH ₃	6-fluoro-2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
18	3-NH	CH ₃	2,6-difluoro	4-(4-OCF ₃ benzyl)piperazin-1-yl






Cpd #	X	R ¹		
19	3-NH	CH ₃	2-chloro-6-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
20	3-NH	CH ₃	2,6-dimethyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
21	3-NH	CH ₃	6-chloro-2-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
22	3-NH	CH ₃	2-chloro-6-methyl	4-(benzyloxy)piperidin-1-yl
23	3-NH	CH ₃	6-chloro-2-methyl	4-(benzyloxy)piperidin-1-yl
24	3-NH	CH ₃	2-chloro-6-methyl	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
25	3-NH	CH ₃	2,6-difluoro	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
26	3-NH	CH ₃	5-fluoro-2-methyl	4-(4-chlorophenoxy)piperidin-1-yl
27	3-NH	CH ₃	5-fluoro-2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
28	3-NH	CH ₃	2,6-dimethyl	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
29	3-NH	CH ₃	6-fluoro-2-methyl	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
30	3-NH	CH ₃	6-chloro-2-methyl	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
31	3-NH	CH ₃	2,6-dichloro	6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl


Table III shows representative compounds of Formula (I) where A is phenyl, R⁴ is hydrogen, Y is -O- and other groups are as listed below. Note, the carbon atom in the phenyl ring to which -NHCOR¹ group is attached is position 1




Cpd #	X	R ¹	R ³		
1	3-NH	CH ₃	Cl	H	3,4-dihydro-(1H)-isoquinolin-2-yl
2	3-NH	CH ₃	CH ₃	2-CH ₃	4-(benzyloxy)piperidin-1-yl
3	3-NH	CH ₃	CH ₃	2-CH ₃	4-(4-

					OCF ₃ benzyloxy)piperidin-1-yl
4	3-NH	CH ₃	CH ₃	2-CH ₃	4-(4-chloro-3-fluorophenoxy)-piperidin-1-yl
5	3-NH	CH ₃	CH ₃	2-CH ₃	4-(4-CF ₃ benzyloxy)piperidin-1-yl
6	3-NH	CH ₃	CH ₃	2-CH ₃	4-(4-OCF ₃ benzyl)piperazin-1-yl
7	3-NH	CH ₃	CH ₃	2-CH ₃	4-(3,4-difluorobenzyloxy)piperidin-1-yl
8	3-NH	CH ₃	CH ₂ CH ₃	H	4-(benzyloxy)piperidin-1-yl
9	3-NH	CH ₃	CH ₃	H	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl

Table IV shows representative compounds of Formula (I) where A is phenyl, R³ and R⁴ are hydrogen, Y is -O- and other groups are as listed below. Note, the carbon atom in the phenyl ring to which -NHCOR¹ group is attached is position 1



5

Cpd #	X	R ¹		-NR ⁵ R ⁶
1	3-NH	CH ₃	H	(1R)-1-phenylethylamino
2	3-NH	CH ₃	H	4-(4-chlorophenoxy)phenylamino
3	3-NH	CH ₃	2-CH ₃	3-(4-(trifluoromethoxy)phenoxy)-propylamino
4	3-NH	CH ₃	2-CH ₃	2-(benzyloxy)ethylamino
5	3-NH	CH ₃	2-CH ₃	3-(benzyloxy)propylamino
6	3-NH	CH ₃	2-CH ₃	3-phenylpropylamino
7	3-NH	CH ₃	2-CH ₃	3-phenoxypropylamino
8	3-NH	CH ₃	2-CH ₃	2-phenoxyethylamino
9	3-NH	CH ₃	2-CH ₃	trans-4-(4-chlorophenoxy)-cyclohexylamino
10	3-NH	CH ₃	2-CH ₃	3-(2-fluorophenyl)propylamino
11	3-NH	CH ₃	2-CH ₃	3-(2-(benzyloxy)phenyl)propylamino
12	3-NH	CH ₃	2-CH ₃	3-(4-(1-methylethyl)phenyl)-propylamino
13	3-NH	CH ₃	2-CH ₃	3-(4-fluorophenyl)propylamino




Cpd #	X	R ¹		-NR ⁵ R ⁶
14	3-NH	CH ₃	2-CH ₃	3-(3-fluorophenyl)propylamino
15	3-NH	CH ₃	2-CH ₃	(cis, trans-4-(benzyloxy)-cyclohexyl)amino
16	3-NH	CH ₃	2-CH ₃	3-(2-chlorophenyl)propylamino
17	3-NH	CH ₃	2-CH ₃	3-(3-methylphenyl)propylamino
18	3-NH	CH ₃	2-CH ₃	3-(4-chlorophenyl)propylamino
19	3-NH	CH ₃	2-CH ₃	3-(4-(1-methylethyl)phenyl)-propylamino
20	3-NH	CH ₃	2-CH ₃	3-(2-(benzyloxy)phenyl)propylamino
21	3-NH	CH ₃	2-CH ₃	3-(2-fluorophenyl)propylamino
22	3-NH	CH ₃	2-CH ₃	3-(4-methylphenyl)propylamino
23	3-NH	CH ₃	2-CH ₃	2-(3-methylphenoxy)ethylamino
24	3-NH	CH ₃	2-CH ₃	3-(3-fluorophenyl)propylamino
25	3-NH	CH ₃	2-CH ₃	2-(2-methylphenoxy)ethylamino
26	3-NH	CH ₃	2-CH ₃	(1S)-1-methyl-3-phenylpropylamino
27	3-NH	CH ₃	2-CH ₃	2-(3-fluorophenoxy)ethylamino
28	3-NH	CH ₃	2-CH ₃	2-(3-methoxyphenoxy)-ethylamino
29	3-NH	CH ₃	2-CH ₃	2-(4-methylphenoxy)ethylamino
30	3-NH	CH ₃	2-CH ₃	3-(4-fluorophenyl)propylamino
31	3-NH	CH ₃	2-CH ₃	2-(2-fluorophenoxy)ethylamino
32	3-NH	CH ₃	2-CH ₃	3-(2-fluorophenoxy)propylamino
33	3-NH	CH ₃	2-CH ₃	3-(4-fluorophenoxy)propylamino
34	3-NH	CH ₃	2-CH ₃	2-(2-methoxyphenoxy)-ethylamino
35	3-NH	CH ₃	2-CH ₃	2-(4-methoxyphenoxy)-ethylamino
36	3-NH	CH ₃	2-CH ₃	1-(4-trifluoromethoxybenzyl)piperidin-4-yl)methylamino
37	3-NH	CH ₃	2-CH ₃	2-(4-fluorophenoxy)ethylamino
38	3-NH	CH ₃	2-CH ₃	(cis, trans-4-(benzyloxy)cyclohexyl)amino
39	3-NH	CH ₃	2-CH ₃	1-(4-trifluoromethoxybenzyl)piperidin-4-yl)methylamino
40	3-NH	CH ₃	2-CH ₃	2-(1-isoquinoliny)ethylamino
41	3-NH	CH ₃	2-CH ₃	(8-quinoliny)methylamino
42	3-NH	CH ₃	2-CH ₃	(3R)-1-benzylpiperidin-3-ylamino
43	3-NH	CH ₃	2-CH ₃	(3S)-1-benzylpiperidin-3-ylamino
44	3-NH	CH ₃	2-CH ₃	1-(4-trifluoromethoxybenzyl)piperidin-4-ylamino
45	3-NH	CH ₃	2-CH ₃	1-(4-trifluoromethoxybenzyl)piperidin-4-yl)methylamino

Table V shows representative compounds of Formula (I) where A is phenyl, X is –NH–, R³ is hydrogen, and other groups are as listed below. Note, the carbon atom in the phenyl ring to which –NHCYR¹ group is attached is position 1



5

Cpd #	Y	R ¹		-NR ⁵ R ⁶
1	-O-	CH ₃	2,6-dichloro	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
2	-O-	CH ₃	2,6-dimethyl	6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl
3	N-CN	CH ₃	H	4-(benzyloxy)piperidin-1-yl
4	-O-	CH ₃	2,6-dimethyl	4-(benzyloxy)piperidin-1-yl
5	-O-	CH ₃	2,6-dimethyl	4-(4-Cl-phenoxy)piperidin-1-yl
6	-O-	CH ₃	2,6-dichloro	4-(4-Cl-phenoxy)piperidin-1-yl
7	N-CN	CH ₃	H	4-(4-OCF ₃ benzyloxy)-piperidin-1-yl
8	N-CN	CH ₃	H	4-(4-OCF ₃ benzyl)piperazin-1-yl
9	N-CN	CH ₃	H	4-(4-chlorophenoxy)piperidin-1-yl
10	N-CN	CH ₃	H	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
11	N-CN	CH ₃	6-methyl	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
12	N-CN	CH ₃	6-methyl	4-(4-chlorophenoxy)piperidin-1-yl
13	N-CN	CH ₃	6-methyl	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
14	N-CN	CH ₃	2-methyl	4-(3,4-difluorobenzyloxy)piperidin-1-yl
15	N-CN	CH ₃	2-methyl	4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl
16	N-CN	CH ₃	2-methyl	4-(4-OCF ₃ benzyloxy)piperidin-1-yl
17	N-CN	CH ₃	6-methyl	4-(3,4-difluorobenzyloxy)piperidin-1-yl
18	N-CN	CH ₃	2-methyl	4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl
19	N-CN	CH ₃	H	4-(3,4-difluorobenzyloxy)piperidin-1-yl
20	N-CN	CH ₃	2-methyl	4-(4-OCF ₃ phenyl)piperazin-1-yl
21	N-CN	CH ₃	2-methyl	4-(3,4-dimethylphenyl)piperazin-1-yl
22	N-CN	CH ₃	2-methyl	5-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl
23	N-CN	CH ₃	2-methyl	4-(4-chlorophenyl)piperidin-1-yl

Cpd #	Y	R ¹		-NR ⁵ R ⁶
24	N-CN	CH ₃	2-methyl	4-(2-phenyl-1,3-thiazol-4-yl)-piperidin-1-yl
25	N-CN	CH ₃	2-methyl	4-(4-OCF ₃ phenyl)piperazin-1-yl
26	N-CN	CH ₃	2-methyl	4-(2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl
27	N-CN	CH ₃	2-methyl	4-(3-OCF ₃ benzyloxy)piperidin-1-yl
28	N-CN	CH ₃	2-methyl	4-(3-chloro-4-fluorophenyl)-piperazin-1-yl
29	N-CN	CH ₃	2-methyl	4-(4-OCF ₃ benzyl)piperazin-1-yl
30	N-CN	CH ₃	2-methyl	3-(4-fluorophenoxy)azetidin-1-yl
31	N-CN	CH ₃	2-fluoro	3-(4-chlorophenoxy)piperidin-1-yl
32	N-CN	CH ₃	2-fluoro	3-(4-fluorophenoxy)azetidin-1-yl
33	N-CN	CH ₃	2-CH ₃	3-(4-trifluoromethoxy-phenoxy)-propylamino
34	O	CH ₃	2,6-dimethyl	3-(4-trifluoromethoxyphenoxy)-propylamino

VI. An representative example of a compound of Formula (I) where Y is -S- is N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-ethanethioamide; and where A is pyridyl is N-(6-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-pyridinyl)acetamide.

Names of cpds in Tables I-V above are as follow:

N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)-acetamide;

10 N-(3-((4-(4-phenyl-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(2-methyl-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

20 N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

methyl 2-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydro-5-isoquinolinecarboxylate;

N-(3-((4-(4-(2,5-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-((4-(4-(2-(2H-1,2,3-triazol-2-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

10 N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

15 N-(3-((4-(4-(5-chloro-2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(2-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

20 N-(3-((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(5-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(5-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(3-((4-(4-(2-acetylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-2-methyl-phenyl)acetamide;

N-(3-(((4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

10 2-(((3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)amino)-2-oxoethyl acetate;

N-(3-(((4-(4-(benzylsulfanyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-biphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(4-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3,4-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(3-(((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(2-hydroxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

5 (2RS)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-2-furancarboxamide;

N-(3-(((4-(4-(2-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

10 N-(3-(((4-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyanoacetamide;

N-(3-(((4-(5-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(2-methyl-3-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

25 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopropylacetamide;

N-(3-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(7-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((3RS)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(5-phenyl-1,3,4-thiadiazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

10 N-(3-(((4-(5-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-pyridinyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(7-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)butanamide;

20 N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-2-acetyl-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)glycinamide;

25 N-(3-(((4-(6-(1-hydroxy-1-methylethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((2-methylbenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 (3RS)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-3-furancarboxamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-cyano-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(3,5-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromo-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxyacetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-((2-biphenylmethyl)(methyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-(2-phenoxyphenyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

(3S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxybutanamide;

N-(3-((4-((3RS)-3-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide

5 N-(3-((4-(6-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(2-(1-methylethoxy)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-((4-(4-(2-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-bromophenyl)-4-hydroxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-((4-(2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(3-phenylpropoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

20 N-(3-((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(8-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(2-chloro-4-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

25 N-(3-((4-(4-(3-chloro-4-cyanophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-butoxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-((4-(4-(2-methylphenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(2,4-difluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-cyclopropyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-difluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

5 N-(3-(((4-((1R)-1-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-(RS)-5-oxoprolinamide;

10 N-(3-(((4-(4-((3S)-3-phenyl-1-pyrrolidiny)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6,8-difluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-hydroxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

15 N-(3-(((4-((1RS)-1-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((1RS)-1-benzyl-3,4-dihydro-2(1H)-isoquinoliny)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(5-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-methyl-2-pyridiny)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(7-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

25 N-(3-(((4-(4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-chlorobenzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(6-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(phenylcarbonyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(2-methyl-3-(((4-(4-(phenylsulfany)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-fluorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-((4-((3S)-3-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-((3-methylbenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 Racemic mixture of N-(3-((4-((1S,8R)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-((4-((1R,8S)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3-cyanophenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(8-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(3-((4-(4-((4-chlorophenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(5-(trifluoromethyl)-2-pyridiny)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-((4-(4-((3-chlorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(2-fluorophenyl)-4-hydroxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-((4-(4-(2,3-difluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-((4-(6-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-((4-(4-hydroxy-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(6-hydroxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-cyano-2-(trifluoromethyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(2-chloro-5-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(3-phenyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(3-propyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((3R)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1-naphthalenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

20 N-(3-(((4-(4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyl-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(benzyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-methoxyphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(7-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopentylacetamide;

N-(3-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)oxy)phenyl)acetamide;

N-(3-(((4-(4-(3-(acetylamino)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1,2-benzisoxazol-3-yl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-benzyl-1,4'-bipiperidin-1'-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-cyclohexylethoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(1,3-benzodioxol-5-yl)methyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-methoxy-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((3-chloro-4-cyanophenyl)amino)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-ethoxy-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(4-(((4-(3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(4-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-methoxy-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-bromophenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-4-methoxyphenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-difluoroacetamide;

N-(3-(((4-(4-(2-(1-methylethyl)phenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(4-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-(((4-(4-(5-methyl-1H-benzimidazol-2-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(2-methyl-3-((4-((3RS)-3-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide

N-(3-((4-(4,4-dimethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-((4-((3RS)-3-(2-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-((4-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-((4-((3RS)-3-(2-methoxy-4-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(4-morpholinyl)acetamide;

15 (2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-hydroxypropanamide;

N-(3-((4-(4-(2-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

20 N-(3-((4-(4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-((4-(4-((6-methyl-3-pyridinyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(2,4-bis(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-((3R)-3-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5-hydroxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3,3-dimethyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(2-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(7-sulfamoyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-(4-methylphenyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(1-pyrrolidiny)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 Racemic mixture of N-(3-(((4-((4aS,8aR)-octahydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide and N-(3-(((4-((4aR,8aS)-octahydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide

N-(3-(((4-(4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-5-methylphenyl)-acetamide;

N-(3-(((4-(4-(3,4-dichlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(cyclopropylmethoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 ethyl 1-(4-(((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxylate;

N-(3-(((4-(7-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-L-alaninamide;

30 N-(3-(((4-(5-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

Racemic mixture of N-(3-(((4-((1S,8R)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-(((4-((1R,8S)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-amino-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-((3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-((1S)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(6-(3-methylphenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(methylsulfonyl)acetamide;

15 N-(3-(((4-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-cyclopropanecarboxamide;

20 N-(3-(((4-(4-(4-propyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-((1RS)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(8-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-((4-methylphenyl)sulfanyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(3,5-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-isoxazolecarboxamide;

5 N-(3-(((4-(4-(4-(1H-pyrrol-1-yl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(8-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

10 N-(3-(((4-(4-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-(acetylamino)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(5,6,7,8-tetrahydro-1-naphthalenylamino)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(4-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1-piperidiny)acetamide;

20 N-(3-(((4-(((3RS)-3-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-(3-fluorophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

25 N-(3-(((4-(4-phenyl-4-propanoyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(((2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-tert-butylphenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(4-(tetrahydro-2-furanylmethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

2-((1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinyloxy)-N-propylbenzamide;

N-(3-(((4-(4-(3-pyridinyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-4-chlorophenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-5-chlorophenyl)acetamide;

5 N-(3-(((4-(2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1H-imidazol-4-yl)acetamide;

10 2-(4-(((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydro-5-isoquinolinecarboxylic acid;

N-(3-(((4-(4-(6-(1-pyrrolidiny)-3-pyridaziny)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((4-methoxyphenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-((2RS)-2-phenyl-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2-(trifluoromethyl)phenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(phenylsulfonyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(2-furanylcarbonyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(1-methylethyl)-1-piperaziny)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide

N-(3-(((4-(4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-1-methyl-1H-imidazole-2-carboxamide;

N-(3-(((4-(4-(3-(2-pyraziny)-1,2,4-oxadiazol-5-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-((2-methyl-1,3-thiazol-4-yl)methyl)-1-piperaziny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-N-2-,N-2-dimethylglycinamide;

N-(3-(((4-(6-tert-butyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(4-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-pyrimidinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 N-(3-(((4-(4-(2-biphenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-((3RS)-3-(5-methyl-1H-benzimidazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(2-chloro-6-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(methyl(2-(trifluoromethoxy)phenyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2-(trifluoromethyl)phenyl)sulfonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)glycinamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-4-fluorophenyl)acetamide;

N-(3-(((4-(4-(6-quinolinylamino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-phenylacetamide;

N-(3-(((4-(4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((1-benzyl-4-piperidinyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(1-(methylsulfonyl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzylsulfonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methyl-phenyl)acetamide;

10 N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-5-fluorophenyl)-acetamide;

N-(3-(((4-(4-((2-(1H-indol-3-yl)ethyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(2-pyrimidinyl)-1-piperazinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(8-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(4-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide

N-(3-(((4-(4-(3-pyridinylmethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

25 N-(3-(((4-(4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(8-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-((3RS)-3-(4-cyano-2-methoxyphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-3-furancarboxamide;

1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxamide;
N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)-phenyl)cycloheptanecarboxamide;

N-(3-((4-(4-((3-fluorophenyl)carbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(8-quinoliny)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

2-(4-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1-piperazinyl)-N-cyclopropyl-3-pyridinecarboxamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)cyclopentanecarboxamide;

N-(3-((4-(4-((2-(trifluoromethyl)phenyl)carbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-(2-thiophenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-4-pyridinecarboxamide;

N-(3-((4-(4-(3-hydroxypropyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)sulfany)-phenyl)acetamide;

1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxylic acid;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-1-methyl-1H-pyrrole-2-carboxamide;

N-(3-((4-(4-(3-methoxybenzyl)-3-oxo-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-((3S)-3-(hydroxymethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-((dimethylamino)methyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-1,3-thiazole-5-carboxamide;

N-(3-(((4-(4-(tetrahydro-2-(RS)-furanylcarbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-N-2-carbamoylglycinamide;

10 N-(2-chloro-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(2-chloro-5-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(2-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(2-methyl-5-(((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-(((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

(2R)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)-2-methoxypropanamide;

N-(3-(((4-(4-(((4-bromobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzylsulfanyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(4-(2-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(5-((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-(4-(3,4-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-cyano-2-methylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-4-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxyacetamide;

N-(3-((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-((4-(6-tert-butyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(5-((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-tetrahydro-2-furancarboxamide;

N-(3-((4-(4-((4-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(2-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((2,6-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(1,3-benzothiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

(2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)-2-methoxypropanamide;

5 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)propanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2,2-trifluoroacetamide;

10 N-(2-methyl-3-((4-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopropylacetamide;

N-(2-methyl-5-((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-((4-(4-(5-chloro-2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

20 N-(3-((4-(4-(3-chloro-4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxy-3-methylbutanamide;

N-(3-((4-(4-(3,4-dichlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(4-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

(2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)tetrahydro-2-furancarboxamide;

30 N-(3-((4-(4-(4-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(1,3-benzoxazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

(3S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N-(2-methyl-3-((4-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyanoacetamide;

5 (2S)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxypropanamide;

(3S)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

10 N-(3-((4-(6,8-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(5-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-((4-(6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(2-methyl-3-((4-(6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(2-methoxyethoxy)-5-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5,6-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N~2~-carbamoylglycinamide;

5 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxypropanamide;

(2R)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)tetrahydro-2-furancarboxamide;

10 (3R)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxybutanamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-hydroxy-2-methylpropanamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2,2,2-trifluoroacetamide;

15 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N~2~-carbamoylglycinamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)tetrahydro-2-furancarboxamide;

20 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-D-prolinamide;

(3R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N~2~-acetyl-N-(3-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)glycinamide;

25 (2R)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)tetrahydro-2-furancarboxamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-dimethylpropanamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methylpropanamide;

(2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxypropanamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxypropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

5 Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-R-2-methylbutanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-2-methylbutanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-methylbutanamide;

10 Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-R-2-fluoropropanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-2-fluoropropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)butanamide;

15 Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-R-4,4,4-trifluoro-3-methylbutanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-4,4,4-trifluoro-3-methylbutanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-difluoropropanamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methoxypropanamide;

20 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methoxypropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methylpropanamide;

25 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-5-oxo-D-prolinamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-cyclopropylacetamide;

N~2~-acetyl-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)glycinamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-L-prolinamide;

N~2~-acetyl-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)glycinamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxy-2-methylpropanamide;

Racemic mixture of N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-L-prolinamide and N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-D-prolinamide;

(3R)-N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxy-2-methylpropanamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1-methylethoxy)acetamide;

N-(2-methyl-3-(((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(benzyl-1,4-diazepan-1-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3-methylphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-cyanobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

Racemic mixture of N-(2-methyl-3-(((4-(4-((1R)-1-phenylethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(2-methyl-3-(((4-(4-((1S)-1-phenylethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3,5-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((4-chlorophenyl)carbonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-(dimethylamino)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-3-(((4-(3-phenoxy-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(benzyloxy)-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(3-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chlorobenzyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-phenyl-1,3-thiazol-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((4-butylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-((4-(1-methylethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((4-methylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-((4-(difluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2,4,6-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2,3,6-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2,3-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-((2,3,4-trifluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((4-cyanobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyano-2-fluorophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chlorobenzyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-phenoxy-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-((3-fluoro-4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-(((4-((3R,4R)-3-fluoro-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-(((4-((3S,4S)-3-fluoro-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 Racemic mixture of N-(3-(((4-((3R)-3-(4-fluoro-2-methylphenoxy)-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-(((4-((3S)-3-(4-fluoro-2-methylphenoxy)-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3,4-dichlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-((4-((3R)-3-(2-chlorophenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-((4-((3S)-3-(2-chlorophenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-biphenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-methyl-4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(3-((4-(trifluoromethoxy)benzyl)oxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3R,4R)-3-fluoro-4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3S,4S)-3-fluoro-4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(3-(2,5-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(2-phenyl-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(8-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((4-tert-butylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-((4-chloro-1-naphthalenyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chloro-3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(3-(3-fluoro-4-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(3-(trifluoromethoxy)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(3-(3-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(2-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(3-(4-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(3-(4-fluoro-3-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3-chloro-4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-(((4-(3-(3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3,4-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,3-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,4-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,6-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(3-(4-cyanophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-(((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

10 N-(2-fluoro-3-(((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-benzyl-4-fluoro-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(methylsulfonyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-methoxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(4-hydroxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-methoxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-5-(((4-(4-(2-methylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-methylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-chloro-5-(((4-(4-(3-chlorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(2,3-dichlorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(6-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-5-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

10 N-(2-chloro-5-((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-fluoro-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-phenyl-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(2-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,5-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-5-((4-(4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-(((4-(4-(3,4-dichlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(2-phenylethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3,4-difluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-(4-tert-butylbenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,4-difluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-(3-fluoro-4-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-fluoro-3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-((4-(4-(6-ethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-difluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(3,4-dimethylbenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(6-(1-hydroxy-1-methylethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(3-((4-(4-((3-fluoro-5-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((4-fluoro-3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-5-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(7-chloro-4-quinolinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(2-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-(((4-(6-acetyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-(((4-(6-(R)-(1-fluoroethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-(((4-(6-(S)-(1-fluoroethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-((2,4,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(6-ethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((3,4,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-((2-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((3-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((2,3,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,5-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-((2,5-bis(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-((4-(4-(6-acetyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-((4-(4-(2-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,3-dichlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-(3-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(2,3-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dihydro-2(1H)-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(6-(1,3-thiazol-5-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(2-thiophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(6-(2-thiophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(3-thiophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-thiophenylmethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(6-(3-thiophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-(6-(1,3-thiazol-4-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

Racemic mixture of N-2-methyl-3-(((4-((3R)-3-(4-(trifluoromethyl)phenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-2-methyl-3-(((4-((3S)-3-(4-(trifluoromethyl)phenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluoro-5-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-fluoro-4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(4-fluoro-3-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,6-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,3-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(3-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(2,4,6-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2,3,6-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(1-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-(4-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-(2,3,4-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-((3R)-3-(benzyloxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-(3-(3-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(phenylethynyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(2-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(4-cyano-2,3-difluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,5-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-chloro-5-(((4-(4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-chloro-5-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(methylsulfanyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(6-methyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(5-chloro-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(4-chlorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(5-(1,3-thiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(8-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-5-(((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-((4-(2,2,2-trifluoroethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(5,6-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-(4,5-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-((4-chlorophenoxy)methyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(phenoxymethyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(6-(1,3-thiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(4-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3,4-dimethylphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dimethylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(4-(2,2,2-trifluoroethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-(4-chloro-2-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide

N-(2-methyl-3-(((4-(4-(2-methylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-(4-chlorophenyl)ethyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-fluoro-5-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

2,2-dimethyl-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

5 2-methyl-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(2-chloro-5-((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methoxyphenyl)acetamide;

N-(4-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-biphenyl)acetamide;

N-(3-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(5-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(5-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(5-((4-(4-(2-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(5-((4-(4-(2-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-((4-(4-(2-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-5-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-5-((4-(4-((2-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(5-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-fluoro-3-(((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-5-fluorophenyl)acetamide;

N-(5-(((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(4-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-fluoro-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-cyclopropyl-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(trifluoromethoxy)-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(4-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-biphenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(4-cyano-3-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3,5-difluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(2,4,5-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-chloro-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(4-(4-(4-cyano-2-(trifluoromethyl)phenyl)piperidin-1-yl)-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-fluoro-5-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(5-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-cyclopropylphenyl)acetamide

5 N-(5-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-(trifluoromethoxy)phenyl)acetamide;

N-(5-(((4-(4-(3,4-dimethylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-fluoro-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(trifluoromethoxy)-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(5-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-fluoro-5-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

25 N-(2-fluoro-5-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

30 N-(2-fluoro-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(2-fluoro-3-((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

5 N-(2-fluoro-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

10 N-(2-fluoro-5-((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-(2-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-fluoro-3-((4-(4-(2-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-fluoro-5-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-bromophenyl)acetamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

10 N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)cyclopropanecarboxamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

15 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-bromophenyl)acetamide;

N-(2-fluoro-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

20 N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-tert-butylphenyl)acetamide;

N-(2-fluoro-5-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)cyclopropanecarboxamide;

N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)propanamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)propanamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-cyanophenyl)acetamide;

N-(2-methyl-3-(((4-(2-(4-(trifluoromethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(2-(4-chlorophenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(2-(4-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-(((4-(2-(3-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(2-(4-(2-methoxyethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(2-(1-piperidiny)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(2-(1-pyrrolidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dichlorophenyl)acetamide;

20 N-(4-fluoro-2-methyl-3-(((4-(4-(((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(4-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-(((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

25 N-(3-(((4-(3-(4-chloro-3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-(4-chlorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-(((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

5 N-(2,6-dimethyl-3-(((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dichloro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(6-fluoro-2-methyl-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-difluoro-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-chloro-6-methyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(6-chloro-2-methyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chloro-6-methylphenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-6-chloro-2-methylphenyl)acetamide;

30 N-(2-chloro-6-methyl-3-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-difluoro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-5-fluoro-2-methylphenyl)acetamide;

N-(5-fluoro-2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(6-fluoro-2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(6-chloro-2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2,6-dichloro-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-chloro-6-(3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(2-methyl-3-((4-methyl-6-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-((4-methyl-6-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-methyl-6-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-6-ethyl-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-6-methyl-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(((1R)-1-phenylethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-((4-(4-chlorophenoxy)phenyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(benzyloxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(benzyloxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-((4-((3-phenylpropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-((3-phenoxypropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-((4-((2-phenoxyethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((trans-4-(4-chlorophenoxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-((3-(2-(benzyloxy)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(1-methylethyl)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-((3-(4-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(3-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((cis, trans-4-(benzyloxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-((3-(2-chlorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(3-methylphenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-((3-(4-chlorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(1-methylethyl)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3-(2-(benzyloxy)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-methylphenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-3-((4-((2-(3-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3-(3-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-((4-((2-(2-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(((1S)-1-methyl-3-phenylpropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(3-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-((2-(3-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((2-(4-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-((3-(4-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((2-(2-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-((3-(4-fluorophenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((2-(2-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-((2-(4-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((1-(4-(trifluoromethoxy)benzyl)-4-piperidinyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(4-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((cis, trans-4-(benzyloxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-((4-((2-(1-isoquinoliny)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((8-quinoliny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-((4-(((3R)-1-benzyl-3-piperidiny)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(((3S)-1-benzyl-3-piperidiny)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2,6-dimethyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-((4-((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2,6-dichlorophenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

(1Z)-N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-N'-cyanoethanimidamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

30 N-(2,6-dichloro-3-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

(1E)-N'-cyano-N-(3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

5 (1E)-N'-cyano-N-(2-methyl-5-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N-(5-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

10 (1E)-N'-cyano-N-(5-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

15 (1E)-N'-cyano-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

20 (1E)-N'-cyano-N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

25 (1E)-N'-cyano-N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

30 (1E)-N-(3-((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(2-phenyl-1,3-thiazol-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

5 (1E)-N-(3-((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

10 (1E)-N'-cyano-N-(3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-fluoro-3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

15 (1E)-N'-cyano-N-(2-methyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide; and

N-(6-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-pyridinyl)acetamide.

20 Embodiments

(1) Within compounds of Formula (II):

I. In one embodiment, X is -NH-.

II. In another embodiment, X is -O-.

25 III. In yet another embodiment, X is -S- or -SO₂-.

IV. In yet another embodiment, X is -NH- and Y is O or S. Within this embodiment IV, in one group of compounds Y is O. Within this embodiment IV, in another group of compounds Y is S.

V. In yet another embodiment, Y is N-CN.

30

(2) Within compounds of Formula (II'):

I'. In one embodiment, X is -NH-.

II'. In another embodiment, X is -O-.

35 III'. In yet another embodiment, X is -S- or -SO₂-.

IV'. In yet another embodiment, X is -NH- and Y is O or S. Within this embodiment IV', in one group of compounds Y is O. Within this embodiment IV', in another group of compounds Y is S.

5 (3) Within compounds of Formula (II) and (II'):

VI. In one embodiment, A is aryl. Within this embodiment, in one group of compounds A is phenyl. Within this embodiment, in another group of compounds A is phenyl, R⁴ is hydrogen, and R² is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, or .
10 Within this embodiment, in yet another group of compounds A is phenyl, R⁴ is hydrogen, and R² is hydrogen, methyl, ethyl, propyl fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl. Within this embodiment, in one group of compounds A is phenyl, R⁴ is hydrogen, and R² is hydrogen, methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably hydrogen, methyl, chloro or fluoro and the
15 R¹CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is phenyl, R⁴ is hydrogen, and R² is hydrogen, methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably hydrogen, methyl, chloro or fluoro, and the R² group is ortho to R¹CONH- and the R¹CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is
20 phenyl and R⁴ and R² are hydrogen. Within this embodiment, in another group of compounds A is phenyl, R⁴ is hydrogen, and R² is alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxyl, preferably alkyl or halo, preferably methyl, chloro, or fluoro and the R² group is ortho to R¹CONH- and the R¹CONH- group is meta to the triazinylamino (X is NH) group.

Within this embodiment, in another group of compounds A is phenyl and R⁴ and R² are
25 independently alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this embodiment, in yet another group of compounds A is phenyl, R⁴ and R² are independently methyl, ethyl, propyl, fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxy. Within this embodiment, in one group of compounds A is phenyl, R⁴ and R² are
30 independently methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably methyl, chloro or fluoro and the R¹CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is phenyl, R⁴ and R² are independently methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably methyl, chloro or fluoro, and the R² and R⁴ groups are ortho to R¹CONH- and the R¹CONH- group is meta to the triazinylamino (X is NH) group.

VII. In another embodiment, A is heteroaryl. Within this embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, R⁴ is hydrogen, and R² is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this
 5 embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, R⁴ and R² are independently alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy.

VIII. In yet another embodiment,  is heteroaryl substituted as defined in the
 10 Summary.


IX. In yet another embodiment,  is heterocyclyl substituted as defined in
 the Summary. Within this embodiment, in one group of compounds  is monocyclic
 heterocyclyl substituted as defined in the Summary. Within this embodiment, in another


group of compounds  is pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl substituted
 15 as defined in the Summary, preferably substituted at the 4-position with phenyl or monocyclic heteroaryl wherein phenyl and monocyclic heteroaryl ring is optionally substituted with R^d and R^e as defined in the Summary. Within this embodiment, in another group of compounds
 is unsaturated monocyclic heterocyclyl, preferably 1,2,5,6-tetrahydropiperidin-1-yl,
 substituted as defined in the Summary, preferably substituted at the 4-position with phenyl or
 20 monocyclic heteroaryl wherein phenyl and monocyclic heteroaryl ring is optionally substituted with R^d and R^e as defined in the Summary .


(i) Within this embodiment IX, in another group of compounds  is
 piperidin-1-yl or piperazin-1-yl, each ring substituted at the 3- or 4-position, preferably 4-
 position, with R^b where R^b is phenyl optionally substituted with R^d, R^e, or R^f as defined in the
 25 Summary, and R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy,


or alkoxy. Preferably,  is piperidin-1-yl substituted at the 4-position with phenyl


which is optionally substituted with R^d and R^e where R^d and R^e are independently cyano, alkyl, haloalkyl, halo, alkoxy, hydroxyl, phenyl, or heteroaralkyl, preferably phenyl.

Preferably,  is piperazin-1-yl substituted at the 4-position with phenyl which is optionally substituted with R^d and R^e where R^d and R^e are independently cyano, alkyl,


haloalkyl, halo, alkoxy, hydroxyl, phenyl, or heteroaralkyl. Preferably,  is piperazin-1-yl substituted at the 4-position with phenyl wherein the phenyl ring is optionally substituted at the 3-position with R^d where R^d is alkyl, haloalkyl, halo, or alkoxy and optionally substituted at the 2-position with R^e where R^e is alkyl, halo, alkoxy, haloalkyl or phenyl.


Preferably,  is piperazin-1-yl substituted at the 4-position with 2,3-dichlorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 2,3-dimethylphenyl, 2-fluorophenyl, 3-trifluoromethylphenyl, or 2-biphenyl.


(ii) Within this embodiment IX, in another group of compounds  is 4-phenylpiperazin-1-yl, 4-(3-methylphenyl)piperazin-1-yl, 4-(2,5-dimethylphenyl)piperazin-1-yl, 4-(2-[1.2.3]-triazol-2-ylmethylphenyl)piperazin-1-yl, 4-(2-methylphenyl)piperazin-1-yl, 4-(2-methoxyphenyl)piperazin-1-yl, 4-(2,3-dichlorophenyl)piperazin-1-yl, 4-(2-methoxy-5-chlorophenyl)piperazin-1-yl, 4-(2-chlorophenyl)piperazin-1-yl, 4-(3-chlorophenyl)piperazin-1-yl, 4-(3-methoxyphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperazin-1-yl, 4-(3,4-dimethylphenyl)piperazin-1-yl, 4-(2-acetylphenyl)piperazin-1-yl, 4-(2-fluorophenyl)piperazin-1-yl, 4-(3-trifluoromethylphenyl)piperazin-1-yl, 4-(2,3-dimethylphenyl)piperazin-1-yl, 4-(2-biphenyl)piperazin-1-yl, 4-(4-biphenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperazin-1-yl, 4-(3,4-dichlorophenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperidin-1-yl, 4-(4-cyanophenyl)-piperidin-1-yl, 4-(2-hydroxyphenyl)-piperazin-1-yl, 4-(2-ethoxyphenyl)-piperazin-1-yl, 4-(4-chlorophenyl)piperazin-1-yl, 4-(3,5-dichlorophenyl)piperazin-1-yl, 4-(2-[1.2.3]-triazol-1-ylmethylphenyl)piperazin-1-yl, 4-(4-cyanophenyl)piperazin-1-yl, 4-(4-chlorophenyl)-piperidin-1-yl, 4-(4-bromophenyl)-4-hydroxy-piperidin-1-yl, 4-(4-hydroxyphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperidin-1-yl, 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl, 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl, 4-(phenyl)-4-hydroxypiperidin-1-yl, 4-(4-trifluoromethylphenyl)-4-hydroxypiperidin-1-yl, or 4-ethylcarbonyl-(phenyl)piperidin-1-yl.

Preferably,  is 4-(4-cyanophenyl)piperidin-1-yl, 4-(5-chloro-2-methoxyphenyl)-


piperazin-1-yl, 4-(3,4-dichlorophenyl)piperazin-1-yl, 4-(2-1.2.3-triazol-2-ylphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperazin-1-yl, 4-(2,5-dimethylphenyl)piperazin-1-yl, 4-(3,4-dimethylphenyl)piperazin-1-yl, 4-phenylpiperazin-1-yl, 4-(2-chlorophenyl)piperazin-1-yl, 4-(2-methoxyphenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperazin-1-yl, or 4-(2-methylphenyl)piperazin-1-yl.


(iii) Within this embodiment IX, in another group of compounds  is piperidin-1-yl or pyrrolidin-1-yl, each ring substituted at the 3- or 4-position, preferably at the 4-position in case of piperidin-1-yl ring, with R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy, or alkoxy, preferably hydrogen and R^b where R^b is aryloxy, heteroaryloxy, cycloalkoxy, aralkyloxy, aralkylthio, heteroaralkyloxy, heterocyclalkyloxy, or cycloalkylalkyloxy, preferably R^b is aryloxy, aralkyloxy, or aralkylthio, where the aromatic ring in R^b is optionally substituted with R^d, R^e, or R^f as defined in the Summary, preferably optionally substituted with R^d and R^e each independently alkyl, alkoxy, cyano, alkylcarbonylamino, halo or haloalkyl. Within this embodiment (iii), in one group of


compounds  is piperidin-1-yl substituted at the 4-position with benzyloxy, 4-chlorophenyl, or 4-fluorophenyl.


(iv) Within this embodiment IX, in another group of compounds  is 4-benzyloxy piperidin-1-yl, 4-(4-chlorophenyl)oxy piperidin-1-yl, 4-(4-fluorophenyl)oxy piperidin-1-yl, 4-(2-trifluoromethylphenyl)oxy piperidin-1-yl, 4-(3-chloro-4-fluorophenyl)oxy piperidin-1-yl, 4-(2-methylbenzyloxy) piperidin-1-yl, 4-(3,5-dimethylphenyl)oxy piperidin-1-yl, 4-(3-trifluoromethylphenyl)oxy piperidin-1-yl, 4-(3-methylphenyl)oxy piperidin-1-yl, 4-(2-isopropoxyphenyl)oxy piperidin-1-yl, 4-(pyridine-2-yl)oxy piperidin-1-yl, 4-(2-chloro-4-fluorophenyl)oxy piperidin-1-yl, 4-(2-chlorophenyl)oxy piperidin-1-yl, 4-(3-chloro-4-cyanophenyl)oxy piperidin-1-yl, 4-(2,4-difluorophenyl)oxy piperidin-1-yl, 4-(3-phenylpropyl)oxy piperidin-1-yl, 4-(3-methylbenzyloxy) piperidin-1-yl, 4-(2-methylphenyl)oxy piperidin-1-yl, 4-(3-methyl-benzyloxy) piperidin-1-yl, 4-(3,4-difluorophenyl)oxy piperidin-1-yl, 4-(2-trifluoromethyl-4-cyanophenyl)oxy piperidin-1-yl, 4-(2-methoxyphenyl)oxy piperidin-1-yl, 4-(2-chloro-5-methylphenyl)oxy piperidin-1-yl, 4-(3-acetylamino phenyl)oxy piperidin-1-yl, 4-(2-cyclohexylethoxy) piperidin-1-yl, 4-(3-bromophenyl)oxy piperidin-1-yl, 4-(3-isopropyl-phenyl)oxy piperidin-1-yl, 3-(2-cyanophenyl)oxy piperidin-1-yl, 3-(2-methoxy-4-methyl-phenyl)oxy piperidin-1-yl, 4-(2-

cyanophenylloxy)piperidin-1-yl, 4-(2-methylpyridin-5-yl-oxy)piperidin-1-yl, 4-(2,4-difluoromethylphenylloxy)piperidin-1-yl, 4-(2-fluoro-phenylloxy)piperidin-1-yl, 4-(3,4-dichlorophenylloxy)piperidin-1-yl, 4-(cyclopropylmethyl-oxy)piperidin-1-yl, 4-(4-bromophenylloxy)piperidin-1-yl, 4-(4-pyrrol-1-ylphenylloxy)piperidin-1-yl, 3-(4-chlorophenylloxy)piperidin-1-yl, 4-(4-tert-butylphenylloxy)piperidin-1-yl, 4-(2-n-propylaminocarbonylphenylloxy)piperidin-1-yl, 4-(pyridine-3-ylloxy)piperidin-1-yl, 4-(4-chloro-2-trifluoromethylphenylloxy)piperidin-1-yl, 4-(4-pyrimidin-2-ylloxy)piperidin-1-yl, 4-(2-biphenylloxy)piperidin-1-yl, 4-(pyridin-4-ylloxy)piperidin-1-yl, 4-(1,2,3,4-tetrahydronaphth-6-ylloxy)piperidin-1-yl, 4-(2-dimethylaminocarbonylphenylloxy)piperidin-1-yl, 4-(quinolin-8-ylloxy)piperidin-1-yl, 4-(tetrahydrofuran-2-ylmethyloxy)piperidin-1-yl, 4-(4-dimethylaminomethylphenylloxy)piperidin-1-yl, 3-(4-methylphenylloxy)piperidin-1-yl, 4-(2-isopropylaminocarbonylphenylloxy)piperidin-1-yl, 4-(1,2,3,4-tetrahydronaphth-5-ylloxy)piperidin-1-yl, 4-(3-tert-butylphenylloxy)piperidin-1-yl, 4-(3-isopropyl-5-methylphenylloxy)piperidin-1-yl, 4-(4-biphenylloxy)piperidin-1-yl, or 4-benzylthiopiperidin-1-yl.


15 Preferably,  is 4-(4-chlorophenoxy)piperidin-1-yl, 4-benzyloxy piperidin-1-yl, 4-(2-trifluorophenoxy)piperidin-1-yl, or 4-benzylthiopiperidin-1-yl


(v) Within this embodiment IX, in another group of compounds  is piperidin-1-yl or piperazin-1-yl, preferably piperidin-1-yl, each ring substituted at the 3 or 4-position (preferably 4-position) with R^b where R^b is heteroaryl, preferably five or six membered heteroaryl ring, even more preferably oxazolyl, thiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzisoxazolyl, benzoxazolyl, benzimidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyrazolyl, each ring optionally substituted with R^d, R^e, or R^f as defined in the Summary, and R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy, or alkoxy. Preferably, each of above heteroaryl ring is substituted with alkyl, halo, five membered heteroaryl, unsaturated 5 or 6-membered cycloalkyl, or phenyl


optionally substituted as defined in the Summary. Preferably,  is piperidin-1-yl substituted at the 4-position with 1,3-thiazol-2-yl or 1,2-pyrazol-1-yl, each substituted at the 4-position with phenyl, thiophen-3-yl or cyclohex-1-enyl.


(vi) Within this embodiment IX, in another group of compounds  is 4-(4-phenylthiazol-2-yl)piperidin-1-yl, 4-(3-phenyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-n-



propyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(5-phenyl-[1.2.4]-oxadiazol-3-yl)piperidin-1-yl, 4-(4-phenylpyrazol-1-yl)piperidin-1-yl, 4-(5-phenyl-[1.3.4]-thiadiazol-2-yl)piperidin-1-yl, 4-(4-phenyl-[1.2.3]-triazol-1-yl)piperidin-1-yl, 4-(3-cyanopyridin-2-yl)piperazin-1-yl, 4-(4-bromopyrazol-1-yl)piperidin-1-yl, 4-(4-phenylpyrazol-1-yl)piperidin-1-yl, 4-[3-(4-trifluoromethylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(4-methylpyridin-2-yl)-piperazin-1-yl, 4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl, 4-(3-phenylisoxazol-5-yl)piperidin-1-yl, 4-(3-pyridin-3-yl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-n-propylisoxazol-5-yl)piperidin-1-yl, 4-(3-ethyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(benxisoxazol-3-yl)piperazin-1-yl, 4-[4-(4-methoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3-methyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(4-methylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(5-methylbenzimidazol-2-yl)piperidin-1-yl, 4-[3-(4-chlorophenyl)-[1.2.4]-oxadiazol-5-yl]piperidin-1-yl, 4-[4-(4-chlorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-trifluoromethylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-methylsulfonylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(2,5-dimethoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 3-(3-ethyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-(2-chloro-4-fluorophenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(4-n-propyl-[1.2.3]-triazol-1-yl)piperidin-1-yl, 4-[4-benzo-1,3-dioxol-5-ylpyrazol-1-yl]piperidin-1-yl, 4-(5-fluorobenzimidazol-2-yl)piperidin-1-yl, 3-(5-fluorobenzimidazol-2-yl)piperidin-1-yl, 4-(6-(pyrrolidin-1-yl)pyridazin-3-yl)piperazin-1-yl, 4-[4-(2-chlorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-cyanophenyl)pyrazol-1-yl]piperidin-1-yl, 4-(5-methylbenzimidazol-2-yl)piperidin-1-yl, 4-(3-(3-chloro-pyridin-4-yl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(2-methylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(5-fluoro-2-methoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3-(4-methylsulfonylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-(3-trifluoromethylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(3-trifluoromethylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-quinolin-8-ylpyrazol-1-yl]piperidin-1-yl, 4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl, 4-[4-(3,4,5-trifluorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3,5-dichloropyridin-2-yl)piperazin-1-yl, 4-[4-(4-acetylaminophenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(3-methylphenyl)pyrazol-1-yl]piperidin-1-yl, or 4-[3-phenylpyrazol-5-yl]piperidin-1-yl. Preferably, 4-[3-(phenyl)-[1.2.4]-oxadiazol-5-yl]-piperidin-1-yl, 4-(3-propyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, or 4-[4-phenylpyrazol-1-yl]piperidin-1-yl.


X. In yet another embodiment,  is bicyclic heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring substituted as defined in the Summary. Within this embodiment, in

one group of compounds  is 1,2,3,4-tetrahydroisoquinolin-2-yl, 5,6,7,8-tetrahydro-1,6-


naphthyridin-6-yl, 5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl, , 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl, 1,2,3,4-tetrahydroindol-1-yl or 1,2,3,4-tetrahydroisoindol-2-yl, substituted as defined in the Summary. Within this embodiment, in

5 another group of compounds  is 1,2,3,4-tetrahydroisoquinolin-2-yl substituted as defined in the Summary, preferably substituted at 5- or 6-position of the 1,2,3,4-tetrahydroisoquinolin-2-yl ring. Within this embodiment, in another group of compounds


 is , substituted at the nitrogen atom with alkyl or aryl, preferably

phenyl. Within this embodiment, in another group of compounds  is 1,2,3,4-


10 tetrahydroisoquinolin-2-yl substituted with at 5-position with R^a where R^a is halo, alkoxy, alkoxy, or cyano.

XI. In yet another embodiment,  is 1,2,3,4-tetrahydroisoquinolin-2-yl, 6-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-methoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-trifluoromethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(1-hydroxy-1-methylethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 3-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6,8-difluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl,

6-hydroxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 3-chloro-5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl, 6-trifluoromethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl, 7-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl, 4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 4-hydroxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 3,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-SO₂NH₂-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(4-methylphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-amino-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(3-methylphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-acetylamino-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(3-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 1,1-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-NH₂CO-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-carboxy-1,2,3,4-tetrahydroisoquinolin-2-yl, or 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl. Preferably, 1,2,3,4-tetrahydroisoquinolin-2-yl, 6-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, or 7-methoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-2-yl. XI(a). In yet another embodiment,



is heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl. Within this embodiment,




in one group of compounds is heterocyclyl.

XII. In yet another embodiment, R¹ is alkyl, preferably methyl.


XIII. In yet another embodiment, R¹ is haloalkyl, preferably trifluoromethyl.

XIV. In yet another embodiment, R¹ is substituted alkyl. Within this embodiment, in one group of compounds R¹ is alkyl substituted with alkoxy or cyano. Within this embodiment, in one group of compounds R¹ is methoxymethyl. Within this embodiment, in one group of compounds R¹ is cyanomethyl.


XV. In yet another embodiment, R¹ is cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is monocyclic cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is cyclopropylmethyl.



XVI. In yet another embodiment, is spirocarbocyclic substituted as defined in the Summary.

XVII. In yet another embodiment,  is heterospirocyclic substituted as defined in the Summary.

XVIII. In yet another embodiment,  is bridged heterocyclyl, preferably



where R^b is as defined in the Summary.

5 XIX. In yet another embodiment, R^1 is cycloalkylalkyl or heterocyclalkyl substituted as defined in the Summary.

(A) Within independent groups I, II, III, IV, V, I', II', III', IV', XII, XIII, XIV, and XV and embodiments contained therein and groups formed independently via combination of groups I, II, III, IV and V, I', II', III', and IV', and groups XII, XIII, XIV, and XV and
10 embodiments contained therein, in one group of compounds A is aryl.


Within this embodiment, in one group of compounds A is phenyl. Within this embodiment, in another group of compounds A is phenyl, R^4 is hydrogen, and R^2 is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this embodiment, in yet another group of compounds A is phenyl, R^4 is hydrogen, and R^2 is hydrogen, methyl, ethyl, propyl,
15 fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy, or hydroxy,. Within this embodiment, in one group of compounds A is phenyl, R^4 is hydrogen, and R^2 is hydrogen, methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably hydrogen, methyl, chloro or fluoro and the R^1 CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is phenyl,
20 R^4 is hydrogen, and R^2 is hydrogen, methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably hydrogen, methyl, chloro or fluoro, and the R^2 group is ortho to R^1 CONH- and the R^1 CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is phenyl and R^4 and R^2 are hydrogen. Within this embodiment, in another group of compounds A is phenyl, R^4 is
25 hydrogen, and R^2 is alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxyl, preferably alkyl or halo, preferably methyl, chloro, or fluoro and the R^2 group is ortho to R^1 CONH- and the R^1 CONH- group is meta to the triazinylamino group.

Within this embodiment, in another group of compounds A is phenyl and R^4 and R^2 are independently alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this


embodiment, in yet another group of compounds A is phenyl, R⁴ and R² are independently methyl, ethyl, propyl, fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxy. Within this embodiment, in one group of compounds A is phenyl, R⁴ and R² are independently methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably methyl, chloro or fluoro and the R¹CONH- group is meta to the triazinylamino group. Within this embodiment, in another group of compounds A is phenyl, R⁴ and R² are independently methyl, ethyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably methyl, chloro or fluoro, and the R² and R⁴ groups are ortho to R¹CONH- and the R¹CONH- group is meta to the triazinylamino group.

(B) Within independent groups I, II, III, IV, V, I', II', III', IV', XII, XIII, XIV, and XV and embodiments contained therein and groups formed independently via combination of groups I, II, III, IV and V, I', II', III', and IV' and groups XII, XIII, XIV, and XV and embodiments contained therein, in another embodiment, A is heteroaryl. Within this embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, R⁴ is hydrogen, and R² is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, R⁴ and R² are independently alkyl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy.


(C) Within independent groups I, II, III, IV, V, I', II', III', IV', VI, VII, XII, XIII, XIV, XV, (A), and (B) above and embodiments contained therein and groups formed independently via combination of groups I, II, III, IV and V, I', II', III', and IV', and groups XII, XIII, XIV, and XV and embodiments contained therein, in yet another embodiment,




is heterocyclyl substituted as defined in the Summary. Within this embodiment, in



one group of compounds is monocyclic heterocyclyl substituted as defined in the




Summary. Within this embodiment, in another group of compounds is pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl substituted as defined in the Summary. Within this




embodiment, in another group of compounds is unsaturated monocyclic heterocyclyl, preferably 1,2,5,6-tetrahydropiperidin-1-yl, substituted as defined in the Summary, preferably substituted at the 4-position with phenyl or monocyclic heteroaryl


wherein phenyl and monocyclic heteroaryl ring is optionally substituted with R^d and R^e as defined in the Summary .




Within this embodiment (C), in another group of compounds is piperidin-1-yl or piperazin-1-yl, each ring substituted at the 3 or 4-position, preferably 4-position, with R^b where R^b is phenyl optionally substituted with R^d , R^e , or R^f as defined in the Summary, and R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy,




or alkoxy. Preferably, is piperidin-1-yl substituted at the 4-position with phenyl which is optionally substituted with R^d and R^e where R^d and R^e are independently cyano, alkyl, haloalkyl, halo, alkoxy, hydroxyl, phenyl, or heteroaralkyl, preferably phenyl.




Preferably, is piperazin-1-yl substituted at the 4-position with phenyl which is optionally substituted with R^d and R^e where R^d and R^e are independently cyano, alkyl,



haloalkyl, halo, alkoxy, hydroxyl, phenyl, or heteroaralkyl. Preferably, is piperazin-1-yl substituted at the 4-position with phenyl wherein the phenyl ring is optionally substituted at the 3-position with R^d where R^d is alkyl, haloalkyl, halo, or alkoxy and optionally substituted at the 2-position with R^e where R^e is alkyl, halo, alkoxy, haloalkyl or phenyl.




Preferably, is piperazin-1-yl substituted at the 4-position with 2,3-dichlorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-methoxyphenyl, 2,3-dimethylphenyl, 2-fluorophenyl, 3-trifluoromethylphenyl, or 2-biphenyl.



Within this embodiment (C), in another group of compounds is 4-phenylpiperazin-1-yl, 4-(3-methylphenyl)piperazin-1-yl, 4-(2,5-dimethylphenyl)piperazin-1-yl, 4-(2-[1,2,3]-triazol-2-ylmethylphenyl)piperazin-1-yl, 4-(2-methylphenyl)piperazin-1-yl, 4-(2-methoxyphenyl)piperazin-1-yl, 4-(2,3-dichlorophenyl)piperazin-1-yl, 4-(2-methoxy-5-chlorophenyl)piperazin-1-yl, 4-(2-chlorophenyl)piperazin-1-yl, 4-(3-chlorophenyl)piperazin-1-yl, 4-(3-methoxyphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperazin-1-yl, 4-(3,4-dimethylphenyl)piperazin-1-yl, 4-(2-acetylphenyl)piperazin-1-yl, 4-(2-fluorophenyl)piperazin-1-yl, 4-(3-trifluoromethylphenyl)piperazin-1-yl, 4-(2,3-dimethylphenyl)piperazin-1-yl, 4-(2-biphenyl)piperazin-1-yl, 4-(4-biphenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperazin-1-yl, 4-

(3,4-dichlorophenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperidin-1-yl, 4-(4-cyanophenyl)-piperidin-1-yl, 4-(2-hydroxyphenyl)-piperazin-1-yl, 4-(2-ethoxyphenyl)-piperazin-1-yl, 4-(4-chlorophenyl)piperazin-1-yl, 4-(3,5-dichlorophenyl)piperazin-1-yl, 4-(2-[1.2.3]-triazol-1-ylmethylphenyl)piperazin-1-yl, 4-(4-cyanophenyl)piperazin-1-yl, 4-(4-chlorophenyl)-piperidin-1-yl, 4-(4-bromophenyl)-4-hydroxy-piperidin-1-yl, 4-(4-hydroxyphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperidin-1-yl, 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl, 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl, 4-(phenyl)-4-hydroxypiperidin-1-yl, 4-(4-trifluoromethylphenyl)-4-hydroxypiperidin-1-yl, or 4-ethylcarbonyl-(phenyl)piperidin-1-yl.


Preferably,  is 4-(4-cyanophenyl)piperidin-1-yl, 4-(5-chloro-2-methoxyphenyl)-piperazin-1-yl, 4-(3,4-dichlorophenyl)piperazin-1-yl, 4-(2-1.2.3-triazol-2-ylphenyl)piperazin-1-yl, 4-(4-fluorophenyl)piperazin-1-yl, 4-(2,5-dimethylphenyl)piperazin-1-yl, 4-(3,4-dimethylphenyl)piperazin-1-yl, 4-phenylpiperazin-1-yl, 4-(2-chlorophenyl)piperazin-1-yl, 4-(2-methoxyphenyl)piperazin-1-yl, 4-(4-methoxyphenyl)piperazin-1-yl, or 4-(2-methylphenyl)piperazin-1-yl.


Within this embodiment (C), in another group of compounds  is piperidin-1-yl or pyrrolidin-1-yl, each ring substituted at the 3- or 4-position, preferably at the 4-position in case of piperidin-1-yl ring, with R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy, or alkoxy, preferably hydrogen and R^b where R^b is aryloxy, heteroaryloxy, cycloalkoxy, aralkyloxy, aralkylthio, heteroaralkyloxy, heterocyclylalkyloxy, or cycloalkylalkyloxy, preferably R^b is aryloxy, aralkyloxy, or aralkylthio, where the aromatic ring in R^b is optionally substituted with R^d, R^e, or R^f as defined in the Summary, preferably optionally substituted with R^d and R^e each independently alkyl, alkoxy, cyano, alkylcarbonylamino, halo or haloalkyl. Within this embodiment, in one group of compounds

 is piperidin-1-yl substituted at the 4-position with benzyloxy, 4-chlorophenyl, or 4-


fluorophenyl. Within this embodiment (C), in another group of compounds  is 4-benzyloxypiperidin-1-yl, 4-(4-chlorophenyloxy)piperidin-1-yl, 4-(4-fluorophenyloxy)-piperidin-1-yl, 4-(2-trifluoromethylphenyloxy)piperidin-1-yl, 4-(3-chloro-4-fluorophenyloxy)piperidin-1-yl, 4-(2-methylbenzyloxy)piperidin-1-yl, 4-(3,5-dimethylphenyloxy)-piperidin-1-yl, 4-(3-trifluoromethylphenyloxy)piperidin-1-yl, 4-(3-methylphenyloxy)-piperidin-1-yl, 4-(2-isopropoxyphenyloxy)piperidin-1-yl, 4-(pyridine-2-yloxy)piperidin-1-yl,

4-(2-chloro-4-fluorophenoxy)piperidin-1-yl, 4-(2-chlorophenyl-oxy)piperidin-1-yl, 4-(3-chloro-4-cyanophenoxy)piperidin-1-yl, 4-(2,4-difluorophenoxy)-piperidin-1-yl, 4-(3-phenylpropyloxy)piperidin-1-yl, 4-(3-methylbenzyloxy)piperidin-1-yl, 4-(2-methylphenyl-oxy)piperidin-1-yl, 4-(3-methyl-benzyloxy)piperidin-1-yl, 4-(3,4-difluorophenoxy)-
 5 piperidin-1-yl, 4-(2-trifluoromethyl-4-cyanophenoxy)piperidin-1-yl, 4-(2-methoxy-phenyloxy)piperidin-1-yl, 4-(2-chloro-5-methylphenyloxy)piperidin-1-yl, 4-(3-acetylamino-phenyloxy)piperidin-1-yl, 4-(2-cyclohexylethoxy)piperidin-1-yl, 4-(3-bromophenoxy)piperidin-1-yl, 4-(3-isopropyl-phenyloxy)piperidin-1-yl, 3-(2-cyanophenoxy)piperidin-1-yl, 3-(2-methoxy-4-methyl-phenyloxy)piperidin-1-yl, 4-(2-cyanophenoxy)piperidin-1-yl, 4-(2-methylpyridin-5-yl-oxy)piperidin-1-yl, 4-(2,4-di-trifluoromethylphenyloxy)piperidin-1-yl, 4-(2-fluoro-phenyloxy)piperidin-1-yl, 4-(3,4-dichlorophenoxy)piperidin-1-yl, 4-(cyclopropylmethyl-oxy)piperidin-1-yl, 4-(4-bromophenoxy)piperidin-1-yl, 4-(4-pyrrol-1-ylphenyloxy)-piperidin-1-yl, 3-(4-chlorophenoxy)piperidin-1-yl, 4-(4-tert-butylphenyloxy)piperidin-1-yl, 4-(2-n-propylaminocarbonylphenyloxy)piperidin-1-yl, 4-(pyridine-3-yloxy)piperidin-1-yl, 4-(4-chloro-2-trifluoromethylphenyloxy)piperidin-1-yl, 4-(4-pyrimidin-2-yloxy)piperidin-1-yl, 4-(2-biphenyloxy)piperidin-1-yl, 4-(pyridin-4-yloxy)piperidin-1-yl, 4-(1,2,3,4-tetrahydronaphth-6-yloxy)piperidin-1-yl, 4-(2-dimethylaminocarbonylphenyloxy)piperidin-1-yl, 4-(quinolin-8-yloxy)piperidin-1-yl, 4-(tetrahydrofuran-2-ylmethyloxy)piperidin-1-yl, 4-(4-dimethylaminomethylphenyloxy)piperidin-1-yl, 3-(4-methylphenyloxy)piperidin-1-yl, 4-(2-isopropylaminocarbonylphenyloxy)piperidin-1-yl, 4-(1,2,3,4-tetrahydronaphth-5-yl-oxy)piperidin-1-yl, 4-(3-tert-butylphenyloxy)piperidin-1-yl, 4-(3-isopropyl-5-methyl-phenyloxy)piperidin-1-yl, 4-(4-biphenyloxy)piperidin-1-yl, or 4-benzylthiopiperidin-1-yl.


Preferably,  is 4-(4-chlorophenoxy)piperidin-1-yl, 4-benzyloxypiperidin-1-yl, 4-(2-trifluorophenoxy)piperidin-1-yl, or 4-benzylthiopiperidin-1-yl

Within this embodiment (C), in another group of compounds  is piperidin-1-yl or piperazin-1-yl, each ring substituted at the 3 or 4-position (preferably 4-position) with R^b where R^b is heteroaryl, preferably five or six membered heteroaryl ring, even more preferably oxazolyl, thiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzisoxazolyl, benzoxazolyl, benzimidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyrazolyl, each ring optionally substituted with R^d, R^e, or R^f as defined in the Summary, and R^a where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, cyano, hydroxy, or alkoxy. Preferably, each

of above heteroaryl ring is substituted with alkyl, halo, five membered heteroaryl, unsaturated 5 or 6-membered cycloalkyl, or phenyl optionally substituted as defined in the Summary.




is piperidin-1-yl substituted at the 4-position with 1,3-thiazol-2-yl or 1,2-pyrazol-1-yl, each substituted at the 4-position with phenyl, thiophen-3-yl or cyclohex-1-enyl





5 Within this embodiment (C), in another group of compounds is 4-(4-phenylthiazol-2-yl)piperidin-1-yl, 4-(3-phenyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-n-propyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(5-phenyl-[1.2.4]-oxadiazol-3-yl)piperidin-1-yl, 4-(4-phenylpyrazol-1-yl)piperidin-1-yl, 4-(5-phenyl-[1.3.4]-thiadiazol-2-yl)piperidin-1-yl, 4-(4-phenyl-[1.2.3]-triazol-1-yl)piperidin-1-yl, 4-(3-cyanopyridin-2-yl)piperazin-1-yl, 4-(4-bromopyrazol-1-yl)piperidin-1-yl, 4-(4-phenylpyrazol-1-yl)piperidin-1-yl, 4-[3-(4-trifluoromethylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(4-methylpyridin-2-yl)-piperazin-1-yl, 4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl, 4-(3-phenylisoxazol-5-yl)piperidin-1-yl, 4-(3-pyridin-3-yl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-n-propylisoxazol-5-yl)piperidin-1-yl, 4-(3-ethyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(benzisoxazol-3-yl)piperazin-1-yl, 4-[4-(4-methoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3-methyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(4-methylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(5-methylbenzimidazol-2-yl)piperidin-1-yl, 4-[3-(4-chlorophenyl)-[1.2.4]-oxadiazol-5-yl]piperidin-1-yl, 4-[4-(4-chlorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-trifluoromethylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-methylsulfonylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(2,5-dimethoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 3-(3-ethyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-(2-chloro-4-fluorophenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(4-n-propyl-[1.2.3]-triazol-1-yl)piperidin-1-yl, 4-[4-benzo-1,3-dioxol-5-ylpyrazol-1-yl]piperidin-1-yl, 4-(5-fluorobenzimidazol-2-yl)piperidin-1-yl, 3-(5-fluorobenzimidazol-2-yl)piperidin-1-yl, 4-(6-(pyrrolidin-1-yl)pyridazin-3-yl)piperazin-1-yl, 4-[4-(2-chlorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(4-cyanophenyl)pyrazol-1-yl]piperidin-1-yl, 4-(5-methylbenzimidazol-2-yl)piperidin-1-yl, 4-(3-(3-chloro-pyridin-4-yl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(2-methylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(5-fluoro-2-methoxyphenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3-(4-methylsulfonylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-(3-(3-trifluoromethylphenyl)-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, 4-[4-(3-trifluoromethylphenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-quinolin-8-ylpyrazol-1-yl]piperidin-1-yl, 4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl, 4-[4-(3,4,5-trifluorophenyl)pyrazol-1-yl]piperidin-1-yl, 4-(3,5-dichloropyridin-2-yl)piperazin-1-yl, 4-[4-(4-acetylamino-


phenyl)pyrazol-1-yl]piperidin-1-yl, 4-[4-(3-methylphenyl)pyrazol-1-yl]piperidin-1-yl, or 4-[3-phenylpyrazol-5-yl]piperidin-1-yl. Preferably, 4-[3-(phenyl)-[1.2.4]-oxadiazol-5-yl]-piperidin-1-yl, 4-(3-propyl-[1.2.4]-oxadiazol-5-yl)piperidin-1-yl, or 4-[4-phenylpyrazol-1-yl]piperidin-1-yl.

- 5 (D). Within independent groups I, II, III, IV, V, I', II', III', IV', VI, VII, XII, XIII, XIV, XV, (A) and (B), and embodiments contained therein and groups formed independently via combination of groups I, II, III, and IV, I', II', III', and IV', and groups XII, XIII, XIV, and



XV and embodiments contained therein, in yet another embodiment,  is bicyclic heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring substituted as defined in the


- 10 Summary. Within this embodiment, in one group of compounds  is 1,2,3,4-tetrahydroisoquinolin-2-yl, 5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl, 5,6,7,8-tetrahydro-1,7-

naphthyridin-7-yl, , 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl, 1,2,3,4-tetrahydroindol-1-yl or 1,2,3,4-tetrahydroisoindol-2-yl, substituted as defined in the Summary.

Within this embodiment, in another group of compounds  is 1,2,3,4-

- 15 tetrahydroisoquinolin-2-yl substituted as defined in the Summary, preferably substituted at 5- or 6-position of the 1,2,3,4-tetrahydroisoquinolin-2-yl ring. Within this embodiment, in another

group of compounds  is , substituted at the nitrogen atom with alkyl

or aryl, preferably phenyl. Within this embodiment, in another group of compounds  is 1,2,3,4-tetrahydroisoquinolin-2-yl substituted with R^a and R^b where R^a is hydrogen, halo, alkoxy, cyano, hydroxyalkyl, hydroxyl, aminosulfonyl, aryl, amino, acetyl amino, or carboxy and R^b is hydrogen, halo, or alkyl. Within this

- 20

embodiment, in another group of compounds  is 1,2,3,4-tetrahydroisoquinolin-2-yl substituted with at 5-position with R^a where R^a is halo, alkoxycarbonyl, alkoxy, or cyano.

(E). Within independent groups I, II, III, IV, V, I', II', III', IV', VII, XII, XIII, XIV, XV, (A) and (B), and embodiments contained therein and groups formed independently via combination of groups I, II, III, and IV, I', II', III', IV', and groups XII, XIII, XIV, and XV

and embodiments contained therein, in yet another embodiment,  is 1,2,3,4-tetrahydroisoquinolin-2-yl, 6-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-methoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-trifluoromethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(1-hydroxy-1-methylethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 3-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-methoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6,8-difluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-hydroxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 3-chloro-5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl, 6-trifluoromethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-6-yl, 7-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl, 4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 4-hydroxy-1,2,3,4-tetrahydroisoquinolin-2-yl, 3,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-SO₂NH₂-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(4-methylphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 7-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 5-amino-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(3-methylphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-trifluoromethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-acetylamino-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-(3-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl, 8-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl, 1,1-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-NH₂CO-1,2,3,4-tetrahydroisoquinolin-2-yl, 6-carboxy-

1,2,3,4-tetrahydroisoquinolin-2-yl, or 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl.

Preferably, 1,2,3,4-tetrahydroisoquinolin-2-yl, 6-bromo-1,2,3,4-tetrahydroisoquinolin-2-yl, or 7-methoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-2-yl.

XX. Within independent groups I, II, III, IV, I', II', III', and IV', in one group of
5 compounds R¹ is alkyl, preferably methyl.

XXI. Within independent groups I, II, III, IV, I', II', III', and IV', in another group of
compounds R¹ is haloalkyl, preferably trifluoromethyl.

XXII. Within independent groups I, II, III, IV, I', II', III', and IV', in another group of
compounds R¹ is substituted alkyl. Within this embodiment, in one group of compounds R¹ is
10 alkyl substituted with alkoxy or cyano. Within this embodiment, in one group of compounds
R¹ is methoxymethyl. Within this embodiment, in one group of compounds R¹ is
cyanomethyl.

XXIII. Within independent groups I, II, III, IV, I', II', III', and IV', in another group of
compounds R¹ is cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is
15 monocyclic cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is
cyclopropylmethyl.

(4) Within compounds of Formula (I):

(a) In one embodiment, X is -NH- or -O- preferably -NH-.
20 (b) In another embodiment, X is -O-.
(c) In yet another embodiment, X is -S- or -SO₂-.
(d) In yet another embodiment, X is -NH- and Y is O or N-CN. Within this
embodiment (d), in one group of compounds Y is O. Within this embodiment (d), in another
group of compounds Y is N-CN.

25 (e) In yet another embodiment, Y is N-CN.


4A. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d) and 4(e)
above, in one embodiment, A is aryl. Within this embodiment, in one group of compounds A
is phenyl. Within this embodiment, in another group of compounds A is phenyl, R⁴ is
hydrogen, and R² is hydrogen, alkyl, cycloalkyl, aryl, halo, haloalkyl, haloalkoxy, alkoxy, or
30 hydroxyl. Within this embodiment, in yet another group of compounds A is phenyl, R⁴ is
hydrogen, and R² is hydrogen, methyl, ethyl, propyl, cyclopropyl, phenyl, fluoro, chloro,
trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl. Within this embodiment, in yet one
group of compounds A is phenyl, R⁴ is hydrogen, and R² is hydrogen, methyl, ethyl, chloro,
fluoro, trifluoromethyl, trifluoromethoxy, methoxy, cyclopropyl, hydroxyl or phenyl and the
35 R¹CONH- group is meta to the triazinyl-X- group. Within this embodiment, in another group

of compounds A is phenyl, R^4 is hydrogen, and R^2 is methyl, ethyl, cyclopropyl, phenyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably hydrogen, methyl, chloro or fluoro, and the R^2 group is ortho to R^1 CONH- and the R^1 CONH- group is meta to the triazinyl-X- group. Within this embodiment, in another group of compounds A is phenyl and R^4 and R^2 are hydrogen and R^1 CONH- group is meta to the triazinyl-X- group. Within this embodiment, in another group of compounds A is phenyl, R^4 is hydrogen, and R^2 is alkyl, cycloalkyl, aryl, or halo, preferably alkyl or halo, preferably methyl, chloro, or fluoro and the R^2 group is ortho to R^1 CONH- and the R^1 CONH- group is meta to the triazinyl-X- group.


Within this embodiment, in another group of compounds A is phenyl and R^4 and R^2 are independently alkyl, cycloalkyl, aryl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this embodiment, in yet another group of compounds A is phenyl, R^4 and R^2 are independently methyl, ethyl, propyl, cyclopropyl, phenyl, fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxy. Within this embodiment, in one group of compounds A is phenyl, R^4 and R^2 are independently methyl, ethyl, cyclopropyl, phenyl, chloro, fluoro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl, preferably methyl, chloro or fluoro and the R^1 CONH- group is meta to the triazinyl-X- group. Within this embodiment, in another group of compounds A is phenyl, R^4 and R^2 are independently methyl, chloro, or fluoro and the R^2 and R^4 groups are ortho to R^1 CONH- and the R^1 CONH- group is meta to the triazinyl-X- group.

4B. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d) and 4(e), in another embodiment, A is heteroaryl. Within this embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, R^4 is hydrogen, and R^2 is hydrogen, alkyl, cycloalkyl, aryl, halo, haloalkyl, haloalkoxy, alkoxy or hydroxy. Within this embodiment, in one group of compounds A is monocyclic heteroaryl, preferably pyridinyl or thiophenyl, and R^4 and R^2 are independently hydrogen, methyl, fluoro or chloro.

4C. Within compounds of Formula (I), 4(a), 4(b), 4(c), 4(d), 4(e), 4A and 4B and

groups contained therein, in one group of compound  is heteroaryl, preferably pyrrol-1-yl, indol-1-yl, or indazol-1-yl substituted as defined in the Summary.

4D. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A and 4B and groups contained therein, in one group of compound R^5 and R^6 together with



the nitrogen atom to which they are attached form wherein ring B is a four membered heterocyclyl, heterocyclyl, bridged heterocyclyl or spiroheterocyclyl ring, preferably ring B is azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 8-azabicyclo[3.2.1]oct-8-yl, 2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, 1,4-diazepan-1-yl, or 3,6-dihydro-2(H)pyridin-1-yl, more preferably azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, or 3,6-dihydro-2(H)pyridin-1-yl, even more preferably piperidin-1-yl or piperazin-1-yl; each ring substituted as defined in the Summary. Preferably above rings are substituted with R^a where R^a is hydrogen and R^b and R^c are as defined in the Summary. More preferably, R^a is hydrogen, R^b is hydrogen, alkoxy, halo, or alkyl, preferably hydrogen, methoxy, fluoro, chloro, or methyl, more preferably R^b is hydrogen; and R^c is alkyl, substituted alkyl, substituted alkynyl, halo, haloalkyl, haloalkoxy, alkoxy, acyl, hydroxyalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, aryloxy, heteroaryloxy, aryloxyalkyl, or aralkyloxy, where the aromatic or alicyclic ring in R^a , R^b and R^c is optionally substituted with R^d , R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, disubstituted amino, sulfonyl, alkoxyalkoxy, cycloalkyl, phenyl, or heteroaralkyl where the aromatic or alicyclic ring in R^d , R^e or R^f is optionally substituted with one to three substituents independently selected from haloalkoxy. Preferably, when B is piperidin-1-yl or piperazin-1-yl, these rings are substituted at the 4-position with R^c and when B is azetidin-1-yl, R^c is at the 3-position of the azetidiny ring.

Within these groups, preferably, ring B is 4-(benzyloxy)piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl; 4-(4-chlorophenoxy)piperidin-1-yl; 4-phenylpiperidin-1-yl; 4-(4-cyanophenyl)piperidin-1-yl; 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(benzylsulfanyl)piperidin-1-yl; 4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl; 4-(4-fluorophenoxy)-piperidin-1-yl; 4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-methoxyphenyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidin-1-yl; 4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-pyridinyloxy)piperidin-1-yl; 4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(3-chloro-4-fluorophenoxy)piperidin-1-yl; 4-((2-methylbenzyl)oxy)piperidin-1-yl; 4-(3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-bromo-1H-

pyrazol-1-yl)piperidin-1-yl; 4-(3-methylphenoxy)piperidin-1-yl; 4-(2-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-((2-biphenylmethyl)(methyl)amino)piperidin-1-yl; 4-(4-chlorophenyl)piperidin-1-yl; 4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl; 4-(2-chloro-phenoxy)piperidin-1-yl; 4-(4-bromophenyl)-4-hydroxypiperidin-1-yl; 4-(3-phenylpropoxy)-
5 piperidin-1-yl; 4-(2-chloro-4-fluorophenoxy)-piperidin-1-yl; 4-(3-chloro-4-cyanophenoxy)-piperidin-1-yl; 4-butoxypiperidin-1-yl; 4-(2-methylphenoxy)piperidin-1-yl; 4-(2,4-difluorophenoxy)piperidin-1-yl; 4-(3,4-difluorophenoxy)piperidin-1-yl; (3S)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenylcarbonyl)piperidin-1-yl; 4-(phenylsulfanyl)piperidin-1-yl; 4-(4-fluorophenyl)-
10 piperidin-1-yl; 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl; 4-((3-methylbenzyl)oxy)piperidin-1-yl; 4-((3-cyanophenyl)amino)piperidin-1-yl; 4-((4-chlorophenyl)amino)piperidin-1-yl; 4-((3-chlorobenzyl)oxy)piperidin-1-yl; 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl; 4-(2,3-difluorophenoxy)piperidin-1-yl; 4-hydroxy-4-phenylpiperidin-1-yl; 4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(2-chloro-5-methylphenoxy)piperidin-1-yl; 4-(3-phenyl-5-isoxazolyl)piperidin-1-yl; 4-(3-propyl-5-isoxazolyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(1-naphthalenyloxy)piperidin-1-yl; 4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-benzyl-4-hydroxypiperidin-1-yl; 4-benzylpiperidin-1-yl; 4-((3-fluoro-5-(trifluoromethyl)-benzyl)amino)piperidin-1-yl; 4-(2-methoxyphenoxy)piperidin-1-yl; 4-(3-(acetyl-amino)-
20 phenoxy)piperidin-1-yl; 4-benzyl-1,4'-bipiperidin-1'-yl; 4-(2-cyclohexylethoxy)piperidin-1-yl; 4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((3-chloro-4-cyanophenyl)amino)-piperidin-1-yl; 4-ethoxypiperidin-1-yl; 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-methoxypiperidin-1-yl; 4-(3-bromophenoxy)piperidin-1-yl; 4-(2-(1-methylethyl)phenoxy)-piperidin-1-yl; 4-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; (3RS)-3-(2-cyanophenoxy)piperidin-1-yl; 4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl; (3RS)-3-(2-methoxy-4-methylphenoxy)piperidin-1-yl; 4-(2-cyanophenoxy)piperidin-1-yl; 4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-chloro-2-(trifluoromethyl)phenoxy)-piperidin-1-yl; 4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((6-methyl-3-pyridinyl)oxy)piperidin-1-yl; 4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2-fluorophenoxy)piperidin-1-yl; 4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(1-pyrrolidinyl)piperidin-1-yl; 4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,4-dichlorophenoxy)-piperidin-1-yl; 4-(cyclopropylmethoxy)piperidin-1-yl; 4-ethoxycarbonylpiperidin-1-yl; 4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; (3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-

- yl)piperidin-1-yl; 4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-propyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinoliny)-piperidin-1-yl; 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-bromophenoxy)piperidin-1-yl; 4-((4-methylphenyl)sulfanyl)piperidin-1-yl; 4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)piperidin-1-yl; 4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(5,6,7,8-tetrahydro-1-naphthalenylamino)piperidin-1-yl; (3RS)-3-(4-chlorophenoxy)piperidin-1-yl; 4-phenyl-4-propanoylpiperidin-1-yl; (2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(4-tert-butylphenoxy)piperidin-1-yl; 4-(2-propylaminocarbonylphenoxy)piperidin-1-yl; 4-(3-pyridinyloxy)piperidin-1-yl; 4-((4-methoxyphenyl)amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)amino)piperidin-1-yl; 4-(phenylsulfonyl)piperidin-1-yl; 4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(2-pyrimidinyloxy)piperidin-1-yl; 4-(2-biphenyloxy)piperidin-1-yl; (3RS)-3-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-pyridinyloxy)piperidin-1-yl; 4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(methyl(2-(trifluoromethoxy)phenyl)-amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)sulfonyl)piperidin-1-yl; 4-(6-quinolinylamino)piperidin-1-yl; 4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl; 4-(benzylsulfonyl)piperidin-1-yl; 4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl; 4-(4-(2-pyrimidinyl)piperazin-1-yl)piperidin-1-yl; 4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl; 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl; (3RS)-3-(4-cyano-2-methoxyphenoxy)piperidin-1-yl; 4-aminocarbonylpiperidin-1-yl; 4-(4-(8-quinoliny)-1H-pyrazol-1-yl)piperidin-1-yl; 4-carboxypiperidin-1-yl; 4-((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(4-((dimethylamino)-methyl)phenoxy)piperidin-1-yl; 4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-biphenyl)piperidin-1-yl; 4-(2-biphenyl)piperidin-1-yl; 4-(4-CF₃-benzyloxy)piperidin-1-yl; 4-(4-CF₃O-benzyloxy)piperidin-1-yl; 4-(4-Br-benzyloxy)piperidin-1-yl; 4-(3,4-difluoro-benzyloxy)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-Cl-3-F-phenoxy)piperidin-1-yl; 4-(3-CF₃-benzyloxy)piperidin-1-yl; 4-(4-Cl-3-CH₃-phenoxy)piperidin-1-yl; 4-(4-F-benzyloxy)piperidin-1-yl; 4-(2,6-diF-benzyloxy)piperidin-1-yl; 4-(benzthiazol-2-yl)piperidin-1-yl; 4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-n-propyl-1,3,4-

oxadiazol-5-yl)piperidin-1-yl; 4-(3-Cl-4-CN-phenyl)piperidin-1-yl; 4-(benzoxazol-2-yl)piperidin-1-yl; 4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-(4-chloro-3-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-(4-cyano-3-methylphenyl)piperidin-1-yl; 4-(2-cyanobenzyloxy)piperidin-1-yl; 4-(2-CF₃benzyloxy)piperidin-1-yl; 4-(1-RS-1-phenylethoxy)-piperidin-1-yl; 4-(4-chloro-3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-chlorobenzoyl)piperidin-1-yl; 4-(4-dimethylaminophenyl)piperidin-1-yl; 4-(2-CF₃phenyl)piperidin-1-yl; 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl; 4-(3-OCF₃benzyloxy)piperidin-1-yl; 4-(2-OCF₃benzyloxy)-piperidin-1-yl; 4-(4-butylbenzyloxy)piperidin-1-yl; 4-(4-isopropylbenzyloxy)-piperidin-1-yl; 4-(4-methylbenzyloxy)piperidin-1-yl; 4-(4-OCHF₂benzyloxy)piperidin-1-yl; 4-(2,4,6-trifluoro-
benzyloxy)-piperidin-1-yl; 4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3-difluoro-
benzyloxy)-piperidin-1-yl; 4-(2,4-difluorobenzyloxy)-piperidin-1-yl; 4-(2,3,4-trifluoro-
benzyloxy)-piperidin-1-yl; 4-(4-cyanobenzyloxy)-piperidin-1-yl; 4-(3,3-difluoro-2-oxo-2,3-
dihydro-1H-indol-1-yl)- piperidin-1-yl; 4-(4-chlorobenzyl)piperidin-1-yl; 4-(3-OCF₃phenoxy)-
piperidin-1-yl; 4-(3-fluoro-4-OCF₃benzyloxy)-piperidin-1-yl; 3-fluoro-4-(phenyl)piperidin-1-
yl; 4-(3-cyanophenoxy)piperidin-1-yl; 4-(4-cyanophenoxy)piperidin-1-yl; 4-methyl-4-(4-
trifluoromethoxybenzyloxy)piperidin-1-yl; 4-[4-(2-methoxyethoxy)benzyl-oxy]piperidin-1-yl;
(3R,4R)-3-fluoro-4-phenyl-piperidin-1-yl; (3S,4S)-3-fluoro-4-phenyl-piperidin-1-yl; 4-(4-tert-
butylbenzyloxy)-piperidin-1-yl; 4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl; 4-benzyl-4-
fluoropiperidin-1-yl; 4-(2-methylsulfonylphenoxy)-piperidin-1-yl; 4-(3-fluoro-5-
CF₃benzyloxy)-piperidin-1-yl; 4-(4-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-4-
CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(3-fluoro-4-
CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(2,4,5-
trifluorobenzyloxy)-piperidin-1-yl; 4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl;
4-(2,4-diCF₃benzyloxy)piperidin-1-yl; 4-(2-fluorobenzyloxy)piperidin-1-yl; 4-(3-fluoro-
benzyloxy)piperidin-1-yl; 4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,5-difluoro-
benzyloxy)piperidin-1-yl; 4-(2,5-diCF₃benzyloxy)piperidin-1-yl; 3,3-dimethyl-2,3-dihydro-
1H-indol-1-yl)piperidin-1-yl; 4-(2,3-dichlorophenoxy)piperidin-1-yl; 4-(3-chloro-4-methyl-
phenoxy)-piperidin-1-yl; 4-(4-chloro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-chlorophenoxy)-
piperidin-1-yl; 4-(3,4-dimethylphenoxy)-piperidin-1-yl; 4-(2,3-dimethylphenoxy)-piperidin-1-
yl; 4-(3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(3-thiophenylmethoxy)-piperidin-1-
yl; 4-(2-fluoro-5-OCF₃phenoxy)-piperidin-1-yl; 4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl;
4-(3-fluoro-4-OCF₃phenoxy)-piperidin-1-yl; 4-(4-fluoro-3-OCF₃phenoxy)-piperidin-1-yl; 4-
(2,6-difluorophenoxy)-piperidin-1-yl; 4-(3-fluorophenoxy)-piperidin-1-yl; 4-(2-
fluorophenoxy)-piperidin-1-yl; 4-(2,4,6-trifluorophenoxy)-piperidin-1-yl; 4-(2,3,6-trifluoro-

phenoxy)-piperidin-1-yl; 4-(4-CF₃phenoxy)-piperidin-1-yl; 4-(4-OCF₃phenoxy)-piperidin-1-yl; 4-(2,3,4-trifluorophenoxy)-piperidin-1-yl; 4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-phenylethynylpiperidin-1-yl; 4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,5-difluorophenoxy)-piperidin-1-yl; 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenoxy)-piperidin-1-yl; 4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl; 4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-piperidin-1-yl; 4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl; 4-(4-chlorobenzyloxy)piperidin-1-yl; 4-(4-CF₃phenyl)piperidin-1-yl; 4-(3,4-dimethylphenyl)piperidin-1-yl; 4-(4(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl; 4-(4-chloro-2-OCF₃phenoxy)-piperidin-1-yl; 4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl; 4-(2-fluorophenyl)-piperidin-1-yl; 4-(3-fluorophenyl)piperidin-1-yl; 4-(4-cyano-3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-CF₃phenyl)-piperidin-1-yl; 4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl; 4-(pyridin-2-yloxy)-piperidin-1-yl; 4-phenylpiperazin-1-yl; 4-(3-methylphenyl)piperazin-1-yl; 4-(2,5-dimethylphenyl)piperazin-1-yl; 4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl)piperazin-1-yl; 4-(2-methylphenyl)piperazin-1-yl; 4-(2-methoxyphenyl)piperazin-1-yl; 4-(2,3-dichlorophenyl)piperazin-1-yl; 4-(5-chloro-2-methoxyphenyl)-piperazin-1-yl; 4-(2-chlorophenyl)piperazin-1-yl; 4-(3-chlorophenyl)piperazin-1-yl; 4-(3-methoxyphenyl)piperazin-1-yl; 4-(4-fluorophenyl)piperazin-1-yl; 4-(3,4-dimethylphenyl)-piperazin-1-yl; 4-(2-acetylphenyl)piperazin-1-yl; 4-(2-fluorophenyl)piperazin-1-yl; 4-(3-trifluoromethylphenyl)piperazin-1-yl; 4-(2,3-dimethylphenyl)piperazin-1-yl; 4-(2-biphenyl)piperazin-1-yl; 4-(4-methoxyphenyl)piperazin-1-yl; 4-(3,4-dichlorophenyl)-piperazin-1-yl; 4-(2-hydroxyphenyl)piperazin-1-yl; 4-(2-ethoxyphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(4-chlorophenyl)piperazin-1-yl; 3-cyano-2-pyridinylpiperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-cyanophenyl)piperazin-1-yl; 4-(4-hydroxyphenyl)piperazin-1-yl; 4-(4-methyl-2-pyridinyl)-piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(1,2-benzisoxazol-3-yl)piperazin-1-yl; 4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl; 4-(3,5-dichlorophenyl)piperazin-1-yl; 4-(tetrahydro-2-furanylmethyl)piperazin-1-yl; 4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl; 4-(2-furanylcarbonyl)piperazin-1-yl; 4-(4-(1-methylethyl)piperazin-1-yl; 4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl; 4-(2-chloro-6-fluorobenzyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl; 4-(3-pyridinylmethyl)-piperazin-1-yl; 4-((3-fluorophenyl)carbonyl)piperazin-1-yl; 4-(3-cyclopropylaminocarbonyl-pyridin-2-yl)piperazin-1-yl; 4-((2-(trifluoromethyl)phenyl)carbonyl)piperazin-1-yl; 4-(3-

hydroxypropyl)piperazin-1-yl; 4-(3-methoxybenzyl)-3-oxopiperazin-1-yl; 4-(tetrahydro-2
(RS)-furanylcabonyl)piperazin-1-yl; 4-(4-CF₃phenyl)piperazin-1-yl; 4-(2-CNphenyl)-
piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-
ylmethyl)phenyl)piperazin-1-yl; 4-(4-bromobenzyl)piperazin-1-yl; 4-(3,4-dichlorobenzyl-
5 piperazin-1-yl; 4-(2-phenylethyl)piperazin-1-yl; 4-(3,4-difluorophenyl)piperazin-1-yl; 4-(3-
OCF₃benzyl)piperazin-1-yl; 4-(4-chlorobenzyl)piperazin-1-yl; 4-(4-tert-butylbenzyl)piperazin-
1-yl; 4-(2,4-difluorophenyl)piperazin-1-yl; 4-(3-chloro-4-fluorophenyl)-piperazin-1-yl; 4-(4-
chloro-3-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-methylphenyl)-piperazin-1-yl; 4-(3-
fluoro-4-methylphenyl)-piperazin-1-yl; 4-(4-fluoro-3-methylphenyl)-piperazin-1-yl; 4-(4-
10 chloro-2-fluorophenyl)-piperazin-1-yl; 4-(3,4-difluorobenzyl)piperazin-1-yl; 4-(3,4-
dimethylbenzyl)piperazin-1-yl; 4-(3-CF₃benzyl)piperazin-1-yl; 4-(4-fluorobenzyl)piperazin-1-
yl; 4-(7-chloroquinolin-4-yl)-piperazin-1-yl; 4-(3-chlorobenzyl)piperazin-1-yl; 4-(2-
fluorobenzyl)piperazin-1-yl; 4-(3-fluorobenzyl)piperazin-1-yl; 4-(4-(2-methoxyethoxy)-
phenyl)-piperazin-1-yl; 4-(2-OCF₃benzyl)piperazin-1-yl; 4-(2-SCH₃phenyl)piperazin-1-yl; 4-
15 (2-CF₃phenyl)piperazin-1-yl; 4-(pyridin-2-yl)piperazin-1-yl; 4-(6-methylpyridin-2-yl)-
piperazin-1-yl; 4-(5-chloropyridin-2-yl)piperazin-1-yl; 4-(5,6-dimethylpyridin-2-yl)-piperazin-
1-yl; 4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl;
4-(4-OCF₃benzyl)piperazin-1-yl; 4-(3-OCF₃phenyl)piperazin-1-yl; 4-(4-OCF₃phenyl)-
piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 5-methoxycarbonyl-1,2,3,4-tetrahydro-2-
20 isoquinoline; 6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(trifluoromethoxy)-3,4-dihydro-
(1H)-isoquinolin-2-yl; 5-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-cyano-3,4-dihydro-
(1H)-isoquinolin-2-yl; 3,4-dihydro-(1H)-isoquinolin-2-yl; 5-chloro-3,4-dihydro-(1H)-
isoquinolin-2-yl; 7-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-bromo-3,4-dihydro-(1H)-
isoquinolin-2-yl; 5-trifluoromethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-methoxy-3,4-dihydro-
25 (1H)-isoquinolin-2-yl; 6-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1-hydroxy-1-methyl-
ethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(2-
phenoxyphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-methyl-3,4-dihydro-(1H)-isoquinolin-2-
yl; (3RS)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-chloro-3,4-dihydro-(1H)-isoquinolin-
2-yl; 8-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-fluoro-3,4-dihydro-(1H)-isoquinolin-2-
30 yl; 6-cyclopropyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (1R)-1-methyl-3,4-dihydro-(1H)-
isoquinolin-2-yl; 6,8-difluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; (1RS)-1-methyl-3,4-dihydro-
(1H)-isoquinolin-2-yl; (1RS)-1-benzyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-fluoro-3,4-
dihydro-(1H)-isoquinolin-2-yl; (3S)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-fluoro-3,4-
dihydro-(1H)-isoquinolin-2-yl; 6-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-hydroxy-3,4-

dihydro-(1H)-isoquinolin-2-yl; 7-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 4,4-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (3R)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-hydroxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 3,3-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-sulfamoyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(4-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-amino-3,4-dihydro-(1H)-isoquinolin-2-yl; (1S)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; (1RS)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(acetylamino)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-fluorophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-carboxy-1,2,3,4-dihydro-2-(1H)-isoquinolinyl; 6-tert-butyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-OCF₃-3,4-dihydro-(1H)-isoquinolin-2-yl; 6,8-dimethoxy-3,4-dihydro-2(1H)-isoquinolin-2-yl; 5-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 5,6-dimethoxy-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-ethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-acetyl-3,4-dihydro-1H-isoquinolin-2-yl; 6-(1-fluoroethyl)-3,4-dihydro-1H-isoquinolin-2-yl; 6-(1,3-thiazol-5-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(2-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1,3-thiazol-4-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-OCF₃-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-biphenyl)-1,2,3,6-tetrahydropiperidin-1-yl; 4-(4-CN-2-CH₃-phenyl)-1,2,3,6-tetrahydropiperidin-1-yl; 4-(3-biphenyl)-1,2,3,6-tetrahydropiperidin-1-yl; 4-(4-cyano-2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chloro-4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 2-fluoro-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-cyano-2,3-difluorophenyl-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(3,4-dimethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-methylphenyl)-3,6-dihydro-

(2H)-pyridin-1-yl; 4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-fluoromethoxyphenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-phenyl-3,6-dihydro-(2H)-pyridin-1-yl; 4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl; 4-((1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl; (1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; 2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl; Racemic mixture of (1S,8R)-9-azatricyclo[6.2.1.0-2,7]-undeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.1.0-2,7]-undeca-2,4,6-trien-9-yl; 2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl; 3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 5,8-dihydro-1,7-naphthyridin-7(6H)-yl; 1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl; racemic mixture of (4aS,8aR)-octahydro-2(1H)-isoquinoliny and (4aR,8aS)-octahydro-2(1H)-isoquinoliny; racemic mixture of (1S,8R)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl; 2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl; 3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl; 1-(methylsulfonyl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl; 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl; 4-benzyl-1,4-diazepan-1-yl; 3-phenoxy-8-azabicyclo-[3.2.1]oct-8-yl; 3-benzyloxy-8-azabicyclo-[3.2.1]oct-8-yl; 3-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl; 3-(4-chlorobenzyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl; 2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl; 2-phenyl-2,8-diazaspiro[4.5]dec-8-yl; 5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl; (1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl; 4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl; 1-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl; 5-ethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl; (1S,4S)-5-(4-chlorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; (1S,4S)-5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; 2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-(trifluoromethoxy)-phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-chlorophenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(3-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-(2-methoxyethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(1-piperidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(1-pyrrolidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl; 4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl; 6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; (2RS)-2-phenyl-1-pyrrolidinyl; 3-(4-fluorophenoxy)azetidin-1-yl;

3-(phenoxy)azetidin-1-yl; 4-(4-fluoro-3-methylphenoxy)pyrrolidin-1-yl; 3-(3,4-dichlorophenoxy)azetidin-1-yl; 4-(2-chlorophenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethoxybenzyloxy)azetidin-1-yl; 3-(2,5-difluorophenoxy)azetidin-1-yl; 3-(3-fluoro-4-trifluoromethoxyphenoxy)-azetidin-1-yl; 3-(2-chloro-4-trifluoromethylphenoxy)-azetidin-1-yl; 3-(4-chloro-3-fluorophenoxy)-azetidin-1-yl; 3-(3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluoro-4-methylphenoxy)-azetidin-1-yl; 3-(3-trifluoromethoxyphenoxy)-azetidin-1-yl; 3-(2-trifluoromethylphenoxy)-azetidin-1-yl; 3-(4-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluorophenoxy)-azetidin-1-yl; 3-(3,4-difluorophenoxy)-azetidin-1-yl; 3-(2,3-difluorophenoxy)-azetidin-1-yl; 3-(2,4-difluorophenoxy)-azetidin-1-yl; 3-(2,6-difluorophenoxy)-azetidin-1-yl; 3-(4-cyanophenoxy)-azetidin-1-yl; 3-(4-CF₃phenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethylphenoxy)-azetidin-1-yl; or 3-(4-chlorophenoxy)azetidin-1-yl.

Within these groups, more preferably ring B is 4-(benzyloxy)piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl; 4-(4-chlorophenoxy)piperidin-1-yl; 4-phenylpiperidin-1-yl; 4-(4-cyanophenyl)piperidin-1-yl; 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(benzylsulfanyl)piperidin-1-yl; 4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl; 4-(4-fluorophenoxy)piperidin-1-yl; 4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-methoxyphenyl)piperidin-1-yl; 4-((3RS)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidin-1-yl; 4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-pyridinyloxy)piperidin-1-yl; 4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(3-chloro-4-fluorophenoxy)piperidin-1-yl; 4-((2-methylbenzyl)oxy)piperidin-1-yl; 4-(3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-methylphenoxy)piperidin-1-yl; 4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-((2-biphenyl)methyl)(methyl)amino)piperidin-1-yl; 4-(4-chlorophenyl)piperidin-1-yl; 4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl; 4-(2-chlorophenoxy)piperidin-1-yl; 4-(4-bromophenyl)-4-hydroxypiperidin-1-yl; 4-(3-phenylpropoxy)piperidin-1-yl; 4-(2-chloro-4-fluorophenoxy)piperidin-1-yl; 4-(3-chloro-4-cyanophenoxy)piperidin-1-yl; 4-butoxypiperidin-1-yl; 4-(2-methylphenoxy)piperidin-1-yl; 4-(2,4-difluorophenoxy)piperidin-1-yl; 4-(3,4-difluorophenoxy)piperidin-1-yl; (3S)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenylcarbonyl)piperidin-1-yl; 4-(phenylsulfanyl)piperidin-1-yl; 4-(4-fluorophenyl)piperidin-1-yl; 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl; 4-((3-methylbenzyl)oxy)piperidin-

1-yl; 4-((3-cyanophenyl)amino)piperidin-1-yl; 4-((4-chlorophenyl)amino)piperidin-1-yl; 4-((3-chlorobenzyl)oxy)piperidin-1-yl; 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl; 4-(2,3-difluorophenoxy)piperidin-1-yl; 4-hydroxy-4-phenylpiperidin-1-yl; 4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(2-chloro-5-methylphenoxy)piperidin-1-yl; 4-(3-phenyl-5-isoxazolyl)piperidin-1-yl; 4-(3-propyl-5-isoxazolyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(1-naphthalenyloxy)piperidin-1-yl; 4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-benzyl-4-hydroxypiperidin-1-yl); 4-benzylpiperidin-1-yl; 4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)piperidin-1-yl; 4-(2-methoxyphenoxy)piperidin-1-yl; 4-(3-(acetylamino)-phenoxy)-piperidin-1-yl; 4-benzyl-1,4'-bipiperidin-1'-yl; 4-(2-cyclohexylethoxy)piperidin-1-yl; 4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((3-chloro-4-cyanophenyl)amino)-piperidin-1-yl; 4-ethoxypiperidin-1-yl; 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-methoxypiperidin-1-yl; 4-(3-bromophenoxy)piperidin-1-yl; 4-(2-(1-methylethyl)phenoxy)-piperidin-1-yl; 4-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; (3RS)-3-(2-cyano-phenoxy)piperidin-1-yl; 4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl; (3RS)-3-(2-methoxy-4-methylphenoxy)piperidin-1-yl; 4-(2-cyanophenoxy)piperidin-1-yl; 4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-chloro-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((6-methyl-3-pyridinyl)oxy)piperidin-1-yl; 4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2-fluorophenoxy)piperidin-1-yl; 4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(1-pyrrolidinyl)piperidin-1-yl; 4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,4-dichlorophenoxy)piperidin-1-yl; 4-(cyclopropyl-methoxy)-piperidin-1-yl; 4-ethoxycarbonylpiperidin-1-yl; 4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; (3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-propyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinoliny)lpiperidin-1-yl; 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-bromophenoxy)piperidin-1-yl; 4-((4-methylphenyl)sulfanyl)piperidin-1-yl; 4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)methyl)piperazin-1-yl)piperidin-1-yl; 4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(5,6,7,8-tetrahydro-1-naphthalenylamino)piperidin-1-yl; (3RS)-3-(4-chlorophenoxy)piperidin-1-yl; 4-phenyl-4-propanoylpiperidin-1-yl; (2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(4-tert-butylphenoxy)piperidin-1-yl; 4-(2-propylaminocarbonylphenoxy)piperidin-1-yl; 4-(3-pyridinyloxy)piperidin-1-yl; 4-((4-methoxyphenyl)amino)piperidin-1-yl; 4-((2-

(trifluoromethyl)-phenyl)amino)piperidin-1-yl; 4-(phenylsulfonyl)piperidin-1-yl; 4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(2-pyrimidinyl-oxy)piperidin-1-yl; 4-(2-biphenyloxy)piperidin-1-yl; (3RS)-3-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-pyridinyloxy)piperidin-1-yl; 4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(methyl(2-(trifluoromethoxy)phenyl)amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)-sulfonyl)piperidin-1-yl; 4-(6-quinolinylamino)piperidin-1-yl; 4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl; 4-(benzylsulfonyl)-piperidin-1-yl; 4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl; 4-(4-(2-pyrimidinyl)piperazin-1-yl)piperidin-1-yl; 4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl; 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl; (3RS)-3-(4-cyano-2-methoxyphenoxy)piperidin-1-yl; 4-aminocarbonyl-piperidin-1-yl; 4-(4-(8-quinolinyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-carboxypiperidin-1-yl; 4-((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(4-((dimethylamino)methyl)phenoxy)piperidin-1-yl; 4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-biphenyl)piperidin-1-yl; 4-(2-biphenyl)piperidin-1-yl; 4-(4-CF₃-benzyloxy)piperidin-1-yl; 4-(4-CF₃O-benzyloxy)piperidin-1-yl; 4-(4-Br-benzyloxy)piperidin-1-yl; 4-(3,4-difluoro-benzyloxy)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-Cl-3-F-phenoxy)piperidin-1-yl; 4-(3-CF₃-benzyloxy)piperidin-1-yl; 4-(4-Cl-3-CH₃-phenoxy)piperidin-1-yl; 4-(4-F-benzyloxy)piperidin-1-yl; 4-(2,6-diF-benzyloxy)piperidin-1-yl; 4-(benzthiazol-2-yl)piperidin-1-yl; 4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-Cl-4-CN-phenyl)piperidin-1-yl; 4-(benzoxazol-2-yl)piperidin-1-yl; 4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-(4-chloro-3-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-(4-cyano-3-methylphenyl)piperidin-1-yl; 4-(2-cyanobenzyloxy)piperidin-1-yl; 4-(2-CF₃benzyloxy)piperidin-1-yl; 4-(1-RS-1-phenylethoxy)-piperidin-1-yl; 4-(4-chloro-3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-chlorobenzoyl)piperidin-1-yl; 4-(4-dimethylaminophenyl)piperidin-1-yl; 4-(2-CF₃phenyl)piperidin-1-yl; 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl; 4-(3-OCF₃benzyloxy)piperidin-1-yl; 4-(2-OCF₃benzyloxy)-piperidin-1-yl; 4-(4-butylbenzyloxy)piperidin-1-yl; 4-(4-isopropylbenzyloxy)-piperidin-1-yl; 4-(4-methylbenzyloxy)piperidin-1-yl; 4-(4-OCHF₂benzyloxy)piperidin-1-yl; 4-(2,4,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3-difluorobenzyloxy)-piperidin-1-yl; 4-(2,4-difluorobenzyloxy)-piperidin-1-yl; 4-(2,3,4-

trifluorobenzyloxy)-piperidin-1-yl; 4-(4-cyanobenzyloxy)-piperidin-1-yl; 4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl; 4-(4-chlorobenzyloxy)-piperidin-1-yl; 4-(3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃benzyloxy)-piperidin-1-yl; 3-fluoro-4-(phenyl)-piperidin-1-yl; 4-(3-cyanophenoxy)-piperidin-1-yl; 4-(4-cyanophenoxy)-piperidin-1-yl; 4-methyl-4-(4-trifluoromethoxybenzyloxy)-piperidin-1-yl; 4-[4-(2-methoxyethoxy)benzyloxy]-piperidin-1-yl; (3R,4R)-3-fluoro-4-phenyl-piperidin-1-yl; (3S,4S)-3-fluoro-4-phenyl-piperidin-1-yl; 4-(4-tert-butylbenzyloxy)-piperidin-1-yl; 4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl; 4-benzyl-4-fluoropiperidin-1-yl; 4-(2-methylsulfonylphenoxy)-piperidin-1-yl; 4-(3-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(4-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(3-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(2,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,4-diCF₃benzyloxy)-piperidin-1-yl; 4-(2-fluorobenzyloxy)-piperidin-1-yl; 4-(3-fluorobenzyloxy)-piperidin-1-yl; 4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,5-difluorobenzyloxy)-piperidin-1-yl; 4-(2,5-diCF₃benzyloxy)-piperidin-1-yl; 3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl; 4-(2,3-dichlorophenoxy)-piperidin-1-yl; 4-(3-chloro-4-methylphenoxy)-piperidin-1-yl; 4-(4-chloro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-chlorophenoxy)-piperidin-1-yl; 4-(3,4-dimethylphenoxy)-piperidin-1-yl; 4-(2,3-dimethylphenoxy)-piperidin-1-yl; 4-(3,4-dihydro-(1H)-isoquinolin-2-yl)-piperidin-1-yl; 4-(3-thiophenylmethoxy)-piperidin-1-yl; 4-(2-fluoro-5-OCF₃phenoxy)-piperidin-1-yl; 4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃phenoxy)-piperidin-1-yl; 4-(4-fluoro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(2,6-difluorophenoxy)-piperidin-1-yl; 4-(3-fluorophenoxy)-piperidin-1-yl; 4-(2-fluorophenoxy)-piperidin-1-yl; 4-(2,4,6-trifluorophenoxy)-piperidin-1-yl; 4-(2,3,6-trifluorophenoxy)-piperidin-1-yl; 4-(4-CF₃phenoxy)-piperidin-1-yl; 4-(4-OCF₃phenoxy)-piperidin-1-yl; 4-(2,3,4-trifluorophenoxy)-piperidin-1-yl; 4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-piperidin-1-yl; 4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)-piperidin-1-yl; 4-phenylethynylpiperidin-1-yl; 4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)-piperidin-1-yl; 4-(3,5-difluorophenoxy)-piperidin-1-yl; 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-piperidin-1-yl; 4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)-piperidin-1-yl; 4-(phenoxy)-piperidin-1-yl; 4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-piperidin-1-yl; 4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-piperidin-1-yl; 4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl; 4-(4-chlorobenzyloxy)-piperidin-1-yl; 4-(4-CF₃phenyl)-piperidin-1-yl; 4-(3,4-dimethylphenyl)-piperidin-1-yl; 4-(4(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl; 4-(4-chloro-2-OCF₃phenoxy)-piperidin-1-yl; 4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl; 4-(2-fluorophenyl)-

piperidin-1-yl; 4-(3-fluorophenyl)piperidin-1-yl; 4-(4-cyano-3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-CF₃phenyl)-piperidin-1-yl; 4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl; 4-(pyridin-2-yloxy)-piperidin-1-yl; 4-phenylpiperazin-1-yl; 4-(3-methylphenyl)piperazin-1-yl; 4-(2,5-dimethylphenyl)piperazin-1-yl; 4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl)piperazin-1-yl; 4-(2-methylphenyl)piperazin-1-yl; 4-(2-methoxyphenyl)-piperazin-1-yl; 4-(2,3-dichlorophenyl)piperazin-1-yl; 4-(5-chloro-2-methoxyphenyl)-piperazin-1-yl; 4-(2-chlorophenyl)piperazin-1-yl; 4-(3-chlorophenyl)piperazin-1-yl; 4-(3-methoxyphenyl)piperazin-1-yl; 4-(4-fluorophenyl)piperazin-1-yl; 4-(3,4-dimethylphenyl)-piperazin-1-yl; 4-(2-acetylphenyl)piperazin-1-yl; 4-(2-fluorophenyl)piperazin-1-yl; 4-(3-trifluoromethylphenyl)piperazin-1-yl; 4-(2,3-dimethylphenyl)piperazin-1-yl; 4-(2-biphenyl)piperazin-1-yl; 4-(4-methoxyphenyl)piperazin-1-yl; 4-(3,4-dichlorophenyl)-piperazin-1-yl; 4-(2-hydroxyphenyl)piperazin-1-yl; 4-(2-ethoxyphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(4-chlorophenyl)piperazin-1-yl; 3-cyano-2-pyridinylpiperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-cyanophenyl)piperazin-1-yl; 4-(4-hydroxyphenyl)piperazin-1-yl; 4-(4-methyl-2-pyridinyl)-piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(1,2-benzisoxazol-3-yl)piperazin-1-yl; 4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl; 4-(3,5-dichlorophenyl)piperazin-1-yl; 4-(tetrahydro-2-furanylmethyl)piperazin-1-yl; 4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl; 4-(2-furanylcabonyl)piperazin-1-yl; 4-(4-(1-methylethyl)piperazin-1-yl; 4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl; 4-(2-chloro-6-fluorobenzyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl; 4-(3-pyridinylmethyl)piperazin-1-yl; 4-((3-fluorophenyl)carbonyl)piperazin-1-yl; 4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl; 4-((2-(trifluoromethyl)phenyl)carbonyl)piperazin-1-yl; 4-(3-hydroxypropyl)piperazin-1-yl; 4-(3-methoxybenzyl)-3-oxopiperazin-1-yl; 4-(tetrahydro-2 (RS)-furanylcabonyl)piperazin-1-yl; 4-(4-CF₃phenyl)piperazin-1-yl; 4-(2-CNphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-bromobenzyl)piperazin-1-yl; 4-(3,4-dichlorobenzyl)piperazin-1-yl; 4-(2-phenylethyl)-piperazin-1-yl; 4-(3,4-difluorophenyl)piperazin-1-yl; 4-(3-OCF₃benzyl)piperazin-1-yl; 4-(4-chlorobenzyl)piperazin-1-yl; 4-(4-tert-butylbenzyl)piperazin-1-yl; 4-(2,4-difluorophenyl)piperazin-1-yl; 4-(3-chloro-4-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-methylphenyl)-piperazin-1-yl; 4-(3-fluoro-4-methylphenyl)-piperazin-1-yl; 4-(4-fluoro-3-methylphenyl)-piperazin-1-yl; 4-(4-chloro-2-fluorophenyl)-piperazin-1-yl; 4-(3,4-difluorobenzyl)piperazin-1-yl; 4-(3,4-dimethylbenzyl)piperazin-1-yl; 4-(3-CF₃benzyl)piperazin-1-yl; 4-(4-fluorobenzyl)piperazin-1-

yl; 4-(7-chloroquinolin-4-yl)-piperazin-1-yl; 4-(3-chlorobenzyl)piperazin-1-yl; 4-(2-fluorobenzyl)piperazin-1-yl; 4-(3-fluorobenzyl)piperazin-1-yl; 4-(4-(2-methoxyethoxy)phenyl)-piperazin-1-yl; 4-(2-OCF₃benzyl)piperazin-1-yl; 4-(2-SCH₃phenyl)piperazin-1-yl; 4-(2-CF₃phenyl)piperazin-1-yl; 4-(pyridin-2-yl)piperazin-1-yl; 4-(6-methylpyridin-2-yl)piperazin-1-yl; 4-(5-chloropyridin-2-yl)piperazin-1-yl; 4-(5,6-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4-OCF₃benzyl)piperazin-1-yl; 4-(3-OCF₃phenyl)piperazin-1-yl; 4-(4-OCF₃phenyl)-piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-biphenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(4-CN-2-CH₃-phenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(3-biphenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(4-cyano-2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chloro-4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 2-fluoro-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-cyano-2,3-difluorophenyl-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(3,4-dimethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-methylphenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-fluoromethoxyphenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-phenyl-3,6-dihydro-(2H)-pyridin-1-yl; (2RS)-2-phenyl-1-pyrrolidinyl; 3-(4-fluorophenoxy)azetidin-1-yl; 3-(phenoxy)azetidin-1-yl; 4-(4-fluoro-3-methylphenoxy)-pyrrolidin-1-yl; 3-(3,4-dichlorophenoxy)azetidin-1-yl; 4-(2-chlorophenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethoxy-benzyloxy)azetidin-1-yl; 3-(2,5-difluorophenoxy)azetidin-1-yl; 3-(3-fluoro-4-trifluoromethoxy-phenoxy)-azetidin-1-yl; 3-(2-chloro-4-trifluoromethyl-phenoxy)-azetidin-1-yl; 3-(4-chloro-3-fluorophenoxy)-azetidin-1-yl; 3-(3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluoro-4-methylphenoxy)-azetidin-1-yl; 3-(3-trifluoromethoxyphenoxy)-azetidin-1-yl; 3-(2-trifluoromethylphenoxy)-azetidin-1-yl; 3-(4-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluorophenoxy)-azetidin-1-yl; 3-(3,4-difluorophenoxy)-azetidin-1-yl; 3-(2,3-difluorophenoxy)-azetidin-1-yl; 3-(2,4-difluorophenoxy)-azetidin-1-yl; 3-(2,6-difluorophenoxy)-azetidin-1-yl; 3-(4-cyanophenoxy)-azetidin-1-yl; 3-(4-CF₃phenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethyl-phenoxy)-azetidin-1-yl; or 3-(4-chlorophenoxy)azetidin-1-yl.

Even more preferably, ring B is 4-(benzyloxy)piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl; 4-(4-chlorophenoxy)piperidin-1-yl; 4-phenylpiperidin-1-yl; 4-(4-cyanophenyl)piperidin-1-yl; 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(benzylsulfanyl)piperidin-1-yl; 4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl; 4-(4-fluorophenoxy)piperidin-1-yl; 4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-methoxyphenyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidin-1-yl; 4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-pyridinyloxy)piperidin-1-yl; 4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(3-chloro-4-fluorophenoxy)piperidin-1-yl; 4-((2-methylbenzyl)oxy)piperidin-1-yl; 4-(3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-methylphenoxy)piperidin-1-yl; 4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-((2-biphenylmethyl)(methyl)amino)piperidin-1-yl; 4-(4-chlorophenyl)piperidin-1-yl; 4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl; 4-(2-chlorophenoxy)piperidin-1-yl; 4-(4-bromophenyl)-4-hydroxypiperidin-1-yl; 4-(3-phenylpropoxy)piperidin-1-yl; 4-(2-chloro-4-fluorophenoxy)piperidin-1-yl; 4-(3-chloro-4-cyanophenoxy)piperidin-1-yl; 4-butoxypiperidin-1-yl; 4-(2-methylphenoxy)piperidin-1-yl; 4-(2,4-difluorophenoxy)piperidin-1-yl; 4-(3,4-difluorophenoxy)piperidin-1-yl; (3S)-3-phenyl-1-pyrrolidinylpiperidin-1-yl; 4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenylcarbonyl)piperidin-1-yl; 4-(phenylsulfanyl)piperidin-1-yl; 4-(4-fluoro-phenyl)piperidin-1-yl; 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl; 4-((3-methylbenzyl)oxy)piperidin-1-yl; 4-((3-cyanophenyl)amino)piperidin-1-yl; 4-((4-chlorophenyl)amino)piperidin-1-yl; 4-((3-chlorobenzyl)oxy)piperidin-1-yl; 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl; 4-(2,3-difluorophenoxy)piperidin-1-yl; 4-hydroxy-4-phenylpiperidin-1-yl; 4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(2-chloro-5-methylphenoxy)piperidin-1-yl; 4-(3-phenyl-5-isoxazolyl)piperidin-1-yl; 4-(3-propyl-5-isoxazolyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(1-naphthalenyloxy)piperidin-1-yl; 4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-benzyl-4-hydroxypiperidin-1-yl); 4-benzylpiperidin-1-yl; 4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)piperidin-1-yl; 4-(2-methoxyphenoxy)piperidin-1-yl; 4-(3-(acetlamino)phenoxy)piperidin-1-yl; 4-benzyl-1,4'-bipiperidin-1'-yl; 4-(2-cyclohexylethoxy)piperidin-1-yl; 4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((3-chloro-4-cyanophenyl)amino)piperidin-1-yl; 4-ethoxypiperidin-1-yl; 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-

methoxypiperidin-1-yl; 4-(3-bromophenoxy)piperidin-1-yl; 4-(2-(1-methylethyl)phenoxy)-
piperidin-1-yl; 4-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; (3RS)-3-(2-cyanophenoxy)-
piperidin-1-yl; 4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl; (3RS)-3-(2-methoxy-4-
methylphenoxy)piperidin-1-yl; 4-(2-cyanophenoxy)piperidin-1-yl; 4-(3-(4-chlorophenyl)-
5 1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-chloro-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-
(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((6-methyl-3-pyridinyl)oxy)piperidin-1-
yl; 4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-methylphenyl)-1H-pyrazol-1-
yl)piperidin-1-yl; 4-(2-fluorophenoxy)piperidin-1-yl; 4-(4-(4-(trifluoromethyl)phenyl)-1H-
pyrazol-1-yl)piperidin-1-yl; 4-(1-pyrrolidinyl)piperidin-1-yl; 4-(4-(4-(methylsulfonyl)phenyl)-
10 1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,4-dichlorophenoxy)piperidin-1-yl; 4-(cyclopropyl-
methoxy)piperidin-1-yl; 4-ethoxycarbonylpiperidin-1-yl; 4-(4-(2,5-dimethoxyphenyl)-1H-
pyrazol-1-yl)piperidin-1-yl; (3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(2-
chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-propyl-1H-1,2,3-triazol-1-
yl)piperidin-1-yl; 4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinoliny)l)piperidin-1-yl; 4-hydroxy-4-
15 (4-(trifluoromethyl)phenyl)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-
yl)piperidin-1-yl; 4-(4-bromophenoxy)piperidin-1-yl; 4-((4-methylphenyl)sulfanyl)piperidin-1-
yl; 4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)methyl)piperazin-
1-yl)piperidin-1-yl; 4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(5,6,7,8-tetrahydro-1-
naphthalenylamino)piperidin-1-yl; (3RS)-3-(4-chlorophenoxy)piperidin-1-yl; 4-phenyl-4-
20 propanoylpiperidin-1-yl; (2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(4-tert-
butylphenoxy)piperidin-1-yl; 4-(2-propylaminocarbonylphenoxy)piperidin-1-yl; 4-(3-
pyridinyloxy)piperidin-1-yl; 4-((4-methoxyphenyl)amino)piperidin-1-yl; 4-((2-
(trifluoromethyl)phenyl)amino)piperidin-1-yl; 4-(phenylsulfonyl)piperidin-1-yl; 4-(4-(2-
chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-(4-cyanophenyl)-1H-pyrazol-1-
25 yl)piperidin-1-yl; 4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(2-
pyrimidinyloxy)piperidin-1-yl; 4-(2-biphenylyloxy)piperidin-1-yl; (3RS)-3-(5-methyl-1H-
benzimidazol-2-yl)piperidin-1-yl; 4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-
1-yl; 4-(4-pyridinyloxy)piperidin-1-yl; 4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-
yl)piperidin-1-yl; 4-(methyl(2-(trifluoromethoxy)phenyl)amino)piperidin-1-yl; 4-((2-
30 (trifluoromethyl)phenyl)sulfonyl)piperidin-1-yl; 4-(6-quinoliny)lamino)piperidin-1-yl; 4-(3-(4-
(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethyl)phenyl)-
1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl; 4-
(benzylsulfonyl)piperidin-1-yl; 4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl; 4-(4-(2-
pyrimidinyl)piperazin-1-yl)piperidin-1-yl; 4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-

yl)piperidin-1-yl; 4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl; 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl; (3RS)-3-(4-cyano-2-methoxyphenoxy)-piperidin-1-yl; 4-aminocarbonylpiperidin-1-yl; 4-(4-(8-quinolinyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-carboxypiperidin-1-yl; 4-((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(4-((dimethylamino)methyl)phenoxy)piperidin-1-yl; 4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-biphenyl)piperidin-1-yl; 4-(2-biphenyl)piperidin-1-yl; 4-(4-CF₃-benzyloxy)piperidin-1-yl; 4-(4-CF₃O-benzyloxy)piperidin-1-yl; 4-(4-Br-benzyloxy)piperidin-1-yl; 4-(3,4-difluoro-benzyloxy)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-Cl-3-F-phenoxy)piperidin-1-yl; 4-(3-CF₃-benzyloxy)piperidin-1-yl; 4-(4-Cl-3-CH₃-phenoxy)piperidin-1-yl; 4-(4-F-benzyloxy)piperidin-1-yl; 4-(2,6-diF-benzyloxy)piperidin-1-yl; 4-(benzthiazol-2-yl)piperidin-1-yl; 4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-Cl-4-CN-phenyl)piperidin-1-yl; 4-(benzoxazol-2-yl)piperidin-1-yl; 4-(4-trifluoromethoxy-benzyloxy)-piperidin-1-yl; 4-(4-chloro-3-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-(4-cyano-3-methylphenyl)piperidin-1-yl; 4-(2-cyanobenzyloxy)piperidin-1-yl; 4-(2-CF₃benzyloxy)-piperidin-1-yl; 4-(1-RS-1-phenylethoxy)-piperidin-1-yl; 4-(4-chloro-3,5-dimethylphenoxy)-piperidin-1-yl; 4-(4-chlorobenzoyl)piperidin-1-yl; 4-(4-dimethylaminophenyl)piperidin-1-yl; 4-(2-CF₃phenyl)piperidin-1-yl; 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl; 4-(3-OCF₃benzyloxy)-piperidin-1-yl; 4-(2-OCF₃benzyloxy)piperidin-1-yl; 4-(4-butylbenzyloxy)-piperidin-1-yl; 4-(4-isopropylbenzyloxy)-piperidin-1-yl; 4-(4-methylbenzyloxy)piperidin-1-yl; 4-(4-OCHF₂benzyloxy)piperidin-1-yl; 4-(2,4,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3-difluorobenzyloxy)-piperidin-1-yl; 4-(2,4-difluorobenzyloxy)-piperidin-1-yl; 4-(2,3,4-trifluorobenzyloxy)-piperidin-1-yl; 4-(4-cyanobenzyloxy)-piperidin-1-yl; 4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl; 4-(4-chlorobenzyl)piperidin-1-yl; 4-(3-OCF₃phenoxy)piperidin-1-yl; 4-(3-fluoro-4-OCF₃benzyloxy)-piperidin-1-yl; 3-fluoro-4-(phenyl)piperidin-1-yl; 4-(3-cyanophenoxy)-piperidin-1-yl; 4-(4-cyanophenoxy)piperidin-1-yl; 4-methyl-4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-[4-(2-methoxyethoxy)benzyloxy]piperidin-1-yl; (3R,4R)-3-fluoro-4-phenyl-piperidin-1-yl; (3S,4S)-3-fluoro-4-phenyl-piperidin-1-yl; 4-(4-tert-butylbenzyloxy)-piperidin-1-yl; 4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl; 4-benzyl-4-fluoropiperidin-1-yl; 4-(2-methylsulfonylphenoxy)-piperidin-1-yl; 4-(3-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(4-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(3-

fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(2,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,4-diCF₃benzyloxy)piperidin-1-yl; 4-(2-fluorobenzyloxy)piperidin-1-yl; 4-(3-fluorobenzyloxy)piperidin-1-yl; 4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,5-difluorobenzyloxy)piperidin-1-yl; 4-(2,5-diCF₃benzyloxy)piperidin-1-yl; 3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)piperidin-1-yl; 4-(2,3-dichlorophenoxy)piperidin-1-yl; 4-(3-chloro-4-methylphenoxy)-piperidin-1-yl; 4-(4-chloro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-chlorophenoxy)piperidin-1-yl; 4-(3,4-dimethylphenoxy)-piperidin-1-yl; 4-(2,3-dimethylphenoxy)-piperidin-1-yl; 4-(3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(3-thiophenylmethoxy)-piperidin-1-yl; 4-(2-fluoro-5-OCF₃phenoxy)-piperidin-1-yl; 4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃phenoxy)-piperidin-1-yl; 4-(4-fluoro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(2,6-difluorophenoxy)-piperidin-1-yl; 4-(3-fluorophenoxy)-piperidin-1-yl; 4-(2-fluorophenoxy)-piperidin-1-yl; 4-(2,4,6-trifluorophenoxy)-piperidin-1-yl; 4-(2,3,6-trifluorophenoxy)-piperidin-1-yl; 4-(4-CF₃phenoxy)-piperidin-1-yl; 4-(4-OCF₃phenoxy)-piperidin-1-yl; 4-(2,3,4-trifluorophenoxy)-piperidin-1-yl; 4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-phenylethynylpiperidin-1-yl; 4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,5-difluorophenoxy)-piperidin-1-yl; 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenoxy)-piperidin-1-yl; 4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl; 4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl; 4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl; 4-(4-chlorobenzyloxy)piperidin-1-yl; 4-(4-CF₃phenyl)piperidin-1-yl; 4-(3,4-dimethylphenyl)piperidin-1-yl; 4-(4-(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl; 4-(4-chloro-2-OCF₃phenoxy)-piperidin-1-yl; 4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl; 4-(2-fluorophenyl)piperidin-1-yl; 4-(3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-CF₃phenyl)-piperidin-1-yl; 4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl; 4-(pyridin-2-yloxy)-piperidin-1-yl; 4-phenylpiperazin-1-yl; 4-(3-methylphenyl)piperazin-1-yl; 4-(2,5-dimethylphenyl)piperazin-1-yl; 4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl)piperazin-1-yl; 4-(2-methylphenyl)piperazin-1-yl; 4-(2-methoxyphenyl)piperazin-1-yl; 4-(2,3-dichlorophenyl)-piperazin-1-yl; 4-(5-chloro-2-methoxyphenyl)piperazin-1-yl; 4-(2-chlorophenyl)-piperazin-1-yl; 4-(3-chlorophenyl)piperazin-1-yl; 4-(3-methoxyphenyl)piperazin-1-yl; 4-(4-fluorophenyl)piperazin-1-yl; 4-(3,4-dimethylphenyl)piperazin-1-yl; 4-(2-acetylphenyl)-piperazin-1-yl; 4-(2-fluorophenyl)piperazin-1-yl; 4-(3-trifluoromethylphenyl)piperazin-1-yl; 4-

(2,3-dimethylphenyl)piperazin-1-yl; 4-(2-biphenyl)piperazin-1-yl; 4-(4-methoxyphenyl)-piperazin-1-yl; 4-(3,4-dichlorophenyl)piperazin-1-yl; 4-(2-hydroxyphenyl)piperazin-1-yl; 4-(2-ethoxyphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(4-chlorophenyl)piperazin-1-yl; 3-cyano-2-pyridinylpiperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-cyanophenyl)piperazin-1-yl; 4-(4-hydroxyphenyl)-piperazin-1-yl; 4-(4-methyl-2-pyridinyl)piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(1,2-benzisoxazol-3-yl)piperazin-1-yl; 4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl; 4-(3,5-dichlorophenyl)piperazin-1-yl; 4-(tetrahydro-2-furanylmethyl)piperazin-1-yl; 4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl; 4-(2-furanylcarbonyl)piperazin-1-yl; 4-(4-(1-methylethyl)piperazin-1-yl; 4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl; 4-(2-chloro-6-fluorobenzyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl; 4-(3-pyridinylmethyl)piperazin-1-yl; 4-((3-fluorophenyl)carbonyl)piperazin-1-yl; 4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl; 4-((2-(trifluoromethyl)phenyl)-carbonyl)piperazin-1-yl; 4-(3-hydroxypropyl)piperazin-1-yl; 4-(3-methoxybenzyl)-3-oxopiperazin-1-yl; 4-(tetrahydro-2 (RS)-furanylcarbonyl)piperazin-1-yl; 4-(4-CF₃phenyl)-piperazin-1-yl; 4-(2-CNphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-bromobenzyl)piperazin-1-yl; 4-(3,4-dichlorobenzyl)piperazin-1-yl; 4-(2-phenylethyl)piperazin-1-yl; 4-(3,4-difluorophenyl)-piperazin-1-yl; 4-(3-OCF₃benzyl)piperazin-1-yl; 4-(4-chlorobenzyl)piperazin-1-yl; 4-(4-tert-butylbenzyl)piperazin-1-yl; 4-(2,4-difluorophenyl)piperazin-1-yl; 4-(3-chloro-4-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-methylphenyl)-piperazin-1-yl; 4-(3-fluoro-4-methylphenyl)-piperazin-1-yl; 4-(4-fluoro-3-methylphenyl)-piperazin-1-yl; 4-(4-chloro-2-fluorophenyl)-piperazin-1-yl; 4-(3,4-difluorobenzyl)piperazin-1-yl; 4-(3,4-dimethylbenzyl)piperazin-1-yl; 4-(3-CF₃benzyl)-piperazin-1-yl; 4-(4-fluorobenzyl)piperazin-1-yl; 4-(7-chloroquinolin-4-yl)-piperazin-1-yl; 4-(3-chlorobenzyl)piperazin-1-yl; 4-(2-fluorobenzyl)piperazin-1-yl; 4-(3-fluorobenzyl)piperazin-1-yl; 4-(4-(2-methoxyethoxy)phenyl)-piperazin-1-yl; 4-(2-OCF₃benzyl)piperazin-1-yl; 4-(2-SCH₃phenyl)piperazin-1-yl; 4-(2-CF₃phenyl)piperazin-1-yl; 4-(pyridin-2-yl)piperazin-1-yl; 4-(6-methylpyridin-2-yl)piperazin-1-yl; 4-(5-chloropyridin-2-yl)piperazin-1-yl; 4-(5,6-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4-OCF₃benzyl)piperazin-1-yl; 4-(3-OCF₃phenyl)piperazin-1-yl; 4-(4-OCF₃phenyl)-piperazin-1-yl; or 4-(2-chlorobenzyl)piperazin-1-yl.

Even more preferably, B is 5-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(2-fluorophenyl)piperidin-1-yl, 4-(3-fluorophenyl)piperidin-1-yl, 4-((4-

chlorophenoxy)methyl)piperidin-1-yl, 4-(4-(trifluoromethyl)phenyl)piperidin-1-yl, 4-(3-(trifluoromethoxy)phenyl)piperazin-1-yl, 4-(4-(3-biphenyl)l)piperidin-1-yl, 4-(2,5-dimethylphenyl)piperazin-1-yl, 4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl, 6-(2,2,2-trifluoroethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-chlorophenyl)piperidin-1-yl, 4-(4-(phenoxy)methyl)piperidin-1-yl, 6-(3-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-chloro-3-methylphenyl)piperazin-1-yl, 4-(3-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(3-chlorophenyl)piperidin-1-yl, 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl, 6-(3,3,3-trifluoropropoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-chloro-3-fluorophenyl)piperazin-1-yl, 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl, 4-((4-(trifluoromethyl)benzyl)oxy)piperidin-1-yl, 4-(3-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(3-fluoro-4-methylphenyl)piperazin-1-yl, 4-(2,3-dichlorophenyl)piperazin-1-yl, 4-((4-(trifluoromethoxy)benzyl)oxy)piperidin-1-yl, 6-(2-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-chlorophenoxy)piperidin-1-yl, 4-(3-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl, 4-(3-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-((4-bromobenzyl)oxy)piperidin-1-yl, 4-(4-(2,2,2-trifluoroethoxy)phenoxy)piperidin-1-yl, 4-(4-fluorophenyl)piperidin-1-yl, 4-(4-phenyl)piperidin-1-yl, 4-(4-fluoro-3-methylphenyl)piperazin-1-yl, 4-(3-fluoro-4-(trifluoromethoxy)phenoxy)piperidin-1-yl, 4-(3-fluorophenoxy)piperidin-1-yl, 4-(3-(3-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl, 4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)piperidin-1-yl, 4-(2-(4-chlorophenyl)ethyl)piperidin-1-yl, 4-((4-(1-methylethyl)benzyl)oxy)piperidin-1-yl, 4-(3-chloro-4-fluorophenyl)piperazin-1-yl, 4-(3-(trifluoromethoxy)phenoxy)piperidin-1-yl, 6-(difluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-(trifluoromethyl)phenyl)piperazin-1-yl, 4-(4-(phenylethynyl)piperidin-1-yl, 4-(4-(trifluoromethoxy)benzyl)piperazin-1-yl, 6-(1,3-thiazol-4-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl, 4-(4-chloro-3-fluorophenoxy)piperidin-1-yl, 4-(3-chlorophenoxy)piperidin-1-yl, 4-(3,4-dimethylphenyl)piperazin-1-yl, 4-(3-chlorophenyl)piperazin-1-yl, 4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)piperidin-1-yl, 4-(2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 1,3,5-triazin-2-yl, 4-(4-chlorophenyl)piperazin-1-yl, 4-(2-(trifluoromethoxy)phenyl)piperazin-1-yl, 4-((4-fluoro-3-(trifluoromethyl)benzyl)oxy)piperidin-1-yl, 4-((3-fluoro-4-(trifluoromethoxy)benzyl)oxy)piperidin-1-yl, 4-((4-methylbenzyl)oxy)piperidin-1-yl, 6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(2-methylphenyl)piperazin-1-yl,

4-(3-(2-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl, 4-(2-chlorophenyl)piperazin-1-yl, 4-(2-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-cyano-3,5-difluorophenyl)piperidin-1-yl, 4-(4-chloro-3-(trifluoromethoxy)phenoxy)-piperidin-1-yl, 3-(3-fluoro-4-(trifluoromethoxy)phenoxy)azetidin-1-yl, 4-((4-(2,2,2-trifluoroethoxy)benzyl)oxy)piperidin-1-yl, 4-((3-(trifluoromethyl)benzyl)oxy)piperidin-1-yl, 3-(2-chloro-4-(trifluoromethyl)phenoxy)azetidin-1-yl, 4-(4-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-((2,4,6-trifluorobenzyl)oxy)piperidin-1-yl, 4-(4-fluoro-3-(trifluoromethoxy)phenoxy)piperidin-1-yl, 4-phenoxy piperidin-1-yl, 4-((2,4,5-trifluorobenzyl)oxy)piperidin-1-yl, 4-((2,4-difluorobenzyl)oxy)piperidin-1-yl, 4-((4-(difluoromethoxy)benzyl)oxy)piperidin-1-yl, 4-((3,4-difluorobenzyl)oxy)piperidin-1-yl, 4-(4-cyano-3-(trifluoromethyl)phenyl)piperidin-1-yl, 6-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-((2,3,4-trifluorobenzyl)oxy)piperidin-1-yl, 5-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-((3,4,5-trifluorobenzyl)oxy)piperidin-1-yl, 4-(3,4-difluorophenyl)piperazin-1-yl, 4-(3,4-dichlorophenyl)piperazin-1-yl, 4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 3-(4-chloro-3-fluorophenoxy)azetidin-1-yl, 4-((2,3,6-trifluorobenzyl)oxy)piperidin-1-yl, 4-(2-methylphenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(3-methylphenyl)piperazin-1-yl, 3-(3,4-dichlorophenoxy)azetidin-1-yl, 4-(4-cyano-2-methylphenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 3-((4-(trifluoromethoxy)benzyl)oxy)azetidin-1-yl, 3-(4-chlorophenoxy)azetidin-1-yl, 5-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl, 6-(1,3-thiazol-5-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(2-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(2-(trifluoromethyl)phenyl)piperazin-1-yl, 4-(2-fluorophenyl)piperazin-1-yl, 4-(5-chloro-2-pyridinyl)piperazin-1-yl, 2-(4-(trifluoromethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl, 6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl, 4-(4-cyano-2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl, 4-(1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl, 4-(4-chloro-2-fluorophenyl)piperazin-1-yl, 2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl, or 2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl.

4D'. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A and 4B and groups contained therein, in one group of compound R⁵ is hydrogen, alkyl, substituted alkyl, aryl, or heteroaryl; and R⁶ is aryl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or aralkyl wherein one or two carbon atoms in the alkyl chain in aralkyl are optionally replaced by -N-, -O-, or -CO- provided that -N-, -O-, or -CO- are not on adjacent atoms, preferably 3-(4-(trifluoromethoxy)phenoxy)propyl)amino, 3-(4-(1-methylethyl)phenyl)propyl)amino, 3-(2-(benzyloxy)phenyl)propyl)amino, 2-(3-

methylphenoxy)ethyl)amino, 3-(3-fluorophenyl)propyl)amino, 2-(2-methylphenoxy)ethyl)amino or 3-(2-fluorophenyl)propyl)amino.

4E. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, 4D, and 4D' and groups contained therein, in one group of compounds R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl, more preferably methyl.

4F. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, 4D, and 4D' and groups contained therein, in another group of compounds R¹ is haloalkyl, preferably trifluoromethyl or 1-fluoroethyl.

4F. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, and 4D, and 4D' and groups contained therein, in another group of compounds, R¹ is substituted alkyl. Within this embodiment, in one group of compounds R¹ is alkyl substituted with alkoxy or cyano. Within this embodiment, in one group of compounds R¹ is methoxymethyl or methoxyethyl. Within this embodiment, in one group of compounds R¹ is cyanomethyl.

4G. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, and 4D, and 4D' and groups contained therein, in another group of compounds, R¹ is cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is monocyclic cycloalkylalkyl. Within this embodiment, in one group of compounds R¹ is cyclopropylmethyl.

4H. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, and 4D, and 4D' and groups contained therein, in another group of compounds R¹ is cycloalkylalkyl, heterocyclyl or heterocyclalkyl substituted as defined in the Summary, preferably tetrahydrofuryl.

4I. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, 4D, 4D', 4E, 4F, 4G, and 4H and groups contained therein, in one group of compounds Y is O or N-CN. Within this group in one group of cpds, Y is O. Within this group in another group of compounds Y is -N-CN.

4J. Within compounds of Formula (I) and embodiments 4(a), 4(b), 4(c), 4(d), 4(e), 4A, 4B, 4C, 4D, 4D', 4E, 4F, 4G, 4H and 4I and groups contained therein, in one group of compounds R³ is hydrogen, chloro, methyl, or ethyl, preferably hydrogen.

5. In yet another embodiment, within compounds of Formula (III), R², R³, R⁴, R⁵ and R⁶ are those as described for compound of Formula (I) in 4 above.

General Synthetic Scheme


Compounds of this invention can be made by the methods depicted in the reaction schemes shown below.

The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78°C to about 150°C , more preferably from about 0°C to about 125°C and most preferably at about room (or ambient) temperature, e.g., about 20°C .

Compounds of Formula (I) where X is $-\text{NH}-$ and R^5 and R^6 are ring B and other groups are as defined in the Summary can be prepared as described in Scheme A below:

Scheme A



Reaction of commercially available 2,4-dichloro-1,3,5-triazine with an amine of formula 1 in the presence of a base provides an aminotriazine of formula 2. Suitable solvents include DMF, DME, THF and alcohols such as ethanol, isopropanol, butanol and the like. Suitable bases include amine bases such as Et₃N and DIEA and the like, as well as bases such as K₂CO₃ and NaH and the like. Compounds of formula 1 are either commercially available or they can be prepared by methods well known in the art. For example, N-(3-aminophenyl)-acetamide is commercially available. Compound of formula 2 can then be reacted with an amine of formula 3 in the presence of an acid or a base to give a compound of Formula (I). Suitable solvents include alcohols such as ethanol, isopropanol, butanol and the like, as well as solvents such as THF and DMF and the like. Suitable acids include HCl and TFA and the like. Suitable bases include amine bases such as Et₃N and DIEA and the like, as well as bases such as K₂CO₃ and NaH and the like. Compounds of formula 3 are either commercially available or they can be prepared by methods well known in the art. For example, 5-fluoro-1,2,3,4-tetrahydro-isoquinoline hydrochloride, 4-(benzyloxy)piperidine, 4-(4-chlorophenoxy)-piperidine, 4-phenylpiperidine, methyl 1,2,3,4-tetrahydroisoquinoline-5-carboxylate, 4-(piperidin-4-yl)benzonitrile, 5-methoxy-1,2,3,4-tetrahydroisoquinoline, 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidine, 1,2,3,4-tetrahydroisoquinoline-5-carbonitrile, 4-(4-fluorophenoxy)-piperidine, 4-(4-phenyl-1H-pyrazol-1-yl)piperidine, 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidine, 4-(3-chloro-4-fluorophenoxy)piperidine, 6-methoxy-1,2,3,4-tetrahydroisoquinoline, 6-fluoro-1,2,3,4-tetrahydroisoquinoline, 4-(2-(trifluoromethyl)-phenoxy)-piperidine, 4-(4-chlorophenyl)piperidine, 3-phenylazetidine, 4-(azetidin-3-yl)benzonitrile, 3-(benzyloxy)-azetidine, 4-phenyl-azepane, 4-phenyl-1,2,3,6-tetrahydropyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine, 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine, and 4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine are commercially available.


Compounds of Formula (I) can be converted to other compounds of Formula (I) by methods well known in the art. For example, compounds of Formula (I) where ring B is substituted with aryloxy, heteroaryloxy, cycloalkoxy, aralkyloxy, heteroaralkyloxy, heterocyclylalkyloxy, or cycloalkylalkyloxy can be prepared by reacting the corresponding compound of Formula (I) where ring B is substituted with a hydroxy group with aromatic or alicyclic halide, under nucleophilic aromatic/aliphatic substitution reaction conditions well known in the art. Preferable solvents include DMF and the like and bases include potassium tert-butoxide and the like.

Compounds of Formula (I) where ring B is substituted with amino, mono or disubstituted amino can be prepared by first preparing a compound of Formula (I) wherein ring B carries an oxo group and then reacting it with an amine under reductive amination reaction conditions.

5

Compounds of Formula (I) where X is $-\text{NH}-$, $-\text{O}-$ or $-\text{S}-$ and R^5 and R^6 are ring B and other groups are as defined in the Summary can be prepared as described in Scheme B below:

Scheme B



10


Reactions of 2,4-dichloro-1,3,5-triazine with an amine of formula 3 under the reactions conditions described in Scheme 1 above, provides a compound of formula 4 which upon reaction with a compound of formula 5 in the presence of a base provides a compound of Formula (I) where X is $-\text{NH}-$, S- or $-\text{O}-$. Suitable solvents include DMF, THF and the like. Suitable bases include NaH and K_2CO_3 and the like. Compounds of formula 5 are either commercially available or they can be prepared by methods well known in the art. For example, 3-acetamidophenol is commercially available.

15

20

Alternatively, compounds of Formula (I) where X is $-\text{NH}-$ and R^5 and R^6 are ring B can be prepared as described in Scheme C below.

Scheme C



Treatment of compound 4 with a diamino compound of formula 6 provides a compound of formula 7 which upon reaction with an acid of formula R^1CO_2H or its corresponding acid halide under standing coupling conditions known in the art provides a compound of Formula (I). When acid is utilized, the coupling reaction can be carried out with coupling agents such as EDCI/HOBt, O-(7-azabenzotriazole-1-yl)-N, N,N'-tetramethyluronium hexafluorophosphate (HATU) and chlorodipyrrolidinocarbenium hexafluorophosphate (PyCIU) (see for example, Han, S-Y.; Kim, Y-A. Tetrahedron 2004, 60 (11), 2447-67). When acid halide is utilized, the reaction is carried out in the presence of a non-nucleophilic amine such as triethylamine, pyridine, and the like. The acid chloride can be prepared in situ from the corresponding acid using either oxalyl chloride or thionyl chloride.

It will be apparent to a person skilled in the art that compounds of Formula (I) where R^5 and R^6 are other than ring B can be prepared by the procedure described above using acyclic amino compounds which are either commercially available or can be prepared by methods known in the art.

Utility

The compounds of the invention are Nav1.7 inhibitors and hence are useful in the treatment of diseases such as chronic pain associated with, but are not limited to, post-herpetic neuralgia (shingles), osteoarthritis, painful diabetic neuropathy, complex regional pain syndrome (CRPS), cancer- or chemotherapy-induced pain, chronic back pain, phantom limb pain, trigeminal neuralgia, HIV-induced neuropathy, cluster headache disorders, migraine, Primary Erythromelalgia, and Paroxysmal Extreme Pain Disorder. Other potential indications for Nav1.7 inhibitors include but are not limited to depression (Morinville et al., *J Comp Neurol.*, 504:680-689 (2007)), bipolar and other CNS disorders (Ettinger and Argoff, *Neurotherapeutics*, 4:75-83 (2007)), epilepsy: *ibid.*, and Gonzalez, Termin, Wilson, *Methods and Principles in Medicinal Chemistry*, 29:168-192 (2006)), multiple sclerosis (Waxman, *Nature Neurosci.* 7 :932-941 (2006)), Parkinson's (Do and Bean, *Neuron* 39 :109-120 (2003); Puopolo et al., *J. Neurosci.* 27 :645-656 (2007)), restless legs syndrome, ataxia, tremor, muscle weakness, dystonia, tetanus (Hamann M, Meisler MH, Richter A *Exp Neurol* 184(2):830-838, 2003), anxiety, depression: McKinney BC, Chow CY, Meisler MH, Murphy GG, *Genes Brain Behav.* 7(6):629-638, 2008), learning and memory, cognition (Woodruff-Pak DS, Green JT, Levin SI, Meisler MH, *Behav Neurosci* 120(2):229-240, 2006), cardiac arrhythmia and fibrillation, contractility, congestive heart failure, sick sinus syndrome (Haufe V, Chamberland

C, Dumaine R, J Mol Cell Cardiol 42(3):469-477, 2007), schizophrenia, neuroprotection after stroke, drug and alcohol abuse (Johannessen LC CNS Drugs 22(1)27-47, 2008), Alzheimer's (Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM, Nat Cell Biol 9(7):755-764, 2007), and cancer (Gillet L, Roger S, Besson P, Lecaille F, Gore J. Bougnoux P, Lalmanach G, Guennec LE, J Biol Chem 2009, Jan 28 (epub)).

Testing

The Nav1.7 inhibitory activity of the compounds of the present invention can be tested using the *in vitro* and *in vivo* assays described in working Biological Examples below.

Administration and Pharmaceutical Composition

In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds of Formula (I) may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day.

For oral administration, the compositions are preferably provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound utilized, the route and form of administration, and other factors.

In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take

the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

The compositions are comprised of in general, a compound of formula (I) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of formula (I). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.

Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).

The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of formula (I) based on the total


formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.

Examples

The following preparations of compounds of Formula (I) and intermediates (References) are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Reference A


Synthesis of 4-(4-phenylthiazol-2-yl)piperidine



To a flask charged with 2-bromoacetophenone (0.8 mL, 4092 μ mol) and tert-butyl 4-carbamothioylpiperidine-1-carboxylate (1.00 g, 4092 μ mol) was added EtOH (16 mL). The solution was refluxed for 17 h under nitrogen. The resulting suspension was cooled to RT, dried under reduced pressure and purified using a 10 g SCX column using methanol to transfer the material and wash the column and 2M NH_3 in MeOH to elute product (900 mg, 90%) as a white solid.

Reference B

Synthesis of 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine



Step 1

To a 10-20 mL microwave vial charged with 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.500 g, 2.2 mmol) was added acetonitrile (18.00 mL, 345 mmol), (Z)-N'-hydroxybenzamidinium (0.30 g, 2.2 mmol), Si-carbodiimide (5.8 g, 6.5 mmol), 1-hydroxybenzotriazole hydrate (0.33 g, 2.2 mmol), and DIPEA (1.1 mL, 6.5 mmol) respectively. The vial was irradiated in the microwave at 130 ° for 30 min. The reaction mixture was filtered via vacuum filtration and the solid supports washed with excess CH_2Cl_2 .


The filtrate was dried under reduced pressure. The resulting crude orange oil was chromatographed using MPLC ramping ethyl acetate in hexanes from 0% to 50% over 20 min providing *tert*-butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate (520 mg).

Step 2

tert-Butyl 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate was taken up in CH₂Cl₂ (10 mL) and TFA (2 mL) and stirred overnight at RT. The crude material was dried under reduced pressure providing a white crystalline material. The product was converted to free-base using a 10 g SCX-2 column using MeOH to load and wash the column and 2M NH₃ in MeOH to elute the product.

Reference C

Synthesis of 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidine TFA salt



To a 2-5 mL microwave vial charged with benzoic acid (120.0 mg, 904 μ mol) was added acetonitrile (8.00 mL), (Z)-*tert*-butyl 4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate (200 mg, 822 μ mol), Si-carbodiimide (2202 mg, 2466 μ mol), 1-hydroxybenzotriazole hydrate (126 mg, 822 μ mol), and DIPEA (0.43 mL, 2466 μ mol), respectively.


The vessel was irradiated in the microwave at 130 ° for 30 min. To the suspension was added MP-Carbonate (295 mg, 904 μ mol) and the reaction mixture stirred for 2 h at RT. The reaction mixture was filtered via vacuum filtration which was washed with excess CH₂Cl₂. The filtrate was dried under reduced pressure. The resulting crude orange oil was chromatographed using an MPLC ramping ethyl acetate in hexanes from 0% to 20% over 20 min providing *tert*-butyl 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidine-1-carboxylate (50 mg).

Step 2

tert-Butyl 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidine-1-carboxylate was taken up in CH₂Cl₂ (1 mL) and TFA (200 μ L) and stirred overnight providing product cleanly according to crude LC-MS. The crude material was dried under reduced pressure providing 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidine TFA salt as a white crystalline material.

Reference D

Synthesis of 4-(3-phenylpyrrolidin-1-yl)piperidine



5 Step 1

To a flask charged with 1-boc-4-piperidone (332.00 mg, 1671 μmol) was added THF (3.00 mL), 3-phenylpyrrolidine (246.00 mg, 1671 μmol), and TFA (0.13 mL, 1671 μmol) respectively. The reaction mixture was shaken for 30 min at RT prior to the addition of MP-BH(OAc)₃ (1015 mg, 2507 μmol) and the stirring was continued for 4 h at RT. The resulting mixture was filtered through a frit and washed with excess CH₂Cl₂. The filtrate was dried under reduced pressure. The solid was taken up in ethyl acetate and extracted with sat. aq. NaHCO₃. The aqueous phase was washed once with ethyl acetate. The combined organics were dried with Na₂SO₄, filtered and dried under reduced pressure. The crude material was filtered through a silica gel plug using ethyl acetate as the eluent. The product containing eluents, were combined and dried providing *tert*-butyl 4-(3-phenylpyrrolidin-1-yl)piperidine-1-carboxylate (400 mg, 72%) as a pale yellow oil.

Step 2

To a solution of *tert*-butyl 4-(3-phenylpyrrolidin-1-yl)piperidine-1-carboxylate (400 mg, 1210 μmol) in CH₂Cl₂ (10.00 mL) was added TFA (2.00 mL, 25960 μmol). The solution was stirred for 15 h at RT. The reaction mixture was dried under reduced pressure and purified with a 2 g SCX washing and loading with MeOH, then washing with 2M NH₃ in MeOH leading to the elution of basic materials. The product 4-(3-phenylpyrrolidin-1-yl)piperidine (133 mg, 47.7%) was isolated as a brown oil.


Chiral separation for compounds prepared with this fragment: Analytical Column: Chiralcel OJ-H, 4.6 x 10 cm, Mobile phase: 25% methanol w/ 0.2% diethylamine/CO₂, 100 bar back pressure, 5 ml/min flow rate, monitoring at 220 nm.

The purification conditions were: Chiralcel OJ-H, 2 x 25 cm, 30% methanol w/ 0.2% diethylamine, CO₂, 100 bar back pressure, 80 ml/min flow rate, monitoring at 220 nm. Approximately 15 mg processed per injection.

30

Reference E

Synthesis of 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidine TFA



Step 1


- 5 To a solution of benzoic acid (200.00 mg, 1638 μmol) in CH_2Cl_2 (5.00 mL) was added Si-carbodiimide (2193 mg, 2457 μmol), 1-hydroxybenzotriazole hydrate (263 mg, 1720 μmol), and 4-hydrazinocarbonyl-piperidine-1-carboxylic acid tert-butyl ester (398 mg, 1638 μmol), respectively. The heterogeneous mixture was stirred at RT for 15 h. The resulting mixture was filtered through a frit, and dried under reduced pressure. The resulting crude material was
- 10 chromatographed with MPLC ramping CH_2Cl_2 :MeOH (90:10) in CH_2Cl_2 (0% to 20% for 5 min, 20% over 15 min, then ramping to 100% over 5 min) providing 4-(N'-benzoyl-hydrazinocarbonyl)-piperidine-1-carboxylic acid tert-butyl ester as a white solid in ~80% purity which was used without further purification.

Step 2

- 15 A sealed vial containing 4-(N'-benzoyl-hydrazinocarbonyl)-piperidine-1-carboxylic acid tert-butyl ester 50.00 mg, 143.9 μmol) and Lawesson's reagent (58.21 mg, 143.9 μmol) was stirred and heated with a heat gun until complete melting occurred. The reaction mixture was cooled to RT and diluted with CH_2Cl_2 /MeOH. The material was purified by catch and release with a 500 mg SCX column washing with MeOH and eluting product with 2M NH_3 in
- 20 MeOH. The resulting material containing ~20% impurity was further purified using a Gilson with 0.1% TFA in CH_3CN and 0.1% TFA in H_2O as the eluents ramping from 10% to 90% nonpolar eluent providing 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidine – TFA (15 mg, 29%).

Reference F

- 25 Synthesis of 4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile - TFA



Step 1

To a 40 mL vial charged with *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (500.00 mg, 1617 μ mol) was added dioxane (3.200 mL, 1617 μ mol), Na₂CO₃ (3.234 mL, 6468 μ mol) and 4-bromobenzonitrile (294.3 mg, 1617 μ mol). The reaction mixture was purged with nitrogen prior to the addition of PdCl₂(dppf)-CH₂Cl₂ (132.1 mg, 161.7 μ mol). The reaction mixture was heated to 110 °C for 24 h. The dark mixture was cooled to RT and water was added. The resulting mixture was extracted with ethyl acetate, the combined organics washed with brine, dried with Na₂SO₄, filtered and dried under reduced pressure. The crude black oil was chromatographed ramping 0% EtOAc in hexanes to 25% over 5 min, then remaining at 5% for 15 min, then ramping to 100% over 5 min providing isolation of a pale yellow crystalline material *tert*-butyl 4-(4-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate (390.00 mg, 84.8%).

Step 2

To a solution of *tert*-butyl 4-(4-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate (332 mg, 1168 μ mol) in CH₂Cl₂ (4.00 mL, 62167 μ mol) was added TFA (0.0900 mL, 1168 μ mol). The yellow solution was stirred at RT for 3 h. The reaction mixture was dried under reduced pressure providing an off-white crystalline material 4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile – TFA (305 mg, 87.6%). MS (ESI, pos. ion) *m/z*: 185.4 (M+1).

The following compounds were prepared as described in Reference F above using appropriate starting materials.

2-fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile

4-(biphenyl-2-yl)-1,2,3,6-tetrahydropyridine

4-(2-(trifluoromethoxy)phenyl)-1,2,3,6-tetrahydropyridine

4-(3-(trifluoromethoxy)phenyl)-1,2,3,6-tetrahydropyridine

3-fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile

5-(1,2,3,6-tetrahydropyridin-4-yl)picolinonitrile

5-(1,2,3,6-tetrahydropyridin-4-yl)-2-(3,3,3-trifluoropropoxy)pyridine

4-(2-(thiophen-2-yl)phenyl)-1,2,3,6-tetrahydropyridine

4-(thiophen-3-yl)-1,2,3,6-tetrahydropyridine

4-(thiophen-2-yl)-1,2,3,6-tetrahydropyridine

2-chloro-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile

4-(biphenyl-3-yl)-1,2,3,6-tetrahydropyridine


3-methyl-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile

4-(3-chlorophenyl)-1,2,3,6-tetrahydropyridine
4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine
4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine
4-(2-fluorophenyl)-1,2,3,6-tetrahydropyridine
5 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine
4-(2-chlorophenyl)-1,2,3,6-tetrahydropyridine
2,3-difluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile
2-fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)benzonitrile
6-(1,2,3,6-tetrahydropyridin-4-yl)nicotinonitrile

10

Reference G

Synthesis of 4-(benzylthio)piperidine – TFA



15

Step 1

To a mixture of tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate (500 mg, 1790 μmol) and K_2CO_3 (247 mg, 1790 μmol) in dry DMF was added phenylmethanethiol (0.27 mL, 2327 μmol). The reaction mixture was heated for 15 h at 70 °C. The reaction mixture was cooled to RT and diluted with water. The reaction mixture was extracted twice with EtOAc. The combined organics were washed with 0.5 M NaOH, dried with Na_2SO_4 , filtered and dried under reduced pressure. The crude material was chromatographed using a 40 g redisepp column ramping from 0% to 10% ethyl acetate in hexanes over 5 min, then staying at 10% providing tert-butyl 4-(benzylthio)piperidine-1-carboxylate as a colorless oil (260 mg, 47%).

25


Step 2

tert-Butyl 4-(benzylthio)piperidine-1-carboxylate (130 mg) was dissolved in CH_2Cl_2 (2 mL) and TFA (400 μL) was added. The reaction mixture was stirred at RT overnight. The solution was dried under reduced pressure providing (216 mg, 75%) of material as a pale yellow oil containing trace impurities. This material was used without further purification.

30

Reference H

Synthesis of 4-(phenylthio)piperidine – TFA



5

Step 1


To a mixture of *tert*-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate (100 mg, 358 μ mol) and K_2CO_3 (49 mg, 358 μ mol) in dry DMF was added benzenethiol (0.048 mL, 465 μ mol). The reaction mixture was heated for 15 hr at 70 °C. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organics were washed with 10% Na_2CO_3 , and brine, dried with Na_2SO_4 , filtered and dried under reduced pressure providing a colorless oil. The material was purified on a 12 g redisepp column ramping 0% to 10% EtOAc in hexanes providing *tert*-butyl 4-(phenylthio)piperidine-1-carboxylate (55 mg).

Step 2

tert-Butyl 4-(phenylthio)piperidine-1-carboxylate was dissolved in CH_2Cl_2 (2 mL) and TFA was added (400 μ L). The solution was stirred at RT for 4 h. The solvent was removed under reduced pressure providing 4-(phenylthio)piperidine – TFA (75 mg, 68%).

Reference I

20 Synthesis of 6-cyclopropyl-1,2,3,4-tetrahydro-isoquinoline



Step 1

To an ice-cold solution of 4-bromobenzaldehyde (10 g, 0.05 mol) and 2,2-dimethoxyethylamine (6.8 g, 0.06 mol) in MeOH (200 mL) was added AcOH (2 mL), and the reaction mixture was stirred at RT for 1 h. The reaction mixture was cooled at 0 °C and $NaBH_4$ (6.2 g, 0.15 mol) was added in portions. The reaction mixture was stirred at RT for 10 h. After completion, the reaction mixture was concentrated at reduced pressure and added 10 % aqueous NaOH. Organic content was extracted with EtOAc, dried over Na_2SO_4 , and concentrated at reduced pressure. Purification was done by column chromatography eluting

with 5-15 % EtOAc-Hexane to afford N-(4-bromobenzyl)-2,2-dimethoxyethanamine (10 g, 67 %) as a pale yellow liquid.

Step 2

To a stirring solution of N-(4-bromobenzyl)-2,2-dimethoxyethanamine (10 g, 0.037 mol) in CH₂Cl₂ (100 mL) was added ClSO₃H (21.3 g, 0.18 mol) at -20 °C dropwise. The resulting reaction mixture was allowed to stir at 45 °C for 10 h. After completion of reaction, the reaction was diluted with CH₂Cl₂ and ice cold H₂O and then neutralized with aqueous NaHCO₃. The organic layer was separated and aqueous layer extracted with CH₂Cl₂. The combined organic layer was dried over Na₂SO₄ and concentrated at reduced pressure to get crude 6-bromoisquinoline. Purification was done by column chromatography eluting with 5-15 % EtOAc-hexanes to afford 6-bromoisquinoline (0.9 g, 12 %) as yellow liquid.

Step 3


To a degassed solution of 6-bromoisquinoline (0.9 g, 0.004 mol) in 1,4-dioxane (15 mL) was added cyclopropylboronic acid (0.560 g, 0.007 mol) followed by addition of degassed aqueous solution of K₂CO₃ (3.1 g, 0.02 mol) and PdCl₂(dppf) (0.190 g, 0.002 mol). The resulting reaction mixture was stirred at 110 °C for 10 h. After completion, the reaction mixture was filtered over Celite and the filtrate was concentrated at reduced pressure to obtain crude 6-cyclopropylisoquinoline. Purification was done by column chromatography eluting with EtOAc-Hexane(10-30 %) to afford pure 6-cyclopropyl-isoquinoline (0.500 g, 68 %) as yellow liquid.

Step 4

To a solution of 6-cyclopropylisoquinoline (0.500 g, 0.003 mol) in EtOH (15 mL) was added indium powder (3 g) and saturated aqueous NH₄Cl (5 mL). The reaction mixture was refluxed at 120 °C for 36 h while stirring. After completion, the reaction mixture was filtered through Celite and the filtrate concentrated at reduced pressure to afford crude 6-cyclopropyl-1,2,3,4-tetrahydro-isoquinoline. Purification was done by column chromatography eluting with MeOH- CH₂Cl₂ (0-10 %) to afford pure 6-cyclopropyl-1,2,3,4-tetrahydro-isoquinoline (0.300 g, 58 %) as a white solid.

Reference J

Synthesis of N-(3-amino-2-chlorophenyl)acetamide



Step 1

A round bottom flask was charged with 1-chloro-2,6-dinitrobenzene (0.500 g, 2.47 mmol), molybdenum carbonyl (0.652 g, 2.47 mmol), and DBU (1.12 ml, 7.41 mmol). EtOH (5 mL) was added. The solution was split into three 0.5 - 2 mL microwave vessels which were each sealed and heated in the microwave at 120 °C for 30 min. After concentration, the crude material was chromatographed with MPLC ramping CH₂Cl₂:MeOH (90:10) in CH₂Cl₂ (0% to 20% for 5 min, 20% over 15 min, then ramping to 100% over 5 min) to afford 2-chloro-3-nitrobenzenamine (0.313 g, 73.5%) as a yellow solid.

Step 2


To a solution of 2-chloro-3-nitrobenzenamine (0.400 g, 103% yield) in CH₂Cl₂ (3 mL) was added acetic anhydride (0.68 ml, 7.3 mmol) and the mixture was allowed to stir at RT overnight. The mixture was concentrated to remove excess acetic anhydride and acetic acid to give *N*-(2-chloro-3-nitrophenyl)acetamide. This material was used without purification.

Step 3

A rb flask was charged with *N*-(2-chloro-3-nitrophenyl)acetamide (0.389 g, 1.8 mmol), molybdenum carbonyl (0.48 g, 1.8 mmol), and DBU (0.82 ml, 5.4 mmol). EtOH (5 mL) was added. The solution was split into three 0.5 - 2 mL microwave vessels which were each sealed and heated in the microwave at 120 °C for 30 min. After concentration, the crude material was chromatographed with MPLC ramping CH₂Cl₂:MeOH (90:10) in CH₂Cl₂ (0% to 20% for 5 min, 20% over 15 min, then ramping to 100% over 5 min) to afford *N*-(3-amino-2-chlorophenyl)acetamide (0.300 g, 90%) as a yellow solid.

Reference K

Synthesis of 4-(4-(trifluoromethyl)phenyl)piperidine



Step 1

To a stirred solution of 4-(4-trifluoromethyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid *tert*-butyl ester (2.5 g, 0.00783 mol) (prepared as described in Reference F above) in ethanol (23.0 mL) was added 10% Pd/C (826 mg, 0.00078 mol) under N₂ atmosphere and allowed to stir at RT overnight under hydrogen atmosphere. The reaction mixture was filtered through cellite, washing with EtOAc (2 x 100 mL). The filtrate was concentrated under reduced pressure to obtain 4-(4-trifluoromethyl-phenyl)-piperidine-1-carboxylic acid *tert*-butyl ester (2 g, 80%).

Step 2

To a stirred solution of 4-(4-trifluoromethyl-phenyl)-piperidine-1-carboxylic acid *tert*-butyl ester (2.0 g, 0.0060 mol) in CH₂Cl₂ (19.0 mL), trifluoro acetic acid (3.46 g, 0.0303 mol) was added at 0 °C and allowed to stir at RT overnight. CH₂Cl₂ and TFA were removed under reduced pressure and the crude product was washed with diethyl ether (2 x 20 mL) to obtain 4-(4-trifluoromethyl-phenyl)-piperidine trifluoro acetic acid salt with (1.577 g, 83%).

The following compounds were prepared as described in Reference K above using appropriate starting materials.

2-methyl-4-(piperidin-4-yl)benzonitrile

4-(2-(trifluoromethyl)phenyl)piperidine

4-(biphenyl-2-yl)piperidine

4-(4-chlorophenyl)piperidine

4-(4-fluorophenyl)piperidine

2-fluoro-4-(piperidin-4-yl)benzonitrile

4-(piperidin-4-yl)-2-(trifluoromethyl)benzonitrile

2,6-difluoro-4-(piperidin-4-yl)benzonitrile

4-(piperidin-4-yl)-3-(trifluoromethyl)benzonitrile

4-(3-fluorophenyl)piperidine

4-(2-fluorophenyl)piperidine

4-(piperidin-4-yl)benzonitrile


4-(biphenyl-3-yl)piperidine

2-chloro-4-(piperidin-4-yl)benzonitrile

4-(3-chlorophenyl)piperidine

Reference L

Synthesis of 2-(1,2,3,4-tetrahydroisoquinolin-5-yl)thiazole



Step 1

To a solution of 2-bromothiazole (1 g, 0.00609 mol) and isoquinoline-5-boronic acid (1.16 g, 0.0067 mol) in 1,4-dioxane (15 mL), aqueous solution of Na₂CO₃ (1.9 g in 5 mL water) was added after degassing for 15 min. The reaction mixture was again degassed for


another 45 min then $\text{Pd}(\text{PH}_3)_4$ (427 mg, 0.0006 mol) was added. The reaction mixture was allowed to reflux at 110 °C for 6 h. After completion of the reaction, it was cooled to RT, diluted with dioxane, and filtered through celite. The filtrate was concentrated and crude was purified through 230-400 silica gel column using 2% methanol in CH_2Cl_2 as eluent to give 2-(isoquinolin-5-yl)thiazole (530 mg, 44%).

Step 2

2-(Isoquinolin-5-yl)thiazole (500 mg) was taken in ethanol (10 mL), to this indium powder (3.0 g) and saturated NH_4Cl solution (2 mL) was added. The reaction mixture was allowed to reflux at 120 °C for 48 h. Upon consumption of all starting material the reaction was cooled to RT, diluted with methanol and then filtered through celite. The filtrate was concentrated and crude was purified through 230-400 silica gel column using 6 % methanol in CH_2Cl_2 to afford 2-(1,2,3,4-tetrahydroisoquinolin-5-yl)thiazole (400 mg, 78%).

Reference M

Synthesis of 4-(4-(trifluoromethoxy)benzyloxy)piperidine



Step 1

To a dried flask charged with *tert*-butyl 4-hydroxypiperidine-1-carboxylate (3.60 g, 17887 μmol) was added dry DMF (40 mL) and the resulting solution cooled in an ice water bath prior to the addition of NaH (60% in mineral oil) (748 mg, 18781 μmol) in two portions 5 min apart. The mixture was stirred for 1 hr and allowed to warm to RT over that time. The resulting suspension was cooled in an ice water bath prior to the addition of a solution of 1-(bromomethyl)-4-(trifluoromethoxy)benzene (5018 mg, 19676 μmol) in DMF (5 mL) via syringe. The resulting mixture was allowed to slowly warm to room temperature while stirring for 15 h. The resulting pale yellow suspension was carefully diluted with water (~150 mL) and extracted 2x with EtOAc. The combined organics were dried with Na_2SO_4 , filtered and dried under reduced pressure. The material was purified with a 50 g column using MPLC ramping ethyl acetate in hexanes from 0% to 10% over 5 mins, then remaining at 10% for 10 min, then ramping to 50% over 5 min providing *tert*-butyl 4-(4-(trifluoromethoxy)benzyloxy)piperidine-1-carboxylate as a white crystalline solid upon drying (5 g).

Step 2

tert-Butyl 4-(4-(trifluoromethoxy)benzyloxy)piperidine-1-carboxylate was dissolved in CH₂Cl₂ (40 mL) and TFA (4 mL) was added. The light yellow solution was stirred at room temperature. The mixture was stirred for 20 h at RT after which time complete Boc
5 deprotection was evident by LC-MS. The solution was dried under reduced pressure providing product as a TFA salt in 65-95% overall yield. The material was used as a salt or free based using catch and release with strong cation exchange chromatography (SCX-2) washing first with MeOH, then with 2M NH₃ in MeOH.

The following compounds were prepared as described in Reference M above using
10 appropriate starting materials.

4-(3-fluoro-5-(trifluoromethyl)benzyloxy)piperidine

4-(4-fluoro-3-(trifluoromethyl)benzyloxy)piperidine

4-(2-fluoro-4-(trifluoromethyl)benzyloxy)piperidine

4-(2-fluoro-3-(trifluoromethyl)benzyloxy)piperidine

15 4-(3-fluoro-4-(trifluoromethyl)benzyloxy)piperidine

4-(2-fluoro-5-(trifluoromethyl)benzyloxy)piperidine

2-((piperidin-4-yloxy)methyl)benzonitrile

4-(2-(trifluoromethyl)benzyloxy)piperidine

4-(3-(trifluoromethoxy)benzyloxy)piperidine

20 4-(2-(trifluoromethoxy)benzyloxy)piperidine

4-(4-(trifluoromethyl)benzyloxy)piperidine

4-(4-butylbenzyloxy)piperidine

4-(4-isopropylbenzyloxy)piperidine

4-(4-methylbenzyloxy)piperidine

25 4-(4-(difluoromethoxy)benzyloxy)piperidine

4-(2,4,6-trifluorobenzyloxy)piperidine

4-(2,3,6-trifluorobenzyloxy)piperidine

4-(2,3-difluorobenzyloxy)piperidine

4-(2,4-difluorobenzyloxy)piperidine

30 4-(2,3,4-trifluorobenzyloxy)piperidine

4-((piperidin-4-yloxy)methyl)benzonitrile

4-(1-phenylethoxy)piperidine


4-(3,4-difluorobenzyloxy)piperidine

4-(4-*tert*-butylbenzyloxy)piperidine

4-(2,4,5-trifluorobenzyloxy)piperidine
4-(3,4,5-trifluorobenzyloxy)piperidine
4-(2,4-bis(trifluoromethyl)benzyloxy)piperidine
4-(2-fluorobenzyloxy)piperidine


5

Reference N

Synthesis of *N*-(3-aminophenyl)-*N*-methylacetamide

- 10 Sodium hydride (160 mg, 3995 μmol , 60% in mineral oil) was washed with hexanes under an argon atmosphere. Hexanes were replaced with DMF (7991 μl , 1998 μmol). Then *N*-(3-aminophenyl)acetamide (300 mg, 1998 μmol) was added followed by iodomethane (395 μl , 2597 μmol) at RT. After 2 h, LCMS showed mainly *N*-(3-aminophenyl)acetamide and a small amount of product. An additional 150 mg of 60% NaH in mineral oil was added. After
- 15 20 h, LCMS showed complete conversion of *N*-(3-aminophenyl)acetamide to product. The whole was quenched with water and diluted with DCM. The whole was washed with brine. The organic layer was separated, dried over MgSO_4 , filtered, and concentrated. The product was purified by performing a column chromatography using 30:70 CH_2Cl_2 :(90:10:1 CH_2Cl_2 : MeOH : NH_4OH). Fractions containing the product were combined and concentrated.
- 20 *N*-(3-aminophenyl)-*N*-methylacetamide was obtained as a yellow oil (39 mg, 12%).


Reference O

Synthesis of *N*-(3-mercaptophenyl)acetamide

- 25 To a solution of 3-aminobenzenethiol (254 μL , 2396 μmol) in EtOAc (11982 μL , 2396 μmol) was added acetic anhydride (249 μL , 2636 μmol) at 0 $^{\circ}\text{C}$. The mixture was slowly warmed to RT. After 2 h, LCMS showed mainly product. The reaction was diluted with EtOAc, and washed with 1N aq HCl and brine solution. The organic layer was separated,

dried over MgSO_4 , filtered, and concentrated to afford *N*-(3-mercaptophenyl)acetamide as a viscous colorless oil which was used without purification.


Reference P

5 Synthesis of *N*-(3-amino-5-chlorophenyl)acetamide

To a solution of acetyl chloride (100 mg, 1274 μmol) in CH_2Cl_2 (2 mL) was added a solution of 5-chlorobenzene-1,3-diamine (363 mg, 2548 μmol) and triethylamine (354 μL , 2548 μmol) in CH_2Cl_2 (4 mL). After the mixture was stirred at RT for 3 h the LC/MS showed the desired product appearing as $\text{M}+\text{H}=185.2$ @ 0.914 min. Concentration and purification by MPLC with gradient eluent ($\text{CH}_2\text{Cl}_2:(\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3$ 90:10:1)) afforded *N*-(3-amino-5-chlorophenyl)acetamide (129 mg, 55%) as a white solid.

Reference Q

15 Synthesis of 4-(2-(methanesulfonyl)phenoxy)piperidine hydrochloride



Step 1

To a stirred solution of 2-methanesulfonyl-phenol (2 g, 11.61 mmol) in THF (20 mL) 4-hydroxy-piperidine-1-carboxylic acid *tert*-butyl ester (2.57 g, 12.77 mmol) was added followed by PPh_3 (6.7 g, 25.54 mmol). The resulting reaction mixture was stirred at RT for 15 min. DEAD (4.5 g, 25.54 mmol) was added dropwise at 20 $^\circ\text{C}$ and the reaction mixture was stirred at RT for 18 h. After completion of the reaction (monitored by TLC, visualized by UV or ninhydrin), the excess THF was concentrated under reduced pressure to obtain the crude material, which was further diluted with CH_2Cl_2 (50 mL). The CH_2Cl_2 layer was washed with water (3 x 100 mL) then dried over Na_2SO_4 , filtered and concentrated under reduced pressure to obtain the crude material, which was further purified through silica gel column chromatography, using 8% EtOAc in hexanes to afford 4-(2-(methanesulfonyl-phenoxy)-piperidine-1-carboxylic acid *tert*-butyl ester (2.6 g, 87 %).

Step 2

To 4-(2-methanesulfonyl-phenoxy)-piperidine-1-carboxylic acid *tert*-butyl ester (2.6 g, 7.3 mmol) was added HCl in dioxane solution (4M) (15 mL). The mixture was stirred at RT for 5 h. After completion of the reaction (monitored by TLC), the excess dioxane was removed in vacuo affording an off white solid. The crude material was washed with diethyl ether (3 x 20 mL) to afford 4-(2-(methylsulfonyl)phenoxy)piperidine hydrochloride (1.3 g, 80.7%).

The following compounds were prepared as described in Reference Q above using appropriate starting materials.

4-(4-chloro-3-(trifluoromethyl)phenoxy)piperidine

4-(4-chloro-3,5-dimethylphenoxy)piperidine

3-(piperidin-4-yloxy)benzonitrile

4-(piperidin-4-yloxy)benzonitrile

4-(3-chloro-4-fluorophenoxy)piperidine

4-(4-chloro-3-fluorophenoxy)piperidine

4-(2,4,5-trifluorophenoxy)piperidine

2-chloro-4-(piperidin-4-yloxy)benzonitrile

4-(2,3-dichlorophenoxy)piperidine

4-(2-chlorophenoxy)piperidine

4-(3-chloro-4-methylphenoxy)piperidine

4-(4-chloro-3-(trifluoromethoxy)phenoxy)piperidine

4-(3-chlorophenoxy)piperidine

4-(3,4-dimethylphenoxy)piperidine

4-(2,3-dimethylphenoxy)piperidine

4-(2-fluoro-5-(trifluoromethoxy)phenoxy)piperidine

4-(3,4-difluorophenoxy)piperidine

4-(2,4-difluorophenoxy)piperidine

4-(2-(trifluoromethoxy)phenoxy)piperidine

4-(3-fluoro-4-(trifluoromethoxy)phenoxy)piperidine

4-(4-fluoro-3-(trifluoromethoxy)phenoxy)piperidine

4-(2,6-difluorophenoxy)piperidine

4-(2,3-difluorophenoxy)piperidine

4-(3-fluorophenoxy)piperidine

4-(2-fluorophenoxy)piperidine


4-(2,4,6-trifluorophenoxy)piperidine

4-(2,3,6-trifluorophenoxy)piperidine

4-(4-(trifluoromethyl)phenoxy)piperidine
4-(4-(trifluoromethoxy)phenoxy)piperidine
4-(2,3,4-trifluorophenoxy)piperidine
4-(3,5-difluorophenoxy)piperidine
5 4-(4-chloro-3-methylphenoxy)piperidine

Reference R

Synthesis of 3-phenoxy-8-azabicyclo[3.2.1]octane



10

Step 1

To a stirred solution of phenol (2 g, 0.0212 mol) in THF (42.5 mL), Tropine (3.3 g, 0.0233 mol) and triphenyl phosphine (8.3 g, 0.03187 mol) were added at RT. The mixture was cooled to 0 °C. Diisopropyl azodicarboxylate (DIAD) (6.4 g, 0.03187 mol) was added at 0 °C
15 dropwise. The mixture was allowed to stir at RT overnight. Completion of the reaction was monitored by TLC. Water (40 mL) was added to the resulting solution and the product was extracted with EtOAc (2 x 40 mL). The organic portions were combined, dried over Na₂SO₄ and evaporated. Purification was accomplished with flash chromatography using 100-200-
20 mesh silica gel and gradient eluent (0-30% EtOAc:Hexanes) to obtain 8-methyl-3-phenoxy-8-aza-bicyclo[3.2.1]octane (1.4 g, 30%).

Step 2

To a stirred solution of 8-methyl-3-phenoxy-8-aza-bicyclo[3.2.1]octane (5.0 g, 0.023 mol) in DCE (8.3 mL) was added 1-chloro ethyl chloro formate (4.1 mL, 0.037 mol) at 0 °C for 1 h. Completion of the reaction was monitored by TLC. After concentrated in vacuo the
25 residue was dissolved in MeOH (9.75 mL) and heated at reflux for 45 min, then concentrated in vacuo again. The residue was taken up in acetone (9.75 mL) and water (9.75 mL) and stirred for 1h. NaHCO₃ (7.72 g, 0.092 mol) and Boc₂O (11.7 mL, 0.048 mol) were added and the mixture was stirred overnight. Completion of the reaction was monitored by TLC. After
30 concentration to remove all volatiles, water (50 mL) was added to the resulting solution and the product was extracted with CH₂Cl₂ (3 x 50 mL). The organic portions were combined and dried over Na₂SO₄ and evaporated. Purification was accomplished with flash chromatography


using 100-200-mesh silica gel and gradient eluent (0-10% EtOAc:Hexanes) to obtain 3-phenoxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (3.5g, 50%).

Step 3

To a stirred solution of 3-phenoxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (1.0 g, 0.00329 mol) in CH_2Cl_2 (10 mL), trifluoroacetic acid (1.3 mL, 0.0164 mol) was added at 0 °C and allowed it to stir at RT overnight. Completion of reaction was monitored by TLC. The organics were removed under reduced pressure and the crude was washed with diethyl ether (2 x 10 mL) to obtain 3-phenoxy-8-aza-bicyclo[3.2.1]octane trifluoro acetic acid salt (600 mg, 89%).

Reference S

Synthesis of 3-(benzyloxy)-8-azabicyclo[3.2.1]octane



Step 1

To a stirred solution of 8-methyl-8-aza-bicyclo[3.2.1]octan-3-ol (2.0 g, 0.014 mol) in DCE (5.0 mL) was added 1-chloroethyl chloroformate (2.5 mL, 0.023 mol) at 0 °C and the mixture was allowed to stir at 0 °C for 1 h. Completion of reaction was monitored by TLC. After concentrated in vacuo, the residue was dissolved in MeOH (6.0 mL) and heated at reflux for 45 min, then concentrated in vacuo again. The residue was taken up in acetone (6.0 mL) and water (6.0 mL) and stirred for 1 h. NaHCO_3 (4.7 g, 0.056 mol) and Boc_2O (7.2 mL, 0.029 mol) were added and the mixture was stirred overnight. Completion of the reaction was monitored by TLC. After removal of all volatiles, water (30 mL) was added to the resulting solution and the mixture was extracted with DCM (3 x 40mL). The organic portions were combined, dried over Na_2SO_4 and evaporated. Purification was accomplished with flash chromatogray using 100-200-mesh silica gel and gradient eluent (0-15% EtOAc:Hexanes) to obtain 3-hydroxy-8-aza-bicyclo [3.2.1] octane-8-carboxylic acid tert-butyl ester (1.0 g, 31%).

Step 2

A solution of 3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (2 g, 0.00879 mol) in DMF (11.0 mL) was cooled to 0 °C. NaH (60% suspension) (1.4 g, 0.0351 mol) was added and the mixture was allowed to stir at RT for 1h. Benzyl bromide (3 g, 0.00175 mol) in DMF (3.0 mL) was added at RT and the mixture was allowed to stir at RT overnight. Completion of reaction was monitored by TLC. Water (20 mL) was added and the product was extracted with EtOAc (2 x 50 mL), dried over Na_2SO_4 and evaporated.


Purification was accomplished with flash chromatography using 100-200-mesh silica gel with gradient eluent (0-10% EtOAc: Hexanes) to obtain 3-benzyloxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (1.7 g, 62%).

Step 3

- 5 To a stirred solution of 3-benzyloxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (4.0 g, 0.0126 mol) in CH₂Cl₂ (35 mL), trifluoro acetic acid (5.1 mL, 0.0630 mol) was added at 0 °C and the mixture was allowed to stir at RT overnight. Completion of reaction was monitored by TLC. The organics were removed under reduced pressure and the crude was washed with diethyl ether (2 x 10 mL) to obtain 3-benzyloxy-8-aza-bicyclo[3.2.1]octane
- 10 trifluoro acetic acid salt with (2.0 g, 74%).

Reference T

Synthesis of 3-benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione



15 Step 1

- To a stirred solution of N-Boc piperidone (2.0 g, 0.010 mol) in EtOH (20 mL), ammonium carbonate (2.8 g, 0.0301 mol) and trimethylsilyl cyanide (1.5 g, 0.015 mol) were added at 0 °C, then heated at 90 °C for 24 h. Completion of the reaction was monitored by checking TLC. 100 mL water was added and the mixture was allowed to stir at RT for 1h.
- 20 Solid precipitated out, was filtered off and washed with diethyl ether (40 mL) to obtain 2,4-dioxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a white solid (62%).

Step 2

- To a stirred solution of 2,4-dioxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester (1.5 g, 0.0055 mol) in CH₂Cl₂ (17.5 mL), trifluoroacetic acid (2.23 mL, 0.0278 mol)
- 25 was added at 0 °C and the mixture was allowed to stir at RT overnight. Completion of reaction was monitored by TLC. The organics were removed under reduced pressure and the crude was washed with diethyl ether (2 x 10 mL) to obtain 1,3,8-triaza-spiro[4.5]decane-2,4-dione trifluoroacetic acid salt (1.3g, 86.6%).

Step 3

- 30 To a stirred solution of 1,3,8-triaza-spiro[4.5]decane-2,4-dione trifluoroacetic acid salt (2.5 g, 0.0092 mol) in DMF (21 mL), K₂CO₃ (1.92 g, 0.013 mol) was added at 0 °C and the mixture was allowed it to stir at RT for 10 min. Then benzyl bromide (1.9 g, 0.0111 mol) was

added and the mixture was stirred at RT overnight. Completion of the reaction was monitored by TLC. The reaction mixture was diluted with EtOAc (2 x 40 mL) and washed with water (2 x 20 mL). The organic portions were combined, dried over Na₂SO₄ and evaporated under reduced pressure. The crude was washed with EtOAc:Pentane (2:8) to obtain 3-benzyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a white solid (56%).

Step 4


To a solution of 3-benzyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester (2.4 g, 0.00672 mol) in CH₂Cl₂ (20 mL), trifluoroacetic acid (2.7 mL) was added at 0 °C and the mixture was allowed to stir at RT overnight. Completion of the reaction was monitored by TLC. TFA and CH₂Cl₂ were removed under reduced pressure and the crude was washed with diethyl ether (2 x 20 mL) to obtain the trifluoroacetic acid salt of 3-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione (97%) as a white solid.

The following compound was prepared as described in Reference T above using appropriate starting materials.

3-(4-chlorobenzyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione

Reference U

Synthesis of *N*-(4-aminobiphenyl-2-yl)acetamide



Step 1

To a solution of 2-bromo-5-nitro-phenylamine (1.0 g, 0.0046 mol) and phenylboronic acid (674 mg, 0.0055 mol) in 1,2-dimethoxyethane (20 mL) was added 2 N aqueous sodium carbonate (1.36 g, 0.0129 mol). After degassing with N₂ for 30 min, palladium tetrakis triphenylphosphine (266 mg, 0.00023 mol) was added to this solution under nitrogen and the reaction mixture was heated for 12 h. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organics were dried over sodium sulphate, and concentrated. Purification by flash chromatography using silica gel (100-200 mesh) and eluent gradient (0-10% EtOAc:Hexanes) afforded 4-nitro-biphenyl-2-ylamine (800 mg, 81%).

Step 2

To a solution of 4-nitro-biphenyl-2-ylamine (500 mg, 0.0023 mol) in CH₂Cl₂ (6.7 mL), was added NEt₃ (0.4 mL, 0.003 mol) at RT then excess acetyl chloride at 0 °C and the mixture


was allowed to stir at RT overnight. Completion of the reaction was monitored by TLC. The mixture was diluted with CH₂Cl₂ (30 mL), washed with water (15.0 mL) and brine (15.0 mL). The organic layer was dried over Na₂SO₄ and concentrated to obtain N-(4-nitro-biphenyl-2-yl)-acetamide (300 mg) as yellow solid. This material was used in the next step without further purification.

Step 3

To a stirred solution of N-(4-nitro-biphenyl-2-yl)-acetamide (1.0 g, 0.0039 mol) in EtOAc (12 mL), 10% Pd/C (415 mg, 0.00039 mol) was added at 0 °C under N₂ atmosphere. Then N₂ was removed and H₂ was applied. The mixture was allowed to stir at RT overnight. Completion of reaction was monitored by TLC. The reaction mixture was filtered through celite then concentrated to obtain N-(4-amino-biphenyl-2-yl)-acetamide (500 mg, 56%).

Reference V

Synthesis of N-(5-amino-2-tert-butylphenyl)acetamide



Step 1

To a solution of 2-tert-butyl-phenylamine (2.0 g, 0.0134 mol) in sulfuric acid (26.8 mL) KNO₃ (1.2 g, 0.012 mol) was added at 0 °C portion wise. The mixture was allowed to stir for 1h. Completion of the reaction was monitored by TLC. The crude was quenched with chilled water (50 mL) then diluted with EtOAc (60 mL), washed with sat. NaHCO₃ solution (25 mL) and brine (20 mL). The organic fraction was dried over Na₂SO₄ and concentrated to obtain 2-tert-butyl-5-nitro-phenylamine (2.1 g, 80%).

Step 2


To a solution of 2-tert-butyl-5-nitro-phenylamine (500 mg, 0.0025 mol) in CH₂Cl₂ (7 mL), NEt₃ (1 mL, 0.007 mol) was added followed by acetyl chloride (0.5 mL, 0.0064 mol) at 0 °C and the mixture was allowed it to stir at RT overnight. Completion of reaction was monitored by TLC. The mixture was diluted with CH₂Cl₂ (30 mL), washed with water (15.0 mL) and brine (15.0 mL). The organic layer was dried over Na₂SO₄ and concentrated. Purification by flash chromatography using silica gel (100-200mesh) and eluent gradient (0-40% EtOAc:Hexanes) to obtain N-(2-tert-butyl-5-nitrophenyl)acetamide (400 mg, 65%).

Step 3

To a stirred solution of *N*-(2-tert-butyl-5-nitro-phenyl)-acetamide (400 mg, 0.0021 mol) in EtOAc (7 mL), 10% Pd/C (225 mg, 0.00021 mol) was added at 0 °C under N₂ atmosphere. Then N₂ was removed and H₂ was applied. The mixture was allowed to stir at RT overnight.

- 5 Completion of reaction was monitored by TLC. The reaction mixture was filtered through celite then concentrated to obtain the crude product which was washed with CH₂Cl₂:Pentane (1:9) to obtain *N*-(5-amino-2-tert-butylphenyl)-acetamide with (200 mg , 57%).

Reference W

10 Synthesis of *N*-(5-amino-2-cyclopropylphenyl)acetamide

Step 1

To a solution of 2-bromo-5-nitro-phenylamine (2.0 g, 0.0092 mol) in CH₂Cl₂ (28mL), NEt₃ (3.8 mL, 0.003 mol) was added followed by acetyl chloride (1.3 mL, 0.0184 mol) at 0 °C and the reaction mixture was allowed to stir at RT overnight. Completion of reaction was monitored by TLC. The mixture was diluted with CH₂Cl₂ (50 mL), washed with water (25.0 mL) and brine (25.0 mL). The organic layer was dried over Na₂SO₄ and concentrated to obtain the crude product whic was purified by flash chromatography using silica gel (100-200mesh) and gradient eluent (0-20% EtOAc:Hexanes) to obtain *N*-(2-bromo-5-nitro-phenyl)-acetamide (1.5g, 65%).

Step 2


To a solution of *N*-(2-bromo-5-nitro-phenyl)-acetamide (4.0 g, 0.0154 mol) and cyclopropylboronic acid (2.1 g, 0.0247 mol) in toluene and water (20 mL), was added potassium phosphate (11.6 g, 0.0548 mol). After degassing with N₂ for 30 min, Pd(OAc)₂ (173 mg, 0.00077 mol) was added under nitrogen and the mixture was heated at 80 °C for 12 h. The reaction mixture was cooled to RT and partitioned between EtOAc and water. The organics were dried over sodium sulphate, filtered and concentrated. Purification by flash chromatography using silica gel (100-200 mesh) and gradient eluent (0-13% EtOAc:hexanes) afforded *N*-(2-cyclopropyl-5-nitro-phenyl)-acetamide (1.7 g, 50%).

Step 3

To a stirred solution of *N*-(2-cyclopropyl-5-nitro-phenyl)-acetamide (1.7 g, 0.0077 mol) in THF (38 mL):water (19 mL), ammonium formate was added at rt. The mixture was heated at 80 °C overnight. Completion of the reaction was monitored by TLC. The reaction mixture was filtered through celite then partitioned between EtOAc (100 mL) and water (50 mL). The organics were dried over sodium sulphate, and concentrated to obtain the crude product which was dissolved in minimum EtOAc (approx. 5mL). Pentane (approx. 35 mL) was added to precipitate *N*-(5-amino-2-cyclopropyl-phenyl)-acetamide (500 mg, 35%).

Reference X

Synthesis of 2-phenyl-4-(piperidin-4-yl)thiazole



Step 1

To a stirred solution of piperidine-1,4-dicarboxylic acid mono-(9H-fluoren-9-ylmethyl) ester (5 g, 14.2 mmol) in CH₂Cl₂ (50 mL) was added DMF (0.5 mL) in catalytic amount and this solution was cooled to 0 °C. To this solution oxalyl chloride (3.6 g, 28.44 mmol) was added dropwise and the reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated at reduced pressure to afford (9H-fluoren-9-yl)methyl 4-(chlorocarbonyl)-piperidine-1-carboxylate (5 g, 95%) as brown liquid.

Step 2

To a stirred solution of (9H-fluoren-9-yl)methyl 4-(chlorocarbonyl)piperidine-1-carboxylate (5 g, 13.6 mmol) in toluene at 0 °C was added TMS-diazomethane (30 mL). This reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated at reduced pressure to afford of (9H-fluoren-9-yl)methyl 4-(diazoacetyl)piperidine-1-carboxylate (5 g, 98%) as dark brown liquid.

Step 3

A 0 °C solution of (9H-fluoren-9-yl)methyl 4-(diazoacetyl)piperidine-1-carboxylate (5 g, 13.3 mmol) in THF, was treated with an HBr solution (10 mL). This reaction mixture was stirred at RT for 2 h. The reaction mixture was diluted with water and the organic content was extracted using EtOAc, dried over Na₂SO₄, filtered and concentrated at reduced pressure. The crude product was chromatographed over silica gel eluting with a gradient (0-15 %

EtOAc:Hexanes) to afford (9H-fluoren-9-yl)methyl 4-(bromoacetyl)piperidine-1-carboxylate (3 g, 53%) as an off white solid.

Step 4


To a stirred solution of (9H-fluoren-9-yl)methyl 4-(bromoacetyl)piperidine-1-carboxylate (3 g, 7.03 mmol) in EtOH (20 mL) was added thiobenzamide (0.96 g, 7.03 mmol). This reaction mixture was stirred at RT for 24 h. NaHCO₃ (3 g) was added and the reaction mixture was further stirred for 5 d. The mixture was concentrated to afford the crude material which was chromatographed over silica gel eluting with a gradient (0-10 % EtOAc:Hexanes) to afford (9H-fluoren-9-yl)methyl 4-(2-phenylthiazol-4-yl)piperidine-1-carboxylate (2 g, 61%) as an off white solid.

Step 5

To a stirred solution of (9H-fluoren-9-yl)methyl 4-(2-phenylthiazol-4-yl)piperidine-1-carboxylate (2 g, 4.29 mmol) in CH₂Cl₂:MeOH (15:5 mL) was added piperidine (5 mL). This reaction mixture was stirred at RT for 8 h. The mixture was concentrated at reduced pressure and the crude material was chromatographed over silica gel eluting with a gradient (0-10 % MeOH:CH₂Cl₂) to afford 2-phenyl-4-(piperidin-4-yl)thiazole (1 g, 96%) as an off white solid.

Reference Y

Synthesis of 2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridine




A mixture of phenylboronic acid (297 mg, 2438 μmol) and 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride (500 mg, 2438 μmol) in 1,4-dioxane (4876 μl, 2438 μmol) and Na₂CO₃ (2.0 M) (4876 μl, 2438 μmol) was purged with argon prior to the addition of PdCl₂(dppf)-CH₂Cl₂ (199 mg, 244 μmol). The vessel was sealed and heated to 100 °C for 18 h. LC-MS showed clean conversion to desired product at 0.949 min (MH⁺ - 211.2). The mixture was cooled to RT and diluted with water and extracted with EtOAc (2x). The combined organics were dried with Na₂SO₄, filtered and dried under reduced pressure. The crude material was purified with a 50 g column using MPLC ramping CH₂Cl₂:MeOH:NH₄OH (90:10:1) in CH₂Cl₂ from 0% to 100% over 10 min, then remaining at 100% for 10 min to afford 2-phenyl-5,6,7,8-tetrahydro-1,6-naphthyridine (150 mg, 29.3%) as a brown oil.

Reference Z

Synthesis of (3S,4S)-3-fluoro-4-phenylpiperidine, (3R,4R)-3-fluoro-4-phenylpiperidine
(racemate)

5



Step 1

To a mixture of *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (3 g, 9.70 mmol) in 1,4-dioxane (19.40 mL) and 2M Na₂CO₃ (aq) (19.40 mL) was added bromobenzene (1.016 mL, 9.70 mmol) and PdCl₂(dppf)-CH₂Cl₂ (0.792 g, 0.970 mmol). The vessel was heated to 100 °C overnight under nitrogen. LC-MS showed the product as the main species (M+Na). The resulting black mixture was cooled to RT, diluted with water and extracted 2x with EtOAc. The combined organics were dried with Na₂SO₄, filtered, and dried under reduced pressure. The crude black oil was purified with a 100 g Snap column ramping EtOAc in hexanes from 0% to 15% over 5 min, then remaining at 15% leading to product elution. The material was obtained as a yellow oil upon drying which solidified to *tert*-butyl 4-phenyl-5,6-dihydropyridine-1(2H)-carboxylate (2.08 g, 83%) as a light yellow waxy solid.

20 Step 2

To a solution of *tert*-butyl 4-phenyl-5,6-dihydropyridine-1(2H)-carboxylate (1.7 g, 6.56 mmol) in THF (5.1 mL) cooled in an ice water bath was added borane tetrahydrofuran complex, 1.0 M in THF (9.37 mL, 9.37 mmol) dropwise over 15 min. The solution was stirred for 5 min at 0 °C, then 1 h at RT. To the solution was added sodium perborate tetrahydrate (2.88 g, 18.75 mmol) and water (10.5 mL) (Carefully) and the resulting mixture stirred for another 2 at RT. The desired product was the main species according to LC-MS (M+23). The mixture was diluted with water and EtOAc. The organic layer was separated and the aqueous phase washed again with EtOAc. The combined organics were dried with Na₂SO₄, filtered and dried under reduced pressure. The material was purified using a 25 g column ramping EtOAc in hexanes (0% to 100%) providing (3S,4S)-*tert*-butyl 3-hydroxy-4-phenylpiperidine-1-carboxylate (1.56g, 86 %) as a sticky white solid.

Step 3

To a solution of (3*S*,4*S*)-*tert*-butyl 3-hydroxy-4-phenylpiperidine-1-carboxylate (0.77 g, 2.78 mmol) in CH₂Cl₂ (27.8 mL) cooled in a dry ice/acetone bath was added 'Deoxofluor' (0.512 mL, 2.78 mmol) dropwise. The mixture was allowed to stir overnight and slowly warm to RT. LC-MS showed the product as the major species (M+23) in the 215 nm trace. To the light yellow solution was added sat. aq. NaHCO₃ and the organic phase separated. The aqueous phase was washed with CH₂Cl₂ and the combined organics collected and dried with Na₂SO₄, filtered and dried under reduced pressure. The resulting oil was purified with a 25g column ramping CH₂Cl₂:MeOH:NH₄OH (90:10:1) in CH₂Cl₂ from 0 to 5% over 15 min leading to early elution of product (monitoring at 215 nm) which was obtained as a colorless oil upon drying (3*S*,4*S*)-*tert*-butyl 3-fluoro-4-phenylpiperidine-1-carboxylate (518 mg, 1.854 mmol, 66.8%). The *trans* configuration was confirmed by subsequent NMR studies of the Boc deprotected species.

Step 4


To a solution of (3*S*,4*S*)-*tert*-butyl 3-fluoro-4-phenylpiperidine-1-carboxylate (.51 g, 1.826 mmol) in CH₂Cl₂ (9.13 mL) was added TFA (1.407 mL, 18.26 mmol). The solution was stirred at RT (16 h) open to the atmosphere (needle in septum) leading to complete consumption of SM according to LC-MS and conversion to the desired product with a couple of close eluting impurities. The solution was dried under reduced pressure and the material purified using catch and release with a 5g SCX-2 column, loading with MeOH, washing with MeOH and washing off basic materials with 2M NH₃ in MeOH providing (3*S*,4*S*)-3-fluoro-4-phenylpiperidine (0.304 g, 93%) as an orange oil. 1H NMR structural analysis of this material confirmed the *trans* configuration.

The following compounds were prepared as described in Reference Z above using appropriate starting materials:

(3*R*,4*R*)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidine

Reference AA

Synthesis of 3-(4-(trifluoromethoxy)benzyloxy)azetidine



Step 1


A solution of 1-boc-3-(hydroxy)azetidine (1.00 g, 5.77 mmol) in DMF (19.24 mL) was cooled in an ice water bath and NaH (60% in mineral oil) (0.242 g, 6.06 mmol) was added. The ice bath was removed and the mixture stirred for 90 min at RT. The resulting white suspension was cooled to 0 °C and 4-(trifluoromethoxy)benzyl bromide (0.970 mL, 6.06 mmol) was added. The mixture was allowed to slowly warm to RT overnight. The major species according to LC-MS (215 nm) was the desired product (M+23, 2.793 min). The mixture was diluted with water and extracted with water (2x). The combined organics were dried with Na₂SO₄, filtered and dried under reduced pressure. The crude residue was purified with a 50 g column monitoring at 215 nm ramping CH₂Cl₂:MeOH (90:10) in CH₂Cl₂ from 0% to 100% leading to a smeary trace. The product was carefully located with TLC and LC-MS and isolated tert-butyl 3-(4-(trifluoromethoxy)benzyloxy)azetidine-1-carboxylate (1.70 g) as a colorless oil.

Step 2

To tert-butyl 3-(4-(trifluoromethoxy)benzyloxy)azetidine-1-carboxylate (1.70 g) was added CH₂Cl₂ (20 mL) and TFA (1.5 ml) and the mixture stirred at RT overnight leading to clean conversion to the desired product with trace impurities. The mixture was dried under reduced pressure and purified with a 10g SCX-2 column using catch and release by washing with MeOH, then with 2M NH₃ in MeOH leading to isolation of 3-(4-(trifluoromethoxy)benzyloxy)azetidine (950 mg, 3.84 mmol, 66.6%) as a colorless oil.

Reference BB

Synthesis of 4-(4-(2-methoxyethoxy)benzyloxy)piperidine



Step 1

To a solution of 4-(2-methoxy-ethoxy)-benzaldehyde (0.500 mL, 2.77 mmol) in MeOH (13.87 mL) cooled in an ice water bath was added MP-BH₄ (0.442 g, 1.387 mmol). The mixture was allowed to stir and warm slowly overnight to RT. LC-MS after overnight stirring

shows ~85% conversion to desired alcohol (215 nm trace). An additional 0.25 equiv. MP-BH₄ was added and stirring continued at RT. After stirring for 4 h at RT complete conversion was observed by LC-MS (M+23, 215 nm trace). The mixture was filtered and the solid supports washed with CH₂Cl₂. The filtrate was dried under reduced pressure providing (4-(2-methoxyethoxy)phenyl)methanol (0.492 g, 2.70 mmol, 97 % yield) as a white solid. 1H NMR was consistent with the presence of ~ 15% impurity. The material was used without further purification.

Step 2

A suspension of (4-(2-methoxyethoxy)phenyl)methanol (0.48 g, 2.63 mmol) in CH₂Cl₂ (10.54 mL) was cooled in an ice water bath, then SOCl₂ (0.288 mL, 3.95 mmol) was added dropwise. The mixture was allowed to warm on its own slowly to RT. After 2 h, LC-MS shows ~50% conversion to desired product with starting material present, as well as a methyl ether side product. After another h, no further conversion was evident. To the mixture was added additional SOCl₂ (0.288 mL, 3.95 mmol) and stirring at RT was continued. No further conversion was observed according to LC-MS after 2 h of stirring. The mixture was dried under reduced pressure providing 1-(chloromethyl)-4-(2-methoxyethoxy)benzene (0.515 g, 97 %) as a pale white oil.

Step 3

To a solution of *tert*-butyl 4-hydroxypiperidine-1-carboxylate (0.517 g, 2.57 mmol) in DMF (5 mL) cooled in an ice water bath was added NaH (0.103 g, 2.57 mmol). The ice bath was removed and the mixture stirred at RT for 1 h. The resulting yellow suspension was cooled in an ice water bath and a solution of 1-(chloromethyl)-4-(2-methoxyethoxy)benzene (0.515 g, 2.57 mmol) in DMF (3 mL) was added. The resulting mixture was allowed to warm slowly to RT. after 3 h at RT LC-MS revealed the desired product as the major species (215 nm detection, 2.573 min, M+23). To the vessel was added water and the mixture extracted with EtOAc (2x). The combined organics were dried with Na₂SO₄, filtered and dried under reduced pressure. The crude material was purified with a 50g column ramping CH₂Cl₂:MeOH (90:10) in CH₂Cl₂ from 0% to 100% (monitoring at 215 nm) to afford *tert*-butyl 4-(4-(2-methoxyethoxy)benzyloxy)piperidine-1-carboxylate (0.78 g, 83%) as a yellow oil.


Step 4

To a solution of *tert*-butyl 4-(4-(2-methoxyethoxy)benzyloxy)piperidine-1-carboxylate (0.48g, 1.31 mmol) in MeOH (2.63 mL) was added 2N NaOH (2.63 mL) in a 20 ml microwave vial. The vessel was sealed and irradiated for 40 min at 165 °C leading to complete conversion to the desired product. The mixture was diluted with water and extracted 2x with EtOAc and

the combined organics dried with Na₂SO₄, filtered, and dried under reduced pressure. The crude oil was filtered through a 5g SCX-2 column washing first with MeOH, then with 2M NaOH in MeOH providing 4-(4-(2-methoxyethoxy)benzyloxy)piperidine (0.187 g, 53.7 %) as a yellow oil.

5

Reference CC
Synthesis of 3-aryloxyazetidines



10

This chemistry can be done in a single reaction or parallel fashion. Below is a description is based on parallel chemistry.

Vials were charged with phenol (0.25 mmol). A stock solution was prepared of *N*-boc-3-hydroxyazetidine (0.275 mmol, 1.1 equiv.) in THF (1 mL). To this was added triphenylphosphine (0.55 mmol, 2.2 equiv.). (multiply by the number of reactions to get total for stock solution)

From this stock solution, 1.2 mL was added to each phenol containing vial. Then to each individual vial was added DEAD (0.087 mL, 0.55 mmol, 2.2 equiv.). The vessels were sealed and shaken at RT overnight. The resulting solutions were dried under reduced pressure (using a genevac). To each vessel was added CH₂Cl₂ (1 mL), followed by TFA (0.3 mL). The vessels were sealed and the mixtures shaken at RT overnight. The resulting mixtures were dried under reduced pressure and purified using SCX-2 catch and release washing with MeOH, then with 2M NH₃ in MeOH to elute basic products. The vessels were dried and the crude azetidines were used as is. Yields between 20% and 80% were obtained via this process.

The following compounds were prepared as described in Reference CC above using appropriate starting materials.

3-(3-fluoro-4-(trifluoromethoxy)phenoxy)azetidine

3-(2-chloro-4-(trifluoromethyl)phenoxy)azetidine

3-(4-chloro-3-fluorophenoxy)azetidine

30 3-(4-chlorophenoxy)azetidine

3-(3-fluoro-4-methylphenoxy)azetidine


3-(3-(trifluoromethoxy)phenoxy)azetidine

3-(3-chlorophenoxy)azetidine

- 3-(2-(trifluoromethyl)phenoxy)azetidine
3-(p-tolyloxy)azetidine
3-(4-fluoro-3-methylphenoxy)azetidine
3-(3-chloro-4-fluorophenoxy)azetidine
5 3-(3-fluorophenoxy)azetidine
3-(3,4-difluorophenoxy)azetidine
3-(2,3-difluorophenoxy)azetidine
3-(2,4-difluorophenoxy)azetidine
3-(2,6-difluorophenoxy)azetidine
10 4-(azetidin-3-yloxy)benzonitrile

Reference DD

Synthesis of 3-phenyl-5-(piperidin-4-yl)isoxazole




15

- To a solution of *tert*-butyl 4-ethynylpiperidine-1-carboxylate (315 mg, 1505 μ mol) in EtOAc (7.500 mL, 76613 μ mol) was added potassium bicarbonate (0.14 mL, 3010 μ mol) and (Z)-benzoyl chloride oxime (281 mg, 1806 μ mol). The suspension was stirred overnight at RT
20 providing a milky suspension. Crude LC-MS revealed the product as the main peak. The solution was diluted with EtOAc and extracted with water. The organic layer was dried under reduced pressure. To the resulting orange oil was added CH₂Cl₂ (5 mL) and TFA (1 mL). The solution was stirred for 2 h at RT. The mixture was dried under reduced pressure, and the material purified with a 2g SCX-2 column using MeOH to load material and wash column,
25 followed by 2M NH₃ in MeOH to elute 3-phenyl-5-(piperidin-4-yl)isoxazole (87 mg, 25.3%).

Reference EE

Synthesis of (E)-N-(3-aminophenyl)-N'-cyanoacetimidamide



5

Step 1

To a suspension of 3'-nitroacetanilide (1.00 g, 5551 μmol) in toluene (6.00 mL, 56328 μmol) was added Lawesson's Reagent (1123 mg, 2775 μmol). The mixture was heated to 100 °C under nitrogen for 2 h. The resulting yellow solution contained desired product as the major species according to crude LC-MS (1.796 mins, MH^+ - 197.0). The mixture was cooled to RT and the resulting yellow suspension dried under reduced pressure. The residue was taken up in ether (~75 mL) and extracted twice with water. The organic layer was dried with Na_2SO_4 , filtered and dried under reduced pressure. The crude material was purified using a 50 g column ramping CH_2Cl_2 :MeOH (90:10) in CH_2Cl_2 from 0% to 20% over 5 min, then remaining at 20% providing *N*-(3-nitrophenyl)ethanethioamide (660 mg, 61%) as a yellow solid.

15

Step 2

To a solution of *N*-(3-nitrophenyl)ethanethioamide (300 mg, 1529 μmol) in acetonitrile (2038 μL , 1529 μmol) was added iodomethane (381 μL , 6115 μmol). The mixture was stirred at RT. After 2 h, LC-MS was performed, and when the yellow solution was disturbed, crystallization began to occur. The suspension was stirred for 1 h at RT, prior to the addition of diethyl ether. The precipitate was collected via vacuum filtration and washed with diethyl ether. LC-MS revealed 3-nitroaniline, implying a hydrolytic decomposition of the desired product, accompanied with a strong thiol odor. $^1\text{H-NMR}$ was consistent with (E)-*N*-(1-(methylthio)ethylidene)-3-nitrobenzenaminium iodide (330 mg, 64%) as a light yellow solid.

20

Step 3

To a mixture of (E)-*N*-(1-(methylthio)ethylidene)-3-nitrobenzenaminium iodide (470 mg, 1390 μmol) in EtOH (13899 μL , 1390 μmol) was added cyanamide (46 μL , 1390 μmol) followed by EtOH (13899 μL , 1390 μmol). The mixture was heated in a sealed vessel to 80 °C for 6 h. LC-MS revealed product present at 1.581 min along with starting material about 1:1 without any change in the LC-MS from 3 to 6 h. An additional 2 equiv. of cyanamide was added and heating continued another 15 h then another 300 mg cyanamide was added and heating continued overnight. The mixture was cooled to RT and dried under reduced pressure.

30

The crude residue was purified with a 50 g column ramping CH₂Cl₂:MeOH 90:10 in CH₂Cl₂ ramping from 0% to 20% over 5 min, then remaining at 20% for 15 min, then ramping to 100% over 5 min to afford (E)-N'-cyano-N-(3-nitrophenyl)acetamidine (160 mg, 56%) in about 80% purity as a white solid. This material was used without further purification.

5 Step 4

To a 0.5-2.0 mL microwave vial charged with (E)-N'-cyano-N-(3-nitrophenyl)-acetamidine (160 mg, 784 μmol) was added EtOH (3134 μL, 784 μmol), DBU (354 μL, 2351 μmol) and molybdenum carbonyl (106 μL, 784 μmol) respectively. The yellow suspension was irradiated for 30 min at 120 °C in the microwave providing an orange solution which
10 contained primarily product according to LC-MS (175.2 at 0.634 min). The orange solution was dried under reduced pressure and purified with the Gilson HPLC. The major peak eluted very early and appeared to co-elute with some DBU according to LC-MS. The main peak eluents were dried under reduced pressure and purified with catch and release (2 g, SCX-2) washing first with methanol then with 2M NH₃ in MeOH providing (E)-N-(3-aminophenyl)-N'-
15 cyanoacetamidine (60 mg, 44%) with about 80% purity according to ¹H-NMR. This was used without further purification.


The following compounds were prepared as described in Reference EE above using appropriate starting materials:

(E)-N-(3-amino-2-methylphenyl)-N'-cyanoacetimidamide

20

Reference FF

Synthesis of 2-phenyl-2,8-diazaspiro[4.5]decane 2,2,2-trifluoroacetate




25 To a light green suspension of 2-phenyl-2,8-diazaspiro[4.5]decan-1-one (500 mg, 2171 μmol) in Et₂O (4342 μL, 2171 μmol) cooled in an ice water bath was added dropwise LiAlH₄ (1M in Et₂O) (4342 μL, 4342 μmol). The mixture was allowed to stir and warm slowly to room temp over 3 h providing a milky white suspension. LC-MS revealed conversion to
30 desired product. The mixture was cooled in an ice water bath and water was carefully added (~15 mL). The resulting mixture was extracted with ethyl acetate. The organic layer was dried with Na₂SO₄, filtered and dried under reduced pressure. The colorless oil isolated was purified

on a Gilson preparative RP-HPLC providing 2-phenyl-2,8-diazaspiro[4.5]decane 2,2,2-trifluoroacetate (404 mg, 56%) as a white solid upon drying.

Reference GG

5 Synthesis of N-(5-amino-2-(2-methoxyethoxy)phenyl)acetamide



Step 1

To 2-amino-4-nitrophenol (108.4 mg, 0.703 mmol) in DMF (3 mL) in a disposable sealed tube at RT was added anhydrous granular potassium carbonate (214 mg, 1.547 mmol) followed by 2-bromoethyl methyl ether (0.066 mL, 0.703 mmol). The resulting mixture was stirred at RT for 18 h, then heated to 40 °C for 3.5 d, then heated to 65 °C for 1.5 d, cooled to RT, and transferred to a separatory funnel with EtOAc and water. The organic layer was washed with brine. The aqueous layer and washings were extracted 1 x EtOAc. The organic layers were combined, dried over Na₂SO₄, concentrated and purified (MPLA, 5 g cartridge, 12 g column, 0 to 75% EtOAc in hexanes) to give 2-(2-methoxyethoxy)-5-nitroaniline (241.8 mg) contaminated with the bis-alkylation product, 2-(2-methoxyethoxy)-N-(2-methoxyethyl)-5-nitroaniline. This material was used without further purification.

Step 2


To the mixture of 2-(2-methoxyethoxy)-5-nitroaniline (241.8 mg, 1.139 mmol) from step 1 in pyridine (3.0 mL) at RT was added acetic anhydride (0.108 mL, 1.139 mmol). The resulting mixture was stirred at RT for 25 h, concentrated and purified (MPLA, 5 g cartridge, 40 g column, 0 to 40% 90/10 CH₂Cl₂-MeOH in CH₂Cl₂). Fractions containing the desired product were combined, concentrated and purified (MPLA, 5 g cartridge, 12 g column, 0 to 100% EtOAc-hexanes) to give N-(2-(2-methoxyethoxy)-5-nitrophenyl)acetamide (161.1 mg).

25 Step 3

To N-(2-(2-methoxyethoxy)-5-nitrophenyl)acetamide (97.5 mg, 0.383 mmol) in a 2-5 mL microwave vial was added EtOH (3 mL), DBU (0.172 mL, 1.150 mmol) and molybdenum carbonyl (101 mg, 0.383 mmol). The vial was sealed and heated at 120 °C in the microwave for 45 min, concentrated and purified (MPLA, 5 g cartridge, 12 g column, 0 to 100% 90/10 CH₂Cl₂-MeOH in CH₂Cl₂) to give N-(5-amino-2-(2-methoxyethoxy)phenyl)acetamide (72.9 mg).

Reference HH

Synthesis of 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethanone hydrochloride



Step 1

- 5 To a degassed solution of 6-bromoisoquinoline (5 g, 24.2 mmol) in 1,4 dioxane (50 mL) was added tributyl (1-ethoxyvinyl)tin (9.6 g, 26.5 mmol) and $(\text{PPh}_3)_2\text{PdCl}_2$ (0.842 g, 1.2 mmol) at RT and reaction mixture was heated at reflux for 4 h. The reaction mixture was cooled to RT and hydrolyzed by adding 6N HCl followed by further stirring for 1 h. After completion of reaction (checked by TLC) the mixture was basified up pH 8-9 by K_2CO_3 solution. The organic contents were extracted with EtOAc (3 x 200 mL), dried over Na_2SO_4 and finally concentrated to obtain crude material which was purified by column chromatography using 100-200 silica mesh with EtOAc:hexane (3:10) as eluent to yield 1-isoquinolin-6-yl-ethanone (4.1 g, 56%).

Step 2


- 15 To a degassed solution of 1-isoquinolin-6-yl-ethanone (0.700 g, 4.09 mmol) in AcOH (5 mL) was added platinum oxide (0.100 g) and the reaction mixture was stirred at RT for 6 h under hydrogen atmosphere. After completion of reaction (checked by TLC) the mixture was filtered over a celite pad and the filtrate was concentrated to furnish the crude product which was purified by flash column chromatography with MeOH: CH_2Cl_2 (2:10) as eluent to obtain 1-(1,2,3,4-tetrahydro-isoquinolin-6-yl)-ethanone (0.430 g, 60 %)

Step 3

- 25 A solution of 1-(1,2,3,4-tetrahydro-isoquinolin-6-yl)-ethanone (0.300 g, 1.71 mmol) in HCl in dioxane (5 mL) was stirred at RT for 2 h. After completion of the reaction (monitored by TLC), the solvent was removed under reduced pressure and the solid obtained was washed thoroughly with diethyl ether to obtain 1-(1,2,3,4-tetrahydro-isoquinolin-6-yl)-ethanone hydrochloride (0.320 g, 88.6%)

Reference II

Synthesis of 6-(1-fluoroethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride



Step 1

To a solution of 1-isoquinolin-6-yl-ethanone (1.2 g, 7.01 mmol) [prepared according to Reference HH] in MeOH (10 mL) was added sodium borohydride (0.265 g, 7.01 mmol) at 0 °C and the reaction mixture was stirred for 1 h at RT. After completion of reaction (monitored by TLC), the mixture was quenched by adding a saturated solution of NH₄Cl (5 mL).

Afterwards MeOH was removed under reduced pressure and the solid obtained was dissolved in water (6 mL). The organic contents were then extracted with EtOAc (3 x 25 mL), dried over Na₂SO₄ and concentrated under reduced pressure to afford 1-isoquinolin-6-yl-ethanol (0.750 g, 60.4 %)

Step 2

To a degassed solution of 1-isoquinolin-6-yl-ethanol (1g, 4.14 mmol) in AcOH (8 mL) was added platinum oxide (0.100 g) and the reaction mixture was stirred at RT for 6 h under hydrogen atmosphere. After completion of the reaction (monitored by TLC), the mixture was filtered over a celite pad and the filtrate was concentrated to furnish the crude product which was purified by flash column chromatography with MeOH:CH₂Cl₂ (2:10) as eluent to afford 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-ethanol (0.900 g, 87.9%).

Step 3

To a solution of 1-(1,2,3,4-tetrahydro-isoquinolin-6-yl)-ethanol (0.900 g, 5.20 mmol) in CH₂Cl₂ (10 mL) was added DAST (1.4 g, 8.84 mmol) at 0 °C and the reaction mixture stirred for 4 h at RT. After completion of the reaction (monitored by TLC), the mixture was quenched with a saturated solution of NaHCO₃ (40 mL, with the release of CO₂). Then the organic contents were extracted with CH₂Cl₂ (3 x 50 mL), washed with brine (100 mL), dried over Na₂SO₄ and concentrated to give the crude material (1.0 g). The crude material was purified by flash column chromatography using MeOH:CH₂Cl₂ (1.6:10) as eluent to afford 6-(1-fluoroethyl)-1,2,3,4-tetrahydroisoquinoline (0.300 mg, 32.9 %) as brown solid.


Step 4

A solution of 6-(1-fluoroethyl)-1,2,3,4-tetrahydroisoquinoline (0.340 g, 1.89 mmol) in HCl in dioxane (6 mL) was stirred at RT for 2 h. After completion of the reaction (monitored by TLC), the solvent was removed under reduced pressure and the solid obtained was washed

thoroughly with ether to afford 6-(1-fluoroethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride (0.410 g, 98 %).

Reference JJ

5 Synthesis of 6-ethyl-1,2,3,4-tetrahydroisoquinoline



Step 1

To a solution of 1-isoquinolin-6-yl-ethanone (1.2 g, 7.01 mmol) {prepared according to
10 Reference HH] in 10 mL methanol was added sodium borohydride (0.265 g, 7.01 mmol) at 0 °C and the reaction mixture was stirred for 1 h at RT. After completion of the reaction (monitored by TLC), the mixture was quenched with a saturated solution of NH₄Cl (5 mL). MeOH was removed under reduced pressure and the solid obtained was dissolved in water (6 mL). The organic contents were then extracted with EtOAc (3 × 25 mL), dried over Na₂SO₄
15 and concentrated under reduced pressure to afford 1-isoquinolin-6-yl-ethanol (0.750 g, 60.4%).

Step 2


To a solution of 1-isoquinolin-6-yl-ethanol (0.900 g, 5.20 mmol) in CH₂Cl₂ (10 mL) was added DAST (1.4 g, 8.84 mmol) at 0 °C and the reaction mixture was stirred for 4 h at RT. After completion of reaction (monitored by TLC), the mixture was quenched with saturated
20 solution of NaHCO₃ (40 mL). Then the organic contents were extracted with CH₂Cl₂ (3 × 50 mL), washed with brine (100 mL), dried over Na₂SO₄ and concentrated to give crude material (1.0 g). The crude material was purified by flash column chromatography using MeOH:CH₂Cl₂ (1.6:10) as eluent to afford 1-(6-fluoroethyl)-isoquinoline (0.300 mg, 32.9%) as brown solid.

25 Step 3

To a degassed solution of 1-(6-fluoroethyl)-isoquinoline (1g, 4.14 mmol) in AcOH (8 mL) was added platinum oxide (0.100 g) and the reaction mixture was stirred at RT for 6 h under hydrogen atmosphere. After completion of the reaction (monitored by TLC), the mixture was filtered over a celite pad and the filtrate was concentrated to furnish the crude
30 product, which was purified by flash column chromatography using MeOH:CH₂Cl₂ (2:10) as eluent to afford 6-ethyl-1,2,3,4-tetrahydroisoquinoline (0.900 g, 87.9%).

Reference KK

Synthesis of 4-[3-(2-trifluoromethoxy-phenyl)-pyrazol-1-yl]-piperidine hydrochloride



5 Step 1

To a stirred solution of 4-hydroxy-piperidine-1-carboxylic acid *tert*-butyl ester (7.94 g, 0.039 mol) in CH₂Cl₂ (100 mL) was added triethylamine (5.54 mL, 0.039 mol) at 0 °C. After stirring for 10 min, to the mixture was added methane sulphonyl chloride (3.06 mL, 0.039mol) and DMAP (0.048 g, 0.0039 mol) at 0 °C. The mixture was stirred at RT overnight. After completion of the reaction (monitored by TLC), the mixture was diluted with water and extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo to obtain the crude material which was purified by crystallization to obtain 4-methanesulfonyloxy-piperidine-1-carboxylic acid *tert*-butyl ester (11 g, 99%).

Step 2

To a solution of compound 4-methanesulfonyloxy-piperidine-1-carboxylic acid *tert*-butyl ester (7.5 g, 0.0268 mol) in DMSO (80 mL) was added Cs₂CO₃ (17.46 g, 0.054 mol) and 3-bromo-1H-pyrazole (4.83 g, 0.0322 mol), then the mixture was heated and stirred at 90 °C overnight. After completion of the reaction (monitored by TLC), the mixture was diluted with water and extracted with CH₂Cl₂ (3 ×100 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo to obtain the crude material which was purified using flash chromatography (8% EtOAc:hexane) to obtain 4-(3-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid *tert*-butyl ester (2.50 g, 28.3%).

Step 3

To a suspension of Na₂CO₃ in dioxane:water (40:10) was added 4-(3-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid *tert*-butyl ester (2.5 g, 0.0076 mol) and 2-trifluoromethoxy phenyl boronic acid (1.89 g, 0.0091 mol). After 0.5 h degassing under argon atmosphere, to the reaction mixture was added tetrakis(triphenylphosphine)palladium (0.89 g, 0.00076 mol). The mixture was heated at reflux for 18 h under argon atmosphere. After completion of the reaction (monitored by TLC), the excess dioxane was removed in vacuo to obtain the crude material, which was purified using flash chromatography (10 % EtOAc:hexanes) to afford 4-[3-(2-trifluoromethoxy-phenyl)-pyrazol-1-yl]-piperidine-1-carboxylic acid *tert*-butyl ester (1.80 g, 57.7%).

Step 4

To 4-[3-(2-trifluoromethoxy-phenyl)-pyrazol-1-yl]-piperidine-1-carboxylic acid *tert*-butyl ester (1.8 g, .0044 mol) was added HCl in dioxane (4M) (15 mL). The mixture was stirred at RT for 5 h. After completion of the reaction (monitored by TLC), the excess dioxane was removed in vacuo to obtain the crude material, which was washed with diethyl ether (3 × 20 mL) to obtain 4-[3-(2-trifluoromethoxy-phenyl)-pyrazol-1-yl]-piperidine hydrochloride (1.3 g, 85.5%).


The following compounds were prepared as described in Reference KK above using appropriate starting materials.

4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidine

4-(3-(3-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidine

Reference LL

Synthesis of 3,3-dimethyl-1-(piperidin-4-yl)indoline



Step 1

Oxindole (20.0 g; 0.15 mol) and lithium chloride (21.0 g; 0.49 mol) were suspended in THF (400 mL) and the mixture cooled to -78 °C. *n*-Butyllithium (120.0 mL; 0.30 mol, 2.5M in hexanes) was added slowly and the mixture was stirred for 20 min, then iodomethane (18.7 mL; 0.30 mol) was added. The mixture was warmed to 25 °C, stirred overnight and then quenched with saturated aqueous ammonium chloride and diluted with diethyl ether. The organic layer was washed with water and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by flash chromatography (0-20% EtOAc:hexanes) afforded 3,3-dimethyl-1,3-dihydro-indol-2-one (10.0 g, 41%) as a yellow solid.

Step 2

To a solution of 3,3-dimethyl-1,3-dihydro-indol-2-one (1.0 g) in THF at 0 °C was added LiAlH₄ (1M THF solution, 2.2 equiv.) under nitrogen. The resulting slurry was heated at reflux for 4 h. While cooling in an ice bath, saturated Na₂SO₄ was added carefully to quench the extra un-reacted LiAlH₄. The solids were filtered out, and were rinsed with EtOAc. The organic was washed with H₂O, brine, dried over MgSO₄, filtered, and concentrated to afford 3,3-dimethylindoline, which was used without purification.

Step 3


A solution of 3,3-dimethylindoline (10 mmol) in glacial acetic acid (30 mL) was treated with piperidone (1.1 equiv.) maintaining the temp below 30 °C. The solution was treated by portion-wise addition of sodium triacetoxymethylborohydride (1.5 equiv.). Mixture was stirred at RT for 1 h and then partitioned between EtOAc and water. The mixture was neutralized to ~ pH 8 and the organic phase separated. The aqueous layer was washed with EtOAc and the combined organic layers were concentrated. The residue was purified by flash chromatography to afford *tert*-butyl 4-(3,3-dimethylindolin-1-yl)piperidine-1-carboxylate (82%).

Step 4

To a soln. of *tert*-butyl 4-(3,3-dimethylindolin-1-yl)piperidine-1-carboxylate (1.5 g, 4.5 mmol) in CH₂Cl₂ (15 mL) was added 1,4-dioxane HCl (15 mL, 2M) at 0 °C. The mixture was allowed to stir at RT for 2 h. After completion of the reaction the mixture was washed with sat. sodium bicarbonate and extracted with CH₂Cl₂. The combined organic extracts were washed with brine and dried over anhydrous Na₂SO₄. After removal of the solvent and purification using flash chromatography, 3,3-dimethyl-1-(piperidin-4-yl)indoline was obtained (75%).

Reference MM

Synthesis of 1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine



Step 1

DMF dimethyl acetal (5.82 mL, 0.044 mol) was added to a stirred solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (8.73 g, 0.044 mol) in DMF (80 mL) and the reaction mixture was heated to 80 °C under N₂ for 18 h. After cooling, the DMF was removed under reduced pressure and the residue was partitioned between EtOAc and H₂O. The organic layer was washed with H₂O and saturated brine, then dried over MgSO₄ and evaporated to afford *tert*-butyl 3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylate (8.44 g, 76%).

Step 2

Tert-butyl 3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylate (2.1 g, 8.3 mmol) was dissolved in 100 mL MeOH, and water (50 mL) was added followed by the addition of sodium carbonate (0.53 g, 5.0 mmol) and phenyl hydrazine hydrochloride (1.43 g, 9.9 mmol). Finally, acetic acid (1 mL) was added and the resulting mixture was stirred at RT


for 1 h. The mixture was made basic by adding saturated aqueous sodium bicarbonate (ca. 20 mL) and the MeOH was removed on a rotary evaporator. The resulting mixture was extracted with CH₂Cl₂ (3.x.40 mL) and the combined extracts were dried over anhydrous sodium sulfate, filtered, and concentrated to afford the crude product. Purification by flash chromatography on silica gel using 20% EtOAc in hexanes as the eluent afforded 1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (1.63 g, 66%) as a yellow oil.

The following compound was prepared as described in Reference MM above using appropriate starting materials.

1-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine

Reference NN

Synthesis of (1R,4R)-4-(4-chlorophenoxy)cyclohexanamine



Step 1


To an ice cold solution of 4-chlorophenol (0.299g, 2.32 mmol), tert-butyl (1S,4s)-4-hydroxycyclohexylcarbamate (0.5g, 2.32 mmol), and triphenylphosphine (0.731 mg, 2.79 μmol) in THF (20.00 μL) was added diethyl azodicarboxylate (0.441 μL, 2.79 μmol) and stirred over night while slowly warming up to RT. Reaction mixture was concentrated and dried on high vacuum.

Step 2

The resulting yellow oil was redissolved in DCM (20 mL) and trifluoroacetic acid (5 mL) was added and stirred over night at RT. Reaction mixture was concentrated to obtain (1R,4R)-4-(4-chlorophenoxy)cyclohexanamine as yellow oil. MS (ESI, pos. ion) m/z: 426.2 (M+1).

Reference OO

Synthesis of (E)-N-(5-amino-2-methylphenyl)-N'-cyanoacetimidamide



Step 1

To a suspension of 2-methyl-5-nitroaniline (55 g, 361 mmol) in chloroform (100 mL) at 0 °C, acetic anhydride (110 mL, 1084 mmol) and pyridine (25 mL, 390 mmol) were added. The reaction mixture was stirred at RT for 4 h. After the starting material was consumed (monitored by TLC), the reaction mixture was concentrated to afford crude product. The crude was dissolved in EtOAc (700mL) and the organic layer was washed with a saturated solution of sodium bicarbonate (2 x 150 mL). The organic layer was separated, dried over anhydrous sodium sulphate and concentrated to afford *N*-(2-methyl-5-nitrophenyl)acetamide (60 g, 78 %).

Step 2

To a suspension of *N*-(2-methyl-5-nitrophenyl)acetamide (66 g, 340 mmol) in toluene (500 mL) was added Lawesson's reagent (96 g, 240 mmol). The reaction mixture was heated at 100 °C under nitrogen environment for 3h. After the starting material was consumed (monitored by TLC), the reaction mixture was concentrated to afford crude product, which was purified by flash chromatography (eluent 50% CH₂Cl₂/hexanes) to afford *N*-(2-methyl-5-nitrophenyl)ethanethioamide (60g, 79 %).

Step 3

To a suspension of *N*-(2-methyl-5-nitrophenyl)ethanethioamide (46 g, 219 mmol) in acetonitrile (40 mL) was added methyl iodide (54.78 mL, 876 mmol). The reaction mixture was stirred at RT for 2 h. The reaction mixture was filtered and the solid was washed with diethyl ether (400 mL) to afford the iodo salt of *N*-(2-methyl-5-nitrophenyl)ethanethioamide (55 g, 60 %).

Step 4

To the suspension of the iodo salt of *N*-(2-methyl-5-nitrophenyl)ethanethioamide (25 g, 71 mmol) in acetonitrile (60 mL) was added cyanamide (24.15 g, 574 mmol) and NEt₃ (20.48 mL, 142 mmol). The reaction mixture was heated in sealed tube at 85 °C for 15 h. After the starting material was consumed (monitored by TLC), the reaction mixture was filtered and the solid thus obtained was washed with acetonitrile (2 x 20mL). The filtrate was concentrated under reduced pressure to afford crude product, which was purified by flash chromatography (eluent 50% EtOAc/hexanes) to afford *N'*-cyano-*N*-(2-methyl-5-nitrophenyl)acetimidamide (4 g, 28 %).


Step 5

To the suspension *N'*-cyano-*N*-(2-methyl-5-nitrophenyl)acetimidamide (4 g, 18.32 mmol) in EtOAc (100 mL) was added 10% Pd/C (180 mg) and acetic acid (1 mL). The reaction mixture was stirred in parr shaker at 30 psi under hydrogen atmosphere. After the

completion of the reaction (monitored by TLC), the reaction mixture was filtered through celite. The filtrate was concentrated under reduced pressure to afford crude product, which was purified by flash chromatography (eluent 1% MeOH/CH₂Cl₂) to afford *N*-(5-amino-2-methylphenyl)-*N'*-cyanoacetimidamide (3 g, 80 %).

5

Reference PP

Synthesis of 2-phenyl-4,5,6,7-tetrahydrofuro[3,2-*c*]pyridine

10 Step 1

To a solution of 1-benzylpiperidin-4-one (10.0g, 0.0529 mmol) and morpholine (6.9 g, 0.079 mol) in dry benzene was added a catalytic amount of PTSA (450 mg, 0.00262 mol). A round bottom flask was attached with a Dean Stark assembly then the reaction mixture was heat at reflux under nitrogen for 17 to 18 h. The reaction was monitored by LCMS. The reaction mixture was concentrated under a nitrogen atmosphere. Then the crude mass was diluted with dry benzene and cooled to 0 °C and a solution of phenacyl bromide (12.63 g, 0.063 4mol) (lachromatic compound) in benzene was added to the reaction mixture. The reaction was allowed to warm to RT and stirred over night. The mixture was diluted with water and stirred at RT for 1 h, then extracted with EtOAc (300 x 3 mL), dried over Na₂SO₄ and concentrated to afford the crude product which was purified by flash chromatography (eluent: 10% EtOAc/hexanes) to afford 1-benzyl-3-(2-oxo-2-phenylethyl)piperidin-4-one (4.5 g, 45.0%).

15

20 Step 2

A solution of 1-benzyl-3-(2-oxo-2-phenylethyl)piperidin-4-one (4.0 g, 0.0129 mol) in Conc. HCl (50 mL) was heated at reflux for 3 h. After consumption of the starting material as determined by TLC, the reaction mixture was cooled down to RT and made alkaline by the addition of NH₄OH, then extracted with diethyl ether, dried over Na₂SO₄ and concentrated to afford 5-benzyl-2-phenyl-4,5,6,7-tetrahydrofuro[3,2-*c*]pyridine (2.0 g, 66.66%) as a white solid.

25

30 Step 3


To a solution of 5-benzyl-2-phenyl-4, 5, 6, 7-tetrahydrofuro [3, 2-*c*] pyridine (1.5 g, 0.00649 mol) in EtOH (30 mL) under nitrogen was added Pd-C (10%) (200 mg, 0.3 mmol). Hydrogen (1 atm) was applied and the reaction mixture was stirred for 3 to 4 h at RT. After

consumption of starting materials as determined by TLC, The mixture was filtered through celite, washing with bed EtOH. The filtrate was concentrated to afford a solid which was washed with ether to afford 2-phenyl-4,5,6,7-tetrahydrofuro[3,2-c]pyridine (620 mg, 48.06%).

5

Reference QQ

Synthesis of N-(3-amino-2-bromophenyl)acetamide



Step 1

10 A hot solution of 2,6-dinitroaniline (10 g, 0.054 mol) in acetic acid (100 mL) was added to a solution of NaNO₂ (4.52 g, 0.065 mol) in sulphuric acid (50 mL, NaNO₂ was dissolved at 70 °C and cooled) at such a rate that temperature remained below 40 °C. After the addition was completed, the solution was stirred at 40 °C for 0.5 h. A solution of CuBr (15 g, 0.1 mol) in 48 % aq. HBr (100 mL) was prepared and cooled in an ice bath, and the solution of
15 the diazonium salt was added in portions over a period of about 10 min. The reaction was heated to 80 °C for 1 h and cooled. Water (500 mL) was added to the reaction mixture to afford a brown precipitate, which was filtered, dried and washed with ether to afford 2-bromo-1,3-dinitrobenzene (8.6 g, 65%)

Step 2

20 Fe powder (3.62 g, 0.064 mol) was added into a solution of 2-bromo-1,3-dinitrobenzene (8.0 g, 0.032 mol) in AcOH (80 mL) at RT over a period of 15 min. After the addition was completed, the reaction mixture was heated to 75 °C and stirred at this temperature for 3 h. The cooled reaction was filtered through celite and washed with acetic acid (2 x 20 mL). The filtrate was concentrated to afford the crude product. The crude material
25 was suspended in water and basified with sodium carbonate to pH ~10, then extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine, dried over sodium sulphate and concentrated to afford 2-bromo-3-nitroaniline (5.1 g, 72 %) as yellow solid.

Step 3

30 2-Bromo-3-nitroaniline (5.0 g, 0.023 mol) was added to acetic anhydride (50 mL) at 0 °C followed by the addition of DMAP (0.5 g, 0.0041 mol). The reaction was then allowed to warm to RT and was stirred at same temp for 3 h. After the starting material was consumed,


the volatiles were removed under reduced pressure, crude mass was poured into water, and it was then neutralized with sodium bicarbonate solution. The aqueous layer was then extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine, dried over sodium sulphate and concentrated to afford N-(2-bromo-3-nitrophenyl)acetamide (4.3 g, 72 %) which was used as such without further purification

Step 4

Fe powder (1.0 g, 0.019 mol) was added into a solution of N-(2-bromo-3-nitrophenyl)acetamide (2.5 g, 0.09 mol) in AcOH (40 mL) at RT over a period of 15 min. After the addition was completed, the reaction mixture was heated to 75 °C and stirred at this temperature for 3 h. The cooled reaction was filtered through celite and washed with acetic acid (3 x 20 mL). The filtrate was concentrated to get the crude material. The crude was suspended in water and basified with sodium carbonate to pH ~10 and extracted with ethyl acetate (3 x 150 mL). The combined organic extracts were washed with brine, dried over sodium sulphate and concentrated afford the crude material, which was purified by flash chromatography (eluent: 40% EtOAc in Hexanes) to afford N-(3-amino-2-bromophenyl)-acetamide (1.3 g, 59%) as yellow solid.

Example 1

Synthesis of N-(3-(4-(5-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)-phenyl)acetamide



Step 1

To 2,4-dichloro-1,3,5-triazine (2.00 g, 13.3 mmol) in 10 mL DMF at 0 °C was added DIEA (2.32 mL, 13.3 mmol) followed by N-(3-aminophenyl)acetamide (2.00 g, 13.3 mmol). The resulting mixture was stirred at 0 °C for 10 min, then at RT for 2.5 h, diluted with water, filtered, rinsed with water, and dried to a constant weight, giving 2.18 g of a white solid. The crude solid was adsorbed onto silica gel with CH₂Cl₂ and MeOH, concentrated and purified using preparative MPLC (25 g cartridge, 80 g column, 0 to 100% EtOAc in hexanes) giving N-(3-(4-chloro-1,3,5-triazin-2-ylamino)phenyl)acetamide (1.49 g, 42%) as a white solid.

Step 2

To a slurry of N-(3-(4-chloro-1,3,5-triazin-2-ylamino)phenyl)acetamide (120.0 mg, 455 μ mol) in 3 mL IPA in a disposable sealed tube at RT was added DIEA (238 μ L, 1365 μ mol) followed by 5-fluoro-1,2,3,4-tetrahydroisoquinoline hydrochloride (89.7 mg, 478 μ mol). The resulting white slurry was heated at 100 °C for 2 h, cooled to RT, filtered, rinsed with IPA, and dried on a vacuum pump to a constant weight, giving N-(3-(4-(5-fluoro-3,4-dihydro-isoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide (138.8 mg, 81%) as a white solid. MS (ESI, pos. ion) m/z: 379.2 (M+1).

The following compounds were prepared as described in Example 1 above using appropriate starting materials.

N-(5-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

methyl 2-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydro-5-isoquinolinecarboxylate;

N-(5-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(5-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(7-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide

N-(3-((4-(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(7-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(6-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(6-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(8-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(6-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-((1R)-1-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(6,8-difluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(1-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

25 N-(3-(((4-(6-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-((3S)-3-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(8-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-cyclopropyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(7-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-((4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

15 N-(3-((4-(4-((3*RS*)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(5-phenyl-1,3,4-thiadiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-((4-(4-(4-bromo-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(3-phenyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(3-propyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(3-((4-(4-(3-(acetylamino)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)-acetamide;

30 N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-ethanethioamide;


N-(3-((4-(4-(benzylsulfanyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide; and

N-(3-((4-(4-((3RS)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide.

Example 2

Synthesis of N-(3-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-yloxy)phenyl)acetamide



Step 1


To 2,4-dichloro-1,3,5-triazine (2.00 g, 13.3 mmol) in 10 mL DMF at 0 °C was added DIEA (2.32 mL, 13.3 mmol) followed by 1,2,3,4-tetrahydroisoquinoline (1.69 mL, 13.3 mmol). The resulting mixture was stirred at 0 °C for 10 min then at RT for 2 h. Water was added and the resulting in an orange gum was stirred for 20 min. EtOAc was added and stirring was continued for 10 min. The resulting mixture was transferred to a separatory funnel with EtOAc. The organic layer was washed with water and brine. The combined aqueous layer and washings were extracted twice with EtOAc. The organics were combined, dried and concentrated. The crude product was adsorbed onto silica gel with CH₂Cl₂ and MeOH and purified using preparative MPLC (25 g cartridge, 80 g column, 0 to 40% EtOAc in hexanes). Fractions with desired product were combined and concentrated, giving 2-(4-chloro-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydroisoquinoline (1.76 g, 54%).

Step 2

To 3-acetamidophenol (91.9 mg, 608 μ mol) in 3 mL DMF at RT was added sodium hydride, 60% dispersion in mineral oil (23.3 mg, 608 μ mol). The resulting mixture was stirred at RT for 30 min, and 2-(4-chloro-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydroisoquinoline (150.0 mg, 608 μ mol) was added in one portion. The resulting mixture was stirred at RT for 17 h, quenched with water and diluted with EtOAc. The organic layer was washed with water and brine, dried and concentrated. The crude material was purified using preparative MPLC (5 g cartridge, 12 g column, 0 to 90% EtOAc in hexanes) giving N-(3-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-yloxy)phenyl)acetamide (164.7 mg, 75%). MS (ESI, pos. ion) m/z: 362.0 (M+1).

Example 3

Synthesis of N-(3-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)-phenyl)butyramide



Step 1

To a mixture of 6-bromo-2-(4-chloro-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydroisoquinoline (687 mg, 2112 μ mol) and benzene-1,3-diamine (233 mg, 2112 μ mol), prepared as described in Example 2, Step 1, in i-PrOH (7038 μ l, 2112 μ mol) in a disposable sealed tube at RT was added DIEA (736 μ l, 4223 μ mol). The resulting mixture was heated at 100 $^{\circ}$ C overnight. The reaction mixture was cooled to RT. Water was added until all of the solids had precipitated out of the solution. The solid was filtered off to give N1-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-yl)benzene-1,3-diamine (780 mg, 93% yield) as a gray solid. The crude product was used directly in the next step without further purification.

Step 2

To a disposable sealed tube was added butyric acid (44 mg, 0.50 mmol), followed by HOBt (130 mg, 0.85 mmol), Si-carbodiimide (893 mg, 1.0 mmol) and finally N1-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-yl)benzene-1,3-diamine (199 mg, 0.500 mmol) in 2.5 mL of DMF. The reaction mixture was stirred for several days at RT until LCMS indicated the consumption of the starting material. MP-carbonate (369 mg, 1.1 mmol) was

added and the resulting mixture was stirred for 2 h to neutralize excess HOBt and carboxylic acid. After filtration, the resulting solution was purified using preparative HPLC (Gilson; eluent of 10-95% CH₃CN in water). The desired fractions were combined and treated with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was washed with water and brine, dried over MgSO₄ and concentrated to give N-(3-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)phenyl)butyramide (43 mg, 18% yield) as light brown powder. MS (ESI, pos. ion) m/z: 467.2 (M+1).

(Note: The coupling reaction also can be achieved by using HATU and Hunig's base.)

The following compounds were prepared as described in Example 3 above using appropriate starting materials.

2-((3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)amino)-2-oxoethyl acetate;

(2RS)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-2-furancarboxamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyanoacetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopropylacetamide;

N-2-acetyl-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)glycinamide;

(3RS)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-3-furancarboxamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxyacetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-DL-prolinamide;


N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopentylacetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N-2-carbamoylglycinamide; and

(3S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxybutanamide.

Example 4

Synthesis of N-(3-(4-(4-(pyridin-2-yloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide



5

To N-(3-(4-(4-hydroxypiperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, prepared as described in Example 1 above, (50 mg, 0.152 mmol) in DMF (0.5 mL) was added 2-fluoropyridine (29.6 mg, 0.305 mmol) and potassium tert-butoxide (85 mg, 0.76 mmol). The reaction vessel was sealed under argon and heated to 100 °C for 60 h. The resulting mixture was cooled to RT, diluted with water (3 mL) and extracted with CH₂Cl₂. The combined organics were dried under reduced pressure and purified with reverse phase HPLC using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) as the eluent providing N-(3-(4-(4-(pyridin-2-yloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)-acetamide (19 mg, 30.8%). MS (ESI, pos. ion) m/z: 406.2 (M+1).


15

N-(3-((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide was prepared as described in Example 4 above

Example 5

Synthesis of N-(3-(4-(4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide

20




25

To N-(3-(4-(4-hydroxypiperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, prepared as described in Example 1 above, (50 mg, 0.152 mmol) in DMF (0.5 mL) was added 4-fluoro-3-(trifluoromethyl)benzonitrile (58 mg, 0.305 mmol) and potassium tert-butoxide (85 mg, 0.76 mmol). The reaction vessel was sealed under argon and heated to 100 °C for 60 h.

The resulting mixture was cooled to RT, diluted with water (3 mL) and extracted with CH₂Cl₂. The combined organics were dried under reduced pressure and purified with reverse phase HPLC using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) as the eluent providing N-(3-(4-(4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)-acetamide (6.3 mg, 8.3%). MS (ESI, pos. ion) m/z: 498.2 (M+1).

Example 6

Some compounds in Table 1 above were prepared using the general procedure described below.



Libraries were prepared in a 24 reaction format in sealable vials using reagents and conditions as described in Scheme A and Example 1. For example, to a solution N-(3-(4-chloro-1,3,5-triazin-2-ylamino)phenyl)acetamide (65 mg, 0.25 mmol) in DMF (0.6 mL) was added amine (0.25 mmol) and DIEA (87 μ L, 0.50 mmol). The reaction vessels were sealed and heated to 95 $^{\circ}$ C for 15 h. The resulting solutions were purified by preparative mass triggered HPLC using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) or TFA (0.1% aq) in CH₃CN (with 0.1% TFA) as the eluents providing products as either free bases or TFA salts.

The following compounds were prepared as described in Example 6 above using appropriate starting materials.

- N-(3-((4-(4-phenyl-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;
- N-(3-((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;
- N-(3-((4-(4-(2,5-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;
- N-(3-((4-(4-(2-(2H-1,2,3-triazol-2-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;
- N-(3-((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;
- N-(3-((4-(4-(2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(5-chloro-2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(2-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 N-(3-(((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(3-(((4-(4-(2-acetylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-biphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(3-(((4-(4-(3,4-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(4-(2-hydroxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3-cyano-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

5 N-(3-(((4-(4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(2-((cyclopropylmethyl)(methylsulfonyl)amino)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-hydroxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(3-(((4-(4-(4-methyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(5-(trifluoromethyl)-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(1,2-benzisoxazol-3-yl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

30 N-(3-(((4-(4-(4-methoxyphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((2-methylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

5 N-(3-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 N-(3-(((4-(4-(2-(1-methylethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(2-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

20 N-(3-(((4-(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-butoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

25 N-(3-(((4-(4-(3-phenylpropoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(phenylcarbonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(4-(4-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((3-methylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-((3-chlorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

5 N-(3-(((4-(4-(2-fluorophenyl)-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

10 N-(3-(((4-(4-(3,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-hydroxy-4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

15 N-(3-(((4-(4-(2-methoxyphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(2-chloro-5-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1-naphthalenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-benzyl-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 N-(3-(((4-(4-benzyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-cyclohexylethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(2-methyl-3-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-(phenylsulfanyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(6-(1-hydroxy-1-methylethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(5-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;


racemic mixture of N-(3-((4-((1S,8R)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide and N-(3-((4-((1R,8S)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

15 N-(3-((4-(6-hydroxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide; and

N-(3-((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide.

Example 7

20 Some compounds in Table 1 above were prepared using the general procedure described below.



Libraries were prepared in a 24 reaction format in sealable tubes. To the tubes charged with primary or secondary amine (0.25 mmol, 1.63 eq) was added a solution of N-(3-(4-(4-oxopiperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide (50 mg, 0.153 mmol) (prepared according to Scheme A and Example 1) in DME (0.5 mL). To each reaction mixture TFA (118 μ L, 10 eq) was added. The reaction vessels were shaken at RT for 20 min prior to the addition of MP-BH(OAc)₃ (solid supported reagent from Biotage) (192 mg/reaction, 3.1 equiv.). An additional aliquot of DME was added to each reaction vessel (0.5 mL). The reaction vessels were sealed and shaken at RT for 1 h. DMF (0.5 mL) was added to reaction mixtures which appeared to be insoluble or partially soluble. Shaking was continued for an

additional 60 h at RT. The reaction vessels were individual filtered into a 24-well plate through PE filtration tubes using a Radleys stacker (Brinkmann). The solid supports were washed with CH₂Cl₂ (3 mL, 15 min shaking). The solutions were dried under reduced pressure using a Genevac instrument. The resulting solutions were purified by preparative mass triggered HPLC using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) providing products.

The following compounds were prepared as described in Example 7 above using appropriate starting materials.

N-(3-((4-(4-((2-biphenylmethyl)(methyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(1-benzyl-3,4-dihydro-2(1H)-isoquinoliny)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3-cyanophenyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;


N-(3-((4-(4-((4-chlorophenyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-((4-(4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide; and

N-(3-((4-(4-benzyl-1,4'-bipiperidin-1'-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide.

Example 8

Some compounds in Table 1 above were prepared using the general procedure described below.



Libraries were prepared in a 24 reaction format in a bohdan reaction block. To each reaction vessel was added a solution of N-(3-(4-(4-hydroxypiperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide (50 mg, 0.152 mmol) (prepared according to Scheme A example 1) and t-butyl azodicarboxylate (70.1 mg, .221 mmol) in THF (1.0 mL). To each resulting mixture was added PS-PPh₃ (132 mg, 2.0 eq). The vessels were shaken for 30 min at RT prior to the addition of phenol (0.25 mmol) in THF (1 mL). The resulting mixtures were shaken for

20 h at RT. The heterogeneous mixture was filtered into a 24 well plate and the polystyrene beads washed with CH_2Cl_2 (shaking for 15 min). The CH_2Cl_2 was combined with the other filtrate and the plate dried under reduced pressure in a genevac. The resulting solutions were purified by preparative mass triggered HPLC using NH_4OH (0.1% aq) in CH_3CN (with 0.1% NH_4OH) providing the following compounds.

The following compounds were prepared as described in Example 8 above using appropriate starting materials.

N-(3-((4-(4-(4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;


N-(3-((4-(4-(3,5-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(4-(3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide; and

N-(3-((4-(4-(2,3-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide.

Example 9

Some compounds in Table 1 above were prepared using the general procedure described below.



Libraries were prepared in a 24 reaction format in a bohdan reaction block. A solution of N-(3-(4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)-phenyl)acetamide (60 mg, 0.137 mmol), $\text{Pd}(\text{P}^t\text{Bu}_3)_2$ (3.8 mg, 0.0075 mmol, 5.5 mol%) in THF (1.3 mL) and DMF (0.4 mL) was added to a vial (dried under nitrogen) via syringe containing boronic acid (0.50 mmol). To each vessel was added Cs_2CO_3 (1M aq., 1 mL) and the reaction mixtures were heated and shaken for 15 h at 95° C. The reaction vessels were cooled to RT and ethyl acetate (3 mL) was added to each reaction vessel. The reaction vessels were shaken and the organic layer decanted and filtered through frits into a 24-well plate. The plate was

dried in a genevac and the resulting crude materials were purified by preparative mass triggered HPLC using NH_4OH (0.1% aq) in CH_3CN (with 0.1% NH_4OH) providing products.


Using the procedure described above, N-(3-((4-(6-(2-phenoxyphenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide was prepared.

5

Example 10

Some compounds in Table 1 above were prepared using the general procedure described below.

10



15

To reaction vessels charged with boronic acid (0.5 mmol) was added bromide (75 mg) in THF (1.2 mL). This was followed by the addition of Na_2CO_3 (2M aq., 0.75 mL) and PS-Pd- PPh_3 . The reaction vessels were sealed under argon and heated to 120 °C for 18 hr. The reaction vessels were cooled to RT and water (2 mL) and dichloromethane (3 mL) was added. The reaction mixtures were filtered through phase separator columns and the crude materials dried in a genevac and the resulting crude materials were purified by preparative mass triggered HPLC using NH_4OH (0.1% aq) in CH_3CN (with 0.1% NH_4OH) providing products.

20

Using the procedure described in Example 10 above and appropriate starting materials, the following compounds were synthesized.

N-(3-((4-(4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;


25

N-(3-((4-(4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide; and

N-(3-((4-(4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide.

Example 11

Some compounds in Table 1 above were prepared using the general procedure described below.



10 To a solution of 2,4-dichloro-1,3,5-triazine (0.600 g, 4.00 mmol) in DMF (16.00 mL) and DIPEA (2.096 mL, 8.00 mmol)(additional equivalents of base added as needed depending on if amines are salts) cooled in an ice water bath was added substituted anilino-aryl acetamide (0.673 g, 4.00 mmol). The reaction mixture was stirred for 1 h and allowed to slowly warm to RT after which time LC-MS showed the desired triazine monochloride as the major species.

15 To the reaction mixture was added primary or secondary amine (1.494 g, 4.00 mmol) and the solution stirred for 2 h at RT leading to conversion to the desired product as the major species according to LC-MS.


This process was performed to prepare single compounds or in a parallel fashion. In the instances of parallel synthesis, the crude solutions were purified by preparative mass triggered HPLC (Agilent or Waters preparative system) using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) as the eluents providing products upon drying.

20

In the instances of single compound synthesis, the vessels were dried under reduced pressure and purified with MPLC ramping CH₂Cl₂:MeOH:NH₄OH (90:10:1) in CH₂Cl₂ from 0% to 100% in CH₂Cl₂ providing elution of product. In some instances repurification was performed with RP-HPLC using a Gilson system ramping acetonitrile in water with 0.1% TFA modifier present throughout.

25

Example 12



Step 1

2,4-dichloro-1,3,5-triazine (5.8 g, 37 mmol) was dissolved in 50 mL of dry DMF and the solution was cooled to 0 °C. To this solution were added DIPEA (19 mL, 111 mmol) and 4-(benzyloxy)piperidine hydrochloride (8.4 g, 37 mmol). The resulting mixture was stirred at 0 °C to RT for 4 h. The reaction solution was added to excess water, and then extracted with EtOAc. The crude residue was taken up in minimal EtOAc and purified by MPLC (MPLC: absorbed onto a large loading cartridge and passed through a Redi-Sep® pre-packed silica gel column (330 g) using eluent gradient: 5-80% EtOAc in hexanes over 20 min.) to afford 2-(4-(benzyloxy)piperidin-1-yl)-4-chloro-1,3,5-triazine (7.25 g, 64% yield) as a white solid.

Step 2


To a vial charged with anilino-aryl acetamide (68 mg, 328 µmol) and 2-(4-(benzyloxy)piperidin-1-yl)-4-chloro-1,3,5-triazine (100 mg, 328 µmol) was added DMF (1094 µL, 328 µmol) and DIPEA (115 µL, 656 µmol). The vessel was sealed and shaken at 95 °C for 18 h.

This process was performed to prepare single compounds or in a parallel fashion. In the instances of parallel synthesis, the crude solutions were purified by preparative mass triggered HPLC (Agilent or Waters preparative system) using NH₄OH (0.1% aq) in CH₃CN (with 0.1% NH₄OH) as the eluents providing products upon drying.

In the instances of single compound synthesis, the vessels were dried under reduced pressure and purified with MPLC ramping CH₂Cl₂:MeOH:NH₄OH (90:10:1) in CH₂Cl₂ from 0% to 100% in CH₂Cl₂ providing elution of product. In some instances repurification was performed with RP-HPLC using a Gilson system ramping acetonitrile in water with 0.1% TFA modifier present throughout.

Example 13

Synthesis of *N*-{3-[4-(6-bromo-3,4-dihydro-1*H*-isoquinolin-2-yl)-6-methyl-[1,3,5]triazin-2-ylamino]-phenyl}-acetamide



Step 1

To a solution of cyanuric chloride (3 g, 0.01626 mol) in toluene (12 mL), a 3M solution of methylmagnesium chloride (5.42 mL) in THF was added dropwise at 0 °C. This reaction mixture was allowed to stir at 0 °C for 30 min. Completion of reaction was monitored by

5 TLC. The crude reaction mixture was quenched by adding 0.4 mL of 0.4M HCl and this was extracted in toluene. The organic layer was dried by using sodium sulphate and concentrated to afford crude 2,4-dichloro-6-methyl-[1,3,5]triazine (350 mg, 43% yield). This material was used without further purification.

Step 2

10 To a solution of 2,4-dichloro-6-methyl-[1,3,5]triazine (2.8 g, 0.01707 mol) in DMF (28 mL), DIPEA (8.89 mL, 0.0495 mol) and 6-bromo-1,2,3,4-tetrahydro-isoquinoline hydrochloride (420 mg, 0.0017074 mol) were added at 0 °C. This was allowed to stir at 0 °C. Completion of reaction was monitored by TLC. Water (20 mL) was added to this reaction mixture and the crude compound was extracted with EtOAc. The product was purified by flash

15 chromatography eluting with 2% EtOAc/hexanes to afford 6-bromo-2-(4-chloro-6-methyl-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydroisoquinoline (730 mg, 15% yield).

Step 3


To a solution of 6-bromo-2-(4-chloro-6-methyl-[1,3,5]triazin-2-yl)-1,2,3,4-tetrahydro-isoquinoline (600 mg, 0.001766 mol) in IPA (0.13 mL) in a sealed tube, DMF (0.64 mL,

20 0.00353 mol) and 3'-aminoacetanilide (185.7 mg, 0.001236 mol) were added at 0 °C. This was allowed to stir at 100 °C. Completion of reaction was monitored by TLC. The reaction mixture was cooled to RT and the crude compound was extracted in EtOAc. This was purified in a 100-200 mesh silica gel flash chromatography using eluent 1.5% EtOH in CH₂Cl₂ to afford *N*-{3-[4-(6-bromo-3,4-dihydro-1*H*-isoquinolin-2-yl)-6-methyl-[1,3,5]triazin-2-

25 *ylamino*]-phenyl}-acetamide (126 mg, 38% yield).

Example 14

Synthesis of *N*-{3-[4-chloro-6-(3,4-dihydro-1*H*-isoquinolin-2-yl)-[1,3,5]triazin-2-ylamino]-phenyl}-acetamide



Step 1


To a stirred solution of *N*-(3-aminophenyl)acetamide (5.69 g, 37.95 mmol) in isopropanol (162 mL) at 0 °C, DIPEA (15 mL, 81.34 mmol) was added dropwise at 0 °C. Cyanuric chloride (10 g, 54.22 mmol) was then added to the reaction mixture and allowed to stir at the same temperature for 2 h. The reaction mixture was concentrated and purified by flash chromatography using 100-200 mesh silica and 0-2 % MeOH in CH₂Cl₂ to obtain *N*-[3-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-phenyl]-acetamide (4.6 g, 28% yield).

Step 2

N-(3-(4,6-Dichloro-1,3,5-triazin-2-ylamino)phenyl)acetamide (4.6 g, 15.48 mmol) and 1,2,3,4-tetrahydroisoquinoline (1.85 g, 13.93 mmol) were taken up in DMF (46.5 mL) and Cs₂CO₃ (7.5 g, 23.22 mmol) was added at 0 °C and the reaction mixture was allowed to stir at RT for 2 h. Water was added to the reaction mixture and extracted with EtOAc (200 mL). The organic portion was washed with water (150 mL, 2X), then with brine (150 mL), dried over Na₂SO₄, filtered and concentrated under vacuum to obtain the crude which was purified by flash chromatography eluting with 0-2% MeOH in CH₂Cl₂ to obtain *N*-{3-[4-chloro-6-(3,4-dihydro-1*H*-isoquinolin-2-yl)-[1,3,5]triazin-2-ylamino]-phenyl}-acetamide (1.8 g, 29%).

Example 15

Synthesis of *N*-(3-(4-(4-(benzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)-2-cyanophenyl)acetamide




To a microwave sealed tube was added Pd₂(dba)₃ (4.51 mg, 4.92 μmol) and (9,9-dimethyl-9*H*-xanthene-4,5-diyl)bis(diphenylphosphine) (6.27 mg, 10.83 μmol) followed by dry dioxane (3 mL). The solution was degassed by N₂ for several min then 2-(4-(benzyloxy)piperidin-1-yl)-4-chloro-1,3,5-triazine (150 mg, 0.492 mmol) and sodium carbonate (157 mg, 1.477 mmol) were added. The mixture was stirred after degassing by N₂ and finally *N*-(3-amino-2-cyanophenyl)acetamide (129 mg, 0.738 mmol) was added and the tube was sealed after degassing again. The mixture was heated in the microwave at 150 °C for 2 h. The crude product was purified by HPLC under basic conditions (NH₄OH) to yield *N*-(3-

(4-(4-(benzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)-2-cyanophenyl)acetamide (63.4mg, 29%) as an off-white solid.

Example 16

5 Synthesis of *N*-(3-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)ethanethioamide




10 To a solution of *N*-(3-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide (50.00 mg, 114 μ mol) in THF (1 mL) was added Lawesson's Reagent (23.0 mg, 57.0 μ mol). The mixture was heated to 55 $^{\circ}$ C. After 2 h ~10% conversion to product was observed. The mixture was heated to 80 $^{\circ}$ C for another 2 h leading to ~30 % conversion. Another 1.0 equiv. Lawesson's Reagent (46 mg) was added and heating at 55 $^{\circ}$ C continued for 15 h. The mixture was cooled to RT and dried under reduced pressure. The
15 material was purified using MPLC with a 12 g Redisep column ramping CH_2Cl_2 :MeOH (90:10) in CH_2Cl_2 providing product which still contained some impurities. The material was repurified on RP-HPLC (10% to 90% ACN in water, 0.1% TFA) to provide *N*-(3-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)ethanethioamide (4.7 mg, 9.3%).

20

Example 17

Synthesis of *N*-(2-methyl-3-(4-(2-(5-methylpyridin-3-yl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide




25

A mixture of N-(3-(4-(2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide (0.1 g, 0.244 mmol), 5-methylpyridin-3-ylboronic acid (0.066 g, 0.488 mmol), sodium carbonate (2M aq.) (0.488 mL, 0.976 mmol) in dioxane (1mL) and t-BuOH (1 mL) in a sealed tube was purged with Argon for 5min, then PdCl₂(dppf)-CH₂Cl₂ (0.020 g, 0.024 mmol) was added and heated up to 110 °C for 18 h. The reaction mixture was diluted with t-BuOH (5 mL) and CH₂Cl₂ (5 mL) and filtered through celite. The filtrate was adsorbed on silica gel and purified by MPLC by dry loading and eluting with CH₂Cl₂/MeOH to obtain N-(2-methyl-3-(4-(2-(5-methylpyridin-3-yl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide as an off-white solid (0.04g, 35%).

Example 18


Synthesis of N-(2-methyl-3-(4-(2-(piperidin-1-yl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide



A mixture of DIEA (0.134 mL, 0.750 mmol), N-(3-(4-(2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide (0.102 g, 0.25 mmol) and piperidine (0.097 g, 0.250 mmol) in DMF (1 mL) was heated in the microwave at 180 °C for 10 h. The crude product was purified by Prep RP-HPLC (Gilson) under acidic conditions (0.1% TFA) to obtain N-(2-methyl-3-(4-(2-(piperidin-1-yl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide (0.07 g, 61%) as an off-white solid.

Example 19

Synthesis of N-(2-methyl-3-(4-((1-(4-(trifluoromethoxy)-benzyl)piperidin-4-yl)methylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide



5 Step1

To a solution of N-(3-(4-chloro-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide (750 mg, 2.70 mmol) and DIPEA (1415 μ L, 8.10 mmol) in DMF (9002 μ L) was added tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (579 mg, 2.70 mmol) and stirred over the weekend at RT. The reaction mixture was concentrated and purified by MPLC by dry loading and eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to obtain tert-butyl 4-((4-(3-acetamido-2-methylphenylamino)-1,3,5-triazin-2-ylamino)methyl)piperidine-1-carboxylate (1.03 g, 2.261 mmol, 84 % yield) as white solid.

Step2

A mixture of tert-butyl 4-((4-(3-acetamido-2-methylphenylamino)-1,3,5-triazin-2-ylamino)methyl)piperidine-1-carboxylate (0.5 g, 1.098 mmol) and trifluoroacetic acid (0.423 mL, 5.49 mmol) in CH_2Cl_2 (5 mL) was stirred at RT for 18 h. The reaction mixture was concentrated and dried in high vacuum to obtain N-(2-methyl-3-(4-(piperidin-4-ylmethylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide as a clear oil, which was used without purification.

20 Step3

A mixture of 4-(trifluoromethoxy)benzaldehyde (0.193 g, 1.013 mmol), N-(2-methyl-3-(4-(piperidin-4-ylmethylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide (0.3 g, 0.844 mmol), acetic acid (0.145 mL, 2.53 mmol) in Ethanol (5 mL) was stirred at 40 $^\circ\text{C}$ for 1 h and then sodium cyanotrihydroborate (0.064 g, 1.013 mmol) was added and the mixture was stirred at 40 $^\circ\text{C}$ for 18 h. The reaction mixture was concentrated and purified by MPLC by dry loading and eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ to obtain N-(2-methyl-3-(4-((1-(4-(trifluoromethoxy)-benzyl)piperidin-4-yl)methylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide (0.120 g, 0.227 mmol, 26.8 % yield) as white solid.

Cell-based assays

Compounds were tested on human Nav1.7 expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patch-clamp assays were used. In both, peak current through Nav1.7 was evoked by a depolarizing voltage pulse, and currents were monitored as a function of time in response to exposure to several different concentrations of drug. Automated electrophysiology uses the PatchXpress 7000A system. Up to sixteen cells at a time were voltage-clamped in parallel, and the steady-state voltage dependence of inactivation was determined experimentally for each cell. For each cell, fractional inactivation was set at 20%, and peak current through Nav1.7 as a function of time was measured in response to increasing concentrations of test compound. Manual electrophysiology refers to conventional whole-cell patch-clamping (Hamill et al., 1981). After formation of the whole-cell clamp, cells were lifted off the bottom of the dish with the patch pipette and positioned directly in front of an array of glass microperfusion tubes each with internal diameter ~ 250 microns, with individual compound concentrations flowing from each tube. Current as a function of time in response to increasing drug concentrations was measured with Nav1.7 fully in the resting state (holding voltage set to -140 mV) and on the same cells with the holding voltage set to produce ~ 20% inactivation. Compounds were not applied for a prespecified time, but for as long as required to achieve a stable level of block. For both forms of electrophysiology, offline analysis was used to correct for rundown of channel current and to determine percent inhibition as a function of drug concentration. IC_{50} were determined by fitting to the Hill equation.

Approximate IC₅₀ value of a representative number of compounds of Formula (I) in this assay is provided in the table below.

Cpd#	IC ₅₀ (M)	Cpd#	IC ₅₀ (M)
T-I-1	0.26	T-I-464	0.6
T-I-10	3.8	T-I-703	0.6
T-I-12	0.52	T-I-526	0.2
T-I-17	0.76	T-I-473	1.5
T-I-20	0.59	T-I-786	10.0
T-I-24	0.65	T-I-601	0.7
T-I-26	1.0	T-I-481	5.9
T-I-58	1.9	T-I-484	5.0
T-I-97	3.4	T-II-23	1.2
T-I-103	4.4	T-I-489	1.6
T-I-155	12.9	T-I-494	3.1
T-I-159	14.7	T-V-8	4.9
T-I-160	15.9	T-I-721	6.7
T-I-195	5.6	T-I-711	1.2
T-I-338	0.5	T-V-12	1.1
T-I-344	1.4	T-III-5	1.5
T-I-363	2.5	T-I-604	1.8
T-I-415	3.0	T-I-799	11.9
T-I-533	8.3	T-III-8	18.4
T-I-671	0.3	T-I-795	1.7
T-I-542	1.4	T-I-488	1.2
T-I-462	9.2	T-I-761	0.04
T-I-696	1.1	T-I-770	0.08
T-V-15	3.0	T-I-571	0.08

5 * T-I-1 means Table I, compound #1.

In vivo Assays

Rat Formalin Model of Persistent Pain

On the test day, animals (Naïve, male Sprague Dawley rats weighing between 260-300g at the start of testing were obtained from Harlan (Indianapolis, IN). All animals were housed under a 12/12h light/dark cycle with lights on at 0600. Rodents were housed two to a cage on solid bottom cages with corn cob bedding and had access to food and water *ad libitum*. Animals were allowed to habituate to the vivarium for at least five days before testing was begun) and were brought into the testing room at least 30 minutes prior to dosing. Animals were pretreated with the appropriate test compound either by oral gavage or intraperitoneal injection at the desired pretreatment time (typically two hours before test onset) and then returned to their home cages. After dosing and at least 30 minutes prior to test onset, animals were acclimated to the individual testing chambers. At test time, each animal was gently wrapped in a towel with the left hindpaw exposed. A dilute solution of formalin (2.5%) in phosphate buffered saline was injected subcutaneously into the dorsal surface of the left hindpaw in a volume to 50 µL with a 30 g needle. Immediately following injection, a small metal band was affixed to the plantar side of the left hindpaw with a drop of loctite. Animals were then placed into the testing chambers and the number of flinches was recorded between 10-40 minutes after formalin injection. A flinch was defined as a quick and spontaneous movement of the injected hindpaw not associated with ambulation. Flinches were quantified with the aid of the Automated Nociception Analyzer built by the University of California, San Diego Department of Anesthesiology. Individual data was expressed as a % maximal potential effect (%MPE) calculated with the following formula:

$$(-(Individual\ score - Vehicle\ average\ score) / Vehicle\ average\ score) * 100 = \%MPE$$

Statistical analysis was performed by analysis of variance (ANOVA), with post-hoc analysis using Bonferroni compared to the vehicle group for a significant main effect. Data was represented as mean %MPE +/- standard error for each group.

Cpd#	MED (p.o., mg/kg)
T-I-363	60
T-I-526	30
T-I-26	30
T-I-484	10

Rat Open Field Assay

On the test day, animals (Naïve, male Sprague Dawley rats weighing between 260-300g at the start of testing) were obtained from Harlan (Indianapolis, IN). All animals were housed under a 12/12h light/dark cycle with lights on at 0600. Rodents were housed two to a cage on solid bottom cages with corn cob bedding and had access to food and water *ad libitum*. Animals were allowed to habituate to the vivarium for at least five days before testing was begun) were brought into the testing room at least 30 minutes prior to dosing. In a room separate from the testing room, animals were pretreated with the appropriate test compound either by oral gavage or intraperitoneal injection at the desired pretreatment time (typically two hours before test onset) and then returned to their home cages until the pretreatment had elapsed. At test time, animal were transferred to the open field testing room in their home cages. Each animal was placed in a separate testing chamber and the motion tracking system was started. The house lights in the testing room were turned off and the animals were allowed to explore the novel open field for 30 minutes.

An automated motion tracker, made by San Diego Instruments, San Diego, CA, was used to capture animal exploration with the aid of infrared photo beams to detect animal movement. These behaviors include basic movement and vertical rearing, which were used as the primary endpoints for this assay. At the end of the test, house lights were turned on and the animals were removed from the testing apparatus. Data was expressed as a percent change from the vehicle control using the following equation.

$$(1-(\text{Test mean}/ \text{Vehicle mean})) * 100 = \% \text{Change}.$$

Statistical analysis was performed by analysis of variance (ANOVA), with post-hoc analysis using Dunnett to follow up significant main effects.

CFA-Thermal Assay

Animals (Naïve, male Sprague Dawley rats weighing between 260-300g at the start of testing) were obtained from Harlan (Indianapolis, IN). All animals were housed under a 12/12h light/dark cycle with lights on at 0600. Rodents were housed two to a cage on solid bottom cages with corn cob bedding with access to food and water *ad libitum*. Animals were allowed to habituate to the vivarium for at least five days before testing was begun and were brought into the testing room at least 30 minutes prior to dosing. The Complete Freund's Adjuvant (CFA)-thermal assay utilizes a three continuous day testing schedule consisting of a habituation day, a baseline day, and a test day. On day 1, animals were brought into the testing

room, labeled, and placed in their individual testing boxes on the testing apparatus. Animals were allowed to explore this environment for at least an hour without actually being testing. After habituating, animals were placed back in their home cages and returned to the vivarium. On day 2, animals were brought back into the testing room and placed on the testing apparatus and allowed to calm down (typically 30-45 minutes). A basal thermal threshold was then taken with the following procedure: once calm, a Ugo Basile plantar device was placed under the animals left hindpaw; the start button was depressed turning on a steadily increasing thermal source and a timer; when the animal reaches its thermal threshold it will flinch its hindpaw, stopping the timer and the thermal stimulus. This latency to flinch was recorded three times for each animal, with at least 5 minutes between trials, and the mean score was used as the animal's baseline threshold. After testing, animals were injected intraplantarly with a 25 µg/50 µl of complete Freund's adjuvant into the left hindpaw. Animals were then returned to their home cages and returned to the vivarium. On test day, animals were again placed on the thermal testing apparatus and their post-CFA baselines were obtained with the procedure outlined above. Animals were pretreated with the appropriate test compound either by oral gavage or intraperitoneal injection at the desired pretreatment time (typically two hours before test onset) and then returned to their home cages. Thirty minutes prior to testing, animal were placed on the apparatus again. Once the pretreatment time has elapsed, animals were again tested with the procedure above. Data was expressed as a percent maximal potential effect with the following formula:

$$((\text{Post-Drug Mean} - \text{Pre-Drug Mean}) / (\text{Baseline Mean} - \text{Pre-Drug Mean})) * 100 = \% \text{MPE}$$

Statistical analysis was performed by analysis of variance (ANOVA), with post-hoc analysis using Bonferroni compared to the vehicle group for a significant main effect. Data was represented as mean %MPE +/- standard error for each group.

Spinal Nerve Ligation (Chung)

Animals (Naïve, male Sprague Dawley rats weighing between 150-200g at the start of first time testing) were obtained from Harlan (Indianapolis, IN). All animals were housed under a 12/12h light/dark cycle with lights on at 0600. Rodents were housed two to a cage on solid bottom cages with corn cob bedding with access to food and water *ad libitum*. Animals were allowed to habituate to the vivarium for at least five days before testing was begun. Surgery was then performed based on the method described by Kim and Chung (1992). Briefly, animals were placed under isoflurane anesthesia and placed in a sterile surgical field. The area of the lumbar spine is excised and the spinal nerves at L4-L5 are exposed. The L5

spinal nerve is identified and tightly ligated with 5-0 silk suture. The muscle is then closed with absorbable suture and the skin with wound clip. Animal are returned to the vivarium for 7-14 days and monitored daily. On test day, animals were brought into the testing room and placed on a wire mesh floor in individual testing chambers. They were allowed to acclimate to the chambers until they were calm. A series of Semmes-Weinstein monofilaments (von Frey hairs) with calibrated bending forces were then applied to determine a hyperalgesic baseline following the method set forth by Chaplan et al. (1994). Briefly, filaments are applied with an increasing force (if there was not reaction to the previous stimulus) or decreasing force (if there was a reaction to the previous stimulus) until a baseline value is reached. Animals were then pretreated with the appropriate test compound either by oral gavage or intraperitoneal injection at the desired pretreatment time (typically two hours before test onset) and then returned to their home cages. Thirty minutes prior to testing, animal were placed on the apparatus again. After the pretreatment time had elapsed, the procedure above is repeated to determine drug efficacy. Data is expressed as the mean gram force to elicit a nociceptive behavior. Statistical analysis was performed by analysis of variance (ANOVA), with post-hoc analysis using Bonferroni compared to the vehicle group for a significant main effect

Formulation Examples

The following are representative pharmaceutical formulations containing a compound of Formula (I).

Tablet Formulation

The following ingredients are mixed intimately and pressed into single scored tablets.

25	Ingredient	Quantity per tablet
		<u>mg</u>
	compound of this invention	400
	cornstarch	50
30	croscarmellose sodium	25
	lactose	120
	<u>magnesium stearate</u>	<u>5</u>

Capsule Formulation

The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

5	Ingredient	Quantity per capsule
		<u>mg</u>
	compound of this invention	200
	lactose spray dried	148
10	<u>magnesium stearate</u>	<u>2</u>


The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims.

15 Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

All patents, patent applications and publications cited in this application are hereby
20 incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

What is Claimed:

1. A compound of Formula (I):



5 where:

X is -NH-, -O-, -S-, or -SO₂-;

Y is O, S, or N-CN

A is aryl or heteroaryl;

10 R¹ is alkyl, haloalkyl, substituted alkyl, acyloxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclalkyl, aralkyl, or heteroaralkyl wherein the ring in cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclalkyl, aralkyl, or heteroaralkyl is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, alkoxy, hydroxyl, or haloalkoxy;

15 R² is hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy, alkoxyalkoxy, hydroxy, carboxy, alkoxy carbonyl, cyano, amino, monosubstituted or disubstituted amino, sulfonyl, or alkoxyalkyl;


R³ is hydrogen, halo, alkyl, alkoxy, cyano, or haloalkyl;

20 R⁴ is hydrogen, alkyl, substituted alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxy carbonyl, aryl, heteroaryl, cycloalkyl, cyano, amino, monoalkylamino, or dialkylamino;

R⁵ is hydrogen, alkyl, substituted alkyl, aryl, or heteroaryl; and

R⁶ is aryl, heteroaryl, heteroaralkyl, heterocyclalkyl, cycloalkyl, or aralkyl wherein one or two carbon atoms in the alkyl chain in aralkyl are optionally replaced by -N-, -O-, or -CO- provided that -N-, -O-, or -CO- are not on adjacent atoms; or

25 R⁵ and R⁶ together with the nitrogen atom to which they are attached form ring B having the formula:



wherein ring B is a heteroaryl, four membered heterocyclalkyl, heterocyclalkyl, bridged heterocyclalkyl, or spiroheterocyclalkyl ring, and

wherein each aforementioned ring in R⁵, R⁶ and ring B is substituted with R^a, R^b or R^c where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, thio, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, or acylamino and R^b and R^c are independently selected from hydrogen, alkyl, substituted alkyl, substituted alkynyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, sulfonylamino, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, aryloxy, heteroaryloxy, cycloalkoxy, aryloxyalkyl, aralkyloxy, aralkylthio, heteroaralkyloxy, heterocyclylalkyloxy, or cycloalkylalkyloxy where the aromatic or alicyclic ring in R^a, R^b and R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, cycloalkyl, cycloalkenyl, phenyl, phenoxoy, heteroaryl, heterocyclyl, heterocyclylalkyl, aralkyl or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxyl, alkoxy, acetylamino, alkylsulfonyl, or cyano;

or a pharmaceutically acceptable salt thereof, provided that:

- (ii) two of R^a, R^b and R^c are not simultaneously amino; (ii) the compound of Formula (I) is not N-(4-(4-(2-amino-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-phenylcyclopropylamino)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(benzylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)-acetamide, N-(3-(4-(2-(indol-5-ylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, and N-(4-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)-1,3,5-triazin-2-yl)phenylamino)acetamide; (iii) when A is phenyl, Y is O, R¹ is alkyl or phenyl, R² is hydrogen or alkyl, R³ is hydrogen or halo, R⁴ is hydrogen, halo, or haloalkyl, R⁵ is hydrogen; and R⁶ is phenyl, then (a) when two of R^a, R^b and R^c are hydrogen then the third of R^a, R^b and R^c is not halo, aminocarbonyl, or acylamino or (b) R^a, R^b and R^c are not all simultaneously alkoxy; (iv) when A is phenyl, Y is O, R¹ is alkyl, R² is hydrogen, R³ is hydrogen, R⁴ is hydrogen, R⁵ is hydrogen; and R⁶ is pyrazole, then when two of R^a, R^b and R^c are hydrogen

then the third of R^a, R^b and R^c is not furanyl; (v) when A is phenyl, Y is O, R¹ is alkyl, R² is hydrogen or alkyl, R³ is hydrogen, R⁴ is hydrogen, and R⁵ is hydrogen or alkyl; and R⁶ is indazolyl, then when two of R^a, R^b and R^c are hydrogen then the third of R^a, R^b and R^c is not alkyl or aralkyl; and (vi) when A is phenyl, Y is O, R¹ is alkyl or phenyl, R² is hydrogen or alkoxy, and R³ is alkyl or halo, and R⁴ is hydrogen or alkoxy, then ring B is not 4-(2-hydroxyethyl)piperazin-1-yl, or 4-(4-methoxyphenyl)piperazin-1-yl or salts thereof.


2, The compound of Claim 1 wherein:

R² is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxy carbonyl, cyano, amino, monosubstituted or disubstituted amino, sulfonyl, or alkoxyalkyl;

R³ is hydrogen;

R⁴ is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkoxy, hydroxy, carboxy, alkoxy carbonyl, cyano, amino, monoalkylamino, or dialkylamino;

R⁵ and R⁶ together with the nitrogen atom to which they are attached form ring B having the formula:



wherein ring B is a heteroaryl, heterocyclyl, bridged heterocyclyl, or spiroheterocyclyl ring, each ring substituted with R^a, R^b or R^c where R^a is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, thio, acyl, carboxy, alkoxy carbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, hydroxyalkoxyalkyl, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, or acylamino and R^b and R^c are independently selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxy carbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, sulfonylamino, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, aralkyl, heteroaralkyl, heterocyclylalkyl, aryloxy, heteroaryloxy, cycloalkoxy, aralkyloxy, aralkylthio, heteroaralkyloxy, heterocyclylalkyloxy, or cycloalkylalkyloxy where the aromatic or alicyclic ring in R^a, R^b and R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, sulfonyl, acyl, carboxy, alkoxy carbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, aminosulfonyl, aminocarbonyl, acylamino, cycloalkenyl, phenyl, heteroaryl, heterocyclyl,

heterocyclylalkyl, aralkyl or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxyl, alkoxy, acetylamino, alkylsulfonyl, or cyano; or a pharmaceutically acceptable salt thereof, provided that (i) two of R^a, R^b and R^c are not simultaneously amino, and (ii) the compound of Formula (I) is not N-(4-(4-(2-amino-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(benzylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, N-(3-(4-(2-(indol-5-ylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide, and N-(4-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)-1,3,5-triazin-2-yl)phenylamino)acetamide, or salts thereof.

3. The compound of Claim 1 wherein X is -NH- or -O-.

4. The compound of Claim 1 wherein X is -NH-.

5. The compound of Claim 2 wherein X is -NH-.

6. The compound of any of the Claims 1 to 5 wherein R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl.

7. The compound of any of the Claims 1 to 6 wherein Y is O or -N-CN, preferably O.

8. The compound of any of the Claims 1, 3, or 4 wherein R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl; Y is O or -N-CN, preferably O; and A is phenyl.

9. The compound of any of the Claims 1, 3, or 4 wherein R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl; Y is O or -N-CN, preferably O; and A is phenyl R⁴ is hydrogen, and R² is hydrogen, alkyl, cycloalkyl, aryl, halo, haloalkyl, haloalkoxy, alkoxy, or hydroxyl.


10. The compound of Claim 3 or 4 wherein R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl; Y is O or -N-CN, preferably O; and A is phenyl, R⁴ is hydrogen, and R² is methyl, chloro, or fluoro and the R² group is ortho to R¹CONH- and the R¹CONH- group is meta to the triazinylamino (X = NH) group.

11. The compound of any of the Claims 1, 3, or 4 wherein R¹ is alkyl, preferably methyl, ethyl, propyl, isopropyl, isobutyl, or t-butyl; Y is O or -N-CN, preferably O; and A is phenyl and R⁴ and R² are independently methyl, ethyl, propyl, cyclopropyl, phenyl, fluoro, chloro, trifluoromethyl, trifluoromethoxy, methoxy or hydroxyl.


12. The compound of any of the Claims 1, 3, 4, 8, 9, 10 and 11 wherein R⁵ and R⁶ together

with the nitrogen atom to which they are attached form .


13. The compound of any of the Claims 1, 3, 4, 8, 9, 10 and 11 wherein R⁵ and R⁶ together

with the nitrogen atom to which they are attached form  wherein ring B is azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 8-azabicyclo[3.2.1]oct-8-yl, 2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, 1,4-diazepan-1-yl, or 3,6-dihydro-2(H)pyridin-1-yl, more preferably azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, or 3,6-dihydro-2(H)pyridin-1-yl, each ring substituted with R^a, R^b and R^c.

14. The compound of any of the Claims 1, 3, 4, 8, 9, 10 and 11 wherein R⁵ and R⁶ together

with the nitrogen atom to which they are attached form  wherein ring B is azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 8-azabicyclo[3.2.1]oct-8-yl, 2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, 1,4-diazepan-1-yl, or 3,6-dihydro-2(H)pyridin-1-yl, more preferably azetidin-1-yl, piperidin-1-yl, piperazin-1-yl, 3,4-dihydro-1(H)-isoquinolin-2-yl, or 3,6-dihydro-2(H)pyridin-1-yl, each ring substituted with R^a, R^b and R^c even more preferably piperidin-1-yl or piperazin-1-yl, each ring substituted with R^a where R^a is hydrogen, R^b is hydrogen, alkoxy, halo, or alkyl, and R^c is alkyl, substituted alkyl, substituted alkynyl, halo, haloalkyl, haloalkoxy, alkoxy, acyl, hydroxyalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, aryloxy, heteroaryloxy, aryloxyalkyl, or aralkyloxy, where the aromatic or alicyclic ring in R^c is optionally substituted with R^d, R^e or R^f which are independently selected from alkyl, halo, haloalkyl, haloalkoxy, alkylthio, cyano, hydroxy, disubstituted amino, sulfonyl, alkoxyalkoxy, cycloalkyl, phenyl, or heteroaralkyl where the aromatic or alicyclic ring in R^d, R^e or R^f is optionally substituted with one to three substituents independently selected from haloalkoxy.

15. The compound of any of the Claims 1, 3, 4, 8, 9, 10 and 11 wherein R⁵ and R⁶ together

with the nitrogen atom to which they are attached form  wherein ring B is 4-(benzyloxy)piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl; 4-(4-chlorophenoxy)piperidin-1-yl; 4-phenylpiperidin-1-yl; 4-(4-cyanophenyl)piperidin-1-yl; 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(benzylsulfanyl)piperidin-1-yl; 4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl; 4-(4-fluorophenoxy)-piperidin-1-yl; 4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-methoxyphenyl)piperidin-1-yl; 4-((3RS)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidin-1-yl; 4-(4-(2-methylphenyl)-1H-pyrazol-1-

- yl)piperidin-1-yl; 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-pyridinyloxy)piperidin-1-yl; 4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(3-chloro-4-fluorophenoxy)piperidin-1-yl; 4-((2-methylbenzyl)oxy)piperidin-1-yl; 4-(3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-methylphenoxy)piperidin-1-yl; 4-(2-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-((2-biphenylmethyl)(methyl)amino)piperidin-1-yl; 4-(4-chlorophenyl)piperidin-1-yl; 4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl; 4-(2-chloro-phenoxy)piperidin-1-yl; 4-(4-bromophenyl)-4-hydroxypiperidin-1-yl; 4-(3-phenylpropoxy)-piperidin-1-yl; 4-(2-chloro-4-fluorophenoxy)-piperidin-1-yl; 4-(3-chloro-4-cyanophenoxy)-piperidin-1-yl; 4-butoxypiperidin-1-yl; 4-(2-methylphenoxy)piperidin-1-yl; 4-(2,4-difluorophenoxy)piperidin-1-yl; 4-(3,4-difluorophenoxy)piperidin-1-yl; (3S)-3-phenyl-1-pyrrolidiny)piperidin-1-yl; 4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenylcarbonyl)piperidin-1-yl; 4-(phenylsulfanyl)piperidin-1-yl; 4-(4-fluorophenyl)-piperidin-1-yl; 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl; 4-((3-methylbenzyl)oxy)piperidin-1-yl; 4-((3-cyanophenyl)amino)-piperidin-1-yl; 4-((4-chlorophenyl)amino)piperidin-1-yl; 4-((3-chlorobenzyl)oxy)piperidin-1-yl; 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl; 4-(2,3-difluorophenoxy)piperidin-1-yl; 4-hydroxy-4-phenylpiperidin-1-yl; 4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(2-chloro-5-methylphenoxy)piperidin-1-yl; 4-(3-phenyl-5-isoxazolyl)piperidin-1-yl; 4-(3-propyl-5-isoxazolyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidiny)piperidin-1-yl; 4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(1-naphthalenyloxy)piperidin-1-yl; 4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-benzyl-4-hydroxypiperidin-1-yl; 4-benzylpiperidin-1-yl; 4-((3-fluoro-5-(trifluoromethyl)-benzyl)amino)piperidin-1-yl; 4-(2-methoxyphenoxy)piperidin-1-yl; 4-(3-(acetyl-amino)-phenoxy)piperidin-1-yl; 4-benzyl-1,4'-bipiperidin-1'-yl; 4-(2-cyclohexylethoxy)piperidin-1-yl; 4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((3-chloro-4-cyanophenyl)amino)-piperidin-1-yl; 4-ethoxypiperidin-1-yl; 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-methoxypiperidin-1-yl; 4-(3-bromophenoxy)piperidin-1-yl; 4-(2-(1-methylethyl)phenoxy)-piperidin-1-yl; 4-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; (3RS)-3-(2-cyanophenoxy)piperidin-1-yl; 4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl; (3RS)-3-(2-methoxy-4-methylphenoxy)piperidin-1-yl; 4-(2-cyanophenoxy)piperidin-1-yl; 4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-chloro-2-(trifluoromethyl)-phenoxy)-piperidin-1-yl; 4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((6-methyl-3-pyridinyl)oxy)piperidin-1-yl; 4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2-fluorophenoxy)piperidin-1-yl; 4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(1-pyrrolidiny)piperidin-1-yl; 4-

(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,4-dichlorophenoxy)-piperidin-1-yl; 4-(cyclopropylmethoxy)piperidin-1-yl; 4-ethoxycarbonylpiperidin-1-yl; 4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; (3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-propyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyloxy)piperidin-1-yl; 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-bromophenoxy)piperidin-1-yl; 4-((4-methylphenyl)sulfonyl)piperidin-1-yl; 4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)piperidin-1-yl; 4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(5,6,7,8-tetrahydro-1-naphthalenylamino)piperidin-1-yl; (3RS)-3-(4-chlorophenoxy)piperidin-1-yl; 4-phenyl-4-propanoylpiperidin-1-yl; (2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(4-tert-butylphenoxy)piperidin-1-yl; 4-(2-propylaminocarbonylphenoxy)piperidin-1-yl; 4-(3-pyridinyloxy)piperidin-1-yl; 4-((4-methoxyphenyl)amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)amino)piperidin-1-yl; 4-(phenylsulfonyl)piperidin-1-yl; 4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(2-pyrimidinyloxy)piperidin-1-yl; 4-(2-biphenyloxy)piperidin-1-yl; (3RS)-3-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-pyridinyloxy)piperidin-1-yl; 4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(methyl(2-(trifluoromethoxy)phenyl)amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)sulfonyl)piperidin-1-yl; 4-(6-quinolinylamino)piperidin-1-yl; 4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl; 4-(benzylsulfonyl)piperidin-1-yl; 4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl; 4-(4-(2-pyrimidinyl)piperazin-1-yl)piperidin-1-yl; 4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl; 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl; (3RS)-3-(4-cyano-2-methoxyphenoxy)piperidin-1-yl; 4-aminocarbonylpiperidin-1-yl; 4-(4-(8-quinolinyloxy)-1H-pyrazol-1-yl)piperidin-1-yl; 4-carboxypiperidin-1-yl; 4-((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(4-((dimethylamino)-methyl)phenoxy)piperidin-1-yl; 4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-biphenyl)piperidin-1-yl; 4-(2-biphenyl)piperidin-1-yl; 4-(4-CF₃-benzyloxy)piperidin-1-yl; 4-(4-CF₃O-benzyloxy)piperidin-1-yl; 4-(4-Br-benzyloxy)piperidin-1-yl; 4-(3,4-difluoro-benzyloxy)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-Cl-3-F-

phenoxy)piperidin-1-yl; 4-(3-CF₃-benzyloxy)piperidin-1-yl; 4-(4-Cl-3-CH₃-phenoxy)piperidin-1-yl; 4-(4-F-benzyloxy)piperidin-1-yl; 4-(2,6-diF-benzyloxy)piperidin-1-yl; 4-(benzthiazol-2-yl)piperidin-1-yl; 4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-Cl-4-CN-phenyl)piperidin-1-yl; 4-(benzoxazol-2-yl)piperidin-1-yl; 4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-(4-chloro-3-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-(4-cyano-3-methylphenyl)piperidin-1-yl; 4-(2-cyanobenzyloxy)piperidin-1-yl; 4-(2-CF₃benzyloxy)piperidin-1-yl; 4-(1-RS-1-phenylethoxy)-piperidin-1-yl; 4-(4-chloro-3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-chlorobenzoyl)piperidin-1-yl; 4-(4-dimethylaminophenyl)piperidin-1-yl; 4-(2-CF₃phenyl)piperidin-1-yl; 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl; 4-(3-OCF₃benzyloxy)piperidin-1-yl; 4-(2-OCF₃benzyloxy)-piperidin-1-yl; 4-(4-butylbenzyloxy)piperidin-1-yl; 4-(4-isopropylbenzyloxy)-piperidin-1-yl; 4-(4-methylbenzyloxy)piperidin-1-yl; 4-(4-OCHF₂benzyloxy)piperidin-1-yl; 4-(2,4,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3-difluorobenzyloxy)-piperidin-1-yl; 4-(2,4-difluorobenzyloxy)-piperidin-1-yl; 4-(2,3,4-trifluorobenzyloxy)-piperidin-1-yl; 4-(4-cyanobenzyloxy)-piperidin-1-yl; 4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl; 4-(4-chlorobenzyl)piperidin-1-yl; 4-(3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃benzyloxy)-piperidin-1-yl; 3-fluoro-4-(phenyl)piperidin-1-yl; 4-(3-cyanophenoxy)piperidin-1-yl; 4-(4-cyanophenoxy)piperidin-1-yl; 4-methyl-4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-[4-(2-methoxyethoxy)benzyl-oxy]piperidin-1-yl; (3R,4R)-3-fluoro-4-phenyl-piperidin-1-yl; (3S,4S)-3-fluoro-4-phenyl-piperidin-1-yl; 4-(4-tert-butylbenzyloxy)-piperidin-1-yl; 4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl; 4-benzyl-4-fluoropiperidin-1-yl; 4-(2-methylsulfonylphenoxy)-piperidin-1-yl; 4-(3-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(4-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(3-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(2,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,4-diCF₃benzyloxy)piperidin-1-yl; 4-(2-fluorobenzyloxy)piperidin-1-yl; 4-(3-fluorobenzyloxy)piperidin-1-yl; 4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,5-difluorobenzyloxy)piperidin-1-yl; 4-(2,5-diCF₃benzyloxy)piperidin-1-yl; 3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)piperidin-1-yl; 4-(2,3-dichlorophenoxy)piperidin-1-yl; 4-(3-chloro-4-methylphenoxy)-piperidin-1-yl; 4-(4-chloro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-chlorophenoxy)-piperidin-1-yl; 4-(3,4-dimethylphenoxy)-piperidin-1-yl; 4-(2,3-dimethylphenoxy)-piperidin-1-yl; 4-(3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(3-thiophenylmethoxy)-piperidin-1-yl; 4-(2-fluoro-5-OCF₃phenoxy)-piperidin-1-yl; 4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl;

- 4-(3-fluoro-4-OCF₃phenoxy)-piperidin-1-yl; 4-(4-fluoro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(2,6-difluorophenoxy)-piperidin-1-yl; 4-(3-fluorophenoxy)-piperidin-1-yl; 4-(2-fluorophenoxy)-piperidin-1-yl; 4-(2,4,6-trifluorophenoxy)-piperidin-1-yl; 4-(2,3,6-trifluorophenoxy)-piperidin-1-yl; 4-(4-CF₃phenoxy)-piperidin-1-yl; 4-(4-OCF₃phenoxy)-piperidin-1-yl;
- 5 4-(2,3,4-trifluorophenoxy)-piperidin-1-yl; 4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-phenylethynylpiperidin-1-yl; 4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,5-difluorophenoxy)-piperidin-1-yl; 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenoxy)-piperidin-1-yl;
- 10 4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl; 4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-piperidin-1-yl; 4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl; 4-(4-chlorobenzyloxy)piperidin-1-yl; 4-(4-CF₃phenyl)piperidin-1-yl; 4-(3,4-dimethylphenyl)piperidin-1-yl; 4-(4(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl; 4-(4-chloro-2-OCF₃phenoxy)-piperidin-1-yl; 4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl; 4-(2-fluorophenyl)-
- 15 piperidin-1-yl; 4-(3-fluorophenyl)piperidin-1-yl; 4-(4-cyano-3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-CF₃phenyl)-piperidin-1-yl; 4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl; 4-(pyridin-2-yloxy)-piperidin-1-yl; 4-phenylpiperazin-1-yl; 4-(3-methylphenyl)piperazin-1-yl; 4-(2,5-dimethylphenyl)piperazin-1-yl; 4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl)piperazin-1-yl; 4-(2-methylphenyl)piperazin-1-yl; 4-(2-methoxy-
- 20 phenyl)piperazin-1-yl; 4-(2,3-dichlorophenyl)piperazin-1-yl; 4-(5-chloro-2-methoxyphenyl)-piperazin-1-yl; 4-(2-chlorophenyl)piperazin-1-yl; 4-(3-chlorophenyl)piperazin-1-yl; 4-(3-methoxyphenyl)piperazin-1-yl; 4-(4-fluorophenyl)piperazin-1-yl; 4-(3,4-dimethylphenyl)-piperazin-1-yl; 4-(2-acetylphenyl)piperazin-1-yl; 4-(2-fluorophenyl)piperazin-1-yl; 4-(3-trifluoromethylphenyl)piperazin-1-yl; 4-(2,3-dimethylphenyl)piperazin-1-yl; 4-(2-
- 25 biphenyl)piperazin-1-yl; 4-(4-methoxyphenyl)piperazin-1-yl; 4-(3,4-dichlorophenyl)-piperazin-1-yl; 4-(2-hydroxyphenyl)piperazin-1-yl; 4-(2-ethoxyphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(4-chlorophenyl)piperazin-1-yl; 3-cyano-2-pyridinylpiperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-cyanophenyl)piperazin-1-yl; 4-(4-hydroxyphenyl)piperazin-1-yl; 4-(4-methyl-2-pyridinyl)-
- 30 piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(1,2-benzisoxazol-3-yl)piperazin-1-yl; 4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl; 4-(3,5-dichlorophenyl)piperazin-1-yl; 4-(tetrahydro-2-furanylmethyl)piperazin-1-yl; 4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl; 4-(2-furanylcarbonyl)piperazin-1-yl; 4-(4-(1-methylethyl)piperazin-1-yl;


4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl; 4-(2-chloro-6-fluorobenzyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl; 4-(3-pyridinylmethyl)-piperazin-1-yl; 4-((3-fluorophenyl)carbonyl)piperazin-1-yl; 4-(3-cyclopropylaminocarbonylpyridin-2-yl)piperazin-1-yl; 4-((2-(trifluoromethyl)phenyl)carbonyl)piperazin-1-yl; (4-(3-hydroxypropyl)piperazin-1-yl; 4-(3-methoxybenzyl)-3-oxopiperazin-1-yl; 4-(tetrahydro-2 (RS)-furanlylcarbonyl)piperazin-1-yl; 4-(4-CF₃phenyl)piperazin-1-yl; 4-(2-CNphenyl)-piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-bromobenzyl)piperazin-1-yl; 4-(3,4-dichlorobenzyl)-piperazin-1-yl; 4-(2-phenylethyl)piperazin-1-yl; 4-(3,4-difluorophenyl)piperazin-1-yl; 4-(3-OCF₃benzyl)piperazin-1-yl; 4-(4-chlorobenzyl)piperazin-1-yl; 4-(4-tert-butylbenzyl)piperazin-1-yl; 4-(2,4-difluorophenyl)piperazin-1-yl; 4-(3-chloro-4-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-methylphenyl)-piperazin-1-yl; 4-(3-fluoro-4-methylphenyl)-piperazin-1-yl; 4-(4-fluoro-3-methylphenyl)-piperazin-1-yl; 4-(4-chloro-2-fluorophenyl)-piperazin-1-yl; 4-(3,4-difluorobenzyl)piperazin-1-yl; 4-(3,4-dimethylbenzyl)piperazin-1-yl; 4-(3-CF₃benzyl)piperazin-1-yl; 4-(4-fluorobenzyl)piperazin-1-yl; 4-(7-chloroquinolin-4-yl)-piperazin-1-yl; 4-(3-chlorobenzyl)piperazin-1-yl; 4-(2-fluorobenzyl)piperazin-1-yl; 4-(3-fluorobenzyl)piperazin-1-yl; 4-(4-(2-methoxyethoxy)-phenyl)-piperazin-1-yl; 4-(2-OCF₃benzyl)piperazin-1-yl; 4-(2-SCH₃phenyl)piperazin-1-yl; 4-(2-CF₃phenyl)piperazin-1-yl; 4-(pyridin-2-yl)piperazin-1-yl; 4-(6-methylpyridin-2-yl)-piperazin-1-yl; 4-(5-chloropyridin-2-yl)piperazin-1-yl; 4-(5,6-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4-OCF₃benzyl)piperazin-1-yl; 4-(3-OCF₃phenyl)piperazin-1-yl; 4-(4-OCF₃phenyl)-piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 5-methoxycarbonyl-1,2,3,4-tetrahydro-2-isoquinoline; 6-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(trifluoromethoxy)-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 3,4-dihydro-(1H)-isoquinolin-2-yl; 5-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-trifluoromethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(2-phenoxyphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (3RS)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-methoxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-cyclopropyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (1R)-1-methyl-3,4-dihydro-(1H)-

isoquinolin-2-yl; 6,8-difluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; (1RS)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (1RS)-1-benzyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; (3S)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-fluoro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-hydroxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 4,4-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; (3R)-3-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-hydroxy-3,4-dihydro-(1H)-isoquinolin-2-yl; 3,3-dimethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-sulfamoyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(4-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 7-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-amino-3,4-dihydro-(1H)-isoquinolin-2-yl; (1S)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-methylphenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; (1RS)-1-methyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-bromo-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-(trifluoromethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(acetylamino)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-fluorophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-carboxy-1,2,3,4-dihydro-2(1H)-isoquinolinyl; 6-tert-butyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-cyano-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-chloro-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-OCF₃-3,4-dihydro-(1H)-isoquinolin-2-yl; 6,8-dimethoxy-3,4-dihydro-2(1H)-isoquinolin-2-yl; 5-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolin-2-yl; 5,6-dimethoxy-3,4-dihydro-2(1H)-isoquinolin-2-yl; 6-ethyl-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1-hydroxy-1-methylethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-acetyl-3,4-dihydro-1H-isoquinolin-2-yl; 6-(1-fluoroethyl)-3,4-dihydro-1H-isoquinolin-2-yl; 6-(1,3-thiazol-5-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(2-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(3-thiophenyl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1,3-thiazol-4-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 5-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 8-OCF₃-3,4-dihydro-(1H)-isoquinolin-2-yl; 6-(1,3-thiazol-2-yl)-3,4-dihydro-(1H)-isoquinolin-2-yl; 4-(4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-biphenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(4-CN-2-CH₃-phenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(3-biphenyl)-1,2,3,6-tetrahydro-piperidin-1-yl; 4-(4-cyano-2-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chloro-4-cyanophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-thiophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 2-fluoro-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-

- fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-chlorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-cyano-2,3-difluorophenyl-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(3,4-dimethyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-methylphenyl)-3,6-dihydro-
- 5 (2H)-pyridin-1-yl; 4-(4-cyano-3-fluorophenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-fluoromethoxyphenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-(2H)-pyridin-1-yl; 4-phenyl-3,6-dihydro-(2H)-pyridin-1-yl; 4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl; 4-((1R,4R)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl; (1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; 2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl;
- 10 Racemic mixture of (1S,8R)-9-azatricyclo[6.2.1.0-2,7]-undeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.1.0-2,7]-undeca-2,4,6-trien-9-yl; 2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl; 3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 5,8-dihydro-1,7-naphthyridin-7(6H)-yl; 1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl; racemic mixture of (4aS,8aR)-octahydro-2(1H)-isoquinoliny and
- 15 (4aR,8aS)-octahydro-2(1H)-isoquinoliny; racemic mixture of (1S,8R)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl and (1R,8S)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl; 2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl; 3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl; 1-(methylsulfonyl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl; 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl; 4-benzyl-1,4-
- 20 diazepan-1-yl; 3-phenoxy-8-azabicyclo-[3.2.1]oct-8-yl; 3-benzyloxy-8-azabicyclo-[3.2.1]oct-8-yl; 3-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl; 3-(4-chlorobenzyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl; 2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl; 2-phenyl-2,8-diazaspiro[4.5]dec-
- 25 8-yl; 5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl; (1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]-hept-2-yl; 4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl; 1-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl; 5-ethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl; (1S,4S)-5-(4-chlorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; (1S,4S)-5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl; 2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-
- 30 yl; 2-(4-(trifluoromethoxy)-phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-chlorophenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(3-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(4-(2-methoxyethoxy)-phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(1-piperidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 2-(1-pyrrolidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl; 1'H,3H-

- spiro[1-benzofuran-2,4'-piperidin]-1'-yl; 4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; 5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl; 6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl; (2RS)-2-phenyl-1-pyrrolidinyl; 3-(4-fluorophenoxy)azetidin-1-yl; 3-(phenoxy)azetidin-1-yl; 4-(4-fluoro-3-methylphenoxy)pyrrolidin-1-yl; 3-(3,4-dichlorophenoxy)azetidin-1-yl; 4-(2-chlorophenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethoxybenzyloxy)azetidin-1-yl; 3-(2,5-difluorophenoxy)azetidin-1-yl; 3-(3-fluoro-4-trifluoromethoxyphenoxy)-azetidin-1-yl; 3-(2-chloro-4-trifluoromethylphenoxy)-azetidin-1-yl; 3-(4-chloro-3-fluorophenoxy)-azetidin-1-yl; 3-(3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluoro-4-methylphenoxy)-azetidin-1-yl; 3-(3-trifluoromethoxyphenoxy)-azetidin-1-yl; 3-(2-trifluoromethylphenoxy)-azetidin-1-yl; 3-(4-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-methylphenoxy)-azetidin-1-yl; 3-(4-fluoro-3-chlorophenoxy)-azetidin-1-yl; 3-(3-fluorophenoxy)-azetidin-1-yl; 3-(3,4-difluorophenoxy)-azetidin-1-yl; 3-(2,3-difluorophenoxy)-azetidin-1-yl; 3-(2,4-difluorophenoxy)-azetidin-1-yl; 3-(2,6-difluorophenoxy)-azetidin-1-yl; 3-(4-cyanophenoxy)-azetidin-1-yl; 3-(4-CF₃phenoxy)pyrrolidin-1-yl; 3-(4-trifluoromethylphenoxy)-azetidin-1-yl; or 3-(4-chlorophenoxy)azetidin-1-yl.

16. The compound of any of the Claims 1, 3, 4, 8, 9, 10 and 11 wherein R⁵ and R⁶ together



with the nitrogen atom to which they are attached form wherein ring B is 4-

- (benzyloxy)piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl; 4-(4-chlorophenoxy)piperidin-1-yl; 4-phenylpiperidin-1-yl; 4-(4-cyanophenyl)piperidin-1-yl; 4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(benzylsulfanyl)piperidin-1-yl; 4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl; 4-(4-fluorophenoxy)piperidin-1-yl; 4-(4-phenyl-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-methoxyphenyl)piperidin-1-yl; 4-((3RS)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(5-phenyl-1,3,4-thiadiazol-2-yl)piperidin-1-yl; 4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-phenyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-pyridinyloxy)piperidin-1-yl; 4-(3-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(3-chloro-4-fluorophenoxy)piperidin-1-yl; 4-((2-methylbenzyl)oxy)piperidin-1-yl; 4-(3,5-dimethylphenoxy)piperidin-1-yl; 4-(4-bromo-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-methylphenoxy)piperidin-1-yl; 4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-((2-biphenyl)methyl)(methyl)amino)piperidin-1-yl; 4-(4-chlorophenyl)piperidin-1-yl; 4-(2-(1-methylethoxy)phenoxy)piperidin-1-yl; 4-(2-chlorophenoxy)piperidin-1-yl; 4-(4-bromophenyl)-4-hydroxypiperidin-1-yl; 4-(3-phenylpropoxy)piperidin-1-yl; 4-(2-chloro-4-

fluorophenoxy)-piperidin-1-yl; 4-(3-chloro-4-cyanophenoxy)-piperidin-1-yl; 4-butoxypiperidin-1-yl; 4-(2-methylphenoxy)piperidin-1-yl; 4-(2,4-difluorophenoxy)piperidin-1-yl; 4-(3,4-difluorophenoxy)piperidin-1-yl; (3S)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenylcarbonyl)piperidin-1-yl; 4-(phenylsulfanyl)piperidin-1-yl; 4-(4-fluorophenyl)-piperidin-1-yl; 4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl; 4-((3-methylbenzyl)oxy)piperidin-1-yl; 4-((3-cyanophenyl)-amino)piperidin-1-yl; 4-((4-chlorophenyl)amino)piperidin-1-yl; 4-((3-chlorobenzyl)oxy)-piperidin-1-yl; 4-(2-fluorophenyl)-4-hydroxypiperidin-1-yl; 4-(2,3-difluorophenoxy)piperidin-1-yl; 4-hydroxy-4-phenylpiperidin-1-yl; 4-(4-cyano-2-(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(2-chloro-5-methylphenoxy)piperidin-1-yl; 4-(3-phenyl-5-isoxazolyl)piperidin-1-yl; 4-(3-propyl-5-isoxazolyl)piperidin-1-yl; 4-((3R)-3-phenyl-1-pyrrolidinyl)piperidin-1-yl; 4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(1-naphthalenyloxy)piperidin-1-yl; 4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-benzyl-4-hydroxypiperidin-1-yl); 4-benzylpiperidin-1-yl; 4-((3-fluoro-5-(trifluoromethyl)-benzyl)amino)piperidin-1-yl; 4-(2-methoxyphenoxy)-piperidin-1-yl; 4-(3-(acetylamino)-phenoxy)piperidin-1-yl; 4-benzyl-1,4'-bipiperidin-1'-yl; 4-(2-cyclohexylethoxy)piperidin-1-yl; 4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((3-chloro-4-cyanophenyl)amino)-piperidin-1-yl; 4-ethoxypiperidin-1-yl; 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-methoxypiperidin-1-yl; 4-(3-bromophenoxy)piperidin-1-yl; 4-(2-(1-methylethyl)phenoxy)-piperidin-1-yl; 4-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; (3RS)-3-(2-cyanophenoxy)piperidin-1-yl; 4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl; (3RS)-3-(2-methoxy-4-methylphenoxy)piperidin-1-yl; 4-(2-cyanophenoxy)piperidin-1-yl; 4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-chloro-2-(trifluoromethyl)-phenoxy)-piperidin-1-yl; 4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-((6-methyl-3-pyridinyl)oxy)piperidin-1-yl; 4-(2,4-bis(trifluoromethyl)phenoxy)piperidin-1-yl; 4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2-fluorophenoxy)piperidin-1-yl; 4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(1-pyrrolidinyl)piperidin-1-yl; 4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3,4-dichlorophenoxy)-piperidin-1-yl; 4-(cyclopropylmethoxy)piperidin-1-yl; 4-ethoxycarbonylpiperidin-1-yl; 4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; (3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-propyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl; 4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinoliny)-piperidin-1-yl; 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-bromophenoxy)piperidin-1-yl; 4-((4-methylphenyl)-sulfanyl)piperidin-1-yl; 4-(4-(1H-pyrrol-1-yl)phenoxy)piperidin-1-yl; 4-(4-(1,3-benzodioxol-5-

ylmethyl)piperazin-1-yl)piperidin-1-yl; 4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(5,6,7,8-tetrahydro-1-naphthalenylamino)piperidin-1-yl; (3RS)-3-(4-chlorophenoxy)-piperidin-1-yl; 4-phenyl-4-propanoylpiperidin-1-yl; (2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(4-tert-butylphenoxy)piperidin-1-yl; 4-(2-propylaminocarbonylphenoxy)piperidin-1-yl; 4-(3-pyridinyloxy)piperidin-1-yl; 4-((4-methoxyphenyl)amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)amino)piperidin-1-yl; 4-(phenylsulfonyl)piperidin-1-yl; 4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(2-pyrimidinyloxy)piperidin-1-yl; 4-(2-biphenyloxy)piperidin-1-yl; (3RS)-3-(5-methyl-1H-benzimidazol-2-yl)piperidin-1-yl; 4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-pyridinyloxy)piperidin-1-yl; 4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(methyl(2-(trifluoromethoxy)phenyl)-amino)piperidin-1-yl; 4-((2-(trifluoromethyl)phenyl)sulfonyl)piperidin-1-yl; 4-(6-quinolinylamino)piperidin-1-yl; 4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-((1-benzyl-4-piperidinyl)amino)piperidin-1-yl; 4-(benzylsulfonyl)piperidin-1-yl; 4-((2-(1H-indol-3-yl)ethyl)amino)piperidin-1-yl; 4-(4-(2-pyrimidinyl)piperazin-1-yl)piperidin-1-yl; 4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)piperidin-1-yl; 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl; (3RS)-3-(4-cyano-2-methoxyphenoxy)-piperidin-1-yl; 4-aminocarbonylpiperidin-1-yl; 4-(4-(8-quinolinyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-carboxypiperidin-1-yl; 4-(((3S)-3-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(4-((dimethylamino)-methyl)phenoxy)piperidin-1-yl; 4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-biphenyl)piperidin-1-yl; 4-(2-biphenyl)piperidin-1-yl; 4-(4-CF₃-benzyloxy)piperidin-1-yl; 4-(4-CF₃O-benzyloxy)piperidin-1-yl; 4-(4-Br-benzyloxy)piperidin-1-yl; 4-(3,4-difluoro-benzyloxy)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(4-Cl-3-F-phenoxy)piperidin-1-yl; 4-(3-CF₃-benzyloxy)piperidin-1-yl; 4-(4-Cl-3-CH₃-phenoxy)piperidin-1-yl; 4-(4-F-benzyloxy)piperidin-1-yl; 4-(2,6-diF-benzyloxy)piperidin-1-yl; 4-(benzthiazol-2-yl)piperidin-1-yl; 4-(3-phenyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-n-propyl-1,3,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-Cl-4-CN-phenyl)piperidin-1-yl; 4-(benzoxazol-2-yl)piperidin-1-yl; 4-(4-trifluoromethoxy-benzyloxy)piperidin-1-yl; 4-(4-chloro-3-(trifluoromethyl)-phenoxy)piperidin-1-yl; 4-(4-cyano-3-methylphenyl)piperidin-1-yl; 4-(2-cyanobenzyloxy)piperidin-1-yl; 4-(2-CF₃benzyloxy)-piperidin-1-yl; 4-(1-RS-1-phenylethoxy)-piperidin-1-yl; 4-(4-chloro-3,5-dimethylphenoxy)-piperidin-1-yl; 4-(4-chlorobenzoyl)piperidin-1-yl; 4-(4-dimethylaminophenyl)piperidin-1-yl;

4-(2-CF₃phenyl)piperidin-1-yl; 4-(2-phenyl-1,3-thiazol-4-yl)piperidin-1-yl; 4-(3-OCF₃benzyloxy)piperidin-1-yl; 4-(2-OCF₃benzyloxy)-piperidin-1-yl; 4-(4-butylbenzyloxy)piperidin-1-yl; 4-(4-isopropylbenzyloxy)-piperidin-1-yl; 4-(4-methylbenzyloxy)piperidin-1-yl; 4-(4-OCHF₂benzyloxy)piperidin-1-yl; 4-(2,4,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3,6-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,3-difluorobenzyloxy)-piperidin-1-yl; 4-(2,4-difluorobenzyloxy)-piperidin-1-yl; 4-(2,3,4-trifluorobenzyloxy)-piperidin-1-yl; 4-(4-cyanobenzyloxy)-piperidin-1-yl; 4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-piperidin-1-yl; 4-(4-chlorobenzyl)piperidin-1-yl; 4-(3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃benzyloxy)-piperidin-1-yl; 3-fluoro-4-(phenyl)piperidin-1-yl; 4-(3-cyanophenoxy)piperidin-1-yl; 4-(4-cyanophenoxy)piperidin-1-yl; 4-methyl-4-(4-trifluoromethoxybenzyloxy)piperidin-1-yl; 4-[4-(2-methoxyethoxy)benzyl-oxy]piperidin-1-yl; (3R,4R)-3-fluoro-4-phenyl-piperidin-1-yl; (3S,4S)-3-fluoro-4-phenyl-piperidin-1-yl; 4-(4-tert-butylbenzyloxy)-piperidin-1-yl; 4-(4-chloro-1-naphthalenyloxy)-piperidin-1-yl; 4-benzyl-4-fluoropiperidin-1-yl; 4-(2-methylsulfonylphenoxy)-piperidin-1-yl; 4-(3-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(4-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-3-CF₃benzyloxy)-piperidin-1-yl; 4-(3-fluoro-4-CF₃benzyloxy)-piperidin-1-yl; 4-(2-fluoro-5-CF₃benzyloxy)-piperidin-1-yl; 4-(2,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,4,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(2,4-diCF₃benzyloxy)piperidin-1-yl; 4-(2-fluorobenzyloxy)piperidin-1-yl; 4-(3-fluorobenzyloxy)piperidin-1-yl; 4-(2,3,5-trifluorobenzyloxy)-piperidin-1-yl; 4-(3,5-difluorobenzyloxy)piperidin-1-yl; 4-(2,5-diCF₃benzyloxy)piperidin-1-yl; 3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)piperidin-1-yl; 4-(2,3-dichlorophenoxy)piperidin-1-yl; 4-(3-chloro-4-methylphenoxy)-piperidin-1-yl; 4-(4-chloro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(3-chlorophenoxy)-piperidin-1-yl; 4-(3,4-dimethylphenoxy)-piperidin-1-yl; 4-(2,3-dimethylphenoxy)-piperidin-1-yl; 4-(3,4-dihydro-(1H)-isoquinolin-2-yl)piperidin-1-yl; 4-(3-thiophenylmethoxy)-piperidin-1-yl; 4-(2-fluoro-5-OCF₃phenoxy)-piperidin-1-yl; 4-(2-trifluoromethoxyphenoxy)-piperidin-1-yl; 4-(3-fluoro-4-OCF₃phenoxy)-piperidin-1-yl; 4-(4-fluoro-3-OCF₃phenoxy)-piperidin-1-yl; 4-(2,6-difluorophenoxy)-piperidin-1-yl; 4-(3-fluorophenoxy)-piperidin-1-yl; 4-(2-fluorophenoxy)-piperidin-1-yl; 4-(2,4,6-trifluorophenoxy)-piperidin-1-yl; 4-(2,3,6-trifluorophenoxy)-piperidin-1-yl; 4-(4-CF₃phenoxy)-piperidin-1-yl; 4-(4-OCF₃phenoxy)-piperidin-1-yl; 4-(2,3,4-trifluorophenoxy)-piperidin-1-yl; 4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-(3-(3-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-yl; 4-phenylethynylpiperidin-1-yl; 4-(3-(2-(trifluoromethoxy)-phenyl)-1H-pyrazol-1-yl)piperidin-1-

yl; 4-(3,5-difluorophenoxy)-piperidin-1-yl; 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl; 4-(phenoxy)-piperidin-1-yl; 4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl; 4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-piperidin-1-yl; 4-(4-(2,2,2-trifluoroethoxy)-benzyloxy)-piperidin-1-yl; 4-(4-chlorobenzyloxy)piperidin-1-yl; 4-(4-CF₃phenyl)piperidin-1-yl; 4-(3,4-dimethylphenyl)piperidin-1-yl; 4-(4(2,2,2-trifluoroethyl)phenyl)-piperidin-1-yl; 4-(4-chloro-2-OCF₃phenoxy)-piperidin-1-yl; 4-(2-(4-chlorophenyl)ethyl)-piperidin-1-yl; 4-(2-fluorophenyl)-piperidin-1-yl; 4-(3-fluorophenyl)piperidin-1-yl; 4-(4-cyano-3-fluorophenyl)-piperidin-1-yl; 4-(4-cyano-3-CF₃phenyl)-piperidin-1-yl; 4-(4-cyano-3,5-difluorophenyl)-piperidin-1-yl; 4-(4-phenyl-1,3-thiazol-2-yl)-piperidin-1-yl; 4-(pyridin-2-yloxy)-piperidin-1-yl; 4-phenylpiperazin-1-yl; 4-(3-methylphenyl)piperazin-1-yl; 4-(2,5-dimethylphenyl)piperazin-1-yl; 4-(2-(2H-1,2,3-triazol-2-ylmethyl)-phenyl)piperazin-1-yl; 4-(2-methylphenyl)piperazin-1-yl; 4-(2-methoxyphenyl)piperazin-1-yl; 4-(2,3-dichlorophenyl)piperazin-1-yl; 4-(5-chloro-2-methoxyphenyl)-piperazin-1-yl; 4-(2-chlorophenyl)piperazin-1-yl; 4-(3-chlorophenyl)piperazin-1-yl; 4-(3-methoxyphenyl)piperazin-1-yl; 4-(4-fluorophenyl)piperazin-1-yl; 4-(3,4-dimethylphenyl)-piperazin-1-yl; 4-(2-acetylphenyl)piperazin-1-yl; 4-(2-fluorophenyl)piperazin-1-yl; 4-(3-trifluoromethylphenyl)piperazin-1-yl; 4-(2,3-dimethylphenyl)piperazin-1-yl; 4-(2-biphenyl)piperazin-1-yl; 4-(4-methoxyphenyl)piperazin-1-yl; 4-(3,4-dichlorophenyl)-piperazin-1-yl; 4-(2-hydroxyphenyl)piperazin-1-yl; 4-(2-ethoxyphenyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(4-chlorophenyl)piperazin-1-yl; 3-cyano-2-pyridinylpiperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-cyanophenyl)piperazin-1-yl; 4-(4-hydroxyphenyl)piperazin-1-yl; 4-(4-methyl-2-pyridinyl)-piperazin-1-yl; 4-(2-chlorobenzyl)piperazin-1-yl; 4-(1,2-benzisoxazol-3-yl)piperazin-1-yl; 4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl; 4-(3,5-dichlorophenyl)piperazin-1-yl; 4-(tetrahydro-2-furanylmethyl)piperazin-1-yl; 4-(6-(1-pyrrolidinyl)-3-pyridazinyl)piperazin-1-yl; 4-(2-furanylcarbonyl)piperazin-1-yl; 4-(4-(1-methylethyl)piperazin-1-yl; 4-((2-methyl-1,3-thiazol-4-yl)methyl)piperazin-1-yl; 4-(2-chloro-6-fluorobenzyl)piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl; 4-(3-pyridinylmethyl)-piperazin-1-yl; 4-((3-fluorophenyl)carbonyl)piperazin-1-yl; 4-(3-cyclopropylaminocarbonyl)-pyridin-2-yl)piperazin-1-yl; 4-((2-(trifluoromethyl)phenyl)carbonyl)piperazin-1-yl; 4-(3-hydroxypropyl)piperazin-1-yl; 4-(3-methoxybenzyl)-3-oxopiperazin-1-yl; 4-(tetrahydro-2(RS)-furanylcarbonyl)piperazin-1-yl; 4-(4-CF₃phenyl)piperazin-1-yl; 4-(2-CNphenyl)-piperazin-1-yl; 4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl; 4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)piperazin-1-yl; 4-(4-bromobenzyl)piperazin-1-yl; 4-(3,4-dichlorobenzyl-

piperazin-1-yl; 4-(2-phenylethyl)piperazin-1-yl; 4-(3,4-difluorophenyl)piperazin-1-yl; 4-(3-OCF₃benzyl)piperazin-1-yl; 4-(4-chlorobenzyl)piperazin-1-yl; 4-(4-tert-butylbenzyl)piperazin-1-yl; 4-(2,4-difluorophenyl)piperazin-1-yl; 4-(3-chloro-4-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-fluorophenyl)-piperazin-1-yl; 4-(4-chloro-3-methylphenyl)-piperazin-1-yl; 4-(3-fluoro-4-methylphenyl)-piperazin-1-yl; 4-(4-fluoro-3-methylphenyl)-piperazin-1-yl; 4-(4-chloro-2-fluorophenyl)-piperazin-1-yl; 4-(3,4-difluorobenzyl)piperazin-1-yl; 4-(3,4-dimethylbenzyl)piperazin-1-yl; 4-(3-CF₃benzyl)piperazin-1-yl; 4-(4-fluorobenzyl)piperazin-1-yl; 4-(7-chloroquinolin-4-yl)-piperazin-1-yl; 4-(3-chlorobenzyl)piperazin-1-yl; 4-(2-fluorobenzyl)piperazin-1-yl; 4-(3-fluorobenzyl)piperazin-1-yl; 4-(4-(2-methoxyethoxy)-phenyl)-piperazin-1-yl; 4-(2-OCF₃benzyl)piperazin-1-yl; 4-(2-SCH₃phenyl)piperazin-1-yl; 4-(2-CF₃phenyl)piperazin-1-yl; 4-(pyridin-2-yl)piperazin-1-yl; 4-(6-methylpyridin-2-yl)-piperazin-1-yl; 4-(5-chloropyridin-2-yl)piperazin-1-yl; 4-(5,6-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4,5-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(3,4-dimethylpyridin-2-yl)-piperazin-1-yl; 4-(4-OCF₃benzyl)piperazin-1-yl; 4-(3-OCF₃phenyl)piperazin-1-yl; 4-(4-OCF₃phenyl)-piperazin-1-yl; or 4-(2-chlorobenzyl)piperazin-1-yl.

17. The compound of any of the Claims 1, 3, 4, 8, 9 and 10-16 wherein R³ is hydrogen, chloro, methyl, or ethyl, preferably hydrogen.

18. The compound of Claim 1 wherein the compound is selected from:

- N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;
- N-(3-((4-(4-phenyl-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;
- N-(3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;
- N-(3-((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;
- N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;
- N-(2-methyl-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;
- N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;
- methyl 2-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydro-5-isoquinolinecarboxylate;

N-(3-(((4-(4-(2,5-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-(2H-1,2,3-triazol-2-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(5-chloro-2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(2-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-(((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(3-(((4-(4-(2-acetylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-2-methyl-phenyl)acetamide;

5 N-(3-(((4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

2-(((3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-phenyl)amino)-2-oxoethyl acetate;

N-(3-(((4-(4-(benzylsulfany1)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(2-biphenyly1)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(3-(((4-(4-(3,4-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(1-oxo-2-phenyl-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

25 N-(3-(((4-(4-(4-(3-thiophenyl)-1H-pyrazol-1-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(4-(2-hydroxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(1-cyclohexen-1-yl)-1H-pyrazol-1-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

(2RS)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-2-furancarboxamide;

5 N-(3-(((4-(4-(2-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyanoacetamide;

15 N-(3-(((4-(5-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

20 N-(2-methyl-3-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopropylacetamide;

25 N-(3-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-((3RS)-3-phenyl-1-pyrrolidinyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(5-phenyl-1,3,4-thiadiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(4-(4-(2-methylphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(5-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(7-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(6-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)butanamide;

N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-2-acetyl-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)glycinamide;

N-(3-(((4-(6-(1-hydroxy-1-methylethyl)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-(3-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((2-methylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

(3RS)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)tetrahydro-3-furancarboxamide;

30 N-(3-(((4-(4-(4-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-cyano-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(5-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,5-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromo-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-((1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxyacetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-(((4-(4-((2-biphenylmethyl)(methyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-(2-phenoxyphenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

30 N-(3-(((4-(6-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

(3S)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxybutanamide;

N-(3-(((4-((3R)-3-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide

N-(3-(((4-(6-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(2-(1-methylethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 N-(3-(((4-(4-(2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-phenylpropoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(8-methoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

25 N-(3-(((4-(4-butoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(5-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(4-(2,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-cyclopropyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-((1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(RS)-5-oxoprolinamide;

N-(3-((4-(4-((3S)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-((4-(6,8-difluoro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-hydroxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-((4-((1RS)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-((4-(4-((1RS)-1-benzyl-3,4-dihydro-2(1H)-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-((4-(4-(4-methyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(7-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-((4-(4-(2-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(6-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-((4-(4-(phenylcarbonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(2-methyl-3-((4-(4-(phenylsulfanyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-((3S)-3-methyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-((3-methylbenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

Racemic mixture of N-(3-(((4-((1S,8R)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-(((4-((1R,8S)-9-azatricyclo[6.2.1.0-2,7-]undeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-((3-cyanophenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(8-fluoro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

15 N-(3-(((4-(4-((4-chlorophenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(5-(trifluoromethyl)-2-pyridiny)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((3-chlorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

20 N-(3-(((4-(4-(2-fluorophenyl)-4-hydroxy-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(2,3-dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-(((4-(4-(2,3-difluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(6-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-hydroxy-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(6-hydroxy-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-cyano-2-(trifluoromethyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(2-chloro-5-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(3-phenyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(4-(3-propyl-5-isoxazolyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(5-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((3R)-3-phenyl-1-pyrrolidinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1-naphthalenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

20 N-(3-(((4-(4-(3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-benzyl-4-hydroxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(4-benzyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-((3-fluoro-5-(trifluoromethyl)benzyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-methoxyphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(7-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopentylacetamide;

N-(3-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)oxy)phenyl)acetamide;

N-(3-(((4-(4-(3-(acetylamino)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(1,2-benzisoxazol-3-yl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-benzyl-1,4'-bipiperidin-1'-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-cyclohexylethoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(1,3-benzodioxol-5-yl)methyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(7-methoxy-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((3-chloro-4-cyanophenyl)amino)-1-piperidiny1)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-ethoxy-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(4-(((4-(3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-methyl-1,2,4-oxadiazol-5-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(4-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-methoxy-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-bromophenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)-4-methoxyphenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny1)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-difluoroacetamide;

N-(3-(((4-(4-(2-(1-methylethyl)phenoxy)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(4-(((4-(4-(4-cyanophenyl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-(((4-(4-(5-methyl-1H-benzimidazol-2-yl)-1-piperidiny1)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(2-methyl-3-((4-((3RS)-3-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide

N-(3-((4-(4,4-dimethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-((4-((3RS)-3-(2-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-((4-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-((4-((3RS)-3-(2-methoxy-4-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(4-morpholinyl)acetamide;

15 (2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-hydroxypropanamide;

N-(3-((4-(4-(2-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

20 N-(3-((4-(4-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-2-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-((4-(4-((6-methyl-3-pyridinyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(7-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(2,4-bis(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-(4-methylphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-((3R)-3-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(5-hydroxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(3,3-dimethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(4-(2-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(7-sulfamoyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(4-(4-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-(4-methylphenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(1-pyrrolidiny)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 Racemic mixture of N-(3-(((4-((4aS,8aR)-octahydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide and N-(3-(((4-((4aR,8aS)-octahydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide

N-(3-(((4-(4-(4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-5-methylphenyl)-acetamide;

N-(3-(((4-(4-(3,4-dichlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(cyclopropylmethoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

25 ethyl 1-(4-(((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxylate;

N-(3-(((4-(7-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-L-alaninamide;

30 N-(3-(((4-(5-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

Racemic mixture of N-(3-(((4-((1S,8R)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-(((4-((1R,8S)-9-azatricyclo[6.2.2.0-2,7]-dodeca-2,4,6-trien-9-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-amino-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-(4-(2,5-dimethoxyphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-((3RS)-3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-((1S)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

10 N-(3-(((4-(6-(3-methylphenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(methylsulfonyl)acetamide;

15 N-(3-(((4-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-cyclopropanecarboxamide;

20 N-(3-(((4-(4-(4-propyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-((1RS)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(8-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(4-(1,3-benzodioxol-5-yl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(4-((4-methylphenyl)sulfanyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(4-(3,5-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-isoxazolecarboxamide;

5 N-(3-(((4-(4-(4-(1H-pyrrol-1-yl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(8-(trifluoromethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

10 N-(3-(((4-(4-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-(acetylamino)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(5,6,7,8-tetrahydro-1-naphthalenylamino)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(4-(((4-(3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1-piperidiny)acetamide;

20 N-(3-(((4-(((3RS)-3-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-(6-(3-fluorophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

25 N-(3-(((4-(4-phenyl-4-propanoyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

N-(3-(((4-(((2RS)-2-(5-fluoro-1H-benzimidazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(4-tert-butylphenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

30 N-(3-(((4-(4-(tetrahydro-2-furanylmethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

2-((1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinyloxy)-N-propylbenzamide;

N-(3-(((4-(4-(3-pyridinyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-4-chlorophenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-5-chlorophenyl)acetamide;

5 N-(3-(((4-(2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1H-imidazol-4-yl)acetamide;

10 2-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1,2,3,4-tetrahydro-5-isoquinolinecarboxylic acid;

N-(3-(((4-(4-(6-(1-pyrrolidiny)-3-pyridaziny)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-((4-methoxyphenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-((2RS)-2-phenyl-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2-(trifluoromethyl)phenyl)amino)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(phenylsulfonyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(2-furanylcarbonyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(1-methylethyl)-1-piperaziny)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide

N-(3-(((4-(4-(4-(4-cyanophenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

30 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-1-methyl-1H-imidazole-2-carboxamide;

N-(3-(((4-(4-(3-(2-pyraziny)-1,2,4-oxadiazol-5-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-((2-methyl-1,3-thiazol-4-yl)methyl)-1-piperaziny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N-2-,N-2-dimethylglycinamide;

N-(3-(((4-(6-tert-butyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(4-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-pyrimidinylloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

10 N-(3-(((4-(4-(2-biphenylloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-(((4-((3RS)-3-(5-methyl-1H-benzimidazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(3-(3-chloro-4-pyridinyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(2-chloro-6-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-pyridinylloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-(5-fluoro-2-methoxyphenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(methyl(2-(trifluoromethoxy)phenyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2-(trifluoromethyl)phenyl)sulfonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

25 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)glycinamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-4-fluorophenyl)acetamide;

N-(3-(((4-(4-(6-quinolinylamino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(3-(4-(methylsulfonyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-phenylacetamide;

N-(3-(((4-(4-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((1-benzyl-4-piperidinyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

5 N-(3-(((4-(1-(methylsulfonyl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzylsulfonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methyl-phenyl)acetamide;

10 N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-5-fluorophenyl)-acetamide;

N-(3-(((4-(4-((2-(1H-indol-3-yl)ethyl)amino)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(4-(2-pyrimidinyl)-1-piperazinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(8-cyano-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)-amino)-phenyl)acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(4-(3-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(4-(4-phenyl-5,6-dihydropyridin-1(2H)-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide

N-(3-(((4-(4-(3-pyridinylmethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-acetamide;

25 N-(3-(((4-(4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(8-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

30 N-(3-(((4-(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-((3RS)-3-(4-cyano-2-methoxyphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-3-furancarboxamide;

1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxamide;
N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)-amino)-phenyl)cycloheptanecarboxamide;

N-(3-((4-(4-((3-fluorophenyl)carbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(8-quinolinyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

2-(4-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-1-piperazinyl)-N-cyclopropyl-3-pyridinecarboxamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)cyclopentanecarboxamide;

N-(3-((4-(4-((2-(trifluoromethyl)phenyl)carbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-((4-(4-(4-(3,4,5-trifluorophenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(2-thiophenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-4-pyridinecarboxamide;

N-(3-((4-(4-(3-hydroxypropyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)-acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)sulfanyl)-phenyl)acetamide;

1-(4-((3-(acetylamino)phenyl)amino)-1,3,5-triazin-2-yl)-4-piperidinecarboxylic acid;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-1-methyl-1H-pyrrole-2-carboxamide;

N-(3-((4-(4-(3-methoxybenzyl)-3-oxo-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-((3S)-3-(hydroxymethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-((dimethylamino)methyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-1,3-thiazole-5-carboxamide;

N-(3-(((4-(4-(tetrahydro-2-(RS)-furanylcarbonyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(4-(4-(3-methylphenyl)-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)-N-2-carbamoylglycinamide;

10 N-(2-chloro-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

N-(3-(((4-(4-(2-biphenylyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(3-(((4-(4-(3-biphenylyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(2-chloro-5-(((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

20 N-(3-(((4-(4-(2-biphenylyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(2-methyl-5-(((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-(((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-(((4-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)-amino)phenyl)acetamide;

(2R)-N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-phenyl)-2-methoxypropanamide;

N-(3-(((4-(4-(((4-bromobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzylsulfanyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(2-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(4-(2-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(5-((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-(4-(3,4-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

N-(3-((4-(4-(4-cyano-2-methylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-4-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxyacetamide;

N-(3-((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-acetamide;

N-(3-((4-(6-tert-butyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)acetamide;

15 N-(5-((4-(4-(2,3-dichlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(4-(3-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-tetrahydro-2-furancarboxamide;

N-(3-((4-(4-((4-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(2-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((2,6-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(1,3-benzothiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-phenyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

(2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)-2-methoxypropanamide;

5 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-phenyl)propanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2,2-trifluoroacetamide;

10 N-(2-methyl-3-((4-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyclopropylacetamide;

N-(2-methyl-5-((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-((4-(4-(5-chloro-2-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

20 N-(3-((4-(4-(3-chloro-4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxy-3-methylbutanamide;

N-(3-((4-(4-(3,4-dichlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(4-methoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

(2S)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)tetrahydro-2-furancarboxamide;

30 N-(3-((4-(4-(4-ethoxyphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(1,3-benzoxazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

(3S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N-(2-methyl-3-((4-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-2-cyanoacetamide;

5 (2S)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxypropanamide;

(3S)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

10 N-(3-((4-(6,8-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(5-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-((4-(6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(6-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-(2-methoxyethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(2-methyl-3-((4-(6-(2,2,2-trifluoroethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(2-methoxyethoxy)-5-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(5,6-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N~2~-carbamoylglycinamide;

5 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxypropanamide;

(2R)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)tetrahydro-2-furancarboxamide;

10 (3R)-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-3-hydroxybutanamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-hydroxy-2-methylpropanamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2,2,2-trifluoroacetamide;

15 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N~2~-carbamoylglycinamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)tetrahydro-2-furancarboxamide;

20 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-D-prolinamide;

(3R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N~2~-acetyl-N-(3-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)glycinamide;

25 (2R)-N-(3-((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)tetrahydro-2-furancarboxamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-dimethylpropanamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methylpropanamide;

(2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxypropanamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-methoxypropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-

5 yl)amino)phenyl)-R-2-methylbutanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-2-methylbutanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-methylbutanamide;

Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-

10 yl)amino)phenyl)-R-2-fluoropropanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-2-fluoropropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)butanamide;

Racemic mixture of N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-

15 yl)amino)phenyl)-R-4,4,4-trifluoro-3-methylbutanamide and N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-S-4,4,4-trifluoro-3-methylbutanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2,2-difluoropropanamide;

(2R)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methoxypropanamide;

20 (2S)-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methoxypropanamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-methylpropanamide;

25 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-5-oxo-D-prolinamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-2-cyclopropylacetamide;

N~2~-acetyl-N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)glycinamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-L-prolinamide;

N~2~-acetyl-N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)glycinamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxy-2-methylpropanamide;

Racemic mixture of N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-L-prolinamide and N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-5-oxo-D-prolinamide;

(3R)-N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-3-hydroxybutanamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-hydroxy-2-methylpropanamide;

N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)-2-(1-methylethoxy)acetamide;

N-(2-methyl-3-(((4-(4-(3-propyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(benzyl-1,4-diazepan-1-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3-methylphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-cyanobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

Racemic mixture of N-(2-methyl-3-(((4-(4-((1R)-1-phenylethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(2-methyl-3-(((4-(4-((1S)-1-phenylethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3,5-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((4-chlorophenyl)carbonyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-(dimethylamino)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-3-(((4-(3-phenoxy-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(benzyloxy)-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(3-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chlorobenzyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-phenyl-1,3-thiazol-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((4-butylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-((4-(1-methylethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((4-methylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-((4-(difluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2,4,6-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-((2,3,6-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((2,3-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-((2,3,4-trifluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-((4-cyanobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(2-phenyl-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyano-2-fluorophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chlorobenzyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-phenoxy-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-((3-fluoro-4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-(((4-((3R,4R)-3-fluoro-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-(((4-((3S,4S)-3-fluoro-4-phenyl-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 Racemic mixture of N-(3-(((4-((3R)-3-(4-fluoro-2-methylphenoxy)-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-(((4-((3S)-3-(4-fluoro-2-methylphenoxy)-1-pyrrolidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3,4-dichlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-((4-((3R)-3-(2-chlorophenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide and N-(3-((4-((3S)-3-(2-chlorophenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-biphenyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(6-(3,3,3-trifluoropropoxy)-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-methyl-4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(3-((4-(trifluoromethoxy)benzyl)oxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-cyano-3',6'-dihydro-3,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3R,4R)-3-fluoro-4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3S,4S)-3-fluoro-4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(3-(2,5-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(2-phenyl-2,8-diazaspiro[4.5]dec-8-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3-chloro-4-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(8-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((4-tert-butylbenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(5-cyano-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-((4-chloro-1-naphthalenyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3-fluoro-4-(trifluoromethoxy)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chloro-3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(4-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(3-(3-fluoro-4-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(3-(trifluoromethoxy)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(3-(3-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(2-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(3-(4-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(3-(4-fluoro-3-methylphenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3-chloro-4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-(((4-(3-(3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(3,4-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,3-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,4-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(3-(2,6-difluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(3-(4-cyanophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(5-(((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

10 N-(2-fluoro-3-(((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-benzyl-4-fluoro-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(methylsulfonyl)phenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-methoxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(4-hydroxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-methoxyphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-5-(((4-(4-(2-methylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-methylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-chloro-5-(((4-(4-(3-chlorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(2,3-dichlorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(6-chloro-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(6-chloro-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-5-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((1S,4S)-5-benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

10 N-(2-chloro-5-((4-(4-(2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-((4-(4-(2,3-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-fluoro-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-phenyl-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-(((4-(4-(2-cyanophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,5-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-5-((4-(4-(2-(1H-1,2,3-triazol-1-ylmethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-bromobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-(((4-(4-(3,4-dichlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(2-phenylethyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3,4-difluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(3-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-(4-tert-butylbenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,4-difluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-(3-fluoro-4-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-fluoro-3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-((4-(6-ethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-chloro-2-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-difluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(3,4-dimethylbenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(6-(1-hydroxy-1-methylethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(3-((4-(4-((3-fluoro-5-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((4-fluoro-3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-3-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-((3-fluoro-4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-((2-fluoro-5-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(7-chloro-4-quinolinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(2-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-fluorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-chlorobenzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-(((4-(6-acetyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

Racemic mixture of N-(3-(((4-(6-(R)-(1-fluoroethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-(3-(((4-(6-(S)-(1-fluoroethyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-((2,4,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(6-ethyl-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((3,4,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-((2-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-((3-fluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-((2,3,5-trifluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,5-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-(4-((2,5-bis(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-((4-(4-(6-acetyl-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-((4-(4-(2-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-(4-(3-chloro-4-cyanophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2,3-dichlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(2-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chloro-3-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-(3-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(2,3-dimethylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-dihydro-2(1H)-isoquinolinyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(6-(1,3-thiazol-5-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(2-thiophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(6-(2-thiophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(3-thiophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-thiophenylmethoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(6-(3-thiophenyl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-(6-(1,3-thiazol-4-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

Racemic mixture of N-2-methyl-3-(((4-((3R)-3-(4-(trifluoromethyl)phenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide and N-2-methyl-3-(((4-((3S)-3-(4-(trifluoromethyl)phenoxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluoro-5-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,4-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-fluoro-4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(4-fluoro-3-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,6-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2,3-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-(((4-(4-(3-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-(((4-(4-(2,4,6-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2,3,6-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(1-phenyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-3-(((4-(4-(4-(trifluoromethyl)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-(2,3,4-trifluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-((3R)-3-(benzyloxy)-1-pyrrolidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-(((4-(4-(3-(3-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(phenylethynyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(2-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(3-(((4-(4-(4-cyano-2,3-difluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3,5-difluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-chloro-5-(((4-(4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(3-cyclohexyl-1,2,4-oxadiazol-5-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-methyl-3-(((4-(4-(2-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(2-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-chloro-5-(((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(methylsulfanyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(trifluoromethyl)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-(((4-(4-(2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-(((4-(4-(6-methyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(4-(5-chloro-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(4-chlorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(5-(1,3-thiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-(((4-(8-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-((1S,4S)-5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.1]hept-2-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-5-(((4-(4-(3-methylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(3-chlorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-((3R,4R)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-((3S,4S)-3-fluoro-4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-((4-(2,2,2-trifluoroethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(5,6-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-((4-(4-(4,5-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-dimethyl-2-pyridinyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-((4-(4-((4-chlorophenoxy)methyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(4-(phenoxymethyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(6-(1,3-thiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-((4-(4-(3-(trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)phenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-methyl-3-((4-(4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(4-(3,4-dimethylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(4-(4-(2,2,2-trifluoroethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-(4-(4-chloro-2-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide

N-(2-methyl-3-((4-(4-(2-methylphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(2-(4-chlorophenyl)ethyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-fluoro-5-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

2,2-dimethyl-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

5 2-methyl-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(2-chloro-5-((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(5-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methoxyphenyl)acetamide;

N-(4-((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-biphenyl)acetamide;

N-(3-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(5-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(5-((4-(4-(2-biphenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(5-((4-(4-(2-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(5-((4-(4-(2-biphenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-((4-(4-(2-(trifluoromethoxy)phenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-methyl-5-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-5-((4-(4-((2-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(5-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-fluoro-3-(((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-((4-(2-methoxyethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-(((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-5-fluorophenyl)acetamide;

N-(5-(((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(3-(4-(trifluoromethyl)phenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(3-(((4-(2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-fluoro-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-cyclopropyl-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(2-chloro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(trifluoromethoxy)-5-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(4-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-biphenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(2-fluorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(3-fluorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-fluorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(3-(((4-(4-(4-cyano-3-fluorophenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3-fluorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(3-(((4-(4-(4-cyano-3-(trifluoromethyl)phenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(4-(2-(2-thiophenyl)phenyl)-3,6-dihydro-1(2H)-pyridiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyano-3,5-difluorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(2-methyl-3-(((4-(4-(2,4,5-trifluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-chloro-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-((3-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(4-(4-(4-cyano-2-(trifluoromethyl)phenyl)piperidin-1-yl)-1,3,5-triazin-2-ylamino)-2-methylphenyl)acetamide;

N-(2-chloro-5-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(2-fluoro-5-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-chlorophenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(5-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-cyclopropylphenyl)acetamide

5 N-(5-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-(trifluoromethoxy)phenyl)acetamide;

N-(5-(((4-(4-(3,4-dimethylphenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-fluoro-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-chloro-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-(trifluoromethoxy)-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(5-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-fluoro-5-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

25 N-(2-fluoro-5-(((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-(((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

30 N-(2-fluoro-5-(((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-(((4-(4-(4-fluorophenyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-cyanophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(2-fluoro-3-((4-(4-(4-phenyl-1H-pyrazol-1-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

5 N-(2-fluoro-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-methylphenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

10 N-(2-fluoro-5-((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenoxy-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-(2-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-fluoro-3-((4-(4-(2-pyridinyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-fluoro-5-((4-(4-phenyl-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-chloro-5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-fluoro-5-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-bromophenyl)acetamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

10 N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)cyclopropanecarboxamide;

N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

15 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-bromophenyl)acetamide;

N-(2-fluoro-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

20 N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-tert-butylphenyl)acetamide;

N-(2-fluoro-5-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)acetamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)cyclopropanecarboxamide;

N-(5-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)propanamide;

30 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)propanamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)propanamide;

N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)cyclopropanecarboxamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2-cyanophenyl)acetamide;

N-(2-methyl-3-(((4-(2-(4-(trifluoromethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-(((4-(2-(4-chlorophenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(2-(4-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-(((4-(2-(3-pyridinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(2-(4-(2-methoxyethoxy)phenyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-(((4-(2-(1-piperidiny)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-(((4-(2-(1-pyrrolidinyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dichlorophenyl)acetamide;

20 N-(4-fluoro-2-methyl-3-(((4-(4-(((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(3-(4-chlorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-(((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

25 N-(3-(((4-(3-(4-chloro-3-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(6-(3,3,3-trifluoropropoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-(((4-(4-(4-chlorophenyl)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(((3-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-(((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

5 N-(2,6-dimethyl-3-(((4-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dichloro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(6-fluoro-2-methyl-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-difluoro-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(2-chloro-6-methyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(6-chloro-2-methyl-3-(((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

25 N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-chloro-6-methylphenyl)acetamide;

N-(3-(((4-(4-(benzyloxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-6-chloro-2-methylphenyl)acetamide;

30 N-(2-chloro-6-methyl-3-(((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-difluoro-3-(((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-(((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-5-fluoro-2-methylphenyl)acetamide;

N-(5-fluoro-2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2,6-dimethyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(6-fluoro-2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(6-chloro-2-methyl-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2,6-dichloro-3-((4-(6-(trifluoromethoxy)-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-chloro-6-(3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(2-methyl-3-((4-methyl-6-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-(4-chloro-3-fluorophenoxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

20 N-(2-methyl-3-((4-methyl-6-(4-((4-(trifluoromethyl)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-methyl-6-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-6-methyl-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidinyl)-6-ethyl-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-6-methyl-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-(((1R)-1-phenylethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-((4-(4-chlorophenoxy)phenyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(benzyloxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(benzyloxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

5 N-(2-methyl-3-((4-((3-phenylpropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-((3-phenoxypropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(2-methyl-3-((4-((2-phenoxyethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((trans-4-(4-chlorophenoxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-((3-(2-(benzyloxy)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(1-methylethyl)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-((3-(4-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(3-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((cis, trans-4-(benzyloxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-((3-(2-chlorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(3-methylphenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

30 N-(3-((4-((3-(4-chlorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-(1-methylethyl)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3-(2-(benzyloxy)phenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((3-(4-methylphenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(2-methyl-3-((4-((2-(3-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((3-(3-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

10 N-(2-methyl-3-((4-((2-(2-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(((1S)-1-methyl-3-phenylpropyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(3-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

15 N-(3-((4-((2-(3-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((2-(4-methylphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-((3-(4-fluorophenyl)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((2-(2-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((3-(2-fluorophenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

25 N-(3-((4-((3-(4-fluorophenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((2-(2-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

30 N-(3-((4-((2-(4-methoxyphenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((1-(4-(trifluoromethoxy)benzyl)-4-piperidinyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(3-((4-((2-(4-fluorophenoxy)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-((cis, trans-4-(benzyloxy)cyclohexyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-(((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

5 N-(3-((4-((2-(1-isoquinoliny)ethyl)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2-methyl-3-((4-((8-quinoliny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

10 N-(3-((4-(((3R)-1-benzyl-3-piperidiny)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(3-((4-(((3S)-1-benzyl-3-piperidiny)amino)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)acetamide;

N-(2,6-dimethyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

15 N-(2-methyl-3-((4-((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

N-(2-methyl-3-((4-(((1-(4-(trifluoromethoxy)benzyl)-4-piperidiny)methyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

20 N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2,6-dichlorophenyl)acetamide;

N-(3-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinoliny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

(1Z)-N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)-N'-cyanoethanimidamide;

25 N-(3-((4-(4-(benzyloxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

N-(3-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)-2,6-dimethylphenyl)acetamide;

30 N-(2,6-dichloro-3-((4-(4-(4-chlorophenoxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)acetamide;

(1E)-N'-cyano-N-(3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidiny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperaziny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

5 (1E)-N'-cyano-N-(2-methyl-5-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N-(5-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

10 (1E)-N'-cyano-N-(5-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-phenyl-1,3-thiazol-2-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

15 (1E)-N'-cyano-N-(2-methyl-3-((4-(4-((4-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(5-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

20 (1E)-N'-cyano-N-(3-((4-(4-(4-cyanophenyl)-3,6-dihydro-1(2H)-pyridinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(4-((3,4-difluorobenzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

25 (1E)-N'-cyano-N-(3-((4-(4-(3,4-dimethylphenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N'-cyano-N-(3-((4-(5-(difluoromethoxy)-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

30 (1E)-N-(3-((4-(4-(4-chlorophenyl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(2-phenyl-1,3-thiazol-4-yl)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(3-(trifluoromethoxy)phenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(2-phenyl-6,7-dihydrofuro[3,2-c]pyridin-5(4H)-yl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-((3-(trifluoromethoxy)benzyl)oxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

5 (1E)-N-(3-((4-(4-(3-chloro-4-fluorophenyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-methyl-3-((4-(4-(4-(trifluoromethoxy)benzyl)-1-piperazinyl)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

10 (1E)-N'-cyano-N-(3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)-2-methylphenyl)ethanimidamide;

(1E)-N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)-2-fluorophenyl)-N'-cyanoethanimidamide;

(1E)-N'-cyano-N-(2-fluoro-3-((4-(3-(4-fluorophenoxy)-1-azetidiny)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide; and

15 (1E)-N'-cyano-N-(2-methyl-3-((4-((3-(4-(trifluoromethoxy)phenoxy)propyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)ethanimidamide;

N-(3-((4-(4-(4-chlorophenoxy)-1-piperidinyl)-1,3,5-triazin-2-yl)amino)phenyl)-ethanethioamide;

20 N-(6-((4-(6-bromo-3,4-dihydro-2(1H)-isoquinolinyl)-1,3,5-triazin-2-yl)amino)-2-pyridinyl)acetamide; or

a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound of any of the Claims 1-18 and a pharmaceutically acceptable excipient.

20. A method of treating pain in a patient which method comprises administering to the
25 patient a pharmaceutical composition comprising a compound of any of the Claims 1-19 and a pharmaceutically acceptable excipient.